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Abstract 
The quality and safety of medicines use is as important in paediatrics as in adult medicine, and 
closely linked to the skills, knowledge, attitudes and behaviours of health professionals responsible 
for patient care.  The aim of this research was to investigate advanced paediatric pharmacy practice; 
how to develop and assess advanced skills; and how these skills improve outcomes for children. 
Prevention of adverse medication events (AMEs) is the most researched pharmacy impact on 
patient outcomes.  However, there is limited evidence in paediatrics.  The first phase of this 
research investigated AMEs in children, with the hypothesis that: 
Voluntary reports of AMEs can be used to identify trends over time in response to safety 
improvement initiatives, and identify associated skills required of health practitioners. 
The first component of this phase reviewed six months of potential and actual AMEs identified 
from three databases: clinical incident reports, pharmacist intervention reports and administrative 
coding using the International Classification of Diseases 10th Revision (ICD-10).  Analysis 
identified 447 individual AMEs.  Little duplication between data sources was found.  ICD-10 
coding identified the most cases of harm, and intervention and incident reports identified the most 
cases of error.  ICD-10 events rarely involved error and were time-consuming to retrieve, hence this 
method was not used in subsequent research. 
The next component reviewed eight years of voluntary reports of medication related events 
(MREs).  10,865 MREs were investigated.  Two categories were reviewed in detail: chemotherapy 
prescribing and potassium errors.  Potassium errors reduced from 6.3 to 2.2 per 10,000 occupied 
bed days from 2008 to 2012.  Chemotherapy prescribing errors decreased from 4.2 to 1.1 per 100 
oncology separations from 2005 to 2012, particularly errors in chemotherapy protocols.  Education 
alone did not produce sustained change.  System changes including forcing functions, executive 
endorsement and strong multidisciplinary engagement resulted in most improvement.  Health 
practitioners required advanced skills in education, change and risk management, communication, 
teamwork, leadership, and research methodology. 
The second phase of research tested the hypothesis that: 
 iii 
Paediatric hospital pharmacists value formal recognition of advanced pharmacy practice, 
can describe the characteristics of advanced practitioners and identify preferred methods of 
assessment of advanced practice.  
Four focus groups, involving 31 Australian paediatric pharmacists, concluded that advanced 
practice should be formally recognised, and include a foundation in clinical practice, together with 
education, research and service improvement outside the institution.  Multiple methods of 
assessment were recommended; most preferred were direct observation of practice, peer review and 
portfolio review.  Knowledge of paediatric diseases and drug handling, and skills in communication 
with children and families, were important. 
The third phase of the project reviewed two existing datasets to test two hypotheses, the first of 
which was: 
Pharmacist interventions can document progression to advanced practice.  
Six hundred interventions recorded by four pharmacists from one paediatric hospital were 
retrospectively reviewed over three separate periods from 2005 to 2012.  Skills demonstrated in 
these interventions were rated using a pilot scale from 1 to 5, representing skills typical of intern 
pharmacists through to advanced practice.  Skills increased over time, with more Level 3-5 
interventions recorded in the later time periods, and mean skill level increasing from 1.9 to 2.6 
(p<0.01).   
The second hypothesis in this phase was: 
Training and development priorities in paediatric pharmacy can be identified by direct 
observation of pharmacists working in clinical practice.   
This study retrospectively reviewed six years of paediatric pharmacist competency assessments 
using the General Level Framework (GLF).  Fifty assessments were retrieved from ten Queensland 
hospitals, including specialist and general hospitals.  Ethics, confidentiality, legal compliance and 
appropriate dosages were performed consistently well.  However, assessment of patients’ 
understanding of illness and treatment, and assessment of adherence, were not performed well.  
This study demonstrated that the GLF could be used to evaluate competency and identify training 
needs in the paediatric setting. 
The final phase of the research tested the hypothesis that: 
 iv 
Advanced level paediatric pharmacy practice is most reliably evaluated using multiple 
assessment methods  
Thirty-six pharmacists were recruited from four Australian paediatric hospitals.  Six assessment 
methods (direct observation of practice, peer review, portfolio review, viva voce, knowledge 
assessments and self-assessment) were tested over 12 months.  Each method was scored against the 
Paediatric Advanced Level Framework.  Qualitative and quantitative analysis of scores, ranking, 
and participant and evaluator feedback found the most reliable methods were portfolio review, peer 
review and oral viva.  Postgraduate qualifications, CPD records, and direct observation of practice 
using the GLF or shpaclinCAT, provided less reliable scores and were not preferred by participants 
or evaluators. 
This research project demonstrates the value of advanced practice to Australian paediatric 
pharmacists as a career pathway; the importance of advanced skills to safe medication use in 
paediatrics; and the importance of using a combination of assessment methods to evaluate advanced 
practice.  Future work includes development of an electronic portfolio, a paediatric curriculum 
linked to accessible training, and formal credentialing of advanced pharmacy practitioners. 
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1 Chapter One: Introduction 
1.1 Introduction 
Recognition of advanced pharmacy practice has developed rapidly over the past 5-10 years, both in 
Australia and internationally.1,2  The concept of advanced pharmacy practice links professional 
development and formal recognition of practice for pharmacists, analogously to the journey to 
consultant practice for medical officers.  Despite the apparent interest in the published arena, it is 
unknown whether this is something desired by the general pharmacy workforce, and what are the 
most suitable methods of assessment for the Australian environment. 
There has also been an increasing focus on improving child health worldwide, including the safe, 
effective and appropriate use of medicines.3,4  In Australia this has coincided with major changes in 
funding of public health systems; integration of children’s health services at a state levels; new 
guidelines on the care of children in hospitals; and building of three substantial new paediatric 
hospitals in Australian capital cities.5  These changes in paediatric health care have forced providers 
to re-consider models of care, and professional development of health practitioners to meet these 
evolving needs.6 
This research project aims to investigate paediatric pharmacists’ understanding of advanced 
pharmacy practice; how to develop and assess advanced skills; and how these skills contribute to 
improved medication outcomes for children, with particular reference to adverse medication events. 
1.2 Background to Research 
1.2.1 What are the issues with children and medications? 
In 1911, the ‘father of paediatrics’ in the United States, Dr Abraham Jacobi, made the statement that 
‘pediatrics does not deal with miniature men and women, with reduced doses and the same class of 
diseases in smaller bodies, but has its own independent range and horizon’.7  This concept that 
‘children are not just small adults’ has been a common refrain ever since, and has coincided with 
many health practitioner groups, including pharmacy, recognising the need for specialised training 
and expertise in paediatrics.  Children grow at different rates, handle medications in different ways, 
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have different diseases than adults and are psychologically and physically different to adults, which 
impact on how medications should be used. 
Despite the incredible advances in paediatric medical care, it is known that children experience 
harm from medicines.  Parents report that 17% of children have experienced an adverse event from 
medications in their lifetime.8  Investigations of adverse medication events across five countries 
including Australia found that 16.5% of hospitalised children experience harm from medications.9 
A study in the UK found 29 children were reported in the media to have died due to medication 
errors over an eight year period.10  Some of these adverse medication events relate to differences in 
medication handling in children, and some due to increased risks of error, and reinforce the need to 
prevent unnecessary harm to children from medications.  Improvement in the safety and the quality 
of medication use is highly dependent upon the skills of the health practitioners involved, as well as 
the systems in which they work.  Pharmacists have a key role in this area, whether providing care to 
individual patients or influencing practice at a system level. 
1.2.2 Defining Errors and Adverse Events 
There are many different definitions used in patient safety literature, which make comparisons 
between different studies difficult.  A discussion of the terms, and the definitions used for this paper 
are described below: 
Medication, Medicine and Drugs 
There has been a move towards using the word “medication” or “medicine” rather than “drug” for 
chemical substances used therapeutically.  However some phrases have traditionally used the word 
drug, for example “adverse drug reaction”, “drug interaction” or “therapeutic drug monitoring” and 
some have used the word medication such as “medication error” and “medication chart”.  Although 
they are largely considered interchangeable, the word “medication” has become more preferred in 
recent years.  For the purposes of this thesis, the term medication is used in preference, except when 
included in a direct quote, or in commonly understood terms as above.   
The more commonly used terms as described below.   
Medication Error 
An error has been defined as ‘the failure to complete an action as intended, or the wrong use of or 
the wrong plan to achieve an aim’.11  ‘Errors may occur by doing the wrong thing (commission) or 
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failing to do the right things (omission)’.11  According to the Institute of Safe Medication Practice, a 
simple definition of medication error is ‘any error occurring in the medication use process’.12   
A more detailed definition by the National Coordinating Council for Medication Error Reporting 
and Prevention (NCC MERP) is the most commonly used in the North American literature:  
A medication error is any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the health care 
professional or patient.  Such events may be related to professional practice, health care 
products, procedures, and systems, including prescribing; order communication; product 
labeling, packaging, and nomenclature; compounding; dispensing; distribution; 
administration; education; monitoring; and use.13  
Importantly, these definitions for error do not require injury or harm to have occurred. 
Prescribing Error 
Dean et al developed a definition for a prescribing error in 2000:14 
A clinically meaningful prescribing error occurs when, as a result of a prescribing decision 
or prescription writing process, there is an unintentional significant (1) reduction in the 
probability of treatment being timely and effective or (2) increase in the risk of harm when 
compared with generally accepted practice.14 
This is a more restrictive definition than by NCC MERP, but was developed to ensure no artificial 
inflation of the error rate by including trivial incidents or deviations from guidelines.14,15  This 
definition was determined as applicable for the paediatric setting by a second Delphi process by 
Ghaleb et al in 2005, and used in subsequent studies in paediatrics.15,16 
Incident 
A clinical incident has been defined as: ‘any event or circumstance which has actually or could 
potentially lead to unintended and/or unnecessary mental or physical harm to a patient’.11,17,18 
Medication related incidents can occur at any point in the medication use process (ordering, 
transcribing, dispensing, administrating, and monitoring).19   
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Harm 
Research into medication safety has often not defined harm, or used varied definitions.  A simple 
definition used in Australia is ‘Death, disease, injury and/or disability experienced by a patient.’17  
A more detailed definition from the Institute for Healthcare Improvement (IHI) is used in the North 
American research: ‘Unintended physical injury resulting from or contributed to by medical care 
that requires additional monitoring, treatment or hospitalization, or that results in death’.20  In this 
study we also explicitly included temporary harm, emotional or psychological harm, pain requiring 
intervention and abnormal laboratory values, as used in other recent research.21,22 
Adverse Medication (Drug) Event 
An adverse medication event (AME), previously referred to as an adverse drug event (ADE), 
was initially described as ‘An injury resulting from medical interventions related to a drug’.23-25  
Later studies clarified that the injury could be from the lack of an intended medication, and can 
include the lack of expected disease improvement.26-28  This was clarified further by IHI as events 
which are ‘unintended consequences of medical care, whether preventable or not’.20   
Adverse medication events can be separated into two types – those caused by errors and those that 
occur despite proper usage.   
• A preventable AME is injury or harm caused by an error.19,21,29,30 
• Non-preventable AMEs (i.e. injury but no error) are also called adverse drug 
reactions (ADRs).19,29   
Preventability is often difficult to determine, and IHI makes the important point that ‘today’s 
unpreventable events are only an innovation away from being preventable’.20  Hence in this study 
all events are investigated, although preventability is considered.   
The phrase “Adverse Drug Event” has been most commonly used in past research, however for 
consistency “Adverse Medication Event” (or AME) is used in this study. 
Potential ADE/AME 
Potential AMEs are defined as errors that have the potential to harm or injure a patient.26,29-32  
These may also be called ‘near-misses’.30  This could be because the error was intercepted and 
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corrected before reaching the patient, or reached the patient but did not harm them because of 
specific circumstances or chance.19,29  
Adverse Drug Reaction (ADR) 
In 1972, the World Health Organisation defined an adverse drug reaction as one that is ‘noxious, is 
unintended, and occurs at doses normally used in man for prophylaxis, diagnosis, therapy, or 
modification of physiological function’.33  This was assumed to be unrelated to error, and therefore 
similar to a “side effect” or a non-preventable Adverse Medication Event, as discussed above.34,35   
The WHO definition was recently updated to ‘A response to a medicinal product which is noxious 
and unintended’, which now therefore includes error as a cause of harm.36  Hence an ADR as 
defined by WHO and used in European research is now equivalent to an AME as used in North 
American and most Australian research.37 
Clinical Pharmacist Intervention 
A number of different organisations have proposed definitions for a clinical pharmacist 
intervention.  In this study we will be using the definition by the Society of Hospital Pharmacists 
of Australia (SHPA): ‘any action by a pharmacist that directly resulted in a change to patient 
management or drug therapy’.38  
In many instances pharmacist interventions are ‘near-miss’ events, usually related to prescribing 
error, where the intervention prevents the error getting to the patient.  In other instances pharmacist 
interventions need not be associated with errors: they include interventions where medication use is 
improved or optimised. 
Challenges of Classification 
The varied definitions used by different researchers described above, highlight the challenges in 
comparing results from different studies. The difficulty with these classifications is that, although 
relatively simple to understand, they imply a single error or problem resulting in a single event or 
harm.  In contrast, as described recently by Burkle et al, many errors and events result from a 
complex interaction of multiple medications and processes.39 
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1.2.3 Medication Harm and Errors 
Research into the area of medication safety escalated after the report by The Institute of Medicine 
To Err is Human was released in 2000, which concluded that as many as 98,000 Americans die 
each year as a result of medical errors.40  Medication errors alone were estimated to account for 
over 7,000 deaths annually, and the cost of preventable adverse medication events are around US$2 
billion for the United States in hospital costs alone.40  This report demonstrated the importance of 
patient safety to improvements in medical care, and paved the way for focused research on patient 
safety particularly related to medications.  Similar work undertaken in Australia found that 2-4% of 
all hospital admissions are medication related, accounting for more than AUS$400 million per year, 
and 1% of hospitalised patients experiencing harm from medications.27 A recent review of the 
literature on medication safety in Australia estimated that medication related admissions have 
remained unchanged over recent years and still account for 2-3% of all admissions to Australian 
hospitals.41  Injuries or harm caused by medications, referred to as adverse drug events (ADEs) or 
adverse medication events (AMEs), are common in hospitals in both adults and children.25,42,43  
1.2.4 What do we know about adverse medication events in children? 
Although children usually take fewer medications than adults, they can be subject to the same risks 
of error and adverse medication events as adults, with additional risks related to age, development, 
and availability of suitable formulations.  Safety strategies may be implemented in paediatrics 
without sufficient evaluation, and thus result in harm.  In contrast, new initiatives can be excluded 
from paediatrics unnecessarily due to lack of evidence.  An example of this is medication 
reconciliation. This was widely implemented in adult medicine, but not initially recommended for 
use in paediatrics due to lack of evidence of efficacy.  Since then it has been inconsistently 
implemented in paediatrics.44,45  More recent research has identified that discrepancies at transfer of 
care are indeed a significant source of error in children, with routine medication reconciliation now 
recommended.46 
Subsequent to the To Err is Human Report, Kaushal et al in 2001 published research from two US 
paediatric hospitals which found medication errors in 5.7% of paediatric medication orders, and 
adverse medication events associated with 0.24% of orders.43  Importantly, this study also found 
that the rate of potential adverse medication events was three times higher than in adults.43  
Kaushal’s findings correlated with the earlier report by Barber et al in the UK where the number of 
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prescriptions changed in response to pharmacist interventions in the paediatric wards was second 
only to those in the intensive care units and higher than in geriatric, medical or surgical wards.47  
Since 2001, there has been increasing interest in research on medication safety in paediatrics, with 
particular interest in the incidence and impact of error and harm.  In 2002, Cousins et al described a 
review of press reports of medication errors in children in the UK over an eight year period, which 
identified 29 children who had died due to medication errors.10  Of these reports, 13 were related to 
dosing errors, including five involving a decimal point or ten-fold error.10  A systematic review by 
Wong et al in 2004 on dosing errors in children found that dosing error was probably the most 
common medication error in children.48  In 2010, a prospective study in five hospitals in the UK 
found that there was a prescribing error rate of 13.2% of medication orders and an administration 
error rate of 19.1%.15  More recent studies in Spain have shown that paediatric patients had a four-
fold higher risk of serious errors than the maternity population.49   
When considering harm from medicines (with or without error), research undertaken using parental 
reporting in over 4,000 Finnish children found that the lifetime prevalence of adverse medication 
events in children was 17%.8  The ADVISE trial across five countries found that 16.5% of 
hospitalised children experienced an adverse drug reaction, and 16.6% of these were considered to 
be preventable.9  A contrasting result from Canada, using a much more stringent definition for harm 
(death, disability at discharge, or prolonged stay in hospital), found that 9.2% of hospitalised 
children experienced an adverse event, but only 13.5% of these events were related to medicines.50   
Despite the varied rates of error and harm reported in the literature, and the resilience of children to 
recover from harm, it is clear that many children are exposed to unacceptable rates of error and 
harm from medication, and efforts need to be made to improve the quality and safety of medication 
use in children. 
1.2.5 Why are children at increased risk of harm from medications? 
As described above, the risk of adverse medication events in children is significant, and may require 
a range of different strategies to prevent harm.  A number of contributing factors to increased or 
differing risks in children have been identified: 
Dosing, Calculations and Ten-Fold Errors 
Doses for children are usually calculated on an individual patient basis using actual or gestational 
age, weight (mg/kg) or surface area (mg/m2), and clinical condition.  The dose in weight then needs 
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to be converted to a quantity of the formulation chosen (e.g. tablet portion or volume of a 
liquid).48,51-54  These calculations are required to ensure doses are individualised for the patient.  
However the requirement for multiple calculations increases the opportunities for error. 
These calculations require only basic arithmetic skills, which are generally assumed of health 
practitioners, however a significant proportion fail in these calculations.48,52,55 Rowe et al tested the 
calculation skills of paediatric medical residents over two years and found that 30-60% of the 
residents committed at least one error in a standardized test with 10 scenarios.56  A study by Lesar 
in 1998 found that errors involving children accounted for 69.5% of the calculation-related 
prescribing errors despite children only comprising 20% of the beds in the hospital studied.53  
Confusing dosage regimens or equations and using incorrect units can contribute to calculation and 
dosing errors.48  A small mistake, which might be tolerated in adults, can have more significant 
consequences in a young child.57 
The risk of ten-fold or decimal point errors (10-, 100-, or 1000-fold errors) are linked to the 
calculation errors described above and are a well-recognised risk in children.10,48,58,59  One injection 
vial manufactured for adults will often contain more than ten times the dose required for an infant 
or young child; accounting for nearly one-third of all intravenous drugs prescribed in a neonatal 
unit.60,61  For medications with a narrow therapeutic index, a ten-fold dosage increase may lead to 
serious morbidity or death.  This can go undiagnosed when signs of overdose are assumed to be 
related to the underlying disease.62,63  In contrast a ten-fold under-dose may not be identified but the 
patient may not respond appropriately to therapy.63  This has been found to be a significant problem 
in the community as well as the hospital setting.10,64 
Medication Administration 
There is an increased need for dilutions and manipulations of paediatric medicines to make them 
suitable to administer to children.  They require precise dose measurement and appropriate 
medication delivery systems.52,54,65  Nurses and parents are often required to subdivide tablets, open 
capsules or dilute injections in order to administer the correct dosage due to a lack of available 
dosage forms and concentrations appropriate for administration to neonates, infants and children54.  
Dosage formulations are frequently extemporaneously compounded and lack stability, 
compatibility, or bioavailability data.54  Such practices can potentially lead to a reduction in 
medication effect and/or increase toxicity.61 
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Off-label, unlicensed use 
Most adults would expect to only receive medicines which have been demonstrated to be well 
tolerated, effective and of a high quality.  However in children there is an ongoing lack of published 
information and government-approved labelling regarding dosing, pharmacokinetics, safety, 
efficacy, and clinical use of medications in the paediatric population.54  As long ago as 1968, Dr 
Harry Shirkey coined the term ‘therapeutic orphans’ referring to the absence of evidence and 
appropriate licensing for the use of medicines in infants and children.66  Although significant 
improvements have been made in the United States and Europe, this remains the case in 
Australia.67,68  
Off-label use of medicines refers to use outside the conditions of the product license.  This may be 
non-validated age range or indication, an alternative route of administration, altered regimen (e.g. 
dose, frequency), or disregard of contraindications.69-71  Unlicensed medicines are used when no 
appropriate formulation of a particular medication is commercially available.  This may include 
modifying currently licensed medicines in some way, preparing medicines under a special 
manufacturing license, use of chemicals as medicines, use of medicines before a license has been 
granted, or medicines licensed in another country.70,71  Off-label and unlicensed use of medications 
is common in children, accounting for 30-65% of all prescriptions written for children and neonates, 
and off-label or unlicensed medicines are used in two-thirds of hospitalised children and 90% of 
premature infants.70,72   
Many researchers have found that medicines used in an off-label or unlicensed fashion are more 
likely to be associated with medication errors and more often associated with harm or adverse drug 
reactions to patients than licensed medications, particularly in children less than 2 years old.41,71,73  
In contrast, more recent research from Phan et al found that there was a lower incidence of adverse 
drug reactions associated with off-label or unlicensed use of medicines in patients admitted to a 
paediatric emergency department.74 
Communication of these potential risks to children and families is a challenge for health 
practitioners.  A focus group study from Ireland in children aged 10-14 concluded that children felt 
off-label use of medicines in children was unethical and unsafe, and felt that parents and children 
from the age of 13 should be informed and provide consent for use.75 
These results reflect the ethical dilemma for medicines management in children.  In most 
circumstances these are not obscure or rarely used medicines, but medicines that are used routinely 
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and often the mainstay of paediatric therapeutics.69  A recent policy statement from the American 
Academy of Pediatrics stated that off-label use does not imply improper or unethical use if it is 
based on sound scientific evidence or expert medical judgement.76  Nonetheless, clinicians are left 
with the ethical dilemma of whether to deny an unwell child treatment with potentially beneficial 
medicines, or treat with medicines on the basis of studies in adults or anecdotal empirical 
experience in children.77 
Research and Equity of Access 
There has been significant work undertaken at an international level to improve access to better 
paediatric medicines (and reduce the off-label/unlicensed use described above), in particular to 
stimulate research and licensing of appropriate medicines and formulations for children.  
Legislative changes in the European Union and the United States have contributed to improved 
research and access to medicines for children, particularly over the past 10 years.  However despite 
many years of advocacy, Australia still lacks any legislative and regulatory reforms addressing 
paediatric medicines.67   
There have been some small gains since the introduction of the Paediatric Medicines Advisory 
Group in 2007 by the Australian Department of Health and Aging to provide advice on paediatric 
medicines issues.  By September 2011, seven new medicines had been listed on the Pharmaceutical 
Benefits Scheme for children, with ten amended listings and a further twenty-five medicines that 
are under consideration.78   
In Australia, decision-making for access to medicines in hospitals at an individual patient or 
institution level is often delegated to the hospital’s drug and therapeutics committee.  A review of 
the Australian medication approval process in 2010 found that most committees had poor 
infrastructural support for approval processes, did not formally include a pharmacoeconomic 
evaluation, and significantly duplicated effort across sites.79 
Medication Handling 
Human growth itself is not a linear process.  Age associated changes in body composition and organ 
function are dynamic, and can be discordant during the first decade of life.  Thus, simplified dose 
administration approaches are not adequate for individualizing medication doses across the span of 
childhood.62,80 
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The ongoing developmental changes in children, including organ system maturity and variations in 
body weight, body surface area, and changes in pharmacokinetic parameters such as absorption and 
excretion of medicines increase the risk of medication error in children.54,81  Diseases in neonates, 
infants and children are often different to those observed in adult patients, which will affect the 
benefits and risks of medicines use.82  Developmental changes may alter both the action of a 
medication and the body’s response to it.  Increasing information is also being discovered about the 
genotype-phenotype relationship that can effect a medication’s pharmacokinetics and 
pharmacodynamics and the complicated inter-relationship with developmental changes.82 
High Risk Medications 
Kunac et al in 2009 and 2010 reviewed 520 paediatric admissions to a general hospital in New 
Zealand over a 12 week period and found that the medications most commonly involved in adverse 
medication events and potential adverse medication events were antibacterials (in particular 
aminoglycosides) and narcotic analgesics (in particular morphine).35,83,84  This is comparable to the 
results of Kaushal et al in the US which found anti-infectives, followed by analgesics and sedatives 
and electrolytes and fluids to have the highest rates of potential adverse medication events.43 
Rashed et al also found similar results, with antibacterials then analgesics reported as the 
medication groups most frequently involved in ADRs.9  Clavenna et al also found antibiotics as the 
medication most frequently associated with adverse medication events in children.85   Likewise, a 
review of eleven years of paediatric outpatient and emergency presentations related to adverse 
medication events, antimicrobials, central nervous system agents and hormones were the most 
frequently implicated, with the frequency of presentations related hormone therapy increasing with 
age.86   
The findings above are consistent with the frequent use of these medications in the paediatric 
population.  In contrast, when considering fatalities in UK children, Clarkson and Choonara found 
that anticonvulsants, cytotoxics, anaesthetic agents and antibiotics were the most frequently 
mentioned medicines.87  A different pattern is seen in younger children where a study from the USA 
in children under 2 years of age found palivizumab, cisapride, indomethacin, nitric oxide, 
azithromycin and acetaminophen as the medications most frequently involved in serious or fatal 
outcomes.88 
The categories of medications most often involved in harm in children are in contrast to those in the 
adult population where antiplatelet agents, anticoagulants, diuretics, cardiovascular medications and 
cytotoxic agents are more frequently implicated in harm.84,89 
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These differences in risks and contributing factors mean that separate research needs to be 
undertaken in paediatrics to more clearly define and target areas of risk, and to identify the most 
successful initiatives to improve quality and safety of medication use in children.  The role of the 
pharmacist in these areas is explored further in following sections. 
1.2.6 What do paediatric pharmacists do, and how are they different? 
History of paediatric pharmacy 
Despite the medical specialty of paediatrics emerging more than a century ago, the profession of 
pharmacy has taken significantly longer to appreciate that health-care needs of children are different 
from those of adults.90  The first reports of a specific role in paediatrics for pharmacists appeared in 
the published literature in 1969, where George Provost encouraged hospital pharmacists to take up 
the challenge of improving paediatric medication therapy, and pointed out that this was the 
responsibility of every pharmacist, not only of those in specialist paediatric positions.91 
In the same year, Michael Ellis said there was ‘a need for the hospital pharmacist to come out of his 
basement and become interested and responsibly involved in the clinical life of the hospital.’92 
Also, that the pharmacists ‘were so busy counting inanimate objects that the whole purpose of being 
in the healthcare field seemed to escape them’.92  The focus of the role at that time was preparation 
of unit doses of medicines to aid nursing staff time, but it evolved to a much more clinical role at 
the bedside which included making daily medical rounds with the paediatricians, with enthusiasm 
and support from nursing and medical staff.92  
More research describing the roles and benefits of paediatric pharmacy was reported in the 1970s, 
predominantly from the United States of America.93,94  Responsibilities such as monitoring of 
patient charts, medication information to medical and nursing personnel, therapeutic drug 
monitoring, providing medication histories on admission, consultations on discharge, and an 
evolving role in teaching and research are similar to the responsibilities of current day paediatric 
pharmacists.93,95 
By 2003, the American Academy of Pediatrics had recommended that pharmacists be available to 
prescribers and nurses to participate in medication therapy development and monitoring, and that 
prescribers utilize pharmacist consultation.96  In 2011 the Academy recommended that clinical 
pharmacists trained in paediatrics should be integrated into inpatient rounds and providing 
education of staff and families in all settings as often as possible.81  
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 35 
The important role of the paediatric clinical pharmacist in monitoring medication treatment, 
preventing medication errors and adding value and quality to paediatric medication use is now well 
understood and established in the United Kingdom and the USA, where many neonatal and 
paediatric units have instituted ward-based clinical pharmacy services; in particular participation in 
physician rounds.97  Unfortunately, this service is not universal across all sites, or in other countries 
around the world.25,65,98  There is little published on the Australian paediatric pharmacy experience; 
anecdotally the comprehensive clinical pharmacy services instituted in some Australian paediatric 
hospitals (and described above) are far from consistent across the spectrum of Australian paediatric 
health care.99 
Differences in roles, knowledge and skills of a paediatric pharmacist 
Recently the Board of Pharmacy Specialties from the USA has recognised paediatrics as a specialty, 
with the following definition:100 
Pediatric pharmacy practice specializes in the delivery of patient care services by 
pharmacists that ensures the safe and effective use of medications for all children from 
neonates through adolescents. The practice includes direct patient care for children, often 
provided through interprofessional healthcare teams, as well as advocacy and education for 
children and their families, wellness and health promotion, and activities that advance 
knowledge and skills in pediatric pharmacy.100 
At a global level, the International Pharmaceutical Federation (FIP) has defined specific roles for 
pharmacists in improving newborn and child health, as part of the United Nations Global Strategy 
for Women’s and Children’s Health.3  This report listed specific pharmacist strategies to improve 
child health such as use of child-resistant packaging to reduce risk of poisoning; provision of 
appropriate formulations suitable for children when not available on the market; advice on effective 
medication administration; and participation in research and development on new formulations for 
children.  Other roles were similar to those seen in adult practice, such as prevention of medication 
misadventure by involvement in the selection of medicines, assistance during ward rounds, review 
of medication orders, input into prescribing decisions, development of protocols and guidelines, 
medication formulation and administration advice, and education of other health practitioners.101 
Individual authors and professional bodies from UK and USA have described quite consistently the 
expertise required of paediatric pharmacists, which include 
• Understanding developmental pharmacokinetics and pharmacodynamics; 
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• Determining and calculating doses; 
• Administering medications to children effectively and safely;  
• Modifying available preparations to make them suitable for children;  
• Appropriately using unlicensed and off-label medicines.102-104   
Specific challenges included lack of information sources; lack of suitable formulations; medication 
errors; monitoring of safety and effectiveness; and effective communication with children and 
families.102-105  
Evolving roles for paediatric pharmacists include the application of pharmacogenomics in children.  
This presents technical, ethical and interpretive challenges that require the expertise of pharmacists 
with specialized training in paediatrics.106  Other developing roles for paediatric pharmacists 
include improving the transition between hospital and the home, and enabling children to have care 
at home where possible.  Examples described in Australia include involvement in complex care 
outpatient clinics (e.g. Cystic Fibrosis), Home Medicines Reviews, and Hospital in the Home.107 
These current and evolving roles, and the knowledge and skills required, are largely at a general or 
foundation level of practice rather than at an advanced level.  A definition of the requirements of an 
advanced paediatric pharmacist is still in its infancy, and is described further in the following 
sections. 
1.2.7 What does Advanced Practice in Pharmacy mean? 
The concept of advanced practice in pharmacy has been debated for some time, whether in fact this 
role can be defined, whether it is good for the profession, whether it makes a difference to patients, 
and whether it can be justified as comparable to advanced roles in other professions.2  The 
definition of advanced practice has been uncertain, although Brook and Rushforth made the 
observation in 2011 that ‘advanced practice is a set of attributes which may be ascribed to any 
professional, practising at what might be defined at a senior or expert level’.108  In contrast to the 
poorly defined experience in pharmacy, other professions have had a more defined pathway to 
advanced practice, such as the longstanding pathway to consultant for the medical profession, and 
more recently the option for nursing colleagues to gain endorsement as a nurse practitioner.109,110   
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After some years of discussion and debate amongst the profession, there now appears to be 
consensus internationally among the pharmacy profession that recognition of advanced roles in 
pharmacy, and their contribution to patient care, is warranted: for the individual, for the profession, 
and for our patients.1,2,111-113  The impact on specialist practice areas such as paediatrics, 
implementation in a smaller country such as Australia, and patient outcomes is still to be 
determined. 
United Kingdom 
The first work in this area was described by Meadows et al in 2004 with the development and 
validation of an advanced and consultant level competency framework (ACLF) by the Competency 
and Development Evaluation Group (CoDEG) in the UK.114  A total of 34 separate competencies 
were identified that were grouped into three levels (foundation, excellent and mastery) and six 
separate clusters of “expert professional practice”; “building working relationships”; “leadership”; 
“management”; “education, training and development”, and “research and evaluation”.  
Subsequent to this work, a finalised Advanced Level Competency Framework was introduced in 
2005,115 which has been used for professional recognition and recruitment purposes for positions in 
the UK designated at advanced or consultant level. This format has been further adapted in the UK 
by individual pharmacy specialty groups such as critical care,116 education and training117 and 
oncology,118 and in some cases endorsed by the corresponding medical colleges.  The framework is 
now incorporated into the RPS Advanced Pharmacy Framework (APF) as a pathway for 
membership of the RPS Faculty as an advanced practice pharmacist.119 
Pharmacists in the UK also have the opportunity to become independent or supplementary 
prescribers as an expansion to the traditional scope of practice of a pharmacist.120,121  This has been 
implemented in some paediatric settings in the UK.122  Pharmacist prescribing is however, 
considered separate to advanced practice. 
United States of America 
 “Advanced practice” is not a term used with the same meaning in the USA as in the UK and 
Australia.  For pharmacists working in academia in the United States, “advanced practice” is 
synonymous with the Advanced Pharmacy Practice Experiences (APPE) offered as a component of 
the final year of the Doctor of Pharmacy (PharmD) program, now the entry level degree for 
pharmacy in the United States.123  For other USA pharmacists, “advanced practice” is synonymous 
with an expanded scope of practice requiring an advanced set of skills or practice, rather than 
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advanced practice itself.  In this context, individual state pharmacy laws permit pharmacists to 
initiate, modify and/or discontinue medication therapy as part of a Collaborative Practice 
Agreement with a supervising physician, in a similar fashion to the collaborative prescribing model 
in the UK.124  Eligibility for these agreements is based on education (e.g. degrees), training (e.g. 
residencies), and credentials (e.g. certification by the Board of Pharmacy Specialties).124   
In the USA, the additional training and formal certification as a specialist pharmacist that many 
pharmacists undertake after registration is analogous to “advanced practice pharmacist” as 
understood in the UK and Australia.  Most pharmacists, particularly those who work in clinical 
roles in hospital, undertake a one to two year residency program after obtaining their PharmD.101  
These residency programs are administered by individual hospitals, which are accredited by the 
American Society of Health-System Pharmacists (ASHP).125  The postgraduate year one residency 
program (PGY1) covers generic clinical and interpersonal skills, with educational outcomes and 
competencies similar to the Australian system for competency-based intern training programs, with 
the addition of a mandatory research project.125,126  The second year program (PGY2) is where 
specialties such as paediatrics are addressed in more detail.127 
Some US pharmacists then undertake Board Certification, available in a range of specialities, 
administered by the Board of Pharmacy Specialities (BPS), and required for many clinical positions 
in the USA.128-130  Board certification is a means by which health practitioners can demonstrate 
clinical competence to the public, employers, third-party payers, and other health practitioners.131  
Certification requires passing an exam consisting of 200 multiple-choice questions developed by 
content experts.128  Recertification is required every seven years which is achieved via a 
recertification exam or approved continuing education.129  BPS is currently developing a specialty 
certification in paediatrics, due to be available in 2015.100  
Australia 
The definition for advanced practice used by the Pharmaceutical Society of Australia and others in 
The National Competency Standards Framework for Pharmacists in Australia 2010 is: 
Advanced Practice is practice that is so significantly different from that achieved at initial 
registration that it warrants recognition by professional peers and the public of the 
expertise of the practitioner and education, training and experience from which that 
capability was derived.132 
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A number of groups within Australia adapted the ACLF from the UK for use in particular 
specialties in recent years.  The first of these was paediatrics, when in 2008 the SHPA Paediatric 
COSP (with funding from Queensland Health) first developed an Advanced Level Framework 
(ALF) in Paediatric Pharmacy based on the 2005 version of the UK ACLF.115,133  By 2011, the 
Paediatric ALF was being used through Queensland public hospitals, there was a commitment from 
other states to implement in their local jurisdictions, and the content was integrated into formal and 
informal postgraduate training.134,135  Similar work was undertaken for cancer care,136 emergency 
medicine,137 cardiology,138 infectious diseases,139 and across the range of specialties of one health 
service network.140 
Following on from the work by individual specialty groups, a profession-wide collaboration of 
pharmacy organisations formed the “Advanced Pharmacy Practice Framework Steering 
Committee” in 2011.  This group developed the Advanced Pharmacy Practice Framework, based on 
the UK ACLF and mapped to the existing Australian National Competency Standards 
Framework.141 The Pharmacy Board of Australia endorsed this framework in 2012.142  
Although this work is progressing rapidly, there are still aspects to be defined regarding how these 
frameworks will be used in practice for Australian pharmacists (particularly in specialist areas such 
as paediatrics) and how pharmacists will be evaluated against the frameworks.  It is also as yet 
unproven what benefit an advanced pharmacy practitioner brings to patient care, safety and 
outcomes, in comparison to a general level pharmacist. 
1.2.8 How do other health professions develop and assess advanced 
practice? 
Medical Profession 
For medical officers in Australia, development as a specialist is via vocational training, coordinated 
by a specialist medical college approved by the Australian Medical Council.  After an initial 2-3 
years of postgraduate experience, the medical official enters an accredited specialist or subspecialist 
training program, commonly taking 7 years to complete.110,113  Slightly different processes for 
vocational training and assessment are used by the different medical colleges, such as the Royal 
Australasian College of Physicians, Royal Australian College of General Practitioners and Royal 
Australasian College of Surgeons.  However, each involves supervised practice in the workplace 
coordinated by medical educators, and a requirement to pass a suite of examinations and work 
based assessments via direct observation of practice.113 
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Specialist paediatric training follows the same pathway to that of general physicians and 
coordinated by the Royal Australasian College of Physicians (RACP).  After medical qualification 
and initial postgraduate workplace experience, the paediatrician enters basic training which lasts a 
minimum of three years, and then undertakes an advanced training program, also a minimum of 
three years in duration.143  Completion of this training allows the paediatrician to become a Fellow 
of the Royal Australasian College of Physicians and be employed as a “consultant”.   
Similar processes exist in other countries:  with a requirement for high stakes assessment at various 
points along the journey, the ongoing use of viva voce and examinations, with an increasing use of 
work based assessments. 
In addition to formalised training via the professional colleges, most teaching hospitals offer 
specific training in child health, with some resulting in formal qualifications.  The Women’s and 
Children’s Hospital in Adelaide offers a Diploma in Child Health for medical officers144 and the 
Children’s Hospital at Westmead offers a Diploma in Child Health for doctors and nurses in 
conjunction with the University of Sydney.145 
Nursing Profession 
Similar to pharmacy, there have been many different terms used internationally for nurses who have 
developed additional skills over time and those who have taken on roles with an extended scope of 
practice.  Terms such as nurse practitioner, nurse consultant, advanced nurse practitioner have quite 
different meanings dependant on the institution and country of work.146  Although clarification of 
titles is important, the requirement for standardised assessment formal recognition or endorsement 
has been acknowledged in many settings.108   
In Australia, a set of competencies for an Advanced Practice Nurse has been described by 
professional groups with a system of credentialing being currently investigated, although this title is 
not currently linked to specific positions or qualifications.147  In contrast, the defined endorsed title 
of Nurse Practitioner can be obtained currently by registered nurses in Australia via a process of 
postgraduate qualifications at a Masters level, experience and portfolio submission.109  However, 
the positions of Nurse Practitioner involve extended and defined scope of practice and are specific 
positions within each institution.   
Registered nurses and nurse practitioners work in paediatric healthcare settings, however there is no 
specific additional paediatric qualification as a nurse practitioner in Australia.  Paediatric and child 
health training is available for nurses from a variety of universities across Australia at a 
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Postgraduate Certificate, Diploma and Masters Level.  In addition, the Princess Margaret Hospital 
itself offers a Postgraduate Certificate of Paediatric Nursing.   The Australian College of Children 
and Young People’s Nurses offer online learning for paediatric nurses and have produced 
Competencies for the Specialist Paediatric and Child Health Nurse.148 
Physiotherapists 
Physiotherapists have a path to acknowledgement of advanced practice in Australia via a training 
program and assessments administered by the Australian College of Physiotherapists.  Attainment 
of “Titled APA Physiotherapist” can be via completion of a Masters by coursework and two years 
experience or an experiential pathway including five years experience and assessment of a portfolio 
and examination.149  Further progression to the title of “Specialist Physiotherapist” and “Fellow of 
the Australian College of Physiotherapists” requires completion of a two-year training program in a 
speciality area, submission of a portfolio (including participation in education of others, case 
presentations and at least one significant research project), and demonstration of specialist-level 
skills via final examination.149 
Medical, nursing and physiotherapy professions have all developed formal recognition methods for 
practitioners operating at an advanced level.  The evaluation programs have in common a 
combination of assessment methods.  They all include a requirement for completion of a formal 
training program (although experiential learning is recognised in nursing) and comprehensive 
portfolio review in combination with a variety of formative and summative assessments. 
1.2.9 How do we currently develop advanced practice in paediatric 
pharmacists? 
International paediatric pharmacy networks 
There are a number of paediatric pharmacist organisations in different countries, which have 
focused on networking opportunities and the training of pharmacists new to paediatrics.150  The 
Pediatric Pharmacy Advocacy Group (PPAG) based in the United States is an ’international non-
profit professional association representing the interests of pediatric pharmacists and their 
patients’.150  This group began informally in 1979, officially formed the Pharmacy Directors of 
Pediatric Hospitals in 1985 and was later renamed as the Pediatric Pharmacy Advocacy Group 
(PPAG).151  PPAG has been working closely with the Board of Pharmacy Specialties to develop the 
Certification in Paediatric Pharmacy Specialty due to be available in 2015.100 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 42 
The Neonatal and Paediatric Pharmacists Group (NPPG) was established in the UK in 1994 with 
‘the aim of improving the care of neonates, infants and children by advancing the personal 
development of pharmacists and the provision of quality pharmacy services in relation to practice, 
research and audit, education and training, communication and advice’.152  NPPG has worked 
closely with the Royal Pharmaceutical Society to develop the Professional Curriculum for Neonatal 
and Paediatric Care, linked to membership of the RPS Faculty as an advanced practitioner.153 
Australian paediatric pharmacy networks 
Paediatric pharmacy has been slow to develop in Australia as a recognized speciality and little has 
been published on the role of Australian paediatric pharmacists.  The first networking group was the 
Australian Paediatric Hospital Pharmacists Group, officially formed in 1993, and now renamed as 
the Australasian Paediatric Hospital Pharmacists Forum.  This group has representatives from 
paediatric specific and mixed adult and paediatric sites in Australia and New Zealand.  It is active in 
networking and strategic planning at a high level but is not specifically involved in professional 
development.99 
In 1999 an email network for Australasian paediatric pharmacists (“Paedpharm”) was launched, 
hosted by the University of Otago, to support hospital pharmacists working in paediatrics. This 
network provides a valuable avenue for queries, formulates therapeutic guidelines and shares 
information.  However, it again has no specific responsibilities for professional development.154,155 
In 2002, The Society of Hospital Pharmacists of Australia (SHPA) introduced a new Committee of 
Specialty Practice (COSP) in Paediatrics with representatives from paediatric hospitals from each 
state.  The COSP’s role has been coordination of educational activities (e.g. seminars and 
workshops) on behalf of the society, and to comment on statements and guidelines produced by the 
society with respect to paediatric content and applicability.99 
Paediatric Pharmacy training 
Pesaturo et al in 2008 reported that ‘each year, many pharmacy students and new practitioners 
embark into one of the more feared rotations of the advanced pharmacy practice curriculum: 
pediatrics’.103  This fear was thought to stem from unfamiliarity due to the limited paediatric 
content in undergraduate teaching.  This opinion was reinforced in research from New Jersey, 
which reported that many pharmacists had described being uncomfortable with medication orders 
for the paediatric population, however confidence and competency increased significantly after a 
series of targeted educational lectures.156  A survey in 2003 of 948 practicing pharmacists in Indiana 
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found that, although 94% of them dispensed prescriptions for adolescents, 57% felt inadequately 
trained in adolescent-specific healthcare issues.157  Another study from Michigan found that less 
than half of the pharmacists surveyed had received any formal training in paediatrics, although 55% 
of the respondents estimated that children comprised at least 20% of their patients.158  In this study, 
respondents with formal training in paediatrics were more likely to believe that they have the 
knowledge and expertise to make recommendations in paediatric health issues.158  Likewise in a 
study from the UK, the majority of community pharmacists had been asked to sell off-label 
products for children; underestimated the level of off-label prescribing in paediatrics; and had 
developed their awareness via work experience rather than by undergraduate or postgraduate 
training or professional development.159 
Most pharmacists will be caring for children of all ages regularly during their career.  However, a 
number of researchers have expressed concern regarding the lack of paediatric training for 
pharmacists.  Research beginning over a decade ago in North America found that only 67% of 
pharmacy colleges in the USA included paediatrics in their curriculum, accounting for an average 
of 16.7 hours.160  Similar results were found in Canada with only 14.7 hours of paediatric content in 
undergraduate pharmacy programs.160,161  Subsequent to these studies, North American researchers 
and professional groups recommended an increase in volume and quality of didactic training and 
postgraduate placements in paediatrics at an undergraduate level, and increase in opportunities for 
postgraduate training.105,158  This has had some success: follow-up research in 2014 found that 94% 
of USA pharmacy schools now include paediatric content, with an average of 21.9 contact hours.162  
Similar analysis of paediatric pharmacy training in Australia has not been undertaken.  Nevertheless 
it is expected to face similar challenges, since there are no formal recommendations to guide 
paediatric content.   
There is limited availability of formal training in paediatric pharmacy, in Australia and 
internationally.  Informal seminars, workshops, conferences, and some online educational 
opportunities are available; however, these vary in content and quality.  Paediatric residency 
training, as available in North America, is not available in Australia.  The BPS Certification in 
Paediatric Pharmacy will be available to pharmacists outside of the United States (including 
Australia), but the certification does not itself involve professional development.   
The limited paediatric pharmacy training opportunities are limited to graduate or general level 
rather than aiming to develop advanced practice in paediatric pharmacy.  The next step of 
assessment of advanced practice is an additional topic addressed in the next chapter.  
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1.3 Rationale and Significance 
Despite a large amount of work in recent years to improve knowledge of medication safety issues in 
children and the skills and knowledge required of health practitioners to improve safety and quality, 
there are significant gaps remaining.  It is not yet fully understood what the most effective strategies 
are to improve medication safety, or what differences may be required for the paediatric 
environment.  The skills and knowledge required of pharmacists at different stages of their career in 
paediatrics have not been defined, particularly those required to achieve the improvements in 
medication safety.  How to best assess these skills is also not clear.  These issues will be 
investigated further in this research project. 
1.4 Author Background 
At the time of commencing this research project, the author had 20 years experience in pharmacy, 
predominantly in a tertiary paediatric hospital.  The author had completed formal postgraduate 
training in child health (Postgraduate Diploma in Health Studies, Community Child and Adolescent 
Health), and had been involved in teaching paediatric pharmacy and medication safety at 
workshops, seminars, and at a formal undergraduate and postgraduate level.   This experience led to 
the project to develop and then implement the Paediatric Advanced Level Framework (ALF) in 
Australia in 2008.133-135  Thus, the author brought to the research project the practical experience 
associated with working and teaching in a paediatric hospital pharmacy setting, and familiarity with 
the advanced practice concept. 
These experiences, whilst providing valuable understanding and insight into the topics, may have 
introduced an element of bias into the research design and findings.  Hence, an early step in the 
project was to undertake a series of focus groups within the profession to determine existing 
perceptions and beliefs regarding advanced practice.  This informed the design of subsequent 
projects.  In addition, quality assurance of all coding and analysis was undertaken with a second 
independent researcher rating or coding each of the data sets.  A statistician ensured that valid 
analytical techniques were used. 
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1.5 Conclusion 
The areas of increased risk described above indicate the need for paediatric health practitioners to 
improve the safety and effectiveness of medication use at an individual and population level.  It is 
also becoming apparent that additional skills are required for health practitioners to effectively 
contribute to the targeted and system-wide interventions required.  These interventions may include 
assessment of clinical competencies such as medication calculations, advocacy for research in 
children’s medications, change in practice to improve safety, and effective education strategies that 
truly change practice.  These types of interventions require different and more advanced skills to 
those of a general level pharmacist. 
There is currently little support for pharmacists at an undergraduate or postgraduate level to develop 
the knowledge and skills required to provide pharmaceutical care for children, at a general or 
advanced level.  This is despite children making up a large proportion of the population in all 
countries.  An increase in networking across professional organisations and international boundaries 
may enable sharing of specialised resources in the future.  The option of a residency model for 
training in the USA may not be immediately suitable for use in Australia; however, sharing 
electronic learning resources, access to the BPS certification in paediatrics from 2015, and sharing 
the practice evaluation techniques being piloted in the UK and Australia may offer a way forward.    
This research project investigates some of these options, related to adverse medication event 
identification and prevention, and development and assessment of advanced pharmacy practitioners.  
The next two chapters review the literature regarding these topics. 
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2 Chapter Two: Literature Review – Adverse Drug Events 
2.1 Introduction 
In Chapter 1, the background to: medication risks in paediatrics; advanced pharmacy practice; and 
the existing opportunities for development of paediatric pharmacists was described.  In this chapter 
the current literature regarding adverse medication event measurement and analysis; interventions 
to improve safety; and methods for assessment of advanced practice in health practitioners is 
investigated more deeply. 
2.2 How do we identify and measure adverse medication events and 
medication errors? 
The case identification methods used to identify medication related incidents, adverse medication 
events and medication errors vary widely, and have a significant effect on the rate obtained.  
Similarly, the denominator used also varies widely, from per medication order, or per hospital 
admission.  This variation in case identification and denominator makes it difficult to compare rates 
between different research studies.  The research is also very focused on the hospital environment 
with very limited research on medication errors or events in the community setting. 
2.2.1 Spontaneous or Voluntary Reporting (Incident Reports) 
Spontaneous reporting requires the person who witnessed, committed or discovered an error to 
document the event in a report, commonly referred to as an ‘incident report’.  It is generally 
accepted that spontaneous reporting systems grossly underestimate the overall rate of medication 
errors (estimated from 0.1 to 10% of all adverse events or errors), particularly medication 
administration errors.48,57,163,164   
Low levels of reporting may be due to multiple factors including a range of personal, practical and 
cultural barriers, many of which are possible to overcome at a system level.  A systematic review 
undertaken in 2014, found that an atmosphere of shame and blame, a fear of punishment, complex 
policies and procedures, and a lack of support to learn from errors were significant barriers to 
physician reporting.165  An Australian study investigating behavioural intent in health practitioners 
found that the strongest factors influencing safety behaviours were practitioners’ beliefs that the 
behaviour will lead to improved patient safety, and the patient safety related behaviours of their 
professional peers.166   
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 47 
Other limitations of voluntary reports are that the data collected are thought to be subject to the 
inferences drawn by the reporter and therefore may be less objective than other methods such as 
direct observation.163   
The advantages of using incident reports to review causes of incidents are the relatively low cost 
and the fact that the data relative to a particular medication error has already been gathered.  As 
described above, this method works best if the organisation has a non-punitive culture of review of 
incidents gathered.57,163,167  More recently, research is moving towards use of voluntary reports in 
combination with other collection strategies such as trigger tools, as discussed further below.20,168 
2.2.2 Interventions (Pharmacist or Nursing) 
Nurses and pharmacists frequently make interventions to correct medication orders before they 
reach the patient (near-misses).  They also identify and correct errors that may have already 
occurred.169,170  These may be recorded as part of standard incident reports (ie voluntary reporting 
as above) or recorded in a separate database.  These reports have limitations similar to those of 
incident reports.  Like incident reports, intervention reports tend to underestimate the rate of errors, 
as pharmacists (and nurses) will often correct errors without informing the doctor and without 
noting the error in the patient file or a formal report.171   Research using surveys of pharmacists by 
Williams et al identified the barriers to reporting incidents or interventions to include the 
cumbersome and time consuming nature of the reporting system, the severity of patient harm, 
concerns about harming inter-professional relationships, and whether they had previously witnessed 
positive feedback and system change following an error.172  A similar survey by Patterson et al 
found that communication openness of the individual pharmacist and their environment increased 
the likelihood of error reporting, indicating the need for hospitals to institute non-punitive 
environments and cultures that maximize trust and open communication.173  These results 
correspond closely to the findings listed above with incident reporting and other health 
practitioners.166 
Despite these barriers, and the limitations of pharmacist intervention reporting, the combination of 
incident reports with health practitioner interventions into a single reporting system is considered a 
valuable method to identify faulty processes.170 
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2.2.3 Chart Review 
Chart review involves researchers reviewing charts, prescriptions and computer records to identify 
medication errors.  The data collectors look for specific signals or triggers, such as a sudden change 
in patient condition, transfer to a critical care unit, changes or clarifications in physician orders, and 
orders for antidotes.30  Chart review is commonly performed retrospectively, but can be done 
prospectively with daily review of charts.  
Chart review has been shown to be a valuable method for detection of errors in medication ordering 
and adverse medication events, although it relies heavily on the clinical skills of the researchers to 
detect the error.30,163  Chart review has been found to be only marginally effective in detecting 
errors in medication administration and monitoring.30,48  It was a less expensive method of case 
identification than direct observation, but its lower rate of accuracy made it undesirable for 
measuring the frequency of errors.163   
Overall, chart review has a proven track record as a method for detecting errors in medication 
ordering, and actual AMEs, but less effective to identify administration errors, and is time intensive 
and costly.24,25,30 
2.2.4 Observation 
This involves researchers observing health practitioners undertaking their duties.  It has been used 
successfully since the early 1960’s, with validity reported to be superior to other methods.163  
Observation will identify some errors in medication ordering, but it is particularly valuable in 
detecting errors in preparation and administration of medicines, and is considered more efficient 
and accurate than reviewing charts and incident reports.30,163,174 
A major concern with the observation method is the potential effect of the researcher on the 
individuals under observation, although most studies involve some method of disguise of the 
observer to minimize the impact of the observational effect.48,175,176  It is also expensive, and 
requires specific training for data collectors.163 
2.2.5 Trigger Tools 
Various “trigger tools” have been used, particularly in recent years, to identify adverse medication 
events, with a comprehensive guideline on methodology published by the Institute of Healthcare 
Improvement (IHI).20  Specific “rules” or “triggers” to identify an AME can be determined, and 
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charts, laboratory, prescription, and administrative data can all be reviewed to identify adverse 
medication events.19  Two main systems are used:  manual review of a sample of charts on a regular 
basis, such as recommended by IHI, or analysis of all admissions using an automated or electronic 
trigger identification. The overall number of identified cases can be used to identify trends over 
time, or individual issues can be investigated in more detail as required.    
Automatic detection of events requires an electronic medical record to scan for triggers using a 
predetermined algorithm or set of rules.20,177-179  Early research found these tools to be very 
effective at detecting renal failure, diarrhoea and hypoglycaemia, but not as good as manual chart 
review at detecting symptom-related adverse medication events such as altered mental status.180   
There have been varied results more recently on the efficiency of trigger tools to identify adverse 
medication events.  Franklin et el found that, of the total prescribing errors identified using a range 
of methods (including prospective chart review by a pharmacist, retrospective chart review by a 
researcher, spontaneous reporting and the trigger tool), the trigger tool identified less than one 
percent of the total errors in the study.181  The Franklin study was limited in that the trigger tool was 
used after the retrospective chart review, and counted only additional events identified, only 
identified errors not harm, and was associated with many false positives.181  It was also in the adult 
hospital setting and did not include paediatric patients.181 
Forster et al in 2011 undertook a systematic review to evaluate the accuracy of electronic tools in 
identifying AMEs, and found that detection rules were variable, definitions were variable, rules 
were often not validated against a “gold standard” and few of the detection algorithms considered 
clinical priorities.179  Importantly, the review by Forster et al excluded research in the paediatric 
setting, however these limitations are also likely to exist with information systems used for ADE 
detection in paediatrics.179  In contrast, automated adverse event detection was found to have 
positive effects on quality of care and cost-effectiveness by Lemon et al in the paediatric setting.178 
Manual chart review using the IHI sampling method has had more positive success. Takata et al 
successfully customized the existing IHI set of adult ADE trigger tools (described above) for use in 
the paediatric population, which was later successfully used by Tham et al in 13 paediatric hospitals 
in the United States.182,183  Two recent papers from Cincinnati reviewed adverse event identification 
using the IHI Global Trigger Tool successfully in paediatrics, although there was a need for 
additional triggers in paediatrics for areas such as phlebitis from medication administration.168,184  
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These results indicate that trigger tools have potential for use in identification of adverse medication 
events in children.  The most cost-effective on an ongoing basis may be automated tools, however 
sophisticated health information systems are required for these to work effectively, and detection 
rules appropriate for paediatrics need to be carefully defined.  Manual chart review using a 
sampling approach as suggested by IHI, using the paediatric tool developed by Takata et al, may be 
the best strategy for long term quality improvement measures; however, it is time intensive and as a 
sampling strategy is unlikely to identify uncommon events.20,182 
2.2.6 Administrative or Coding Data 
The International Classification of Diseases 10th revision (ICD-10) is used to code admission data 
for administrative purposes, primarily for reimbursement and legal purposes.  These codes have 
been used increasingly in recent years to identify large scale (e.g. population level) rates of adverse 
medication events.185,186  Their use for clinical purposes has limitations, due to variable accuracy, 
timeliness and a tendency to “code creep” to higher paid diagnostic groups.187  ICD-10 coding also 
does not identify near miss events, or errors that have not caused harm.185   
A systematic review by Hohl et al in 2013 found substantial variability in the methods and codes 
used to identify AMEs using administrative coding data with the majority of researchers using the 
external injury codes Y40.0-59.9 (“drugs, medicaments and biological substances causing adverse 
effects in therapeutic use”).188  ! 
Honigman et al found the positive predictive value of ICD codes for AMEs in outpatients to be very 
low (about 2%) and is even lower for medication errors.19,189  An adult study in Slovenia also found 
that although adverse drug reactions were recorded in the medical record, few were coded via ICD-
10, and none via voluntary reporting.190  Despite these limitations, administrative (ICD) coding may 
be a cost effective method of high-level or population based case identification, although chart 
review of the identified cases is likely to be required for deeper analysis of event characteristics. 
2.2.7 Comparison of Methods 
An early study by Jha et al, comparing voluntary reporting, computer based AME identification and 
chart review found that chart review identified 65% of all AMEs, computer based monitoring 45%, 
and voluntary reports only 4%.191  The overlap between chart reviewing, computer based triggers 
and self-reports was only 1%, hence a combination of methods is valuable.19,191  Flynn et al found 
direct observation was superior to chart review or incident reports in identifying administration 
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errors.163  Similar results were reported by Franklin et al, who found that prospective and 
retrospective chart review, trigger tool and spontaneous reporting identified different prescribing 
errors, with prospective review by a pharmacist and retrospective chart review by a researcher the 
most effective.181  Hence a combination of methods may be required to identify the true 
effectiveness of different interventions.  Nwulu et al investigated two specific electronic triggers 
(high INR and the use of naloxone) in the UK adult setting and found a high positive predictive 
value for naloxone but not for elevated INR.192  This method identified many more adverse events 
than reported via the voluntary reporting system; however, it required a secondary manual review of 
the chart to avoid false positives.192  Christiaans-Dingelhoff et al from the Netherlands compared 
patient reports and incident reports with manual chart review to identify adverse events (not just 
medication related) and found that only 3.6% of the events identified via chart review were also 
reported via one of the reporting systems.  However, many events reported by health professionals 
were not identified via chart review.193  Snyder et al reviewed eight different methods of voluntary 
and non-voluntary case identification methods and found that a 5% sample of charts identified the 
largest number of medication safety events, (34%) followed by pharmacist surveillance (27%), 
automated alerts (24%, via drug use or laboratory values) and then incident reports 11%.164 
Mangino170 and Davis57 recommended that for ongoing quality assurance for institutions (rather 
than for research purposes), incident reports should be combined with practitioner interventions to 
provide a valuable database for analyzing faulty processes.57,170  Likewise Olsen et al found little 
overlap between adverse events identified via retrospective chart review, pharmacist surveillance or 
incident reports and therefore recommended that hospitals use a combination of methods to identify 
adverse events and potential adverse events.194  As discussed above, it is important to overcome the 
practical and cultural barriers to spontaneous reporting.  In the future, these information rich 
‘human’ reports should be able to be combined with increasingly sophisticated automated electronic 
detection systems, to enable real time monitoring of adverse medication events, with high 
sensitivity and specificity.  
2.3 How can health practitioners most effectively improve safety and 
the quality use of medicines? 
Many interventions to reduce the risk of adverse medication events have been proposed and 
investigated over the past decade, with varying success.  In 2003, the American Academy of 
Pediatrics produced the comprehensive policy statement Prevention of Medication Errors in the 
Pediatric Inpatient Setting.96  The Institute for Healthcare Improvement, Institute for Safe 
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Medication Practices and Australian Commission on Safety and Quality in Health Care have also 
recommended many strategies to improve safety, ranging from hospital-wide to health-practitioner-
specific.41  These strategies vary in their complexity, efficacy and cost, and not all have been 
demonstrated to be effective in paediatrics.  Some of these are summarised below. 
2.3.1 Education 
Knowledge and training have been found to be relevant factors in causation of errors, and 
implementation of educational solutions to reduce medication errors has proven to be effective and 
is considered essential for all health care providers.55,96,97,195  Education can include many different 
methods, such as formal lectures, self-learning programs, sharing learning from clinical incidents at 
meetings, one-on-one review of medication errors and educational posters.97   
The importance of specific paediatric training in prescribing was highlighted by the study by Isa et 
al which found that one-third of GP trainees from the UK did not undertake any paediatric specific 
training prior to starting work as a GP, and the majority of GP trainees believed that their 
undergraduate and postgraduate training in paediatric therapeutics was insufficient.196  This 
reinforces the need for support for paediatric health practitioners in the community as well as 
hospital environments. 
Many researchers have shown the benefit of education on performance, especially in the area of 
prescribing.197  However, only a small number of studies have been undertaken in paediatrics.  
Davey et al found a reduction in paediatric prescribing errors from junior doctors after a prescribing 
tutorial, particularly if common incidents and interventions are included.198  Simpson et el found a 
reduction in prescribing errors in the neonatal intensive care unit after introduction of a dose 
calculation competency assessment and a pharmacist-led daily review of medications.65  Conroy 
and Carroll used these two studies and their own experiences to recommend a practical educational 
program for paediatric prescribers, using a combination of interactive lectures and practical 
sessions; in small groups or as part of a teaching ward round or workshop; using real cases where 
possible; and using a structured approach covering key paediatric points.199 
A more recent study from Philadelphia found that personalised performance feedback of prescribing 
errors to prescribers reduced narcotic prescribing errors in the neonatal intensive care unit, but not 
antibiotic prescribing errors.200 
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A focused effort on education can show long-term improvements.  A longitudinal study by Kidd et 
al from the UK found an improvement in paediatric prescribing competency over time, thought to 
be due to a combination of local and national measures to raise awareness of the importance of 
accurate prescribing.201  Gazarian and Graudins recently reported long term reduction in adverse 
medication events of greater than 50% in an Australian tertiary paediatric hospital via use of 
multifaceted interventions including guideline development and dissemination, intensive interactive 
education, broad clinician involvement and continuous feedback of results to stakeholders.37 
However, not all research has shown positive effects.  Kozer et al in a small study from Canada 
found no improvement in paediatric prescribing errors after attendance at a tutorial and completion 
of a written test.202  
A systematic review undertaken in 2013 of educational interventions to improve prescribing 
competency (across all settings) found that tutorials and educational programmes improved 
prescribing competency, and personalised feedback letters could be used effectively with limited 
cost.203  The most effective education strategies were incorporated into multifaceted interventions 
including teamwork, a strong safety culture and a systems based approach.203  Another systematic 
review into educational interventions to change behaviour of new prescribers found that although 
72% of educational interventions were considered effective, results from the same type of 
intervention varied depending on the setting.204   
Conroy and Koren both made the recommendation that all personnel involved with medicines 
should undergo a written test to prove their computational skills and knowledge of appropriate 
doses for age groups, and if the test is failed they should be retrained before being permitted to 
prescribe or administer medications.63,199  This would be an effective method of ensuring 
knowledge and computational ability, however would be a significant culture change for many 
organisations and could be difficult to operationalize at an institutional level.   
There is also significant potential for the use of e-learning programs to develop medication related 
competencies, particularly prescribing.205  Improvement in dose calculation skills has been seen in 
medical students with the use of an online tool to develop and assess dose calculation skills.206  This 
type of program could have potential uses for other health practitioners required to calculate doses, 
such as pharmacists and nurses.  E-learning programs tend to be very costly to produce initially, but 
do show promise for the future, and are increasingly used in postgraduate pharmacy teaching as 
well as for prescribing. 
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The research discussed above largely deals with education to improve doctors’ prescribing 
competency, with little evidence of educational strategies focused on improving pharmacists’ 
competencies in safe and optimal medication use, other than the use of the General Level 
Framework to develop and evaluate clinical pharmacy skills, as discussed further below.207-211  It is 
also important to recognise that skills in providing effective education and training may in fact be 
advanced level skills, particularly when designing courses of study. 
There needs to be some caution with evaluation of effectiveness of education strategies, as 
demonstrating competence indicates that the practitioner “knows how” to do the task, which may 
not always correlate with actual performance.  True change in behaviour may require significantly 
more than merely increasing knowledge and skills. 
2.3.2 Clinical Pharmacists 
Directly involving pharmacists in patient care – particularly via their incorporation into 
multidisciplinary teams – is a highly effective strategy to reduce errors and optimise medication use 
in both adult and paediatric care.96,98,212  The earliest studies of paediatric prescribing errors 
highlighted the positive impacts of a paediatric pharmacist:  
Pharmacists trained in pediatric pharmacotherapy have a significant impact on the 
provision of safe and effective drug therapy for pediatric patients…The greatest potential 
value of such services appears to be in preventing harm, minimizing unnecessary costs 
arising from extended hospital stay and from additional laboratory studies or therapy, and 
minimizing potential liability that may result from drug errors.42 
The American Academy of Paediatrics recommended ‘review of the original drug order by 
appropriate pharmacy and nursing staff before dispensing and before administration’ as an 
important safety strategy.96 
The published research on the impact of paediatric pharmacists on error reduction, quality use of 
medicines and economics is discussed further below. 
2.3.3 Communication 
Many researchers and professional groups have recommended improved communication between 
physicians, nurses and pharmacists as a strategy to improve all aspects of patient safety, including 
medication safety.55,96  Fortescue et al found that improved communication among physicians, 
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nurses and pharmacists could prevent 86% of harmful medication errors.212  Kaushal et al found that 
improved communication between providers and parents and between pharmacists and parents were 
the most potentially effective error preventive strategies in the paediatric ambulatory setting.213  
Associated research in recent years has been undertaken to improve clinical handover and 
identification of the deteriorating patient, including in the paediatric setting.18 
2.3.4 Incident Management and Medication Safety Teams 
Incident reports (also called spontaneous or voluntary reports) were discussed above under case 
identification methods.  As a method of improving safety, the use of continuous incident monitoring 
using a non-punitive approach, and quality improvement through system change has been shown to 
be effective in prevention of errors and is recommended by many groups and researchers.65,96,214,215  
A number of studies have demonstrated the increase in incident reporting that occurs once health 
practitioners are engaged in the process, and can see the benefits and system improvements 
occurring.171,214,216-218  Consequently, trends in incident reporting need to be interpreted carefully as 
increased rates can imply improved safety culture, rather than a true increased rate of error. 
It is also acknowledged that incident reporting systems capture only a small proportion of adverse 
events, with a recent analysis showing that only 14% of adverse events in US hospitals are 
reported.219  There are a number of barriers to incident reporting:  knowledge of what and when to 
report; the effort required to complete a report; the personal fears about the consequences of 
reporting; and the perceived lack of feedback or positive change following an error report, are 
consistently reported as barriers.172   
Medication safety teams or committees have been integral to the success of incident reporting 
systems, and recommended by most safety and quality groups internationally.  The American 
Academy of Paediatrics recommended creation of a paediatric multidisciplinary safety committee 
that reports to the hospital as a productive strategy to ensure cross-communication on safety issues 
for children.81  This was used successfully in an Australian paediatric hospital where a >50% 
reduction in total ADEs was achieved using a combination of strategies including a motivated 
multidisciplinary medication safety team to produce guidelines, early clinician engagement, 
education of health staff, and intermittent in-depth monitoring of adverse events with continual 
feedback to stakeholders.37  Similarly, recent paediatric work from Cincinnati showed a significant 
reduction in serious safety events after introduction of a range of system-wide initiatives; including 
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improving safety governance and culture, investigating events in detail and sharing lessons 
learned.168 
It is clear that medication safety teams need to do more than merely discuss incident reports.  
Identification of underlying risk factors, effective change management, incorporation of lessons 
learned into education at all levels, sharing results, and staff engagement, are all required.  These 
activities require skills in leadership, education, risk management, communication, and teamwork, 
as well as knowledge of medications and how they work.  Hence, being an effective member of a 
medication safety team requires significant advanced skills. 
2.3.5 Computerised Physician Order Entry (CPOE) 
Computerised Physician Order Entry (or CPOE) has been shown to reduce errors and harm in 
hospitalized patients, particularly in the medication ordering process, and is now recommended by 
many professional groups.96,220  In paediatric patients where calculations are often more complex, 
electronic prescribing can potentially reduce the number of prescribing errors by ensuring that 
results are legible and in a standard format.  More complex CPOE systems with clinical decision 
support (CDDS) can prevent some prescribing errors by directing doctors to the correct route and 
age-specific dose, warning them if current laboratory values indicate that the medication or regimen 
would be inappropriate, and alerting them to allergies and interactions.31,51  However, even with 
clinical decision support CPOE will not eliminate all prescribing errors.  In fact many studies have 
shown that CPOE can generate new problems, such as the omission of new tasks required by the 
system, typographical or editing mistakes, or selection errors from drop-down menus.57   
A recent study from two adult hospitals in Australia, found that electronic prescribing (without a 
full CDDS) introduced new errors, but did prevent more errors than were generated.221  In contrast 
to the generally successful introduction in adult settings, the overall safety improvements seen with 
CPOE in paediatric populations remains controversial.37  Significant reduction in paediatric 
prescribing errors has been demonstrated in some studies, such as by Jani et al in the UK where 
prescribing errors reduced from 2.2% to 1.2% of prescriptions.222  However other studies have 
shown a more modest reduction of 7% in non-intercepted serious medication errors and no change 
in the rate of injury.223  Differences in definitions of error and adverse event make interpretation of 
some studies difficult, and some results have been quite conflicting.  For example, the study by 
Potts et al from the USA shows a reduction in potential AMEs (defined as errors which could result 
in injury) from 2.2% to 1.3% of orders, but medication-prescribing errors (where inadequate 
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information was provided or further interpretation was required) reduced from 30.1 to 0.2 per 100 
medication orders (a reduction of 99.4%).31   
Not all studies have demonstrated a reduction in actual AMEs and mortality.  King et al found a 
reduction in medication errors but not AMEs in a Canadian paediatric hospital.32  Han et al found an 
increase in mortality after CPOE introduction into a intensive care unit in a USA paediatric hospital, 
whereas another USA hospital using the same CPOE system found a non-significant reduction in 
mortality.224,225  A meta-analysis undertaken in 2009 found that CPOE in the paediatric setting was 
associated with a significant decrease in medication prescription errors, but no reduction in AMEs 
or mortality.226   
Although CPOE systems still provide great hope in paediatrics, it is clear that they require high 
quality implementation processes to be successful.  In addition, versions suitable for paediatrics are 
not widely available; the cost is not feasible for many hospitals, particularly those in developing 
countries; and there is a likelihood of introduction of new errors with potential for harm.226,227   
2.3.6 Centralised Intravenous Admixture Services (CIVAS) or Unit Dose 
Dispensing Systems 
In 1985, Buehler et al recommended a ‘centralized preparation and distribution of individual doses 
of medicine by hospital pharmacies’ as an effective method to decrease medication errors.228  These 
services remove the need for bedside drug calculations and often-complex preparation of 
intravenous products by nursing staff, which is particularly useful in the neonatal and paediatric 
setting.  Preparation undertaken in a clean room environment under controlled conditions with 
careful documentation and processes should also result in safer, cleaner, more accurate and 
consistent therapy in comparison to when these are prepared in a ward based environment.  A 
systematic review by Conroy et al in 2007 found four published reports of introduction of a unit 
dose dispensing system with great reduction in medication errors.51  A follow-up study identified 
CIVAS as one of the three most promising interventions to reduce the risk of calculation errors in 
the paediatric setting, alongside double-checking and smart-pump technology.229  It is a commonly 
used approach in the United States of America but is not a strategy used widely used in the UK or 
Australia due to the high set-up and recurrent costs, and different funding models. 
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2.3.7 Other Technology – Smart Pumps and Bar Coding 
 “Smart” infusion pumps have been recommended to decrease the incidence of infusion errors.81  
These pumps provide an alarm and halt the infusion if a programmed dose exceeds the pre-set limits 
set up specifically for the patient population.97  Use of these pumps has resulted in improved 
documentation of medication errors and decreases in calculation and administration errors.51,81 
However, as with the introduction of CPOE described above, new systems such as smart pumps can 
introduce new potential errors and must be appropriate for paediatrics.230,231 
Bar-coding is a point-of-care system where identification bands are compared to medications before 
administration.81  It is designed to validate patient identity, verify actual medications administered, 
assure the correct time of administration and provide safety alerts to prevent medication errors from 
reaching the patient.97  One study found that the use of bar-coding reduced wrong medication errors 
by 76% and missed dose errors by 70%.232  Bar-coding is recommended by the American Academy 
of Pediatrics.96  However Merry and Anderson commented in 2011 that in the paediatric anaesthetic 
area, bar-coding and the use of technology may enhance carefulness, but cannot replace it.215 
2.3.8 Combinations of strategies 
Koren described in 2002 the steady decline in reported medication errors across one paediatric 
hospital after introduction of a computerised prescribing system, removal of hazardous medications 
from clinical areas, and training of paediatric residents.195  This study used voluntary reporting as 
the reporting measure, which is known to be an underrepresentation of the total number of events, 
as discussed above.  Research by Muething et al in a Cincinnati paediatric hospital, described 
above, found that overall serious safety events (not just medication events) decreased from 0.9 to 
0.3 per 10,000 bed days as a result of improvements to patient safety culture, better communication 
of what was learnt from safety events, and governance changes.168  The Cincinnati study used 
trigger tool sampling (the IHI method) with spontaneous and patient reporting.168  Gazarian and 
Graudins reported on a long term decrease of 50% in adverse medication events in a paediatric 
hospital in Sydney, after implementation of guidelines for safe prescribing, standardised medication 
chart, clinician engagement, improved communication, interactive education and data feedback.37  
The Sydney study used chart review and spontaneous reporting as case identification methods.37  
Similar results were found from a group of paediatric hospitals in California after a change package 
of interventions including standardisation of medication ordering, automated dispensing cabinets, 
safe pump use, improvement in safety culture and clinical decision support, with a 42% decrease in 
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total adverse medication events.183  The California study also used the IHI sampling chart review 
trigger tool method.20,183 
These studies all demonstrated the importance of implementing a variety of different safety 
initiatives in paediatric hospital environments.  Case identification methods differed, but all 
included the importance of a strong safety culture.  Most were only recently published, and pre-date 
the commencement of this research project. 
2.4 How can we measure the value of a pharmacist in paediatric health 
care? 
There has been much research undertaken over recent decades to describe the impact of a clinical 
pharmacist on health outcomes for patients; however, much of this has been in adult patients.  There 
has been much less research undertaken to demonstrate similar impact in paediatrics, and none on 
the impact of an advanced practice pharmacist.  Paediatric clinical pharmacy services are now well 
established in many countries, which presents challenges to undertaking research to quantify the 
impact on patient care.  This is particularly the case if comparing the presence of a clinical 
pharmacy service to the absence of such a service, as it would be unethical to withdraw an 
established service for research purposes.  Determining an appropriate method to measure impact 
on patient outcomes remains a challenge; however, some of the methods evaluated are discussed 
below. 
2.4.1 Measuring value using interventions and errors 
Pharmacist interventions and the impact on adverse medication events and errors have been 
discussed above.  Interventions have been the most commonly used method of documenting and 
measuring the impact of clinical pharmacists on patient care in the adult and paediatric 
environment, particularly to measure error reduction.25,55,62,65,212,233  There are varied definitions of 
interventions used by organisations and researchers, which makes comparison of results difficult.  
Some broadly define an intervention as any pharmacist action which results in improved quality use 
of medicines; some require a change in therapy to have been made; some only include errors and 
others include all patient-related activities of pharmacists.  The most common definition presently 
used in Australian hospital pharmacy is by the Society of Hospital Pharmacists of Australia 
(SHPA): ‘any action by a pharmacist that directly resulted in a change to patient management or 
drug therapy’.38  Importantly, this definition does not require an error to have occurred. 
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Many studies have investigated reduction in medication errors in paediatrics.  Fortescue et al in 
2003 reviewed 10,778 medication orders from two US paediatric hospitals.  In this study, 
physicians assessed that 81% of the errors were preventable by ward-based clinical pharmacists.212  
Simpson et al in 2004 found that a pharmacist led clinical review of medications was an effective 
way of reducing medication errors in the neonatal intensive care unit.65  A study by Wang et al of 
16,938 medication orders in 678 children admitted to one large academic hospital in the US found 
that medication errors occurred at a rate of 5.2 per 100 medication orders, and pharmacists 
intercepted 78% of the potentially harmful prescribing errors although none of the administration 
errors.234 
The differences between paediatric and adult safety has been investigated by a number of 
researchers. Higher rates of pharmacist interventions in paediatric wards have been identified in 
comparison to adult wards.  In 1997, Barber et al found that there were more pharmacist 
interventions in UK paediatric wards than there were in any other ward except intensive care.47  
Likewise, a recent study from Spain found that paediatrics had a four fold higher risk of serious 
errors in comparison to the maternity population, and pharmacists made 19 interventions per 1000 
patient days in the paediatric population, versus 16 per 1000 patient days in the maternity 
population.49  Although these two studies were more than a decade apart, and from very different 
health care environments, they both found a significantly increased role for a pharmacist in the 
paediatric setting.  An interesting finding from the study by Barber et al, was that higher grade 
pharmacists have 1.4 times as many interventions as a base grade pharmacist, which implies 
pharmacist with more advanced skills make more interventions to improve patient care.47   
A number of different models of paediatric clinical pharmacy service have been investigated, as 
these can influence the impact on errors.  A study from the USA in 2008 by Kaushal et al found that 
there was a 79% decrease in the rate of serious medication errors in the paediatric ICU after 
introduction of a full-time unit-based clinical pharmacist.233  The same study found that a part-time 
clinical pharmacist in general wards (where attendance at ward rounds was more difficult to 
organise) was less effective at decreasing errors.233  Isaac et al found similar results in a recent small 
study from the UK, where pharmacists frequently used their knowledge of altered medication 
handling (e.g. prematurity or renal impairment) to recommend changes to medication therapy in the 
paediatric intensive care unit.  As expected, the more time the pharmacists spent on the ward, the 
more interventions were made.235  Kaline et al found that including a pharmacist in a new 
multidisciplinary trauma team reduced medication prescribing and administration errors in 
paediatric trauma patients.236 
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The impact of introducing new clinical paediatric pharmacy services was investigated in two recent 
studies from Spain and China.  Fernandez-Llamazares et al from Spain found there were 2.4 
interventions in every 100 medical orders, with potentially fatal errors accounting for just over 2% 
of the prescribing errors.237  They found that interventions by a clinical pharmacist had a major 
impact on reducing prescribing errors, thus improving the quality and safety of care provided.237  A 
follow up study by the same authors in eight hospitals in Spain found an average intervention rate 
of 1.4 per 100 bed days.238  The second study, from Zhang et al, compared 160 paediatric patients 
randomized to either a clinical pharmacy service or a control group in a paediatric hospital in China 
over a four month period.239  In the experimental group the clinical pharmacists attended ward 
rounds, answered questions of physicians and nurses, gave advice on treating patients, checked 
prescriptions and counselled patients at discharge.239  The control group had no clinical pharmacy 
service.  A total of 107 clinical pharmacist interventions were made in the intervention group, and 
of these 31 (29%) were related to error.239  Importantly, interventions by a clinical pharmacist were 
associated with a shorter patient stay and increased patient compliance with medication therapy 
after hospital discharge.239 
The published research into clinical paediatric pharmacist services in Australia is limited.  One 
small single centre study described 3.4 pharmacist interventions per 100 patient bed days with 39% 
of interventions rated as high or very high risk. 213  
The risk of relying merely on “interventions” and indeed “errors”, to determine the impact of a 
pharmacist on patient outcomes is that they usually refer only to a single direct patient interaction 
rather than the contribution by pharmacists to population based care by introduction of system 
improvements, including policies, guidelines and protocols, practice chance and education.  
Pharmacists may instigate significant changes to the system in response to a single patient 
intervention; however, this unlikely to be recorded in the report written soon after the event. 
2.4.2 Measuring economic value 
Studies in the adult population have measured the potential economic benefit of pharmacist 
interventions, with respect to cost savings and cost avoidance.  A systematic review of the 
economic effect of US hospital pharmacists reported that positive economic benefits were found in 
the majority of studies (reduced medication expenditures, hospital admissions, lengths of hospital 
stay and emergency department visits).  However, the studies were difficult to compare as many 
used multimodal approaches, some focused on specific medications or treatments and some on 
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specific disease groups.240  In addition, the difference in health care environments and funding 
models makes it difficult to extrapolate results from the USA to Australia. Comparisons in the 
paediatric settings are further impeded by the scarcity of research to date.   
The most significant Australian research into the economic impact of clinical pharmacy was 
undertaken in the adult setting, where Dooley et al reviewed the pharmacist interventions recorded 
from eight large tertiary hospitals.  A total of 1,399 interventions were documented, and it was 
found that for every AU$1 spent on a clinical pharmacist, AU$23 was saved.241  Graham et al using 
the same methodology as the Dooley study, followed a group of paediatric pharmacists in one 
Australian paediatric teaching hospital and found that for every AU$1 spent on a clinical pharmacist 
wage, there was AU$34 saved.242,243 
In paediatrics, the most significant study was from America, where Krupicka et al described the 
effect of a paediatric clinical pharmacist in an American paediatric intensive care unit.244  This 
study demonstrated a saving of US$9,135/year in direct cost savings for a relatively small 
expenditure of less than one hour per day of clinical pharmacist time.  In other words, 7.5 times the 
cost of the pharmacist wage was saved in direct medication costs.244  A similar but longer study 
from New Orleans in a paediatric intensive care unit found annual cost savings of US$119,700 for a 
part-time paediatric clinical pharmacist.245 
2.4.3 Measuring value using patient outcomes 
There has been little research investigating the value of pharmacists on paediatric patient care apart 
from reduction in error or economic impact.  Researchers in the adult setting have identified 
improvements in quality areas such as adherence, quality of life, and readmission rates.  Kaboli et al 
undertook a systematic review in 2006 of the impact of clinical pharmacy services.246  Adverse 
medication events, adverse drug reactions and medication errors were reduced; medication 
adherence, knowledge and appropriateness of therapy was improved; and hospital length of stay 
was shortened by introduction of a clinical pharmacy service.246  Other outcomes in the adult setting 
have included improvement in severity of illness in the psychiatric setting; improved INR control 
with a pharmacist-managed anticoagulation program; and improved quality of life and reduced 
hospitalisation in a renal disease clinic.247-249 
Sanghera et al in 2006 undertook a systematic review of interventions by hospital pharmacists that 
improved medication therapy in children.  They found a small number of heterogeneous studies that 
were difficult to compare.  However all the studies highlighted the importance of hospital 
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pharmacists to medicines management in paediatric patients, with the most evidence related to 
pharmacist reviewing of medication charts.62 
The last three years have seen a small but an encouraging number of published paediatric studies 
investigating other impacts on patient care.  However, these have tended to be small, single centre 
and in many cases related to a single clinical unit.  In the recent study from China mentioned above, 
interventions by clinical pharmacist were associated with a shorter patient stay and increased patient 
compliance with medication therapy after hospital discharge.239  A study from Chile in children 
with asthma found pharmacist care improved quality of life, including emotions, activity and 
symptoms although not spirometry.250  Another study in paediatric asthma from the Netherlands 
found that closer interaction between pharmacists and general practitioners targeting adherence to 
paediatric asthma guidelines significantly improved the use of short-acting betamimetics and the 
use of inhaled corticosteroids while on long-acting betamimetics in children with asthma.251  A 
study in Singapore demonstrated that a pharmacist counselling session increased parent’s 
knowledge about epilepsy and medication adherence.252 
A small study from the USA on paediatric cystic fibrosis patients found that a clinical pharmacy 
service (focusing on therapeutic drug monitoring) reduced length of stay, blood tests and overall 
costs of care when compared to no service.253  A study from Egypt in a paediatric dialysis unit 
found a significant improvement in blood pressure, biochemical markers and patient satisfaction in 
a group of patients provided with a clinical pharmacy service in comparison to the control group.254  
A 2012 study by Marconi and Claudius found that the introduction of a full-time pharmacist based 
in the paediatric emergency department significantly reduced medication omissions and delays.255 
The above research on paediatric pharmacy has demonstrated important improvements in patient 
care, particularly in error prevention.  In recent years, research has begun to move towards analysis 
of direct patient outcomes, although these are still limited by small sample sizes. 
2.5 Conclusion 
Adverse medication events have been intensively investigated over the past two decades, although 
the majority of research has been in the adult setting.  The most effective methods of case 
identification for adverse medication events, and harm prevention initiatives, are still not confirmed 
particularly in the paediatric setting.   
It is clear from published research that multifactorial changes are required to make sustained 
improvements in medication safety.  Technology such as CPOE and smart pumps can be effective 
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but need to be planned and implemented carefully so that new errors are minimised.  Education is 
essential and can be very effective, but it needs to be sustained, and should be measured against 
performance in practice, rather than as mere knowledge.  Significant cultural change at an 
organisational level is possibly the most important strategy, including a non-punitive approach to 
incident management and implementation of multidisciplinary safety teams.   
The impact of a clinical pharmacist on error prevention in paediatric patient care has been 
demonstrated in a number of studies and clinical pharmacy is now well integrated into health-care 
systems in most developed countries.  However the studies to date have been limited by relatively 
small numbers, with an emphasis on prevention of error rather than broader measures of quality use 
of medicines, sustained system improvements and direct patient outcomes.   The tasks or roles 
required of a clinical pharmacist service have been described in some cases, but not the knowledge 
and skills required of a paediatric pharmacist undertaking these roles.  Gaps in research include 
analysis of different models of pharmaceutical care, comparison of outcomes with different 
pharmacist skill sets, and measurement of meaningful direct patient outcomes in children rather 
than just prevention of error.  Assessment of skill is discussed further in the next chapter. 
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3 Chapter Three: Literature Review – Development and 
Assessment of Health Practitioners 
3.1 Introduction 
In Chapter 2, the current literature regarding adverse medication event measurement and analysis 
and interventions to improve safety were described, with some evidence emerging on the impact of 
clinical pharmacists in prevention of adverse medication events and improvement in quality of 
paediatric care.  In this chapter methods for development and assessment of advanced practice in 
health practitioners are investigated more deeply. 
Health practitioners develop from undergraduate to postgraduate to advanced practice, via formal 
education, experiential learning in and outside of the workplace, and formative and summative 
assessments used in formal and informal training.  The capacity of health practitioners to deliver 
improvements in therapeutic outcomes, quality of life for patients, and improvements in care at a 
system level is dependent on a foundation of competence and capability, enhanced by specialist 
knowledge and skills developed over time.112   
The concept of professional competency is well established in healthcare, and articulated clearly in 
the Kennedy Report into the Bristol Hospital Inquiry where it was stated that ‘A healthcare 
professional’s competence from the patient’s point of view is not negotiable’.256  The National 
Competency Standards Framework for Pharmacists in Australia state that ‘Competence is generally 
taken to mean that an individual possesses the required knowledge, skills and attributes sufficient to 
successfully and consistently perform a specific function or task to a desired standard’.132  The 
current challenge for pharmacy is to clearly define where skills, knowledge, attitudes and 
behaviours move from standard professional competence to advanced practice. 
The journey from competence to proficiency to expert practice has been described by some authors 
as moving from knowledge of standardized procedures and handling pressured situations 
(competency, 2-3 years experience); to the ability to perceive situations holistically, detect 
deviations and identify what is important (proficiency, additional 3-5 years); to someone who no 
longer relies on rules or guidelines and has an intuitive grasp of situations (expert, 10,000 hours).257-
259  This explanation of competence versus proficiency and expertise correlates well with the 
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concept of development from newly qualified to advanced practice and has implications for how 
this is assessed or evaluated. 
Assessment and evaluation are terms often used interchangeably.  Cantillon et al described a 
continuum of assessment where ‘at one end of the continuum, formative assessment is essentially 
about providing feedback to students in order to support and enhance learning; at the other end, 
summative assessment is about measuring students’ achievement with the purpose of grading or 
informing decisions about progression’.260  Formative assessment then has the intent of sharing 
information about performance (or giving feedback), in contrast to summative assessment which 
involved conferring judgment.260   Hill et al made similar points that assessment should not only 
determine whether the student has acquitted the set competencies deemed important, but also 
provide feedback on their performance and allow the student to picture the desired level of 
performance.257 
When considering assessment of clinical practice, many researchers have referred to Miller’s 
knows/shows/does triangle from 1990, as shown below in Figure 3.1.261  The “knows” level of 
Miller’s triangle refers to the recall of facts, principles, and theories. The “knows how” level 
involves the ability to solve problems and describe procedures. The “shows how” level usually 
involves human (standardized patient), mechanical, or computer simulations that involve 
demonstration of skills in a controlled setting. The “does” level refers to observations of real 
practice.261,262 
 
 261 
Figure 3.1 Miller's Framework for clinical assessment (left) mapped against methods 
for assessment (right) 
Does!(Action)!
Shows!How!(Performance)!
Knows!How!(Competence)!
Knows!(Knowledge)!
Peer!Review,!Feedback,!Supervisor!Reports,!Direct!Observation!OSCE,!Portfolio,!CaseZBased!Discussion!
Scenario!based!exam!
Exam!
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When considering assessment instruments, educators and evaluators must consider not only factors 
that make the instrument desirable and appropriate (reliability and validity), but also factors that 
make the instrument practical and achievable, including the cost to the individual, institution and 
society, ease of administration and acceptability to candidates and examiners.263  Distinctions need 
to be made between assessment methods that are suitable only for formative use, and those that 
have sufficient psychometric rigor for summative assessment, particularly for high-stakes 
assessment.264  
The challenge is to effectively assess competency at different levels of practice, using reliable and 
sustainable methods.  This is a newer area of research, particularly in pharmacy practice.  Two 
reports from Australia and the UK in the past year have comprehensively reviewed current 
assessment methods for health practitioners and the relevance for pharmacists practicing at an 
advanced level.  The Australian Pharmacy Council recently released a comprehensive report on 
Advanced and Extended Pharmacy Practice in the Australian context.113  The Royal Pharmaceutical 
Society in the UK also recently prepared a report on credentialing of advanced practitioners.112  The 
recommendations from both of these important reports are combined with findings from other 
researchers and summarised below.  
3.2 Professional development without assessment 
Lectures, Workshops and Seminars 
The traditional method of improving health practitioners’ knowledge was to attend a lecture, 
workshop or seminar in the hope that the information provided will be retained and applied to 
improve practice.  A well-designed workshop will require a learner to participate in some kind of 
interactive task to apply the knowledge gained.  More recently, however, the traditional didactic 
style of teaching has been questioned by many, who see it as less effective than other teaching 
methods for promoting thinking skills or changing attitudes, and, at best, improving only the 
“knows” or “knows how” part of Miller’s Triangle.261,265 
Lectures, workshops and seminars do have their role, if well structured, interactive and linked to 
practice, and ideally in combination with other teaching methods such as case discussions.265  They 
can be a cost-effective and valuable method to transmit knowledge, which then needs to be 
contextualised by the learner with activities using higher order thinking.265  
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Online or web-based teaching 
Online or web-based learning is being used increasingly in both undergraduate teaching and 
professional development.  It is an attractive proposition as it offers flexibility for the learner in 
terms of where and when learning occurs, while accommodating large numbers of learners.  It can 
be used for professional development for individual learners, or as a component of formal 
education. 
Blended methods including online lectures followed by face-to-face case-based discussions, have 
been positively evaluated by a number of researchers, particularly when such teaching is based on 
observed gaps in practice and undertaken in a timely fashion before experiential placements.266-270  
Assessment (using before and after quizzes) can be built into online learning to feed back any 
knowledge gaps to the learner, in association with face-to-face learning with a mentor or tutor as 
part of formative or summative assessment.  This has been demonstrated in clinical practice where 
an electronic learning package for paediatric prescribing found a small but significant improvement 
in prescribing skills when doctors were followed up at 1 and 3 months post intervention.271 
Mentoring and Feedback 
Mentoring and feedback are closely linked in professional development, and are also linked to 
many of the assessment methods and tools described below, in particular direct observation and 
peer review.  Cantillon et al defines feedback as providing information to students with the intention 
of narrowing the gap between actual and desired performance.260  Without feedback, good 
performance is not reinforced and poor performance may be repeated at the expense of patients or 
colleagues.260  Govaerts et al concluded that narrative feedback provided in a constructive way is 
the only way to help trainees to accurately identify strengths and weaknesses in their performance, 
and to effectively guide development of competence.272 
Antoniou et al found that the use of effective feedback in conjunction with a structured clinical 
competency assessment tool with hospital pharmacists in the UK improved the patient-related 
competencies significantly more than for hospital pharmacists who were not provided feedback.207  
Epstein and Hundert stated that a strong mentoring system should accompany any comprehensive 
assessment program.  ‘An inadequate system for feedback, mentoring and remediation will subvert 
even the most well-conceived and validated examination’.262  The ability to effectively mentor and 
provide feedback to others, particularly outside the team and professional group, is an important 
skill for an advanced practitioner. 
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Ward-based teaching 
Ward based teaching is commonly used for all hospital based health practitioners, although the 
challenges of ward based teaching in settings such as paediatrics have rarely been described.  Reece 
and Kabler recently described the challenges and opportunities for teaching paediatrics to medical 
officers during ward rounds.273  Although the article primarily describes medical teaching, it is 
relevant for pharmacists.  Reece and Kabler describe the particular challenges in paediatrics where 
examination of (or discussion with) a child can be difficult in the presence of a large group, consent 
can be difficult to obtain, and short stays and rapid turnover result in most of the patients being new 
to the incoming team on the next shift.273  However, they also point out that ward rounds are an 
excellent opportunity to model behaviours, communication and clinical skills, in addition to real-
time learning.273  Furthermore, for those learners less familiar with the nuances of interacting with 
children and young people of various ages, it is a valuable opportunity to observe how it can be 
done by senior members of the team.273 
3.3 Portfolios 
Challis et al described a portfolio as ‘a collection of material, made by a professional, that records, 
and reflects on, key events and processes in that professional’s career’.274  In the health practitioner 
arena they tend to comprise a dossier or collection of evidence acquired over time that demonstrates 
the practitioner’s education, assessment results, practice achievements and the fulfilment of 
personal learning needs.275-277  They can be used for professional development and for formative 
and summative assessment. 
Portfolios can range from a loose collection of personal reflections and individualized goals and 
objectives through to a structured compilation of evidence as defined by a professional program for 
summative assessment or credentialing purposes.277  Some portfolios may be developed to create a 
long-term journey of personal development, to demonstrate the breadth of learning and the process 
of progression in learning.  These may be essentially private documents, for personal review only.  
Or they may be used for formative assessment (as a focus for feedback), where participants 
document and reflect on areas where they could improve and plan with a mentor how they may 
rectify deficiencies.274  Other portfolios will be used for summative assessment against specific 
targets of achievement required by other authorities and open to public scrutiny.274,275  
As they involve the actual experience of the learner, portfolios enable consolidation of the 
connection between theory and practice.274  Portfolios have been shown to improve student’s self-
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awareness, improve self-confidence, identify individual learning needs and achievements, improve 
the ability to learn independently and to integrate theory with practice.113 
Medical use of portfolios 
Portfolios began to be trialled in the medical field in a number of UK settings in the 1990s.  Early 
research with GPs compared a portfolio based learning program (incorporating mentoring groups 
and structured reflection) with a traditional development program based on recording education 
attended.278  They found that the portfolio-based learning scheme gave learners control over how, 
what and when they learned, and encouraged active and peer-supported learning.278  The breadth of 
topics covered by the portfolios was wider than those seen with the traditional process, and the 
learning showed more depth.278  Similar experiences have been observed in the USA, with 
increasing use of portfolios in graduate medical education, to record learning, reflect on 
experiences, and receive feedback on achievements.277   
In contrast, Nagler et al and Roberts et al have recommended caution with the use of portfolios for 
high stakes use, particularly in the medical field.277,279  Concerns regarding patient privacy and 
potential litigation have resulted in suggestions to leave documented reflection out of assessment 
rather than risk the learner’s documentation of insecurities, suboptimal performance and/or bad 
outcomes becoming a source of a malpractice lawsuit.277  The importance of different formats of 
portfolios for formative assessment rather than high stakes summative assessment has also been 
emphasised.279 
Nursing use of portfolios 
Portfolio use in nursing is less commonly described, but it has now been integrated into 
undergraduate training in some settings.280  Endorsement as a nurse practitioner by the Australian 
Health Practitioner Regulation Agency now includes submission of a structured portfolio of 
evidence including description of compliance with the National Competency Standards for the 
Nurse Practitioner.281  
Pharmacy use of portfolios 
Portfolios, increasingly web-based, have been used widely in undergraduate pharmacy teaching, 
with a students tending to favour portfolio assessment over traditional testing.113,282,283  Portfolios in 
a very simple form can be used to record Continuous Professional Development and personal 
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learning plans, which have been a part of the registration process for all pharmacists in the UK, 
Canada, and (since 2010) for all health practitioners in Australia.284,285   
McKenzie and Borthwick described the successful use of portfolios in the UK as part of a multi-
faceted tool for assessment of advanced practice critical care pharmacists.286  The portfolio was 
used in conjunction with peer review using 360 degree appraisal, together with “assessment in 
practice” (observed practice), and was prepared separately for the specific purpose of summative 
assessment.286 
The recent Royal Pharmaceutical Society report on credentialing found that portfolios were strongly 
supported as a principal strategy for credentialing of advanced practitioners.  The format 
recommended mapping of evidence against the Advanced and Consultant Level Framework, and 
including as evidence multiple source feedback (peer review), intervention reports, case based 
examinations or discussions and evidence of directly observed practice.112 
In summary, portfolios can be used to provide evidence of skills that would be difficult to assess 
otherwise, such as behaviour, quality improvement activities, and experience.113  However, 
portfolios are time-consuming to develop and keep up to date, and health practitioners may feel 
uncertain about how to use them without clear guidance.287  User-friendly web-based portfolios will 
hopefully make portfolios easier to maintain in the future.  There is a key difference between 
portfolios maintained for individual development, for formative assessment, and for summative 
high stakes assessment, and the format needs to be flexible enough to accommodate these 
differences.279  The benefits of self-reflection for meaningful learning is important.  However the 
person undertaking it is highly unlikely to willingly present a portfolio identifying their weaknesses 
for high stakes assessment.  Therefore a personal portfolio that can be customised for different 
purposes is essential.277,279 
3.4 Work Based Assessments 
Work Based Assessments (WBAs) are assessments of practice or competency based on what a 
health practitioner actually does in their workplace (usually a clinical setting), using direct 
observation of practice by the assessor/evaluator.   Provision of effective feedback is intrinsic to 
their use as educational as well as assessment tools.  As described in the Millers Triangle, direct 
observation is the best method of assessing the “does” component of professional performance.261  
Direct observation can be undertaken in a number of ways, using a number of different tools, some 
of which are described below.288 
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Work-based assessment using direct observation allows evaluation of a health practitioner’s 
strengths and weaknesses in areas such as interpersonal skills (e.g. interaction with patients, 
families and other health practitioners), professionalism, ethics, self-appraisal and the ability to 
improve, which are difficult to assess using traditional knowledge-based examinations.113,288,289 
Work-based assessments routinely use some kind of checklist evaluation, if the competency can be 
broken down into specific behaviours or actions.290  In addition, training of assessors in providing 
developmental feedback is important for successful use of work-based assessments, and requires 
advanced communication skills.289   
Direct Observation of Practice was highly recommended by the Royal Pharmaceutical Society 
Credentialing paper, including by the Neonatal and Paediatric Pharmacists Group.112  A sample of 
WBA tools with potential relevance for advanced pharmacy practice is discussed below: 
Direct Observation of Procedural Skills (DOPS) 
Direct Observation of Procedural Skills (DOPS) is commonly used as a component of workplace 
assessment in medical training, usually requiring multiple assessments for each procedural 
skill.288,291,292  Comparable assessments in pharmacy practice at a junior level could be procedural 
skills in aseptic compounding of medicines.  However, these types assessments may be less relevant 
for advanced pharmacy practice.  In this context, the acronym DOPS could also be phrased Direct 
Observation of Practice Skills, and therefore comparable to the General Level Framework 
described below. 
General Level Framework 
The competency based performance evaluation and feedback tool called the General Level 
Framework (GLF) was developed in the United Kingdom by the Competency Development and 
Evaluation Group (CoDEG) in the early 2000s, then adapted in Australia by Queensland Health 
pharmacists. 207,209,293-295  This framework is a tool for evaluating pharmacists’ performance, 
providing tailored feedback, and training and guiding professional development.  It uses a 
competency-based checklist and descriptive feedback after a period of direct observation of 
practice.209 In this framework the checklist gives a description of the ‘correct’ behaviours and a 
rating of ‘rarely’, ‘sometimes’, ‘usually’ or ‘consistently’.209  After the feedback session, the 
pharmacist prepares a professional development plan in conjunction with the evaluator.   
Use of this tool has expedited improvements in pharmacist competencies in Australia, Croatia, 
Singapore and the UK.207,209-211,294,296  This tool has been replaced in Australia in recent years by the 
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shpaclinCAT, based on the same original content and format as the GLF, with customisation for the 
Australian healthcare setting and additional examples of behaviours for each criterion.297,298  These 
tools were designed for professional development and training rather than as a summative 
assessment method, and were not designed for assessment of advanced practice (although the 
competencies described would of course be expected of advanced practitioners).113,295  
Mini-CEX 
The “Mini-CEX” (or Mini Clinical Evaluation Exercise) has been widely used in the medical field 
as a short direct observation of a physician and a single patient in real clinical practice, with the aim 
for multiple encounters to be used during a training period.113,299  It is another tool that uses direct 
observation of practice.  Criteria such as interviewing, physical examination, professionalism, 
clinical judgment, counselling, organization and efficiency and overall competency are scored, and 
feedback is provided to the learner at the end of the encounter.299,300  It has been found to have a 
high level of internal consistency and reliability among internal medicine trainees.301  In comparison 
to other formats such as standardized patients, the mini-CEX in the medical environment was found 
to have a higher fidelity, to permit evaluation based on a much broader set of clinical settings and 
patient problems, to be more easily administered on site, and to cost less.299   Subsequent research 
has endorsed the superior psychometric properties of the mini-CEX over the traditional CEX.300 
The Mini-CEX is used as formative assessment for Australian hospital pharmacists; for advanced 
medical trainees in specialties such as general paediatrics and paediatric emergency medicine;110,302 
and for workplace based assessment of international medical graduates in Australia.301  A Mini-
CEX has also been used by pharmacists in the UK, including as part of summative assessment for 
advanced practice in critical care.286 
Case-Based Discussion 
Case-based Discussion involves a comprehensive review and presentation of a clinical case where 
the health practitioner has been significantly involved.113 Case-based discussions have been used in 
health workplaces for many years, in various levels of formality, however most commonly for 
formative assessment.  In medicine, they are used regularly throughout the year as formative 
assessments for advanced medical trainees in specialties such as general paediatrics and emergency 
medicine.110,302  Case-based discussions are used for formative assessment in some postgraduate 
training in Australia and have been used as part of “assessment in practice” for advanced practice 
critical care pharmacists in the UK.286  They are relatively inexpensive to administer and provide 
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the health practitioner with an opportunity to demonstrate and explain their involvement in a real 
case, allowing the assessment of judgement, decision-making and professionalism.113 
Case based discussions have been highly recommended by the Royal Pharmaceutical Society 
credentialing report, including by the Neonatal and Paediatric Pharmacists Group.112 
Procedure or case logs 
The use of procedure or case logs where learners prepare summaries of clinical experiences 
including clinical data is common in the medical field.  Logs are useful to document educational 
experiences and deficiencies290, and can be linked to self-reflection activities in a portfolio.  
An analogous strategy for pharmacists may include recording activities such as therapeutic drug 
monitoring, items manufactured, or interventions in patient care on a regular basis, to aid in self-
reflection and as a demonstration of increasing skill.  Similarly, a study by Barber et al in 1997 
found that pharmacists of a higher pay grade (with the assumption of higher skill) were more likely 
to make interventions than those in a lower grade.47  These logs are easy to maintain on a regular 
basis.  However, they should not be used alone as the number of cases and interventions do not 
necessarily correlate with competence.290  
Summary of Work Based Assessments 
Direct observation assessments generally require the assessor to complete the observation in the 
practitioner’s usual workplace, which may provide difficult to organise.113  An alternative would be 
to have a group of candidates all performing in a environment which is unfamiliar to them but 
which allows them to access appropriate assessors.  This approach was used by the UK critical care 
group.  However, such situations are likely to misrepresent the practitioner’s competency and make 
it difficult to assess how the practitioner interacts in their usual healthcare team.113 
The risk of these types of direct observation assessments is that the assessor makes use of their own 
personal constructs and theories about performance that develop through prolonged task experience, 
which can significantly effect rating outcomes.272  Hawkins et al found that the manner in which 
examiners are trained and selected affects rating outcomes for a mini-CEX, and recommended that 
each trainee should be assessed by as many different examiners as is feasible.300  Concerns were 
also raised by Basu et al regarding the reliability of feedback provided online for work based 
assessments of doctors in the UK.303  This study found that feedback was generally delayed, and 
users felt there was a little positive impact on learning or performance.  This related to the lack of 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 75 
training and engagement of consultants providing the assessment.303  These findings again reflect 
the importance of well trained assessors and timely and effective feedback.  
3.5 Supervisor Reports and Peer Review 
3.5.1 Progress Reports by Supervisors 
Evaluation by supervisors is commonly used to assess clinical practice in medicine.  It is closely 
related to the workplace assessments described above, however supervisor reports tend to reflect 
performance over a period of supervision time rather than a single encounter. Progress reports can 
be presented in many different formats, and are commonly used at regular periods in postgraduate 
medical training for formative assessment, with the final report at the end of the training period 
used for summative assessment.110,143,302 
Progress or supervisor reports have the benefit of including the tacit elements of professional 
competence otherwise overlooked by objective assessment instruments.262  Tools which describe 
behaviours at different levels of practice have been shown in some settings, such as paediatric 
psychiatry, to have good reliability to demonstrate competency and skill progression when multiple 
evaluations are used.304  However there are limitations: evaluators may have different standards and 
be subject to halo effects and racial and sex bias.  Such reports are therefore found to have low 
inter-rater reliability. 262   To compensate for this, multiple assessments should be undertaken using 
standardized rating forms, preferably from multiple supervisors.   
3.5.2 Peer Review and Multi-Source Feedback (MSF) 
Peer assessment, multi-source assessment, multi- source feedback, 360 degree feedback, 360 degree 
appraisal, peer review, and peer rating are different names given to essentially the same process 
whereby the individual receives formal feedback on his/her performance at work from peers, sub-
ordinates and superior managers, often using a rating scale and free text statements.305  These tools 
have been used for many years in leadership roles, and more recently in healthcare.113 
Peer reviews can be done by true “peers”, or can be in the form of “multi-source feedback” (also 
called “360 degree feedback”).  In the latter method, multiple peers are used and include staff 
working “above”, “below” and “around” the health practitioner and not necessarily in the same 
profession (e.g. senior and junior medical staff, nursing staff, administrative staff, technical staff, 
and other health practitioners).290  The feedback is usually anonymous and compiled by an 
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independent facilitator.  It has been commonly used in the medical profession, where a review from 
2002 found that peer ratings are accurate and reliable measures of physician performance and that 
peers may be in the best position to evaluate professionalism.262   
A number of different tools have been developed in the UK for doctors.  One of the early tools used 
was the Sheffield Peer Review Assessment Tool (SPRAT).306  This tool contained 24 questions 
with ratings on a six-point scale, with space for observations and examples, and was sent to 8-10 
reviewers nominated by the doctors themselves.306  Feedback was independently collated, 
summarized numerically, and sent back to the trainee together with comments. The SPRAT was 
then modified with nine questions removed to form the “Mini-PAT”, retaining the six point rating 
scale and space for comments.307  The SPRAT and Mini-PAT were found to be valid methods to 
assess large numbers of doctors, particularly to assess behaviours, which are difficult to evaluate 
with other methods.  The feedback can then be used to inform personal development planning and 
focus quality improvements.306,307 
Another similar form of multi-source feedback called “Team Assessment of Behaviours” (TAB) 
was developed to specifically identify interpersonal attitude and behaviour problems in trainee 
doctors.308  The tool had four domains: maintaining trust/professional relations with patients; verbal 
communication skills;  team-working and working with colleagues; and accessibility.  Each domain 
was rated on a three-point scale as “no concern”, “some concern” or “major concern”.  Assessors 
and trainees found the process practical, valuable and fair, although only 23% of supervisors 
learned something new about their trainees.308  
In 2010, review of UK doctors who used multi-source feedback (MSF) found that attitudes towards 
MSF in principle were positive and the tools were felt to be usable although the perceived 
effectiveness of the tools was low.309  When evaluated as potential tools for high-stakes assessment, 
a study of 119 GPs found that multi-source feedback from clinical and non-clinical colleagues was 
a reliable and feasible assessment suitable for high stakes assessment.310  In this study, six 
colleagues providing feedback on two separate occasions were found to provide adequate 
reliability.310 
Multi-source feedback (in the form of “mini-PAT”) has been used successfully by junior hospital 
pharmacists in the UK as part of formative assessment, as described by Patel et al.  It was 
subsequently implemented as a tool for hospital pharmacists in Queensland.311,312  McKenzie et al 
also used multi-source feedback successfully as a component of a suite of tools used for summative 
assessment of advanced practice in critical care pharmacists.286   
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Some of the important concerns raised by researchers include inter-rater variability, particularly if 
used in high stakes summative assessment versus formative assessment.309  Research by Archer and 
McAvoy found that the ratings by practitioner nominated assessors were higher than that of 
employer nominated assessors.313  The importance of effective feedback of results by the educator 
has been stressed, together with the lack of evidence that the use of peer rating improves or predicts 
patient outcome.305,309  The real impact on performance improvement has also been questioned, 
with recent research finding that the majority of free text comments in multi-source feedback 
included little to facilitate improvement of the assessee’s personal development and performance.314 
On the whole MSF is a reliable and feasible tool to assess practice for health practitioners including 
pharmacists.  Successful use of MSF depends on factors such as number and choice of assessors. 
The format of the tool is also important.  It must be simple to use – preferably electronically – and 
not too time consuming for assessors to complete.286,312    
Peer review was one of the highest favoured evaluation methods in the Royal Pharmaceutical 
Society advanced practice credentialing report.112 
3.6 Objective Structured Clinical Examinations (OSCEs) 
Objective Structured Clinical Examinations (OSCE) were defined by Epstein and Hundert as ‘timed 
multi-station examination often using standardized patients to simulate clinical scenarios’.262  This 
process has been used widely in medical education and has also taken up by nursing and allied 
health professions.  OSCE is included as a component of pre-registration training and assessment 
for pharmacists in the UK and Australia.113,315,316  The use of a standardised patient means that 
OSCEs contain less variation but are closer to a “real world” environment than an examination can 
be.  Another advantage of OSCEs is their ability to assess a range of tasks and skills within the 
same session.113  As long as there is a sufficiently large number of patients/cases, OSCEs allow 
reliable rating of communication, physical examination, counselling and technical skills.262   
However, OSCEs have a number of limitations.  They are time intensive and costly to prepare and 
administer, particularly if paid rather than volunteer patients are used, and if experienced 
practitioners are used as evaluators.113  Epstein and Hundert stated that the OSCE has low test 
reliability for measuring clinical ethics in medical officers.262  Some researchers have found that the 
OSCE’s process, using a set of required steps undertaken in order may not be appropriate for 
evaluation in the postgraduate context where most experienced physicians approach clinical 
decision making in a non-linear fashion.113,290,317  OSCEs were not a favoured technique in the 
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Royal Pharmaceutical Society credentialing report, and not favoured by the Neonatal and Paediatric 
Pharmacists Group.112 
3.7 Knowledge Based Examinations (oral and multiple-choice) 
Standardised multiple-choice question (MCQ) examinations are commonly used for assessment 
across health practitioner fields, particularly for large numbers of undergraduate students.  They are 
economical, easy to use and administer and can test a range of knowledge in a short period of 
time.113  They are thought to offer excellent reliability in evaluation of factual knowledge and 
problem solving skills, and can assess some aspects of context and clinical reasoning.262  However 
even designed well, MCQ examinations only reliably test the “knows” level of the Millers 
Pyramid.261 They do not test the ability of the practitioner to put theory into practice, and 
standardized test scores have been inversely correlated with empathy, responsibility and 
tolerance.113,262   
Despite these reservations, MCQ examinations are used for high stakes evaluation of advanced 
practice in some health practitioner fields. They are one of the two mandatory summative 
assessments for medical officers in Australia to move from basic to advanced training110 and used 
as the assessment for credentialing purposes by the Board of Pharmacy Specialties in the USA.128   
There has been debate about the validity of an exam as the sole evaluation criteria.  The American 
College of Clinical Pharmacy supports board certification, although it acknowledges that the board 
examination is a ‘valid assessment of a pharmacist’s level of specialized knowledge in a designated 
area of practice’, not necessarily assessment of skills, attitudes or behaviours.318  Nevertheless, the 
process of preparing for the examination may in itself improve skills of the pharmacist.  This was 
found by Westanmo et al where pharmacists who had undertaken the Board-Certified 
Pharmacotherapy Specialist examination participated in a nine-month curriculum and email study 
group to assist in preparation for the exam.319  They found that 74% of respondents made 
interventions that they would not have previously undertaken, and 91% agreed or strongly agreed 
that studying for the BCPS examination helped them gain knowledge that improved the care they 
give as pharmacists.319 
MCQs were not a favoured method of evaluation in the Royal Pharmaceutical Society credentialing 
report.112 
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3.8 Reflection and Learning Plans 
Reflection is a key component of education, training and continuing professional development for 
most health professions.  It is used in undergraduate training, for registration and revalidation 
purposes, and is an important component of effective portfolio-based learning.  There is a great deal 
of evidence to support reflection as being an important step in transforming superficial learning into 
deeper learning, with a change in thinking that then changes practice.320  Insight may be developed 
through reflecting on and writing about professional and personal experiences, resulting in greater 
self-knowledge.321  However, for transformation in practice to occur as part of reflective practice, it 
is important to have a trained facilitator or mentor, and a supportive organisation.320  The use of 
such tools has now become so ubiquitous that there are some opinions appearing in the literature 
suggesting that reflection activities have now become “ritualistic” and have lost their potential 
impact.320   
Learning plans are closely related to reflection.  The trainee records their learning needs, the means 
of achieving them, expected time of completion and means of verification.262  This is a required 
learning activity twice yearly for Australian advanced medical trainees and is recommended by 
many professional organisations.102,261  Reflection activities and learning plans can also be included 
in a professional portfolio. 
3.9 Viva Voce (Oral Interview) 
A viva voce, also called an oral interview or examination, is an ‘oral examination characterised by 
face-to-face interaction between an examinee and one or more examiners’.113  Interviews in a 
variety of forms have been used for many decades as a preferred tool for recruitment and selection 
in the workplace, but have declined in use for assessment purposes in undergraduate and 
postgraduate education.  The traditional viva, as used in assessment of research higher degrees and 
medical education, was usually an unstructured oral examination within a particular subject area 
away from direct patient care, with the theoretical advantage of being able to assess clinical 
reasoning.322  
Format of the interview is important for success.  A review of recent studies on interview reliability 
in the employment context found that “structured” interviews show greater predictive validity of job 
performance compared to “unstructured interviews, minimising the impact of self-presentation 
tactics, and without the adverse impact typically found with cognitive ability tests.323,324 Past 
behaviour interview questions (where applicants were asked to recall what they actually did in 
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situations) predicted supervisors’ performance ratings while situational interviews did not.323  
Although both situational and past behaviour description interviews that assessed team playing 
behaviour correlated with typical performance.323  Likewise, research on multiple mini-interviews 
in health practitioner selection found similar results, whereby behavioural interview questions more 
reliably differentiated between candidates than situational judgement questions or free-form 
questions.325 
Oral interviews are relatively easy to administer and not particularly costly, however they can be 
subjective in nature and disadvantage extremely nervous practitioners.  They can be useful tools for 
assessment of clinical reasoning, problem solving and decision making, and were one of the highest 
ranked evaluation methods in the Royal Pharmaceutical Society credentialing report.112,113  Careful 
selection of interview panel, and the use of structured questions is likely to enhance the reliability of 
an oral interview.   
3.10 Combinations of Methods 
It is clear that each assessment method has its own advantages and disadvantages, with no single 
method suitable to assess all components of professional practice.  The use of multiple assessment 
methods can overcome many of the limitations of individual assessment methods.  The use of 
longitudinal assessments avoids the need for excessive testing at one point in time and serves as the 
foundation for monitoring ongoing professional development.264  Many professional bodies now 
use a combination of methods for high stakes assessment, reflecting the substantial research in 
recent years to ascertain the reliability of different combinations. 
Combinations of methods are used by the Royal Australasian College of Physicians (RACP) to 
assess advanced trainees as suitable fellows of the college (and thus grant them consultant status).  
A written multiple choice examination and an oral examination using direct observation of multiple 
standardised patients are used as mandatory summative assessments for trainees to move from basic 
to advanced training.  Advanced training then uses a series of formative assessments (case based 
discussions, mini-CEX, learning needs analysis) and summative assessments using mid and final 
year supervisors reports and completion of a research project.110   
The RACP process is supported by recent research that tested the reliability of a toolbox of 
workplace assessments and found that a combination of five Mini-CEXs, six observations of 
practice (procedural skills), and one peer review (multisource feedback) combined in a portfolio 
provided feasible and reliable method of high stakes assessment.292  A more complex assessment 
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toolkit was recently reviewed to assess the ward skills of surgeons undergoing resident training.  
This toolkit involved assessment of physician and patient, teamwork, and clinical skills with a 
deteriorating patient.326  This combined toolkit showed excellent reliability and consistency in the 
research environment.  However, because it uses direct observation of the surgeon by trained 
assessors, it would be time intensive to implement as part of routine practice.326   
In contrast to these studies, a wide variation was found in the reliability of workplace assessments 
in a naturalistic (rather than experimental) obstetric and gynaecology setting.327  This study found 
that significantly more individual assessments (Case Based Discussions, Mini-CEX and observation 
of procedural skills) than currently recommended by the accreditation body would be required to 
achieve a reliable result.327 
The United Kingdom Clinical Pharmacy Association critical care group used a combination of 
methods for credentialing in advanced practice, including a Mini-CEX, case based discussion, peer 
review, portfolio review and oral viva.286  This was found to be time-consuming and resource-
intensive but considered to be a robust future method of credentialing for other specialties.286  
Feedback from three years of credentialing was reported in 2012 with participants reporting that the 
assessment process was valid and robust.328  
Credentialing of pharmacists to undertake Medication Management Reviews in Australia requires a 
combination of assessment methods including portfolio review, clinical MCQs, completed case 
studies, OSCEs and direct observation of practice using a standardised tool.113 
3.11 Revalidation 
The other challenge is the consideration of revalidation.  Once practitioners are validated or 
certified for the first time, revalidation at a certain period of time is generally considered 
appropriate.  Membership of the Faculty of the Royal Pharmaceutical Society as an advanced 
practitioner will require revalidation every five years.119  Medical revalidation (or recertification) is 
undertaken in the UK, the USA and NZ with varied reports of success.  Often revalidation can be 
onerous, expensive to administer and there are doubts on whether it actually identifies those 
practitioners who are not competent to practice.329  Revalidation is currently proposed for 
introduction to medical registration in Australia. 
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3.12 Conclusion 
A significant amount of research has been undertaken in recent years regarding medication safety 
and practitioner development, particularly in advanced pharmacy practice.  However, the skills and 
knowledge required to improve safety and quality of medication use, and improve patient outcomes 
for children, is still to be determined.  These changes and improvements in practice appear to 
require advanced skills, such as leadership, communication, research and change management.    
To determine whether advanced practice pharmacists make a difference to patient outcomes in 
paediatrics, it is necessary to first define what advanced practice is, and determine how to assess it.  
Assessment of advanced practitioners will likely require a range of methods, to be sufficiently 
reliable to encompass the breadth of qualities and competencies expected of an advanced 
practitioner.  The challenge for advanced practice assessment will be to determine what 
combination of different assessments will form a robust, reliable, valid and feasible evaluation of 
practice across a variety of pharmacy practice settings. 
The issues discussed in these last chapters regarding case identification, measurement of patient 
outcomes, definition of advanced skills, development and assessment of advanced pharmacy 
practice will be investigated in the following chapters. 
 
 
  
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 83 
4 Chapter Four: Characteristics of Adverse Medication Events 
in a Children’s Hospital 
4.1 Introduction 
The first step in investigation of adverse medication events in children is to determine how best to 
identify events.  This chapter investigates three potential data sources for adverse medication events 
in children: clinical incident reports, pharmacist intervention reports, and administrative coding 
using the International Classification of Diseases 10th Revision Australian Modification (ICD-10).  
As discussed in Chapter 2, incident and intervention reports (forms of voluntary reports) are 
valuable sources of information on adverse medication events in hospitals, particularly those with a 
strong safety culture.  However these are known to underestimate the true incidence of error.  ICD-
10 coding is used for administrative purposes, however with specific codes for adverse events 
related to medicines, it is a potential source of additional information on harm in hospitalised 
patients.  This study investigated six months of reports from each of the three data sources to 
investigate the level of cross-over of reporting and identify which data sources were feasible for 
further use in a larger longitudinal study to investigate trends in adverse medication events over 
time. 
The hypothesis for this project is: 
ICD-10 coding identifies different adverse medication events in hospitalised children than 
incident or intervention reports, and is a feasible case identification method for ongoing 
research and quality assurance purposes. 
This chapter has been accepted for publication by the Journal of Paediatrics and Child Health.330  
The definitive version is available at www.wileyonlinelibrary.com. 
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4.2 Manuscript Abstract  
Aim: 
To compare adverse medication events (AMEs) reported in children, via the International 
Classification of Diseases 10th Revision Australian Modification (ICD-10-AM) coding with events 
reported via other data sources. 
Method: 
AME reports were retrieved using codes Y40-Y59 and X40-X44 over 6 months.  Patients’ charts 
were manually reviewed to identify events associated with error and/or harm with medicines, during 
a hospital admission.  Medication name, group, error, harm, and alert documentation were recorded.  
Clinical incidents and pharmacist interventions were reviewed for the same period.  .  
Results: 
263 events from January to June 2011 were recorded by ICD-10 coding in 180 patients.  After 
duplicated, missing or unrelated events were excluded, 146 AMEs remained.  In the same period, 
117 AMEs were reported as incidents and 190 as pharmacist interventions.  In total 276 children 
with 447 events were reported via all sources.  Little duplication between data sources was evident.  
In total 158 events involved harm, with 135 of these from ICD-10 coding, 16 from incident reports 
and 2 pharmacist interventions (including 6 events from multiple sources).  Error was involved in 
3% of ICD10 reports, 97% of incidents and 100% of interventions. Only 14% of harm related 
events from ICD-10 were documented on the medical record clinical alert.  Chemotherapy 
accounted for 31% of harm-related events, antimicrobials 18%, corticosteroids 14% and narcotics 
12%.  
Conclusion: 
Of the harm related events 85% were documented via ICD-10 coding with few documented in other 
databases. Review of ICD-10 coded AMEs can provide valuable information to improve patient 
safety and quality. 
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What is already known on this topic:   
1. Harm from medications is common in children.  
2. Chemotherapy, corticosteroids, narcotics and antimicrobials are  common causes of harm 
from medications in children.  
3. Voluntary reports from health professionals are an incomplete  record of adverse medication 
events in hospital.  
What this paper adds:   
1. Use of ICD-10 coding to identify adverse medication events provides valuable additional 
information to highlight areas to improve quality use of medicines in children. 
2. Administrative coding using ICD-10 identifies many instances of harm from medications 
not identified elsewhere but few events associated with error. 
3. Improvement is required in permanent recording of adverse medication events (including to 
the Therapeutic Goods Administration). 
4.3 Manuscript Introduction 
It is well known that children are at risk of Adverse Medication Events (AMEs) and are 
approximately three times more likely to experience a potential adverse medication event than the 
adult population.43  Although there has been substantial research on AME’s across the world, the 
research in paediatrics is limited.  A large all-ages study conducted in Australia in 2003, using 
routine national data sets, found that 2-4% of all hospital admissions are medication-related with up 
to three-quarters potentially preventable.27  A recent Australian paediatric study using intensive 
chart review and voluntary reporting found that harm-related AMEs occurred in 7 per 100 
patients.37   
Comparison between studies is difficult as there are significant differences between existing 
published research in case identification methods and definitions used for error and harm.  
Voluntary or spontaneous reporting of AME’s is known to significantly underestimate the incidence 
of error, however other methods using chart review or direct observation are extremely time 
intensive.187,331  Adverse events identified via clinical coding using the International Classification 
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of Diseases have been studied, however rarely compared to other data sources of adverse 
medication event data.188,332   
Most healthcare institutions have systems in place for reporting adverse medication events at an 
institutional level, to the regulatory body (Therapeutic Goods Administration in Australia)333, and 
recorded for the individual patient to minimise the risk of inadvertent re-exposure.  However, 
despite this being a routine expectation, this documentation is often poorly completed.334,335 
4.4 Aim 
The aim of this study was to review adverse medication events (AMEs) reported in hospitalised 
children using coding from the International Classification of Diseases and Related Health 
Problems, 10th Revision, Australian Modification (ICD-10-AM), and compare with: 
1) Events reported via other databases, 
2) Patient’s permanent (hard copy) clinical alert record, and 
3) Specialised electronic health records 
4.5 Method 
ICD-10 reported events 
The study retrieved AME reports for patients coded as having an adverse event related to a 
medication using codes Y40-Y59 (“drugs, medicaments and biological substances causing adverse 
effects in therapeutic use”) and X40-X44 (“accidental poisoning by and exposure to noxious 
substances”) over a 6 month period (1st January 2011 to 30th June 2011) in one Australian tertiary 
paediatric hospital.  ICD-10 coding was recorded as part of routine practice for all admitted patients 
by Clinical Coders using the International Classification of Diseases 10th Revision - Australian 
Modification and 3M Codefinder Software™ (3M Australia).  Patients’ medical notes (including 
progress notes, medication charts, discharge and clinical handover notes) were reviewed manually 
to identify date of reaction, medication name and group, and assessment of error and harm. 
Other data bases recording events 
Voluntary reports of clinical incidents recorded in the hospital-wide incident reporting system 
(PRIME®) and clinical pharmacist interventions documented in the hospital dispensing system 
(iPharmacy®) were retrieved for the same time period. 
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Documentation of event in other records: 
Documentation of the ICD-10 coded events in the permanent (hard copy) clinical alert record was 
manually reviewed.  Electronic patient profiles in the pharmacy information system (iPharmacy®) 
and the oncology information management system (Pharmacy Oncology Information Management 
System or POIMS®) were reviewed to determine if the event was documented.   
All Adverse Drug Reaction reports to the Therapeutic Goods Administration were reviewed.   
Exclusion criteria 
Patients and events were excluded if charts were unable to be identified after a minimum of two 
requests to medical records department.  Events were excluded if the report did not relate to 
medicines, occur during admission, or involved neither error nor harm.  
Definitions 
Adverse medication events are referred to as injuries resulting from medical interventions related to 
a medication.23  Potential adverse medication events are defined as medication errors with potential 
for injury but in which no injury occurred.23 Adverse medication events can therefore encompass 
both harm that results from the intrinsic nature of a medication (an adverse drug reaction) and harm 
that results from medication errors.27   This study included potential and actual adverse medication 
events, but excluded error prone conditions where there was neither error nor harm.  (For example, 
pharmacist interventions where a proactive change in therapy was made but was not associated with 
harm or error at that time, or incident reports describing deficiencies in documentation or rule 
violations without risk of harm to the patient.)   
Assessment of severity of harm used in this study was an adaptation of that used by Gazarian et al37 
with additional clarification from the National Coordinating Council for Medication Error 
Reporting and Prevention336 and Kale et al 2012337 (see Table 4.1). 
Assessment of error used the definition by Ghaleb et al ‘A clinically meaningful prescribing error 
occurs when, as a result of a prescribing decision or prescription writing process, there is an 
unintentional significant (1) reduction in the probability of treatment being timely and effective or 
(2) increase in the risk of harm when compared with generally accepted practice’.16  This definition 
was expanded to include other non-prescribing errors. 
Events from incident and pharmacist intervention reports were coded using the same definitions.  
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Table 4.1  Definition for Severity of Harm 
 Definition for Severity of Harm 
Nil  
Minor Increased level of care e.g, medical review and/or referral, additional 
investigations or medical therapy;  
This involved little or no threat to life or function, and could include elevated 
or depressed laboratory tests, dizziness, insomnia or headaches. 
Moderate Permanent reduction in bodily function; or temporary harm increased length 
of hospital stay; or surgical intervention required. 
This could include excess sedation, allergic reactions (more than a rash but not 
anaphylaxis e.g. shaking, chills or fever). An increased length of stay was 
assumed if admitted to the intensive care unit. 
Major Major permanent loss of bodily function or disfigurement. 
An intervention may have been required to sustain life. 
Includes life-threatening adverse medication events such as anaphylaxis. 
Serious Death 
High Risk Medications 
Medications were categorised to groups of known high-risk medications to determine which 
medication groups were most associated with harm in children in this setting.  Categories of high-
risk medications used the commonly used acronym of “PINCH” for Potassium, Insulin, Narcotics, 
Chemotherapy and Heparin and anticoagulants commonly used in adult medicine.338  Additional 
categories included intravenous fluids, antimicrobial, antiepileptic, and anaesthetic agents, and 
corticosteroids and immunosuppressants were added as a significant cause of harm and mortality in 
paediatrics.10,85,87,339 
Quality Assurance 
One research pharmacist retrieved the information regarding the event from the patient notes and 
recorded a description of the event.  A second, more senior pharmacist independently reviewed the 
notes of each event and coded for error and harm.  Differences in coding were identified and 
consensus reached via discussion.  Time spent retrieving the data was also recorded. 
The study was reviewed and approved by the institution’s Human Research Ethics Committee 
(HREC/12/QRCH/22). 
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4.6 Results 
Case Identification 
A total of 263 individual events from January 2011 to June 2011 were recorded by ICD-10 coding 
in 180 patients.  Charts were unable to be accessed for 22 events (15 patients), and 22 events were 
unable to be identified in the medical record.  Events were excluded due to duplication of reports 
(14), admission for management of allergic reaction or allergic challenge (26), adverse event 
occurring prior to admission (38) and event not related to an adverse medication event (4).  After 
missing or unrelated events were excluded, 137 AMEs remained for analysis.  (See Figure 4.1)  An 
additional nine events were identified during review of patient notes that had not been coded as 
adverse events.   
 
Figure 4.1  Case Identification Chart 
 
In the same period 130 adverse medication events were reported as clinical incidents, with 13 
events excluded as not associated with harm or error (e.g. system or documentation issues not 
involving error), with 117 events remaining.  Pharmacist interventions contributed 300 initial 
263 ICD-10 coded events 
137 events included for analysis 
9 Additional events identified via chart review 
447 Adverse Medication Events  
276 children 
(Includes 6 events from multiple sources) 
126 events excluded: 
22 unable to locate chart 
22 unable to locate event 
14 duplicated reports 
26 food reaction/allergy challenge 
38 prior to admission 
4 unrelated events 
130 Clinical Incident Reports 
117 events included for analysis 
13 events excluded 
(not associated with 
either harm or 
error) 
300 Pharmacist Intervention Reports 
110 events excluded 
(not associated with 
either harm or 
error) 
190 events included for analysis 
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reports, with 110 events excluded as not involving harm or error (e.g. optimisation of therapy by a 
pharmacist) leaving 190 events.   
In total 276 children with 447 adverse medication events were reported via ICD-10 codes, clinical 
incident, clinical intervention databases and chart review.  The maximum number of events per 
child was nine, with 32% of the children experiencing two or more adverse medication events 
during the six-month study period. 
Comparison between data sources 
There was little duplication between the data sources, with only six events recorded in two sources: 
four recorded via incident and coding reports, one as an incident and pharmacist intervention and 
one as an intervention and ICD-10 coded report.  No events were recorded in all three sources.   
The datasets reported different rates of medication groups, harm and error.  From the total of 447 
reported events, 158 events (35%) were associated with harm.  Of these 135 (85%) were from ICD-
10 coding, 16 from incident reports, nine from chart review and two pharmacist interventions.  The 
proportion of harm in the reports also differed: 99% of the ICD-10 coded events were associated 
with harm, 14% of the incident reported events and only 1% of the pharmacist intervention reports.  
In contrast, only 3% of the ICD-10 coded events were associated with error, in comparison to 97% 
and 100% of the incident and intervention reports. 
Assessment of harm 
Of the 158 events involving harm, 80% were considered minor, 18% moderate and 2% major.  All 
of the major harm events involved anaphylaxis, unrelated to error.  Of the 28 moderate harm events, 
only three involved error (including incorrect dosing of amphotericin or inadequate monitoring).  
Most of these events involved allergies or known adverse drug reactions such as diabetes from high 
dose steroids, excess sedation or respiratory depression from narcotics and nephro or ototoxicity 
from chemotherapy or aminoglycosides.  
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Comparison between medication groups 
 
 
Figure 4.2  Harm Related Events by Medication Group 
When considering the medication groups most associated with harm, 31% of the harm-related 
events were from chemotherapy, 18% from antimicrobials, 14% from corticosteroids and 12% from 
narcotics.  The individual medications most frequently associated with harm were dexamethasone 
(11), morphine (9), methotrexate (8), vincristine (8) and oxycodone (7).  Almost all dexamethasone 
harm events were when high doses were used as part of chemotherapy protocols, and involved 
either elevated blood glucose levels or avascular necrosis.  There were seven reports of harm 
associated with general anaesthetics, including hypotension, bradycardia, respiratory distress and 
nausea and vomiting.  
Documentation in other sources 
Of the ICD10 coded events, 14% were recorded on the permanent hard copy patient alert record, 
8% were recorded electronically in the dispensing system (iPharmacy), and 11% of the events in 
oncology were recorded in POIMS®. 
No adverse medication events involving medicines were reported to the Therapeutic Goods 
Administration. 
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There were 128 labour hours required to retrieve data on the ICD-10 coded events (excluding 
analysis).  This equates to approximately 29 minutes per event identified, and 56 minutes per event 
meeting inclusion criteria. 
4.7 Discussion 
ICD-10 coded events represent a different set of adverse events related to medicines in children that 
are not reported via other mechanisms in this institution.  This is similar to the findings of Cox et al 
in a general hospital in the UK where no overlap was found between adverse drug reactions 
identified via ICD-10 coding and spontaneous reports.332   
The coded events represent events more associated with harm from medicines than other sources 
researched, however few instances of error.  The high proportion of harm in ICD-10 coded events is 
to be expected, as coding is only undertaken where an indication of harm is documented in patient 
notes.   However, the low incidence of error in the ICD-10 coded events was unexpected.   
Incident reports largely involved events involving error that did not result in harm.  Almost all 
pharmacist intervention reports were “near-miss” events where the intervention prevented either the 
error reaching the patient or harm occurring.  In many respects, these incident and intervention 
reports represent quality and safety systems working to prevent harm.  Voluntary reporting is 
known to underrepresent the total number of safety events, with medical officer reporting 
particularly poor.331   Research in Australia and internationally has found that the organisational 
safety culture (e.g. communication openness, routine feedback, non-punitive culture) has a large 
influence on reporting by health practitioners.165,166,173  Australian research found that the observed 
behaviour of professional peers and a belief that safety behaviours will make a difference, were the 
two factors most influential on the safety behaviours of health care workers.166  
ICD-10 coding is designed as an administrative rather than clinical tool, therefore unlikely to be a 
complete record of all AMEs.  There were 12 harm events during this period reported as incident 
reports that were not identified via ICD-10 coding.  The question of why clinicians do not document 
these events in an easily identifiable way in the medical notes deserves further investigation.  Nine 
additional events were identified during chart review of a specific admission that were also not 
coded as adverse events via ICD-10.  There were 26 ICD-10 coded events excluded from analysis 
as they involved allergy or anaphylaxis to food rather than medicines.  Another 22 events were 
excluded where the details of the event were unable to be identified in the notes.  These examples 
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indicate that the ICD-10 coded events alone do not represent a complete record of all harm events 
related to medicines, consistent with the findings of Bates et al.187 
Incomplete recording on permanent alert records (via hard copy in the medical record, 
electronically in iPharmacy® or POIMS®) increases the risk of harm from unintentional re-
exposure to the medication.  Parents and carers may recall (and relay to the next health care 
provider) significant adverse effects they have observed, however those that occur when they are 
not with the child (such as with anaesthetics during surgery) are a particular risk if not documented 
carefully.  Inadequate documentation of ADR alerts in patient records has been observed by many 
other researchers, with one study finding only 10% of ADRs recorded in the institution’s electronic 
patient record.334  An electronic health record with integrated clinical alerts supported by a well 
designed paediatric clinical decision support system should assist with documentation and 
prevention of AMEs in the future. 
No reactions were reported to the TGA during the study period, including two reported reactions of 
extrapyramidal side effects from metoclopramide at standard doses and one case of extrapyramidal 
effects attributed to ondansetron.  Post-marketing surveillance is an important strategy to identify 
rare adverse drug reactions, particularly in patient populations not well studied during the initial 
research phase (such as in paediatrics).82  In Australia reporting of ADRs to the TGA is included in 
the National Safety and Quality Health Service Standards.333  These standards, now linked to 
hospital accreditation from 2013, may have a positive impact on institutional reporting into the 
future. 
An average of 56 minutes to retrieve data per event is resource-intensive and not suitable for routine 
quality assurance.  This is significantly higher than 19 minutes per event described by Hodgkinson 
in 2009.340  This study did however include multiple researchers reviewing each chart for quality 
assurance purposes, and many of the patients required manual review of multiple chart volumes.  
Future access to electronic patient notes may make this process more efficient and feasible as an 
ongoing safety and quality process. 
Reliance on reports via voluntary reporting is known to be incomplete, and chart review combined 
with direct observation is thought to be the most robust method of identifying adverse medication 
events.187  Use of chart review in conjunction with interventions and incident reports in an 
interrupted time series study provided valuable information on the long term reduction of adverse 
medication events in the study by Gazarian and Graudins.37  Computerised trigger tools as 
evaluated by Bates et al187 are more accurate and cost-effective than voluntary reporting, and other 
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researchers have successfully studied periodic random samples of patients using trigger tools 
validated in paediatrics in conjunction with chart review.182,183  Unfortunately many errors are not 
identified or documented in the patient record by the practitioner involved, and harm (particularly in 
children) may not be identified as associated with the use of medicine.  Subtle signs such as lack of 
improvement, or worsening or new symptoms may be not identified as related to inappropriate 
medication therapy, and therefore would not be reported in any of these data sources.   
This study has found that ICD-10 coding identifies events of harm from medicines that are not 
reported via other databases.  This method could be used for this purpose in other hospital settings, 
however manual data retrieval of ICD-10 coded events is time consuming, and the dataset is not 
sufficiently sensitive or specific for routine use without a computerised medical record.  
Organisational efforts to demonstrate positive change leading from reporting, and senior clinical 
leaders modelling patient safety behaviours may be the most effective strategies to engage 
clinicians in reporting incidents and documenting events in the medical notes.166  With the 
introduction of electronic patient health records, a combination of methods such as computerised 
trigger tools, ICD-10 coding and voluntary reporting may be a feasible long-term strategy to 
identify AMEs for ongoing quality assurance and research purposes.  
4.8 Manuscript Conclusion 
ICD-10 coded AMEs represented 85% of the harm related events documented, and few were 
recorded in other databases.  However, few ICD-10 coded events were associated with error and 
therefore may have limited preventability.  Recording on the clinical alert page in the patient 
medical record, and other permanent electronic records was poor. Review of ICD-10 coded AMEs 
resulted in valuable information on harm from medicines experienced by children in hospital that is 
not recorded in other databases, however is time-consuming and not a viable ongoing process until 
electronic patient records are available. 
4.9 Chapter Conclusion: 
When considering the original hypothesis, ICD-10 coding does identify different adverse 
medication events in hospitalised children than incident or intervention reports, however it is not 
currently a feasible case identification method for ongoing research or quality assurance purposes 
while reliant upon hard copy patient records. 
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5 Chapter Five: Adverse Medication Events – are we making a 
difference with high-risk medications in hospitalised 
children? 
5.1 Introduction to Chapter Five 
This chapter investigates eight years of adverse medication (drug) events in a children’s hospital to 
identify the skills required of pharmacists to effect sustained improvements in patient care, 
particularly with respect to medication safety.  It is important to identify how high-risk medications 
cause harm in children to ensure appropriate safety initiatives are implemented.  
This chapter builds on the results from the adverse medication event research described in Chapter 
4, where adverse medication events identified via ICD-10 coding were compared to those reported 
as clinical incidents and pharmacist interventions.  That study found that ICD-10 coding identified 
the largest proportion of harm events however these events were not associated with error (therefore 
not preventable) and were time intensive to retrieve.  This was in contrast to pharmacist intervention 
and clinical incident reports, which were the most effective at identifying events involving error and 
were more feasible as case identification strategies for a longitudinal retrospective study.   
Safe medication systems and appropriately skilled and competent health practitioners (including 
pharmacists) are essential to ensure effective change in practice and improvement in safety.  It is 
important to identify the most successful safety improvement strategies, and the skills required of 
health practitioners to enact these changes.  The hypothesis of this project is: 
Voluntary reports of medication related events can be used to identify trends in response to 
safety improvement initiatives, and identify associated skills required of health 
practitioners. 
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5.2 Manuscript Introduction 
Adverse medication events (AME) have been defined as ‘an injury, large or small, caused by the 
use (including non-use) of a medication’341 and AMEs are known to be a significant cause of 
morbidity and mortality for hospitalized children.26,43,342  Although children commonly take fewer 
medications than adults, they are at an increased risk of adverse medication events due to changing 
pharmacokinetic parameters, the need to calculate individualized doses, lack of suitable dosage 
forms, precise dose measurement and medication delivery systems, and lack of published 
information and licensed products for use in children.54 
Research into medication safety in children has increased over recent years, from identifying 
incidence of error and harm, particularly in comparison to the adult population, to more recent 
research investigating the effectiveness of safety prevention strategies.  Early research from the 
United States found that potential adverse medication events were three times more common in 
children than in adults, and this has been reinforced by recent research from Spain identifying a 
fourfold higher risk of serious errors in children, in comparison to the maternity population.43,49  A 
recent study across five paediatric hospitals in the UK found a prescribing error rate of 13.2% of 
medication orders and an administration error rate of 19.1% of doses.15 
Contributing factors for adverse medication events have been investigated, with research from the 
1990’s and early 2000’s demonstrating that system related problems including inadequate education 
and training, physical infrastructure, work processes, and interruptions, contributed to many adverse 
medication events.25,54,96,212,232,343,344  A range of strategies have been suggested, with varied 
evidence for their effectiveness in improving safety.41,96 
Recent studies in Australia and the USA involving children, have demonstrated significant 
reductions in adverse medication events (42% and >50%) after introduction of a combination of 
system level error prevention strategies, including targeted multimodal multidisciplinary education, 
audit and feedback and use of a standardized paediatric national inpatient medication chart.37,183  
Likewise, a study in Argentina found a reduction in paediatric medication errors after introduction 
of a non-punitive safety culture and prescribing and administration recommendations.345  Similar 
results have been seen when reviewing all hospital safety events in paediatric institutions after 
introduction of a number of cultural changes.167,168  One of the challenges when comparing results 
from medication safety research is the differing definitions and case identification methods used.  
Consequently studies investigating long-term trends in paediatric medication safety have been 
lacking.   
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The aims of this study were to review trends in medication related events in one tertiary paediatric 
hospital and to determine the impact of the initiatives and identify success factors implemented 
progressively over an eight-year period.  . 
5.3 Method 
Setting 
This retrospective study reviewed medication related events (MREs) in one 170 bed tertiary 
paediatric hospital over an eight year period. The hospital used paper-based medication charts in 
most clinical settings, used a ward-stock system for most medication supply, and had a limited 
clinical pharmacy service (weekdays only, for overnight patients).  Electronic voluntary reporting 
systems, which were anonymous and non-punitive, were introduced in 2005, 
Inclusion and Exclusion Criteria 
Inclusion criteria were voluntary reports of MREs from January 2005 to December 2012 from two 
electronic databases: 
• Medication related incidents from a clinical incident database called “PRIME™”.  Clinical 
incidents were defined as ‘any event or circumstance which has actually, or could 
potentially, lead to unintended and/or unnecessary mental or physical harm to a patient’.346 
• Pharmacist interventions from electronic records documented in the pharmacy dispensing 
system called “iPharmacy™”. Clinical pharmacist interventions were defined as ‘any action 
by a pharmacist that directly results in a change in patient management or therapy’.38 
Reports required a minimum of: date of event, clinical area and a narrative description of the event.  
Most reports also included the patient medical record number, medication name, and the reporter’s 
assessment of severity and harm.  Both electronic databases were significantly upgraded during the 
study period, which modified some additional data recorded, however the core dataset remained 
unchanged. 
Exclusion criteria were:  
• Reports with missing narratives describing the event 
• Reports unrelated to medicines (e.g. blood products) 
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• Event did not occur during the hospital admission.   
Datasets from PRIME and iPharmacy were combined and reviewed to identify multiple reports for 
the same event (different staff reporting the same event, and/or the same event reported in both 
datasets).  Multiple reports were identified using matched date of event, patient medical record 
number and narrative.  Data from each original record were combined to create a single unique 
event record.  
Assessment of Medication Related Events 
Each Medication Related Event (MRE) was then classified as: 
• Harm or no harm 
• Error or no error 
• Stage of the medication cycle during which the MRE occurred was identified (prescribing, 
dispensing and supply, administration or monitoring) 
• Medication group 
Definitions for harm used the trigger tool harm definitions by Tham et al, which included 
significantly abnormal laboratory values such as raised creatinine, hypo/hyperkalaemia, 
hyper/hypoglycaemia and anticoagulation lab values out of range.  Unrelieved pain or vomiting 
were also considered harm.183 
The definition for prescribing error as defined by Dean et al and validated by Ghaleb et al in 
paediatrics was used for events related to prescribing; this included a list of examples of events 
considered to be errors.14,16   The authors chose to extrapolate the prescribing error definition to 
non-prescribing errors, using a broader definition of ‘unintentional significant (1) reduction in the 
probability of treatment being timely and effective or (2) increase in the risk of harm when 
compared with generally accepted practice’14 for other areas such as administration and dispensing.  
Errors related to documentation or variation from local policy, if unlikely to be associated with 
increased risk for the patient, were not classed as errors.  Additional clarification of errors in 
administration included ‘a medication given in a dose different by at least 20% from the 
recommended dose’347,348 or ‘deviation by 2 hours or more from recommended’348 as used by other 
researchers. 
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One researcher coded each of the events, based on the agreed definitions, using the narratives and 
the reporter’s assessment of outcome if available.  Specific scenarios were discussed with the 
research team and definitions refined as required.  An electronic number randomisation generator 
was used to select 10% of the high-risk medication events, which were independently coded by a 
second researcher.  Differences in coding were discussed and consensus reached, with clarification 
of definitions as required. 
All events related to medicines during admission were included, regardless of whether they were 
associated with harm or error.  The total dataset therefore included:  
• Actual Adverse Medication Events – where harm was involved, with or without error 
(therefore including Preventable Adverse Medication Events, and those without error, 
commonly referred to as Adverse Drug Reactions or ADRs)  
• Potential Adverse Medication Events – where error was involved but no harm. The error 
may have been identified before reaching the patient or did not harm the patient.  
• Error Prone Conditions – where no harm or error was involved, however the event did 
involve circumstances or events that have the capacity to cause error.  Many pharmacist 
interventions occurred proactively before an error occurred and belonged to this category.  
These events were included in the initial analysis but removed for the detailed analysis. 
High Risk Medications Investigated 
Events were classified into the following high risk medication groups: Potassium, Insulin, 
Narcotics, Chemotherapy, Heparin and Anticoagulants, Antimicrobials, Intravenous Fluids, 
Anticonvulsants, Anaesthetics and Other.  These groups were derived from the acronym “PINCH” 
(Potassium, Insulin, Narcotics, Chemotherapy, Heparin and Anticoagulants) commonly used to 
classify high risk drugs.338  Antimicrobials, Intravenous Fluids, Anticonvulsants and Anaesthetics 
were added as categories as these groups have also been found to be involved in adverse drug 
events and fatalities in children.9,35,43,83,87 
Three high-risk medication groups (chemotherapy, potassium and narcotics) were reviewed in detail 
over the eight years to identify trends over time after introduction of a range of safety initiatives.  
Inclusion criteria for chemotherapy analysis were events involving chemotherapy, prescribing and 
error (with or without harm).  Chemotherapy included medicines listed in the chemotherapy 
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protocol (including non-cytotoxic agents), but did not include routine supportive therapy such as 
mouth-care and antiemetics.  Events were categorised with a proximal cause related to calculation 
errors, protocol errors, inadequate patient history or related to new technology (which included 
events associated with the information management system and use of pre-printed charts).  To 
minimise reporting bias, categories were described as a proportion of the total events reported for 
the oncology team. 
Inclusion criteria for potassium analysis were events including errors with the use of potassium, 
with or without harm, and included all routes of administration.  Potassium related events were 
categorised as prescribing, dispensing, administration and monitoring related events.   
Inclusion criteria for initial narcotic analysis were events involving errors with narcotic drugs, 
including products containing codeine.  Narratives from narcotic related events were reviewed to 
identify events involving confusion related to oxycodone, OxyContin® and MSContin®.  The 
oxycodone/OxyContin® events underwent further analysis and were categorised as prescribing, 
administration or dispensing errors. 
Safety Initiatives 
Table 5.1 - Safety Initiatives Implemented 2005-2012 
 Institution Wide Chemotherapy Potassium Narcotics 
In place 
prior to 
study 
period 
Medication safety 
concepts included in 
medical and nursing 
orientation. 
Manual incident 
reporting system, 
reviewed by Drug and 
Therapeutics 
Committee. 
Electronic 
documentation of 
pharmacist 
interventions 
(iPharmacy) from 
2004. 
Chemotherapy prescribed 
by oncology registrars. 
All chemotherapy orders 
reviewed by an oncology 
pharmacist before 
preparation. 
Didactic education on 
risks of IV potassium 
in medical and 
nursing orientation. 
National Medication 
Alert on the risks of IV 
potassium.  
Policy on the safe use 
of potassium. 
General risks of 
narcotic use 
included in 
orientation. 
 
2005 Web based incident 
reporting system 
(PRIME). 
Root Cause Analysis 
of significant incidents. 
Standardised national 
inpatient medication 
chart for paediatrics 
implemented, and 
Review of incident and 
interventions related to 
chemotherapy by 
oncology team. 
Chemotherapy 
prescribing limited to 
consultants. 
Pre-printed chemotherapy 
charts progressively 
Pre-mixed 
intravenous fluid bags 
containing 20mmol/L 
potassium were 
introduced. 
Restricted access to 
concentrated 
potassium ampoules 
although still available 
Codeine routinely 
used to treat post-
operative pain, 
alone or in 
combination with 
paracetamol. 
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audited annually implemented from 2005. in most clinical areas.  
2006-
2007 
Incident reports 
reviewed by Drug and 
Therapeutics 
Committee. 
Intervention reports 
reviewed separately by 
Pharmacy 
Department. 
Chemotherapy 
prescribing training and 
competency assessment 
for oncology registrars in 
2007. 
Smart-pumps 
introduced to the 
Paediatric Intensive 
Care Unit in late 2006.   
Oxycodone use 
increased 
dramatically, 
particularly for 
post-operative 
pain, replacing 
codeine. 
2008 Medication Safety 
Sub-Committee 
introduced, with 
responsibility to review 
incident and 
intervention reports. 
Drug Use Guidelines 
produced for high risk 
drugs including some 
antimicrobial and 
antiepileptic 
medications 
An electronic information 
management system for 
oncology patients 
(POIMS®) progressively 
introduced from 2008 to 
2011 (protocol by 
protocol).   
(Two paediatric oncology 
units merged into one at 
the study site) 
Severe harm event 
involving intravenous 
potassium in PICU 
(Root Cause 
Analysis). 
Introduction of 
potassium mini-bags 
(10mmol/100mL and 
40mmol/100mL) to 
allow for higher 
concentration 
infusions. 
Education for 
nursing staff 
provided 
(inservices and 
specific examples 
in orientation). 
Cognitive aid 
(alert chart) on 
drug safe. 
Pharmacist 
annotations on 
medication chart 
alerting to 
sustained or 
prompt release 
product. 
2009 “Good Catch” and 
“Safe Prescriber” 
Awards implemented. 
Medication Safety 
Champions identified 
for each clinical area. 
Strong executive 
support for review of 
potassium use. 
Development of 
hypokalaemia 
management 
guidelines with broad 
multidisciplinary input. 
Letter of concern 
sent to 
manufacturer.  
Targeted 
education to 
medical staff in 
orientation. 
2010 Review of pharmacist 
interventions included 
in performance 
appraisal. 
Medication chart 
audits coordinated 
nationally (annual). 
Hypokalaemia 
guideline published on 
state-wide intranet 
site. 
2011 Annual Grand Rounds 
presentations on 
Medication Safety 
(2011-12). 
Medical orientation 
changed to a case 
based tutorial, 
including a potassium 
supplementation case 
(2011-12). 
Specific 
OxyContin® 
confusion 
example removed 
from medical and 
nursing orientation 
(2011). 
2012 Rapid audit and feedback 
medication chart audits in 
oncology. 
Table 5.1 describes the various institution-wide and drug specific safety initiatives implemented 
during the study period for the three drug groups under review.  Pharmacists were involved in each 
of these initiatives: as primary providers in direct patient care initiatives (such as with annotation of 
prompt or controlled release on narcotic orders); primary providers of institution wide initiatives 
(such as medical and nursing medication safety orientation); or as members or leaders of 
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multidisciplinary working groups (such as with hypokalaemia guidelines).  These pharmacists, in 
collaboration with medical and nursing staff, led many of these system redesign activities.  Skills 
were required in critical evaluation of the literature, written and oral communication, collaboration, 
conflict resolution, negotiation and analysis of clinical incidents.   
The electronic information management system for cancer care patients (POIMS®) included 
information on the patient history, incorporated cancer care pathways with some decision support, 
and enabled electronic prescribing to generate a hard-copy medication chart.  The system was used 
for patients enrolled in specific cancer protocols, for day and overnight patients, but was not used to 
generate outpatient prescriptions for therapy at home.  Pharmacists were intimately involved in the 
development and implementation of this system, which required skills in risk, project and change 
management. 
Data Analysis and Ethics 
Information on patient separations (number of patients discharged from hospital) and occupied bed 
days were obtained from the institutional health information management service to determine 
incident rates. A trend test for comparison of proportions was used to examine error rates over time 
from 2005 to 2012 with a two-sided p<0.05 considered significant.  Statistical analysis was 
undertaken using Stata 12.0 (StataCorp, College Station, TX, USA). 
Ethics approval for the study was obtained from the Queensland Children’s Health Services Human 
Research Ethics Committee in February 2012 and institutional approval obtained from the 
Children’s Health Services Executive in March 2012 (HREC Reference Number: 
HREC/12/QRCH/22, SSA Reference Number: SSA/12/QRCH/31). 
5.4 Results 
Harm and Error 
A total of 2,743 incident reports and 8,336 pharmacist interventions involving all types of MRE 
were retrieved making a total of 11,079 individual reports.  Once duplications and unrelated reports 
were removed, 10,693 separate MREs remained.  There was little duplication overall, with only 
0.4% of events recorded as both pharmacist interventions and incident reports.   
Overall only 3.3% of the events were associated with harm (actual Adverse Medication Events) and 
71% of all events were associated with error.  Further analysis found that 27% of events were 
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associated with neither error nor harm, and therefore “error prone conditions”.  Events associated 
with harm but not error (“Adverse Drug Reactions” or ADRs) accounted for 1.4% of events.  
Events associated with error but not harm (“Potential AMEs”) accounted for 70% of events. There 
were 202 reported events (1.9% of the total) associated with error and harm, therefore a preventable 
AME.  (See Figure 5.1) 
 
Figure 5.1  Medication Event Types 
There was an average of 7.0 Medication Related Events reported per 100 patient separations or 28.3 
per 1000 occupied bed days.  Medication Errors occurred at a rate of 5.0 per 100 separations, and 
0.23 actual AMEs per 100 separations. 
The rate of harm (actual AMEs) reduced slightly from 0.27 to 0.22 AMEs per 100 separations from 
2005 to 2012 (or 1.07 to 0.87 per 1000 bed days.)  The rate of reported potential AMEs reduced 
from 6.4 to 3.0 per 100 separations. 
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Chemotherapy 
There were 925 MRE’s involving chemotherapy over the eight years.  Total chemotherapy 
prescribing errors reduced from 4.2 to 1.1 per 100 oncology separations from 2005 to 2012, despite 
a 54% increase in activity. 
Figure 5.2 shows the change in chemotherapy prescribing errors over the eight year period, 
demonstrating a significant reduction in protocol related errors from 91 to 24 per year, but an 
increase in errors related to technology (from zero to 9), in particular after the introduction of the 
information management system. 
Figure 5.2 - Chemotherapy Prescribing Errors 
 
To reduce the influence of reporting bias, chemotherapy prescribing errors were also analysed as a 
proportion of the total reported events from oncology and per 1000 oncology separations (See Table 
5.2).  Protocol related errors reduced from 17% to 12% of all oncology reported events over the 
eight years (p <0.01). 
Table 5.2 - Chemotherapy Prescribing Errors as a proportion of reported oncology 
events and separations 
 Number of 
Prescribing 
errors 
Per 100 
oncology 
events 
P value 
(2005 to 
2012) 
Per 1000 
oncology 
separations 
P value 
(2005 to 
2012) 
  2005 2012  2005 2012  
Calculation 120 5.7 4.9 0.84 9 2 <0.01 
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Documentation 30 1.9 1.5 0.91 3 1 <0.01 
History 83 0.9 3.4 <0.01 2 1 0.51 
Protocol 338 17 12 <0.01 28 5 <0.01 
Technology 21 0 4.4 <0.01 1 2 <0.01 
Other 2 0 0.5 0.39 0 0 0.91 
 
Potassium 
There were 196 MRE’s involving potassium over the eight years, with reported events (and errors) 
peaking in 2008.  Potassium related errors increased from 2.9 per 10,000 bed days in 2005 to 6.3 in 
2008 and down to 2.2 in 2012.  Prescribing, monitoring and administration related errors all peaked 
in 2008.   
Descriptors of events changed over time, from relatively simple slip/lapse type errors in the early 
years (such as product selection errors and incorrect addition to IV fluid bags) to more complex 
errors in the later years involving monitoring and the safest dose, rate and concentration for 
administration via different routes. 
Figure 5.3 - Potassium Errors 
 
There were five potassium events associated with harm over the eight years, including one event 
involving severe harm in 2008 where a smart pump was incorrectly programmed resulting in a rapid 
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infusion of potassium and cardiac arrest.  The child was resuscitated and survived, and the incident 
resulted in a comprehensive multidisciplinary root cause analysis and a strong institutional drive to 
improve potassium safety.  Manufacturer pump settings were modified nationally, potassium mini-
bags were introduced and clinical guidelines introduced (see Table 5.3).  There were no reports of 
harm events with potassium after 2008. 
Narcotics 
ADEs related to confusion between OxyContin®/oxycodone/MSContin® increased from 2 reported 
events in 2005 to a peak of 8 in 2009 then down to 2 in 2011 after the safety initiatives were 
introduced, as shown in Figure 5.4.  Errors related to administration decreased after introduction of 
targeted education to nursing staff, alert charts and pharmacist annotation on charts.  Prescribing 
errors reduced after targeted education was introduced to medical staff.  Administration and 
prescribing errors both increased in 2012 after removal of the targeted education regarding this type 
of error from the medical and nursing education program.   
Figure 5.4  Oxycodone/OxyContin/MSContin errors 
 
There were only three reports of harm from this type of error, one in 2008 and two in 2009.  There 
were a total of 43 events associated with harm involving all narcotics over the eight years. 
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Other high risk drugs 
In comparison to the reduction in chemotherapy and potassium errors over the eight years, errors 
related to antimicrobials and antiepileptics also halved, intravenous fluids increased marginally, and 
errors related to heparin and anticoagulants increased by a factor of eight.  Reporting of therapeutic 
drug monitoring of antimicrobial and antiepileptics reduced over this period (contributing to an 
decreased number of reported events in the latter years), although no specific safety initiatives.  
There were no safety initiatives implemented addressing heparin and anticoagulants events during 
the study period. 
5.5 Discussion 
This study describes eight years of voluntary reports of medication related events in a paediatric 
hospital, and changes over time in adverse medication events associated with introduction of a 
range of implemented safety initiatives.   
The total AME (ie actual harm) rate of 0.23 per 100 patients is lower than that found with some 
other paediatric research, which is to be expected with the differing case identification methods 
used.  Research using chart review in addition to voluntary reports identified a rate of 3.99 AMEs 
per 100 patients (Australia), 7.6 AMEs per 100 patients (USA) and 12.9 AMEs per 100 patients 
(New Zealand).35,37,234  A more detailed review from the USA using trigger tools in addition to 
voluntary reports and chart review identified 11.1 per 100 patients.182 
The medication error rate of 5 per 100 patients is significantly higher than the 0.15 per 100 patients 
reported in a UK paediatric hospital, also using voluntary reporting alone.349  The potential AME 
(error but no harm) rate of 4.9 per 100 patients is comparable to the Gazarian and Graudins result of 
4.6 at the end of their study in 2007 using chart review and voluntary reports.37  The varied results 
from our study compared to other research reflect not only differences between the case 
identification methods, but also that simple harm events unrelated to error (also called Adverse 
Medication Reactions) were unlikely to be reported via the incident or intervention reporting 
methods, as identified in earlier research.330  However, when considering the impact of safety 
initiatives ADR’s are also less likely to be preventable than events associated with error. 
Voluntary reporting (as used in our study) has been found to significantly underestimate the extent 
of adverse medication events (those causing harm) in comparison to chart review or direct 
observation.84,191,331  However, voluntary reports are relatively inexpensive to maintain on a routine 
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basis and effective at identifying potential adverse medication events (ie errors that are identified 
and resolved before reaching the patient), particularly when including pharmacist intervention 
reports.191  Rates of voluntary reporting in this study were higher than in many other published 
research.15,331  In comparison to voluntary reporting, chart review identifies most harm events 
(actual AMEs), particularly those related to prescribing, whereas direct observation is the most 
effective to identify administration errors that may otherwise go undetected.19  Other case 
identification strategies have included random samples of charts using interrupted time series, 
which has been useful for intensive and longitudinal research.37,177 Trigger tools are also 
increasingly being utilized for ongoing AME surveillance, predominantly in sites with an electronic 
medical record, and have been adapted for paediatrics.182,350  Similarily, ICD coding has been used 
to identify AMEs, however the recorded events are predominantly not related to error.330  None of 
these more intensive case identification methods were suitable in this study due to retrospective 
collection of eight years of data in a setting with reliance on a paper based medical record.  
There were limitations in determining error and harm as it relied upon the written event narrative, 
however standard definitions by previous researchers in paediatrics, were used to determine error 
and harm.14,16,183  In contrast to some published research, this study initially included potential 
adverse medication events and error prone conditions as well as actual adverse medication events, 
which allowed for a large number of events to initially investigate.  However, only those events 
classified as error were included when considering trends for individual medication groups. 
Institution wide initiatives 
The safety initiatives implemented in this institution have been widely recommended to improve 
safety and quality of medication use.41,81,96  True cause and effect are difficult to ascertain due to the 
sequential and progressive nature of the initiatives implemented, in addition to the limitations of 
voluntary reporting.  However, the safety reporting systems themselves appear to be widely 
accepted and utilised by hospital staff, in particular nursing and pharmacy staff.  The introduction of 
the multidisciplinary Medication Safety Committee enabled a more focused analysis of reports and 
implementation of strategies to continue to improve safety.  “Good Catch” and “Safe Prescriber” 
Awards have been a valued acknowledgement of contribution of individuals.  Introduction of a 
standardised medication chart was well accepted with ongoing audits indicating steadily improving 
documentation, as found by other researchers.37,351,352   
All of these initiatives have served to raise clinicians’ awareness of risks, the need for reporting, and 
demonstrating a positive, change orientated approach to medication safety, rather than a traditional 
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punitive process with a culture of blaming individuals involved in errors.  The results from our 
study were similar to that found in similar research in the USA and Australia, where a combination 
of strategies embedded in a strong safety culture is key to reduction in preventable harm.37,167,353 
Is it uncertain what affect the generic educational strategies had on the rate of actual or potential 
AMEs.  The majority of education provided in the earlier years of the project was didactic in nature 
as part of mandatory orientation days, where limited information retention was likely.  It was too 
early to identify whether the case based prescribing tutorials implemented in this site in 2011 had a 
more positive impact on prescribing competency, as suggested by other researchers, particularly if 
combined with audit results and personalised feedback.203 
Chemotherapy 
There was a significant reduction in chemotherapy prescribing errors from 17% of oncology related 
events in 2005 to 12% in 2012, with the main reduction in the first few years after restriction of 
chemotherapy prescribing to consultants, and progressive introduction of pre-printed oncology 
medication charts.  This reduction was maintained from 2008 onwards, despite an increase in 
activity of 40% after merging of two paediatric oncology units into the same institution.  The 
introduction of new technology (electronic prescribing in a new information management system) 
introduced new errors into the system, with 4% of events by 2012 related to the new technology.  
This is consistent with the findings of a recent systematic review which found that computerised 
physician order entry (CPOE) and pre-printed order sheets had the greatest reduction in paediatric 
medication errors.354 
A confounding factor in this analysis is the increasing complexity of chemotherapy treatment 
protocols during the eight years of analysis.  
Potassium 
Reported events involving potassium increased to a peak in 2008 then decreased progressively 
through the following years.  The apparent increase in reports may have merely been due to 
increased awareness of the risks of potassium use, however demonstrated that restriction of access 
to concentrated potassium, and availability of premixed IV fluids had little positive impact on error 
rates initially.  Characteristics of the events changed through the years, indicating improved 
knowledge of appropriate use of potassium over time.  Introduction of “smart pump” technology 
appeared to contribute to a number of new types of errors immediately after introduction.  The 
serious potassium harm event that occurred in 2008 provided significant impetus for change in 
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practice, including strong executive support.  The findings from the root cause analysis were used to 
push for change in the programming by the manufacturer of the smart pumps at a national level, and 
in the development of Hypokalaemia Management Guidelines at a local level.  These guidelines 
were produced in an easy to use, practical format with strong multidisciplinary input, in contrast to 
the poorly utilised policy on safe use of potassium previously in place.  The introduction of 
potassium mini-bags also facilitated higher doses for administration than in the original 20mmol/L 
bags, and meant that concentrated potassium ampoules were rarely required outside of critical care.  
The increased awareness, practical guidelines and potassium mini-bags may have contributed to the 
reduction in reported events since 2008, including the absence of any harm events. 
Narcotics 
Events related to confusion between oxycodone, OxyContin® and MSContin® increased rapidly 
alongside increased use of oxycodone for postoperative pain.   Strategies to improve knowledge and 
awareness via education campaigns and alert posters had an initial positive impact to reduce errors.  
This improvement was not maintained, with an increase in events (particularly administration 
errors) in 2012, possibly related to removal of the targeted content from mandatory education 
programs in 2011.  It is also possible that cognitive aids such as alert posters become “invisible” 
over time and may lose their preventative effect.  The absence of harm related event reports since 
2010 is encouraging.  However, the recurrence of events in 2012 reinforces that education alone is 
not sufficiently effective, and requires continuous effort. 
It is important to note that the majority of efforts to reduce narcotic related events were focused on 
these errors involving confusion with OxyContin®.  This analysis demonstrates that these errors 
contributed only a small proportion of the narcotic events involving harm. 
Skills required to improve safety 
Health practitioners require knowledge of medication uses and administration systems to identify, 
resolve and report medication related problems and errors on an individual patient basis.  However, 
to make more sustained improvements at an institutional level, the changes described above 
required skills in communication and teamwork, including skills in persuasion, negotiation and 
collaboration.  Management skills were required, such as change management, project management 
and risk management.  Educators required skills to prepare and deliver an effective learning activity 
that actually changed practice.  Skills in leadership were required to develop effective improvement 
initiatives and motivate others to participate effectively.  Skills in research methodology are 
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required to design appropriate methods of analysis.  Unfortunately, these skills are often 
underappreciated when building an effective health workforce.  There is a need for a more 
formalised process to develop practitioners with this wider set of skills, which others have called 
advanced practitioners.1,114,141  
Summary 
The large number of events reported, including potential AMEs and error prone conditions, reflects 
a well functioning safety culture within the organisation.  These “near-miss” events are important to 
identify system failures that require action to prevent future events that could harm patients.   
The safety initiatives implemented show some effect in reducing the incidence of errors, and 
adverse medication events.  The most effective strategies involved strong executive support and 
broad system changes supported by significant multidisciplinary input into design and 
implementation.  Education was important but required ongoing commitment to be effective.  The 
use of voluntary reports is a valuable and efficient method to review trends in adverse medication 
events over time, although detailed analysis is required to limit the effect of reporting bias.  
Ongoing quality assurance processes using a combination of voluntary reports with computerised 
trigger tools and ICD-10 reporting would be useful where electronic medical records are in place, 
with the addition of random samples of patients to investigate specific research questions.  Future 
risk reduction efforts should focus on areas of greatest reported harm (and risk of harm), not only 
the area with the greatest number of reported events. 
5.6 Manuscript Conclusion 
This study confirmed the use of voluntary reports of medication related events to demonstrate a 
reduction in reported adverse medication events in a single paediatric hospital over eight years after 
a series of successive safety initiatives.  Multidisciplinary input and executive endorsement was 
essential and broad system changes are the most effective strategy to influence safety, whereas 
education had only a limited effect.  Health practitioners need to develop safe medication 
behaviours at an individual level, but also knowledge and skills on how to effect behaviour change 
at a profession and institutional level, to ensure positive and long-lasting improvement in the safety 
and quality of medication use. 
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5.7 Chapter Conclusion: 
This research confirmed the hypothesis that voluntary reports of medication related events can be 
used to identify trends in response to safety improvement initiatives, and identify associated skills 
required of health practitioners. 
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6 Chapter Six: What does advanced practice mean to 
Australian paediatric pharmacists? A focus group study 
6.1 Introduction to Chapter Six 
This chapter describes the opinions and perceptions of Australian pharmacists who work with 
children regarding advanced pharmacy practice.  This project was undertaken to ensure that 
advanced practice was a concept accepted and desired by the workforce, and to determine the 
preferred methods of assessment of advanced practice.  The findings in this project informed the 
research described in Chapter Nine where different methods of assessment of advanced practice 
were piloted.  Three of the six major Australian tertiary paediatric hospitals were chosen to 
participate in the study, with input from an additional three general hospitals during the fourth focus 
group session. 
Individual authors and professional bodies from UK and USA have described quite consistently the 
specific knowledge and skills required of paediatric pharmacists.  These include the knowledge of 
developmental pharmacokinetics and pharmacodynamics; how to determine and calculate doses; 
how to administer medications to children effectively and safely; how to modify available 
preparations to make suitable for administration for children; and appropriate use of unlicensed and 
off-label medicines.102-104  Specific challenges included lack of information sources; lack of suitable 
formulations; medication errors; monitoring of safety and effectiveness; and effective 
communication with children and families.102-105  These concepts have been assumed but not 
confirmed in the Australian paediatric setting.  Further investigation is also required to determine 
the difference between the expectations of a general level paediatric pharmacist, versus a paediatric 
pharmacist practicing at an advanced level. 
The hypothesis for this research project was: 
Paediatric hospital pharmacists valued formal recognition of advanced pharmacy practice, 
can describe the skills, knowledge, attitudes, and behaviours of advanced practitioners and 
identify preferred methods of assessment of advanced practice.   
This chapter has been published by the International Journal of Pharmacy Practice.355  This is the 
accepted version of the following article: Stacey SR, Coombes I, Wainwright C, Cardiff L, 
Whitfield K. What does advanced practice mean to Australian paediatric pharmacists? A focus 
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group study. Int J Pharm Pract Forthcoming 2014. doi: 10.1111/ijpp.12113, which has been 
published in final form at http://onlinelibrary.wiley.com/doi/10.1111/ijpp.12113/abstract 
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6.2 Manuscript Abstract 
Objectives 
The aim of this study was to explore perceptions and attitudes of Australian paediatric pharmacists 
about advanced pharmacy practice and to identify suitable methods of assessment for this level of 
practice. 
Methods 
Four focus groups (with 31 participants) were held in 2012 with Australian hospital pharmacists 
who work with children. Written notes and audio recordings were used to produce verbatim 
transcriptions and extract themes. 
Key Findings 
There was consensus across groups that formal recognition of advanced pharmacy practice was 
valuable to the profession and to individuals.  Elements should include a strong grounding in 
clinical practice, commitment to education, research and service improvement outside the 
department and institution.  A framework for career development should be used to describe the 
levels of practice leading to advanced practice.  Assessment should involve multiple separate 
criteria, and incorporate direct observation, peer review and a professional portfolio.  Postgraduate 
qualifications are desirable but not considered essential. Different knowledge and skills are required 
in paediatrics however the definition of advanced practice remains the same. 
Conclusions 
Recognition of advanced practice is valuable for the profession and for individuals.  Multiple 
methods of assessment should be used.  Specialty areas such as paediatrics can be defined and 
assessed similar to other specialties, with acknowledgement of the specific paediatric knowledge 
and skills required. 
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6.3 Manuscript Introduction 
The pharmacy profession is evolving in response to changing healthcare requirements, with 
recognition of advanced pharmacy practice increasingly common in many countries.1,356  However, 
definitions and processes for assessment and recognition of advanced pharmacy practice differ 
between countries.   
The most extensive work in this area has been undertaken in the United Kingdom, where the 
Competency and Development Evaluation Group (CoDEG) developed an Advanced and Consultant 
Level Framework (ACLF) in 2005.115  This framework defines knowledge, skills and attributes 
expected of an advanced practitioner, in professional practice, working relationships, management, 
leadership, education and research. The ACLF has been endorsed by the Department of Health, 
used as an evaluation tool for pharmacists seeking consultant pharmacist positions in the UK and as 
the basis for professional recognition of advanced practice by the recently established Royal 
Pharmaceutical Society Faculty.357  In contrast, in the USA formal certification as an advanced 
practitioner in a designated speciality is achieved by successfully passing a Board of Pharmacy 
Specialties professional practice knowledge based examination.128   
In Australia, formal recognition of advanced practice is not yet available, although a definition has 
been endorsed: 
Advanced Practice is practice that is so significantly different from that achieved at initial 
registration that it warrants recognition by professional peers and the public of the 
expertise of the practitioner and the education, training and experience from which that 
capability was derived.132 
A number of specialty pharmacy groups in Australia including cancer care,136 infectious 
diseases,139] cardiology,138 emergency medicine,137 palliative care and paediatrics133,134 have adapted 
the CoDEG frameworks to their own specialties. Their use to date has focused on individual 
professional development rather than assessment. In 2011, a collaborative of Australian pharmacy 
stakeholder groups (Australian Advanced Pharmacy Practice Framework Steering Committee) 
commenced work on a profession-wide framework for advanced practice, based on the CoDEG 
(ACLF) work,115 and cross-referenced to the existing Australian national competency framework.132  
The completed Advanced Pharmacy Practice Framework (APPF) was released in 2012 and 
endorsed by the Pharmacy Board of Australia.141  This was an important step forward in Australian 
pharmacy practice, although not yet linked to a process to formally recognise advanced practice. 
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In paediatrics, advanced pharmacy practice has progressed in a similar form.  The Neonatal and 
Paediatric Pharmacists Group (NPPG) in the UK developed a set of competencies specifically for 
paediatric and neonatal pharmacists, aligned to the ACLF.358  In Australia, the Paediatric Advanced 
Level Framework was developed in 2008 by the Committee of Specialty Practice in Paediatrics, a 
subgroup of the Society of Hospital Pharmacists of Australia (SHPA).133,134  In the USA, 
comprehensive foundation level paediatric training is provided via residency programs that have 
been accredited by the American Society of Health-System Pharmacists.  Formal recognition of 
paediatric advanced practice is not currently available, however the Pediatric Pharmacy Advocacy 
Group (PPAG) is currently working with the Board of Pharmacy Specialties to include paediatrics 
as a recognised specialty in pharmacy practice.359  
The aim of this study was to explore the perceptions of hospital-based pharmacists working in 
paediatrics regarding advanced pharmacy practice and suitable assessment methods. 
6.4 Method 
Participants 
Focus groups were held in Brisbane, Sydney, Adelaide and Auckland from January to June 2012, 
facilitated by a researcher (SS).  Three groups were held at large tertiary paediatric hospitals and the 
fourth was held in conjunction with a meeting of Australasian paediatric pharmacists in Auckland.  
An open invitation was given to all pharmacists working in those hospitals or attending the 
Auckland meeting to attend a session to discuss advanced pharmacy practice.  Pharmacists at each 
of the hospitals were invited via email from the Director or Assistant Director of Pharmacy. 
Pharmacists attending the Auckland meeting were invited verbally.  Meeting rooms were used for 
the hospital sessions, and a section of a hotel lobby for the Auckland meeting.  This format was 
designed to provide an informal environment to facilitate open discussion.  Open invitations were 
used to obtain a purposive sample of pharmacists with a broad range of experience within 
paediatrics.   
Ethical approval and Permissions 
Permission was sought by Directors of Pharmacy at the individual hospitals to undertake the focus 
groups.  Ethical approval was obtained from the Ethics Committee of the School of Pharmacy, The 
University of Queensland. Participation in the focus groups was voluntary, with attendance at the 
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session representing consent to participate.  Additional explicit consent was obtained verbally at the 
commencement of the meeting.  
Data collection 
Demographic information was collected verbally from participants at the commencement of the 
session (see Table 6.1).  A topic guide was used to ensure a common core of data was collected for 
each group.  Topics were developed by the researcher (SS) based on a literature review, discussion 
points raised by current users of the Paediatric ALF,133 and questions posed by the Australian 
Advanced Pharmacy Practice Framework Steering Committee.360  These included: description of 
the characteristics of advanced practitioners; differences between specialist and advanced practice; 
value of formal recognition of advanced practice; appropriate assessment criteria for advanced 
practice; suitability of the current Australian definition of advanced practice;132 and the differences 
between paediatric and general advanced pharmacy practice.  Comments from the earlier groups 
were repeated in the latter group sessions to promote further exploration of the topic. 
Written notes were taken and digital audio recordings of the sessions were transcribed verbatim.  
Data saturation was achieved at the conclusion of the fourth focus group, where no new ideas were 
being added and the group highlighted similar themes to the preceding groups. 
Data Analysis 
A summary of each group session was manually extracted from the written notes and audio 
recording (by SS), including general themes and illustrative quotes. Quotes were identified by 
Group number (e.g. G1) and Participant number (e.g. P2). 
The summary was sent to all participants to provide opportunity for participants to clarify or add 
comments as required.  One session was independently transcribed and themes extracted by a 
separate researcher (LC) to ensure consistency of interpretation and quality assurance.  Minor 
discrepancies were identified, which were discussed and consensus reached.  Thematic analysis was 
undertaken using NVivo qualitative analysis software (QSR International Pty Ltd. Version 10, 
2012).   
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6.5 Results 
Focus group sessions were held for an average of 59 minutes (45-73 minutes) with an average of 8 
participants per group.  Each session included open discussion and debate between the participants, 
and each participant was provided with opportunities to contribute. 
Participant demographics 
Approximately half of the invited pharmacists attended the hospital-based sessions, and all of the 
Australian invited pharmacists attended the Auckland session.  A total of 31 pharmacists were 
involved. Two pharmacists attended two separate focus groups.  
Most participants worked in tertiary paediatric facilities, with three from general hospitals.  Six 
hospitals and five Australian states and territories were represented.  Two participants were 
Directors of Pharmacy, the remainder held a range of different roles providing direct and indirect 
patient care.  
Table 6.1 outlines the demographic characteristics and experience for participants in each group. 
Table 6.1  Participant Demographics 
Session City Participants 
(female) 
Average pharmacy 
experience/participant 
in years (range) 
Average paediatric 
experience/participant 
in years (range) 
1 Brisbane 8 (7) 8.8 (3-25) 7.6 (3-24) 
2 Sydney 6 (6) 9.3 (3-17) 4 (3-5) 
3 Adelaide 12 (6) 11.3 (3-29) 7.3 (1-24) 
4 Auckland 7 (5) 21.4 (5-30) 10.1 (4-23) 
 Total 31 (23) 12.4 (3-30) 7.0 (1-24) 
 
Thematic analysis 
General themes extracted from the meetings included definition of advanced practice, elements of 
advanced practice and assessment of practice. 
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A system of credentialing or formal recognition of advanced practice was thought to be valuable to 
individuals and the profession.   
It is around rewarding and recognizing people…Gives some credence, some credibility, and 
some recognition of people’s practice… it gives you something to aspire to and work 
towards. (G4/P6) 
Definition and description of Advanced Practice 
The current Australian definition of Advanced Practice (listed above) was acceptable to some 
participants, although most described it as too long and difficult to understand.   
Two groups expressed concern regarding the inclusion of “warrants recognition… by the public”.  
The participants felt that the public may be unable to recognise or differentiate an advanced practice 
pharmacist from a general level or newly graduated pharmacist, and were unsure whether the 
demonstration of recognition required a formal public award such as an Order of Australia.   
All groups described professional knowledge and skills as the most important components of 
advanced practice.  More experienced participants described additional factors including research, 
education, and influence outside the institution.  Participants from all practice areas and experience 
levels described personal characteristics such as motivation, commitment to improvement and being 
a professional leader and role model. 
All groups described advanced practice as being more than providing a basic service, using phrases 
such as “above the norm” (G1/P8), “a step ahead” (G2/P2) or “the next level” (G2/P5).  There 
was a range of expectations of advanced practice, from being an exceptional clinical pharmacist 
making a difference at an institutional level, up to practice and influence at a much higher level or 
“someone who really stands out from their whole profession at a national level” (G4/P5).   
Some groups described a journey towards advanced practice, incorporating a series of levels, steps 
or gradient of increasing skills and influence.  A framework describing these levels was 
recommended by participants to provide a career pathway for pharmacists, where each level was 
recognised and each new level was seen as an achievable goal. 
It was acknowledged (particularly by participants from general hospitals) that being a “state or 
national expert” might be easier to achieve in tertiary hospitals, and in some specialties than others.  
The groups agreed that although paediatric pharmacists require different knowledge and skills to 
other pharmacists, the definition of advanced pharmacy practice would apply to all specialities.  
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Advanced practice was considered different to specialisation.  Specialisation was thought to exist 
without advanced practice, and that pharmacists could be practicing at an advanced level in a 
generalist area without specialisation.   
You’re not necessarily an advanced practitioner just because you come and work in a 
children’s hospital.  But you are specialising. (G2/P4) 
Elements of advanced practice 
Knowledge and Skills 
All groups described knowledge and skills as the most important element of advanced practice.  
Some groups discussed the need for advanced practitioners to have a broad base or foundation level 
knowledge and develop a deeper knowledge and skills in specialist areas.  
It is like a pyramid.  Your pyramid is going to look different to other people’s pyramid 
(G1/P1) 
Specific knowledge required by paediatric pharmacists included knowledge of childhood diseases, 
developmental changes and medication handling in children.  All groups stressed the importance of 
effective age-appropriate and family-centred communication skills in paediatrics.   
Working Relationships 
Advanced practitioners were described as having a network of colleagues within and external to the 
profession and the institution, at a state, national and sometimes international level.  Examples 
included being consulted for advice, and acting as a representative for the discipline, department or 
institution on committees or working groups.  
You have come to a level where you have expertise and knowledge that you are approached 
by not only your colleagues, but other people. (G3/P10) 
All groups described the requirement for good teamwork, the ability to communicate effectively 
and build effective working relationships.   
Leadership and Management 
Advanced practitioners were expected to have vision and a strong commitment to quality and 
system improvement at an organisational level or in a specific clinical area.  Advanced practitioners 
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were described as initiating change at least locally, and at higher levels the ability to lead the 
profession or specialty area forward at a state, national and international level.   
Only one group explicitly mentioned management, although other groups described elements of 
management (e.g. providing feedback, project management and quality improvement).   
Education (self and others)  
All groups discussed the need for education and professional development.  Advanced practitioners 
were expected to have completed considerable professional development and learning activities to 
enhance their skills.  Formal postgraduate qualifications were desirable, although not essential.  
Participants were influenced by their own experiences with postgraduate training and by the 
availability of quality educational opportunities locally, in particular the lack of paediatric specific 
training.  Participants described current practitioners who work at an advance level that do not have 
postgraduate training.  
It probably reflects people who are willing to do more.  You often find that advanced 
practitioners have gone out to get further qualifications. (G3/P11) 
Its just a piece of paper, unless it affects your behavior and how you interact when you get 
back to the role.  The fact that you have a diploma in clinical pharmacy doesn’t mean that 
you are advanced in your practice. (G4/P6) 
All groups mentioned education of others as a significant component of advanced practice.  An 
advanced practitioner was expected to be involved in education of others in and outside the 
workplace and discipline, and act as a role model and an expert or leader in the specialised area  
When you start off, you are at foundation, learning for yourself, build up your own 
knowledge.  You get to a point where you start disseminating that… further and wider. 
(G3/P11) 
Research, Evaluation and Publication 
Involvement in research by advanced practitioners was considered important.  Critical evaluation of 
evidence, production of protocols and guidelines and the undertaking of research-driven service 
improvement projects were mentioned as relevant examples.  Publication of research was highly 
desirable but not considered essential, and most relevant to the higher levels of practice.   
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Direct and Indirect Patient Care  
Participants did not consider direct patient care as essential to the advanced practitioner.  It was 
noted that pharmacists in technical and management roles could also have advanced skills.  There 
was, however, an expectation of a strong foundation in clinical practice and to remain “in touch” or 
“integrated” with patient care.  
I am thinking about my managers, they don’t see patients all the time, but to me they are 
advanced practitioners… (G2/P6) 
Personal Characteristics 
Advanced practitioners were described as having an internal motivation or desire to learn and 
advance their skills, to be confident and inspire confidence in others, and to have a commitment to 
improvement. 
With advanced practitioner… its not just about knowledge and skills, also about character, 
because you are going to be a role model… professionalism, integrity, character, how you 
talk to your peers and people in general. (G2/P6) 
Assessment of Advanced Practice 
Participants agreed that there should be a range of methods for assessment and evaluation of the 
advanced practitioner. 
There needs to be many different criteria, and not everyone will be able to meet everything 
because every specialty is different.  Every advanced practitioner will work in slightly 
different ways. (G2/P5) 
The options discussed for assessment were as follows: 
 
Portfolio 
Professional portfolios were strongly supported as a method of assessment.  Suggested evidence for 
a portfolio included contribution to quality improvement activities, production of clinical protocols 
and guidelines, education (e.g. lectures and presentations), research (e.g. reports and publications) 
and examples of leadership.  A portfolio could also include evidence of peer review or recognition 
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(e.g. emails, references, multi-source feedback) or reports on direct observation of practice (e.g. 
General Level Framework209 or shpaclinCAT209).  
Years of Experience as Assessment: 
Experience was considered essential for an advanced practitioner, however there were varied 
opinions of how long it would take to develop advanced practice.  This was linked to the years of 
experience of the participant themselves, and the perceived “level” of an advanced practitioner, 
which varied from approximately 3 years to become proficient as a clinical pharmacist in a 
particular area, to 5-10 years to develop the relationships and influence required for the higher end 
of the scale of advanced practice.  
But there might still be a time frame that it takes fit in those conversations, and those 
relationships, and that learning…Someone can do that quicker than another person.  
Someone might do it in two years and someone might do it in four years.  Someone might 
never get to that spot because of their personal characteristics (G1/P2) 
It took 3-4 rotations to actually see those variety of cases, to been exposed to it, and actually 
get confident enough that I would try new things, and do things differently, learning from 
previous experiences which if I had had only one rotation in there I wouldn’t have done.  
Even though I could have read all the books or gone through all the courses or had all the 
mentoring that still would not have been enough to get me to that point. (G1/P4) 
Peer Review and Feedback 
Most groups discussed peer review as being valuable in assessment although there were different 
perceptions as to what peer review involved.  Suggested tools included structured feedback using 
direct observation of clinical practice in your own site (e.g. General Level Framework or 
shpaclinCAT),209,297 or formalised feedback from multidisciplinary peers (such as 360 degree 
reviews or multisource feedback).312  
Objective Structured Clinical Examinations (OSCEs)  
There was significant doubt expressed regarding OSCE type evaluations to assess advanced 
practice.  Concerns included relevancy of OSCEs only for those providing direct patient care, and 
that OSCEs assess the ability to role-play, not necessarily the ability to provide high level clinical 
care. 
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That is again just a clinical scenario, and at advanced level you are thinking about more 
than the clinical scenario. (G3/P7)   
People fail based on the role-play.  You are being judged on how good you are at role-play. 
(G3/P11) 
Interview/viva 
Some groups discussed an interview or “viva” as being a valuable method to assess and confirm 
level of practice, particularly by an external panel.  This could include discussion and evaluation of 
involvement in research, education, and influencing the profession. 
Someone might pass an OSCE quite comfortably but when you probe more deeply in an 
interview or viva you actually work out that they don’t have that knowledge or skill base. 
(G3/P1) 
Knowledge Assessment 
Knowledge was felt to be an essential component of advanced practice, however formal knowledge 
assessment (e.g. via examination) was not specifically discussed. 
6.6 Discussion 
This study sought to identify pharmacists’ perceptions of advanced practice and processes for 
recognition.  The participants agreed that recognition of advanced practice was valuable for 
individuals and for the pharmacy profession, with a combination of multiple assessment methods 
used to evaluate level of practice.  Expert knowledge and skills, leadership and management, 
working relationships, education and research were all considered important components of 
advanced practice. 
Strengths and Limitations: 
Pharmacists who chose to attend the session were self-selecting and therefore more interested in 
advanced practice than those who did not attend.  However, this method of recruitment ensured that 
the pharmacists who attended were prepared to participate and contribute to the discussion.  The 
open invitation resulted in two pharmacists attending two sessions each.  During analysis, care was 
taken to avoid duplication of comments provided by these pharmacists. 
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Six participants had some previous knowledge or experience of the Paediatric ALF.  These 
participants could have subtly influenced the discussion, however participants without previous 
experience with any of the existing frameworks independently articulated similar concepts of 
advanced practice, and varied opinions on topics were freely expressed during the sessions.  
The groups included only pharmacists who worked with children, however one third of the 
participants had three years or less specific paediatric experience, and most of the discussion was 
not specifically related to paediatrics.  Hence much of the findings from this study could be 
transferrable to other pharmacy settings. 
Definition and description of advanced practice 
Despite previous concerns that a title of advanced practice for pharmacists was encouraging elitism 
within the profession,2 this cohort felt that formal recognition of advanced practice had value for the 
profession and individuals. The participants recommended rewording of the current definition of 
advanced pharmacy practice to improve clarity.   
Professional practice based knowledge and skills were described as core components of advanced 
practice.  Broader attributes such as teamwork, communication, research, education, influence 
outside the institution, and a commitment to service improvement were also considered important.   
The need to describe a series of levels leading towards advanced practice was identified.  Each level 
would require broader skills outside of professional practice, influence extending past the discipline 
and institution, and a contribution toward original research.  This fits well with the three levels of 
advanced practice in the UK ACLF,115 Paediatric ALF134 and the APPF.141  
Peer recognition of skills and abilities was described as an important element of advanced practice, 
in line with a recent environmental snapshot of advanced practice.113  The ability to critically 
evaluate the literature and prepare guidelines and protocols were considered important, although 
formal research was considered more relevant to the higher levels of practice.  Differences in local 
opportunities for research impacted on the participants’ opinion in this area.  
All groups valued professional development as a component of advanced practice, however formal 
postgraduate qualifications were not considered essential.  In contrast, education of others was 
considered a core requirement of advanced practice.  This is consistent with other work describing 
the expectation of education growing with increased level of practice.1 
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Assessment 
The participants felt that multiple assessment methods should be used, with direct observation of 
practice, peer review and portfolio review the most strongly supported. These three methods are 
consistent with the Millers Triangle of Competency Assessment,261  the methodology used by the 
UK advanced practice critical care group,286 and the Australian medical and nursing profession as 
assessment of advanced practice.  
 Portfolios275,276 were strongly supported by the participants as an assessment method.  Portfolios 
have been shown across disciplines to be a valuable tool for formative assessment and have 
provided a reliable method for high-stakes summative assessment when multiple work based 
assessment tools are included.292 
Direct observation of practice was also strongly supported.  Evaluation tools currently in use in 
Australia (such as the General Level Framework, Mini-CEX or SHPA clinCAT) have successfully 
facilitated professional development for pharmacists in general clinical practice.207,209  These tools, 
however, were not designed to differentiate advanced practice from general practice, and only the 
Mini-CEX (mini clinical examination) has been used as a summative assessment tool.286,292,301   
Other forms of peer review using multi-source feedback such as “360 degree feedback” (e.g. “Mini-
PAT”) used in some institutions may require adaptation for use as an assessment as well as a 
development tool.312   
Two other methods discussed with varied opinions were an oral viva and Objective Structured 
Clinical Examinations (OSCEs).  An oral viva (or interview) was suggested by more experienced 
participants familiar with their use for recruitment purposes.  An interview was found to be an 
effective assessment method in medical education,361 and this approach has been used successfully 
with UK advanced practice critical care pharmacists.286,328   
There were differences of opinion related to OSCEs, although these have been successfully used in 
formative and summative assessments in medicine and pharmacy for undergraduate and 
postgraduate students.315,362  Pharmacists who had personal experience with OSCEs were 
comfortable with their use in assessment, whereas more experienced pharmacists believed that 
OSCEs would only assess clinical pharmacy skills rather than the broader components of advanced 
practice.  Similar views have been expressed in medicine, where more experienced physicians 
approach patient care in a “non-linear fashion” unsuitable for evaluation via OSCE.290 
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Formal assessment of knowledge (e.g. via examination) was not discussed by any group.  This may 
have been due to the absence of formal paediatric pharmacy postgraduate training and assessment in 
Australia, and the participants’ reservations regarding the use of postgraduate qualifications as a 
mandatory assessment criterion.  Availability of paediatric assessments such as with the Board of 
Pharmacy Specialties,363 and formal recognition of advanced practice in Australia may change these 
views in the future. 
Paediatric specific knowledge and skills such as medication and disease knowledge in children, and 
communication with children and families were considered important in paediatrics.  The definition 
and other components of advanced practice remain the same as for other areas of practice.  
Further work is required at a national and international level to clarify terminology of levels of 
practice across the various frameworks currently in use.113,134,141,364   Further validation of tools for 
use in evaluation of advanced pharmacy practice is required, particularly if intended for high stakes 
assessment.   
6.7 Manuscript Conclusion 
The current descriptions of advanced practice by Australian pharmacy groups and the Paediatric 
Advanced Level Framework are consistent with the expectations of Australian paediatric 
pharmacists.  The broad components of knowledge, skills and experience; working relationships; 
leadership; education and research are all expectations of an advanced pharmacy practitioner. 
Advanced practice is not restricted to those in direct patient care, and is acknowledged as different 
to specialist practice. A system of assessment that includes multiple methods is preferred.   Portfolio 
review, direct observation of practice and peer review are the most strongly supported strategies.  
Formal recognition of advanced pharmacy practice is beneficial to the profession, and for 
individuals seeking to develop their practice. 
6.8 Chapter Conclusion: 
This research confirmed the hypothesis that paediatric hospital pharmacists valued formal 
recognition of advanced pharmacy practice, can describe the skills, knowledge, attitudes, and 
behaviours of advanced practitioners and identify preferred methods of assessment of advanced 
practice.    
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7 Chapter Seven: Can pharmacist interventions demonstrate 
the journey towards advanced pharmacy practice? 
7.1 Introduction to Chapter Seven 
This chapter follows on from the research described in Chapters 4 and 5 where adverse medication 
events were investigated using pharmacist interventions as a method of case identification.  The 
interventions reviewed during those projects demonstrated the value that pharmacists provide 
during their direct patient care work.  This included optimisation of use where error is not involved, 
in addition to the identification and resolution of errors with significant potential for harm.  During 
the analysis process of those projects it became clear that there was a trend toward increased 
complexity and sophistication of clinical skill described in intervention records by individual 
pharmacists as they increased in years of practice.  These skills in the latter years appeared to 
include not only knowledge of drugs and diseases in childhood, but also the ability to enact 
significant organisational change to improve the safety and quality of medication use.  This role in 
quality improvement as a component of advanced practice was also reinforced in the focus group 
project described in Chapter 6.  These findings identified in earlier research led to the research 
question in this project regarding the usefulness of pharmacist interventions as evidence of 
advanced practice skills. 
The hypothesis for this research project was that: 
Pharmacist interventions can document progression to advanced practice.  
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7.2 Abstract 
Aim 
To identify whether documented pharmacist interventions can be used to demonstrate increasing 
pharmacist skills towards advanced practice. 
Method 
Intervention records were randomly selected and retrospectively reviewed from three separate years 
during 2005 to 2012, for four pharmacists from one Australian paediatric hospital.  Skills 
demonstrated in the intervention record were rated on a five-point scale, from skills expected of an 
intern pharmacist through to those expected of an advanced pharmacist practitioner. 
Results 
One hundred and fifty records were reviewed for each of the four pharmacists, with fifty 
interventions from each of the three periods.  The level of skill demonstrated in the interventions 
increased over time for each of the pharmacists and corresponded to their level of advancing 
practice.  Advanced level clinical skills were rarely recorded as an intervention.  
Conclusion 
Review of pharmacists’ interventions can be used to demonstrate increasing skills and advances in 
clinical practice.  Records of interventions should be documented and form part of a professional 
portfolio.   
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7.3 Background 
Pharmacist interventions have been documented for many years: as a measure of pharmacy 
workload, to document errors, and identify medication risks at an individual or system wide level.  
Interventions also document pharmacist initiated changes in therapy where the patient has not been 
harmed, to identify and resolve ‘near-miss’ events where an error did not reach or harm a patient, 
and value-adding or optimisation of therapy where no error was involved. 
Pharmacist interventions have been defined in a number of ways, from different professional 
organisations and published research.  The definition used by many Australian hospital pharmacists 
is ‘any action by a pharmacist that directly results in a change in patient management or therapy’ 
which is included in the 2005 Society of Hospital Pharmacists of Australia (SHPA) Clinical 
Pharmacy Standards of Practice.38   With the recent 2013 update to the Clinical Pharmacy 
Standards of Practice, SHPA has used a broader definition of ‘any professional activity by the 
pharmacist directed towards improving the quality use of medicines and resulting in a 
recommendation for a change in the patient’s medication therapy, means of administration or 
medication-taking behaviour’.365-367 
Different systems for intervention recording exist in different institutions.  They may be recorded 
routinely or as part of a workload snapshot, and may be documented in the institution’s clinical 
incident reporting system or within a separate pharmacy database.  Interventions may be classified 
or categorised in a number of different ways, for example they may be based on the type of error 
leading to the intervention, or the risk to the patient.   
The use of pharmacist interventions in education and training of pharmacy staff has been 
encouraged.367  However, classification of the skills required of the pharmacist to make the 
interventions is not routinely undertaken, and the skills demonstrated via interventions have not 
been investigated.  There have been a number of specialist advanced level competency frameworks 
developed and implemented in Australia in recent years, including a Paediatric Advanced Level 
Framework (Paediatric ALF).99,133,136  These have led to the development of an Australian 
Advanced Pharmacy Practice Framework (APPF), endorsed in 2013 by the Pharmacy Board of 
Australia.141  It is not yet confirmed what evidence pharmacists will use to demonstrate advanced 
practice, however there may be potential to use pharmacist intervention reports to demonstrate 
advanced skills.113 
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We hypothesised that as pharmacists developed their specialist clinical practice, the increasing 
skills documented in the intervention report would be identifiable and measurable.  The aim of the 
project was to investigate whether intervention records could be used to demonstrate increasing 
pharmacists’ skills over time towards advanced pharmacy practice.  
7.4 Method 
This study investigated interventions recorded by four pharmacists participating in a larger multi-
site study investigating suitable assessment methods of advanced pharmacy practice.  The setting 
was a 170 bed tertiary paediatric hospital in Brisbane, Australia, with an established system of 
routine, continuous documentation of pharmacist interventions.  Interventions were retrospectively 
reviewed over an eight-year period from 2005 to 2012.  A random selection of interventions from 
three separate years of practice was coded on a five-point scale of increasing skill from intern to 
advanced practice (see Table 7.1).   
The scale was developed using the descriptors in the Paediatric Advanced Level Framework 
(ALF).133,134  Expectations for pharmacists in their intern year and early years post registration were 
used to define the first two levels, and descriptors of skill from the three levels of practice from the 
ALF itself used for the remaining three levels.  These draft levels were sent to Directors of 
Pharmacy from Australian paediatric hospitals, and members of the SHPA Paediatric COSP for 
comment.  Feedback was received and incorporated into the descriptors.  The five levels are listed 
in Table 7.1 below. 
Inclusion criteria were pharmacists enrolled in an advanced pharmacy practice research project at 
the site hospital, who had at least six years of interventions recorded in the institution database from 
2005 to 2012.  This project specifically investigated the pharmacist interventions documented as 
part of the pharmacist portfolios.  Exclusion criteria were less than 150 interventions recorded in 
total, and less than six years of recorded interventions.   
  
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 133 
Table 7.1 – Pharmacist Intervention Skill Levels 
Skill Level Description and examples 
LEVEL 1: 
Simple intervention, 
general. 
Student or Intern 
Identification of ‘obvious’ errors (omission and commission) e.g. 
• Incorrect doses based on calculation errors (e.g. easily identifiable 10-
fold errors),  
• Errors from dosing slip/lapses or using non-standard texts.  
• Rounding doses to make it easier to measure 
• Not capping at adult dose 
• Identification of omissions or incorrect doses from medication history 
LEVEL 2: 
Simple intervention, 
patient specific.  
General or Foundation.  
Expected of a newly 
registered pharmacist in 
first 1-2 years of 
practice 
Issues requiring some knowledge of the patient: 
• Identification of new adverse drug reactions (ADR)  
• Identification of well-known drug interactions and contraindications  
• Ensuring appropriate dose for age of the child  
• Appropriate antimicrobial for diagnosis 
Responding to requests from other health practitioners using standard 
reference sources: 
• Dosing enquiry or compatibility of intravenous (IV) medications 
• Annotation or clarification of orders with the aim of reducing the risk of 
error, especially for well-known causes of error   
• Complicated ten-fold errors 
LEVEL 3: 
Paediatric specific or 
other clinical 
intervention 
Advanced Pharmacy 
Practice Framework 
(APPF) “Transition” 
Expected of all 
registered pharmacists 
after 1-2 years of 
practice. 
Identification of missing or incorrect therapy based on routine paediatric 
therapeutics, local protocols and guidelines.  
• Identification of paediatric specific contraindications 
• Identification of chemotherapy discrepancies from standard protocol 
(demonstrating ability to interpret a chemotherapy protocol). 
• Recommendation of change in therapy required due to ADR. 
• Therapeutic drug management (TDM) for standard care patients. This 
may include use of laboratory report and blood cultures for antimicrobial 
therapy. 
• Proactively identifying problems with IV compatibility and recommending 
a complex administration procedure 
 
LEVEL 4: 
Complex 
individualised 
intervention. 
APPF “Consolidation” 
Identification of medication related problems in patients with complex disease 
states, high acuity patients, multiple co-morbidities, and/or unusual 
medicines. 
• Identification of missing medications (symptoms not being treated, as 
opposed to medications missing compared to patient medication history)  
• Identification of medication that should be ceased 
• Therapeutic drug management and application of laboratory data in 
complex cases.   
• Recommendations for dose adjustment for patients with renal or hepatic 
impairment. 
Solving patient related problems requiring search of the literature outside of 
standard references and applying to individual patient circumstances.   
LEVEL 5: 
Complex 
individualised 
intervention resulting 
in system changes. 
APPF “Advanced” 
 
Identification of changes in therapy based on knowledge of paediatrics where 
information is lacking, using abstract knowledge, ability to search information 
and making efforts to implement changes in the system to prevent future 
problems or improve care in the future.   
These may be interventions at an earlier level where the information gained is 
used for education, policy change, guideline development and procedures at 
a broader than institutional level.   
This level also maps to Paediatric ALF Level 3 
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Interventions were randomly selected (using an electronic random number generator) from the first 
and last years of intervention recording, and one year in the middle.  Where less than 50 
interventions were recorded per year, interventions from adjoining years were randomly selected 
and added to make 50 from each time period of early, middle and late.  In total, 150 interventions 
were reviewed for each pharmacist.  Each intervention was assigned a unique study number, and 
identifying information was removed.  Only the medication name, clinical area and intervention 
narrative remained during the coding process, hence the independent raters were blinded to the 
pharmacist and period.  Interventions were sorted by medication and independently rated as level 1 
to 5 by two senior paediatric pharmacists with greater than 20 years clinical experience (SS and 
ST).  The ratings from the first 20 interventions were discussed between the raters with minor 
modifications made to the definitions to aid clarity.  For the remainder of the interventions, where 
disagreement on rating occurred, researchers discussed and agreed on a final rating.  The study 
protocol included an option to ask a third researcher for a final opinion if consensus was not met; 
however this was not required. 
Results were analysed to determine whether the skill level increased with increasing years of 
experience.  The interventions documented in the final years were compared to the level of practice 
established in the larger advanced practice study, to determine whether the skill level demonstrated 
in the interventions matched the observed level of practice and therefore could be used as reliable 
evidence of practice. 
Descriptive statistics for final score (means and standard deviations) were calculated for each 
pharmacist over each of the three periods.  Levene’s test was used initially to test for homogeneity 
of variance.  A two-way ANOVA was then used to determine the effects of pharmacist, period and 
their possible interaction.  In instances of significant interaction, data were further analysed via one-
way ANOVA with Bonferroni multiple comparisons and interaction plots.  All statistical analyses 
were performed with Stata 12.0 (StataCorp, College Station, TX). All tests were undertaken with a 
significance threshold for null hypothesis rejection set to p<0.05.   Ethics and institutional approval 
was obtained from the hospital Health Research Ethics Committee (HREC/12/QRCH/216) and the 
University Ethics committee. 
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7.5 Results 
Four pharmacists met the inclusion criteria with a minimum of 150 interventions recorded over at 
least six years of the study period.  Two participants had two years experience before the 
commencement of study period, and two participants commenced their internship during the first 2-
3 years of the study period.  All of the four pharmacists were evaluated during 2012/13 as practicing 
between the equivalent of “Consolidation” and “Advanced” level in the APPF.  Each had reported 
between 1 and 453 interventions per calendar year, with a total of 3479 interventions reported for 
these four pharmacists over the eight year study period, of which 600 were reviewed as part of this 
study.  Table 7.2 below lists examples of some of the documented interventions at each skill level. 
Table 7.2  Examples of Pharmacist Interventions per Skill Level 
Skill Level Examples of documented interventions. 
Level 1 Patient weight 5.58kg. Charted for 280mg cefotaxime once daily. Notified doctor who 
changed to q8h. Doctor had mistaken cefotaxime for ceftriaxone, hence 24 hourly 
dose. 
20mo patient admitted with ?URTI. Hx of epilepsy- on sodium valproate, 
oxcarbazepine and levetiracetam (100mg bd charted). Med Hx interview with Mum 
revealed Keppra dose increase in last week to 150mg bd - d/w treating team - order 
corrected. 
Level 2 Patient prescribed Cotrimoxazole for Tx of UTI but is not recommended for use under 
the age of 6 weeks and patient was also jaundiced which the reference texts 
recommend not to be used.  Recommended to the doctors to change to Cephalexin.  
Patient's weight recorded incorrectly on the chart by 40%. Doses of gentamicin, tazocin 
& paracetamol all incorrectly written based on wrong weight. Contacted doctor and 
doses adjusted. 
Level 3 Patient with gut obstruction due to Hirsprung's disease. On long-term TPN showing 
symptoms of hypercholestremia. Suggested fish oil (Omegaven) emulsion - organised 
approval, SAS form and make sure stock is available. Team agreed with plan. 
Patient admitted for endoscopy etc. ? GVHD of GIT, vomiting etc. Admitted on maxolon 
10mg qid and domperidone 20mg tds. Had some mouth movements- suggested 
ceasing maxolon. 
Level 4 Oncology patient (medulloblastoma) status epilepticus. On phenytoin, phenobarb, 
Keppra and Midazolam. Low albumin (20g/L). Phenytoin (bound) levels low (reported 
levels does not report free phenytoin levels). D/w fellow - suggest correcting albumin 
and retest phenytoin level 
16mo patient with meningococcal sepsis requiring inotropic support and CVVHDF. On 
Morphine infusion, risk of accumulation of toxic metabolite in renal failure. D/W Dr- 
suggest change to fentanyl. Intensivist agreed. Changed to fentanyl. 
Level 5 5yo treated for Ewings Sarcoma receiving HD Methotrexate (AEWS1031). Charted for 
Sodium bicarb as 60mmol bolus post MTX infusion (instead of NaHCO3 60mmol/L in 
hydration) on Charm (electronic prescribing system). D/W Charm ITS – Program Error 
– program corrected to prevent future errors - Dr contacted to reprint order. 
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Figure 7.1 below shows the skill level of the combined interventions from all pharmacists for each 
study period.  This shows the increase in higher level (levels 3-5) interventions as the years 
progressed.  This correlates to their level of practice where clinical skills at level 4-5 would be 
expected to be demonstrated in the final study period when the pharmacists were evaluated as 
practicing between APPF Consolidation and Advanced.   
 
Figure 7.1  Intervention Scores by Skill Level by Study Period 
A two-way ANOVA performed after Levene’s test indicated no evidence to suggest that the 
variance homogeneity assumption had been violated [F(11,588)=1.34, p=0.20]. While pharmacist 
effect was found to be statistically non-significant [F(3,588)=2.45, p=0.06],  both period  [F(2, 
588)=39.93, p<0.01] and the interaction  of pharmacist by period [F(6,588)=5.43, p<0.01] were 
found to be statistically significant.  The mean skill level for all interventions increased from 1.92 to 
2.52 to 2.64 across the three periods (p<0.01). Mean scores per pharmacist and period are listed 
below in Table 7.3, showing the statistically significant increase in skill level from Period 1 to 
Period 2 or 3 for three out of the four pharmacists. 
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Table 7.3  Mean Scores per pharmacist, with ANOVA 
 Period 1 (P1) Period 2 (P2) Period 3 (P3) P values (ANOVA) 
 N Mean SD N Mean SD N Mean SD P1-P2 P1-P3 
Pharmacist 1 50 1.78 .93 50 2.46 .86 50 2.74 .88 <0.01 <0.01 
Pharmacist 2 50 2 .86 50 2.8 1.01 50 2.78 1.02 <0.01 <0.01 
Pharmacist 3 50 2.18 .72 50 2.54 .81 50 2.16 .82 0.07 1.00 
Pharmacist 4 50 1.72 .76 50 2.28 .90 50 2.9 .79 <0.01 <0.01 
Total 200 1.92 .83 200 2.52 .91 200 2.64 .92 <0.01 <0.01 
 
The presence of a significant interaction effect was further described graphically by interaction plot 
(Figure 7.2).  It shows mean intervention scores increased for all pharmacists over the study period, 
bar one, those being for Pharmacist 3.  For this particular pharmacist, the mean intervention score 
increased from Period 1 to Period 2 then dropped in Period 3.  This pharmacist was not working in 
a routine clinical role during Period 3, with direct patient care limited to relieving for staff leave and 
two years of interventions were combined for the final dataset of 50 interventions.  The significant 
interaction effect of pharmacist and period can also be seen by the absence of parallel curves, with 
Pharmacist 4 having the lowest mean intervention score at period one (i.e. 1.72), but the highest at 
period three (i.e. 2.90). 
When analysis was stratified by period, each one-way ANOVA with Bonferroni multiple 
comparisons showed significant pharmacist effect.  For each period, the effect of pharmacist four 
was seen to differ significantly from one co-pharmacist.  In the first period statistical significance 
was reached when pharmacist four was compared to pharmacist three (mean difference: -0.46, p-
value=0.03).  However in period 2, a significant difference was only detected between pharmacists 
two and four (mean difference: -0.52; p-value=0.03). Finally in period 3, significant difference was 
seen between pharmacists three and four (mean difference: 0.74; p-value<0.01). In addition, 
significant differences were also seen between pharmacists three and the two other pharmacists 
during this period.  
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Figure 7.2  Mean Intervention Scores by Pharmacist per Study Period 
7.6 Discussion 
This study demonstrated the increase in skill level over time using a novel skill assessment matrix.  
Interventions reported by pharmacists were largely changes in therapy for individual patients where 
the knowledge and skills required (such as knowledge of appropriate drug doses, and identification 
and resolution of drug related problems) are expected of pharmacists early in their career.  In 
contrast, the more complex and broader changes at a system or institutional level required more 
advanced skills such as teamwork, change management, education, persuasion and negotiation.   
Documentation of interventions at a lower skill level reduced over time, which may be a selective 
process as pharmacists may prioritise the time to record more complex interventions rather than 
straightforward interventions as their skills increase.  The intent of the study was not to evaluate 
whether advanced practitioners were undertaking simple interventions, but to determine whether the 
interventions involving more advanced skill were only reported once those skills and practice had 
developed.   
This recording of interventions and assessment of skill is analogous to the medical model where 
procedure or case logs are maintained for specialists in particular fields where complex procedures 
are required, such as emergency medicine, anaesthetics and obstetrics.264,290 
As pharmacists develop in experience, many move away from direct patient care, which was also 
observed in this study with one of the pharmacists not in a regular clinical role during the later study 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 139 
period.  When not working in a routine clinical role there may be less opportunity for intervening at 
an individual patient level.  However, there may be more opportunities for improving practices at a 
system level for those who move into more managerial or leadership roles.  These interventions or 
improvements made at a system level may take weeks, months or even years to achieve, and 
therefore unlikely to be recorded in a routine intervention database.  The results in this study 
contrast to those found by Barber et al from the UK, where more interventions were recorded by 
pharmacists at a higher pay scale than basic grade pharmacists.47  However, practice has changed 
significantly since the Barber study was published almost 20 years ago.47  
A more effective or feasible method of capturing and demonstrating advanced or Level 5 skills such 
as “advancing the knowledge base” or “advancing pharmaceutical services” may be via case based 
discussions of individual patients.  This would allow more detail and the follow-up skills and 
contribution to be more clearly described.   
There were a number of limitations in this exploratory study.  It was undertaken in only one 
hospital, with an established intervention recording system, which is not the case in all hospitals.  It 
was undertaken in a paediatric environment, however the skills described were largely general 
clinical skills therefore relevant across all age groups.  It included a small sample size of four 
pharmacists, and only a randomised sample of interventions was rated; however some conclusions 
can still be made. 
There was significant reliance on what and how the pharmacist documented the intervention in the 
narrative.  Some were described in detail, which allowed the complexity of the intervention to be 
described.  Others were described very briefly where nuances of complexity may have been lost.  
However, one expectation of pharmacy practice (particularly those at an advanced level) is to be 
able to clearly and concisely describe patient events in written form. 
The interventions were recorded from 2005 to 2012, with the earliest interventions from almost 10 
years ago.  Practice has changed for many medications in that time, however the panel rated on skill 
demonstrated in the intervention, not whether the intervention was appropriate in today’s healthcare 
environment. 
Standard practice in this hospital was to have pharmacists initially work in general medical and 
surgical areas, then rotate through higher acuity areas once assessed as competent in general clinical 
skills.  This may skew towards a higher demonstrated skill level, as the pharmacists were caring for 
more complex patients in the later periods.  However the fact that the pharmacists were deemed 
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competent to work in the high acuity areas is in itself indicative of increasing knowledge and skills 
over time. 
There are barriers to comprehensive intervention recording, particularly related to the time required 
to complete the documentation and availability of an easy to use database or application at the time 
required.  However, this documentation provides valuable information for the individual pharmacist 
and for the institution to improve safety and quality of patient care. 
Recommendation 
Interventions should be recorded routinely for both individual and institutional learning.   All 
pharmacists should keep a record of all or a selection of their interventions in their professional 
portfolio on at least an annual basis, as a method of demonstrating advancing clinical practice and 
review.  Pharmacists early in practice should regularly discuss interventions with an onsite mentor.  
Interesting cases should be presented to the department as a case based discussion to further gain 
skills in case presentation and these presentations can be used as portfolio evidence.  These cases 
can also be used in teaching of pharmacists and other health professionals.  As skills increase, cases 
should be shared via conference presentation and publication in peer reviewed journals.  This is 
particularly important where the intervention and case review has led to quality improvement 
activities that may benefit others. 
The skill level table (Table 7.1 above) could be used as a guide for appropriate examples of 
interventions to use as evidence at each level of practice. 
7.7 Conclusion 
This study demonstrates that the progression in clinical pharmacist skills over time towards 
advanced practice can be demonstrated using recorded pharmacist interventions. The increase in 
patient complexity and acuity, knowledge of paediatric diseases and appropriate drug use, identify 
problems and resolve them, ability to negotiate change in therapy with other health care 
professionals, and enact changes at an increasingly broad system level, were all observed in these 
pharmacists.  Records of interventions should be documented and form part of a professional 
portfolio.  In addition, pharmacists practicing at an advanced level should document interventions 
and quality improvement achievements via methods such as case based demonstration, conference 
presentations and sharing via publication.  Further research is required to confirm these findings via 
a larger sample and a broader representation of practice environments.     
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8 Chapter Eight: Use of the General Level Framework to guide 
development and training needs of pharmacists working in 
paediatrics 
8.1 Introduction to Chapter Eight 
This chapter investigates the strengths and priority areas for training of pharmacists working in 
paediatrics in Queensland Hospitals.  It describes the use of the General Level Framework, a 
competency assessment tool, used for pharmacists using direct observation of practice.  This tool 
was developed for formative assessment in the adult setting, however this research project 
investigates its use in paediatrics.   
This project follows on from the findings in the focus group study in Chapter 6, where direct 
observation of practice was identified as one of the preferred methods of assessment for advanced 
practice.  This topic is explored further as a tool for summative assessment of advanced practice in 
Chapter Nine.   
The hypothesis for this study was: 
 Training and development priorities of paediatric pharmacists can be identified by 
reviewing the strengths and weaknesses, recorded by direct observation of pharmacists 
working in clinical practice.   
This chapter has been submitted for publication to the Journal of Pharmacy Practice and Research. 
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8.2 Manuscript Abstract 
Background 
The “General Level Framework” (GLF) has been used for many years as a tool for competency 
evaluation and feedback using direct observation of clinical practice, however its use in the 
paediatric environment has not been investigated. 
Aim 
To identify strengths and training and development needs for paediatric pharmacists using the 
General Level Framework. 
Methods 
Retrospective analysis of evaluations of paediatric pharmacists in Queensland hospitals using the 
GLF.  Pharmacists from specialist paediatric hospitals were compared to those from general 
hospitals. 
Results 
Fifty GLF evaluations undertaken between 2006 -2011were identified from 10 hospitals.  
Competencies related to ethical practice, confidentiality, and ensuring prescriptions are legal with 
appropriate doses were performed well.  Assessment of patients understanding of illness and 
treatment, and adherence, or documentation of pharmacist interventions and medication action 
plans were not performed consistently well.  Knowledge of pathophysiology, assessment of the 
patient’s experience and management of medicines were demonstrated more consistently in 
paediatric hospitals than general hospitals.   
Conclusion 
A generic tool such as the GLF can be used in specialist areas such as paediatrics to identify priority 
training areas for pharmacists working in clinical practice.  &
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8.3 Manuscript Introduction 
The public and healthcare organisations alike expect and rely on a competent health workforce.  
The need to ensure the competence of healthcare workers has been highlighted in recent years after 
investigations into tragic events arising from failings in safety and quality in hospitals across the 
world, from Bristol in the United Kingdom to Bundaberg in Australia.256,368,369  
The General Level Framework (GLF) has been used for many years in the United Kingdom (UK), 
Australia and elsewhere as a tool to support structured feedback and assist in the formation of 
individualised development plans after self-assessment and direct observation of pharmacist 
practice.  The tool is commonly used in the hospital setting, although equally applicable in the 
community pharmacy.210,211  The strength of the tool lies in its ability to guide professional 
development as a result of observing individual pharmacists during the daily activities and 
providing tailored feedback.207,209  The GLF has been shown to accelerate individual improvements 
in clinical practice and at a population level to guide content of generic postgraduate pharmacy 
training.207,209-211,295,296  In addition, direct observation tools (similar to the GLF) are currently being 
trialled to evaluate pharmacists working at an advanced level within specialist pharmacy practice 
areas such as critical care.286 
The tool was originally developed by the Competency Development and Evaluation Group in the 
UK and adapted for Australian use by Queensland Health in 2006.207,209  This version was mapped 
against the Australian standards of practice and included newer practice changes such as the use of 
a medication action plan to record medication history, reconciliation, and medication related 
problems and actions during an admission and transfer.132  It has since been adapted further, and is 
known as the “shpaclinCAT” and used throughout Australia.297,370  All versions of the GLF describe 
the competency in detail then the evaluator rating is based on how frequently the pharmacist 
undertakes the task to the quality described in each competency.  The aim is for all pharmacists to 
be “consistently” undertaking all competencies to the described standard of practice.   
A modified version of the GLF was developed and piloted for paediatrics in late 2009.133,135  The 
paediatric version of the GLF included additional descriptors highlighting expectations for 
pharmacists working in paediatrics, under a selection of the original competency elements.  The 
GLF has been used previously in specialist areas such as cancer care, however its use as a 
professional development tool in the paediatric setting has not been previously reviewed.136  
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The aim of this project was to identify strengths and weaknesses in the knowledge, skills and 
behaviours of pharmacists working with children in Queensland hospitals. This information has 
been used to prioritise training and development opportunities for paediatric pharmacists at a 
population level. 
8.4 Method 
This study was a retrospective analysis of observations made using the GLF with pharmacists 
working with children in Queensland Health hospitals.   
The GLF included 102 individual competency elements detailing performance expectations against 
national standards of practice.132  These elements were grouped under three main domains of 
“Delivery of Patient Care”, “Problem Solving” and “Professional Competencies”.  The evaluator 
observed the pharmacist in practice for approximately 2-3 hours, then completed the tool using the 
ratings of “Rarely”, “Sometimes”, “Usually” or “Consistently” for each competency element.  An 
additional rating of “Unable to Comment” was available for use if that particular process or task 
was not observed during the evaluation.  The pharmacist initially self-assessed against each of the 
competencies, and there was space for comments from the pharmacist and the evaluator, however 
the comments and self-assessment scores were not included in this study.  Feedback was provided, 
taking approximately one hour.  A personalised training plan was then prepared jointly between the 
pharmacist and evaluator. 
Multiple evaluators were involved in the observations, all of whom had received standardised 
formal training in clinical education, use of the GLF tool, training plan development and provision 
of structured feedback.  The evaluators were revalidated every 2-3 years to maximise inter-rater 
reliability. 
Existing GLF records for pharmacists working in paediatric wards in Queensland Health hospitals 
undertaken from 2006 to 2011 were retrieved.  Records using the paediatric version of the GLF 
were included in the analysis as the overarching competency elements were the same as the 
standard GLF.  Pharmacist identifiers were removed and individual comments were excluded.  
Competency elements with 20 or less observations were excluded from analysis as valid 
conclusions and comparisons could not be made due to the small sample size. 
Competency elements where all of the pharmacists rated “Usually” or “Consistently” were used to 
identify strengths.  Elements where less than 80% of the pharmacists rated “Consistently” or 
“Usually” were identified as training priorities for the study population.   
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Results were compared for two main comparison sub-groups: Specialist paediatric hospitals versus 
paediatric wards in regional general hospitals, and the Paediatric GLF versus the standard GLF.  An 
additional comparison of evaluations from 2006-8 versus 2009-11 was used to identify changes 
over time, and in multivariate analysis with the Paediatric GLF results to ensure validity of the 
comparison, as the Paediatric GLF results were limited to those used after implementation in 2009.  
Comparisons were made between sub-groups when greater than 50% of the results for that element 
were available (i.e. not coded as “unable to comment”).  Stata version 12.0 (Stata Corporation) was 
used to perform all statistical analyses.  Due to the small sample size, Fisher’s Exact Test was used 
to assess the strength of association between the variables.   
This study was approved by the hospital Health Research Ethics Committee (HREC/13/QRCH/104) 
and the University Ethics Committee (2013/13).  
8.5 Results 
Records were identified for 50 observations, including 35 from pharmacists working in two 
different specialist paediatric hospitals and 15 from paediatric wards in eight different regional 
general hospitals.  Six of the assessments utilised the Paediatric GLF and 44 the Standard GLF.  
Once elements with less than 20 observations were excluded, 83 competencies remained. Results 
for three domains are included in Tables 8.1 to 8.3. 
Table 8.1  Part 1 - Delivery of Patient Care Competencies 
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1.1 Patient History 
Opening the consultation – 
introduction 
40 4  (1-4) 90% 73% 97% 0.06 
Opening the consultation – setting an 
agenda 
39 3 (1-4) 87% 70% 93% 0.10 
Uses appropriate questioning 38 3 (1-4) 95% 80% 100% 0.06 
Allergy / Adverse Drug Reaction 
Review 
44 4 (1-4) 93% 85% 97% 0.20 
Medication history taking 41 3 (1-4) 83% 64% 90% 0.07 
Confirmation of medication history 28 3 (1-4) 75% 43% 86% 0.04 
Relevant patient background retrieved 45 3 (2-4) 87% 67% 94% 0.04 
Patient’s understanding of illness 29 2 (1-4) 45% 14% 55% 0.09 
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elicited 
Patient’s experience of medicines use 
explored 
34 3 (1-4) 68% 33% 80% 0.03 
Patient’s understanding of treatment 
explored 
33 2 (1-4) 45% 13% 56% 0.05 
Adherence assessment 23 2 (1-3) 39% 17% 47% 0.34 
Patient’s medication management 
assessed 
32 3 (1-4) 63% 17% 73% 0.02 
Reconciles medication history on 
admission 
40 3 (1-4) 90% 67% 97% 0.03 
1.2 Assessment of Current Medication Management 
Identifies drug-drug interactions 31 3 (2-4) 90% 80% 92% 0.42 
Prioritises drug-drug interactions 30 3.5 (2-4) 93% 80% 96% 0.31 
Appropriate action is taken regarding 
drug interactions 
29 4 (3-4) 100% 100% 100% . 
Identifies drug-patient interactions  34 3 (2-4) 85% 75% 91% 0.32 
Prioritises drug-patient interactions 30 3 (2-4) 87% 88% 86% 1.00 
Appropriate action is taken regarding 
drug-patient interactions 
28 3.5 (2-4) 96% 100% 95% 1.00 
Identifies drug-disease interactions  35 3 (2-4) 86% 86% 86% 1.00 
Prioritises drug-disease interactions  34 3 (2-4) 91% 83% 93% 0.45 
Appropriate action is taken regarding 
drug-disease interactions 
35 3 (2-4) 91% 83% 93% 0.44 
Ensures prescription is clear and 
unambiguous 
50 4 (3-4) 100% 100% 100% . 
Ensures prescription is legal 48 4 (3-4) 100% 100% 100% . 
Checking of appropriate dose 50 4 (3-4) 100% 100% 100% . 
Checking of route and timing of dose 47 4 (2-4) 91% 92% 91% 1.00 
Selection of formulation, concentration 
or rate 
43 3 (2-4) 91% 73% 97% 0.05 
1.3 Monitoring of Current Drug Therapy 
Identification of drug related problems  50 3 (2-4) 98% 100% 97% 1.00 
Documentation of drug related 
problems 
43 3 (1-4) 65% 50% 71% 0.29 
Prioritisation of drug related problems 47 3 (2-4) 96% 100% 94% 1.00 
Appropriate use of guidelines or 
references 
48 3.5 (2-4) 96% 100% 94% 1.00 
Documents medication action plan  38 2 (1-4) 37% 33% 38% 1.00 
Signs for clinical pharmacist review 42 3.5 (1-4) 67% 69% 65% 1.00 
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Documents interventions 20 2 (1-4) 45% 44% 45% 1.00 
Appropriate consultation or referral 43 4 (2-4) 98% 100% 97% 1.00 
Resolution of drug related problems 42 3 (2-4) 98% 100% 97% 1.00 
Outcomes of contributions 
appropriately assessed 
25 3 (2-4) 88% 88% 88% 1.00 
1.4 Provision of Drug Product 
Ensures prescribed drugs are 
administered correctly 
45 3 (2-4) 93% 92% 94% 1.00 
Ensures availability of medication 41 4 (3-4) 100% 100% 100% . 
Provides prescribed medication for the 
patient in timely manner 
23 4 (3-4) 100% 100% 100% . 
Documents supply on medication 
chart 
30 4 (2-4) 87% 78% 90% 0.56 
1.6 Medicines Information, Patient Education and Liaison 
Need for information identified 36 3 (2-4) 89% 63% 96% 0.03 
Sensitive to Cultural / Social 
Background  
31 4 (2-4) 97% 100% 96% 1.00 
Provision of oral / written information 26 3 (3-4) 100% 100% 100% . 
Assessed patient comprehension of 
information 
22 3 (2-4) 68% 67% 69% 1.00 
* Ranking: 1 = Rarely, 2 = Sometimes, 3 = Usually, 4 = Consistently 
** General = Regional General Hospitals 
# Specialist = Specialist Paediatric Hospitals 
Table 8.1 shows the results for patient care competencies, or the routine tasks expected of a 
pharmacist providing direct patient care. 
Areas that were not undertaken consistently well included communication with children and their 
families, particularly during the patient history taking process. These elements included assessment 
of patient’s understanding of illness and understanding of treatment (both 45% 
usually/consistently), and assessment of adherence (39% usually/consistently).   
Other areas that were not undertaken consistently well included documentation issues such as 
recording of pharmacist interventions (45% usually/consistently), medication action plans (37% 
usually/consistently), and signing for clinical pharmaceutical review (67% usually/consistently).   
There was some improvement in documentation from the earlier to latter years of the study, with 
medication action plan documentation increasing from the 19% to 50% (p =0.09), signing for 
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clinical review increasing from 47% to 80% (p=0.05), although documentation of interventions did 
not change significantly over time (42% to 50%, p=1.00).   
Table 8.2  Part 2 - Problem solving competencies 
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2.1 Knowledge 
Knowledge of pathophysiology 2.1.1 47 3 (1-4) 74% 45% 83% 0.02 
Knowledge of pharmacology 49 3 (2-4) 80% 62% 86% 0.10 
Knowledge of side effects 47 3 (2-4) 89% 77% 94% 0.12 
Knowledge of interactions 29 3 (1-4) 66% 43% 73% 0.19 
2.2 Gathering Information 
Accesses information from appropriate 
information sources 
47 3 (2-4) 98% 92% 100% 0.26 
Abstracts key points from information 
gathered 
43 3 (2-4) 98% 100
% 
97% 1.00 
2.3 Analysing information 
Evaluates information 44 3 (2-4) 95% 100
% 
94% 1.00 
Appraises therapeutic options 43 3 (2-4) 77% 70% 79% 0.67 
Clear decision making 47 3 (2-4) 89% 82% 92% 0.58 
2.4 Providing Information to other Health Care Professionals 
Provides accurate information 40 4 (3-4) 100% 100
% 
100% . 
Provides relevant information 39 3 (2-4) 97% 100
% 
97% 1.00 
Provides timely information 37 4 (2-4) 95% 88% 97% 0.39 
2.5 Follow-up 
Ensures resolution of problem 33 3 (2-4) 97% 100
% 
96% 1.00 
* Ranking: 1 = Rarely, 2 = Sometimes, 3 = Usually, 4 = Consistently 
** General = Regional General Hospitals 
# Specialist = Specialist Paediatric Hospitals 
Table 8.2 lists the problem solving competencies, which were generally performed well, apart from 
knowledge of interactions. 
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Table 8.3  Part 3 - Professional Competencies 
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3.1 Organisation 
Prioritisation 50 3 (2-4) 94% 100% 92% 0.55 
Punctuality 40 4 (2-4) 98% 92% 100% 0.30 
Initiative 47 3 (2-4) 96% 86% 100% 0.08 
Time Management 45 3 (2-4) 91% 100% 88% 0.31 
Delivers work within agreed deadlines 38 3 (2-4) 89% 100% 86% 0.56 
Works efficiently 49 3 (2-4) 86% 100% 80% 0.17 
3.2 Communication 
Communication clear precise and 
appropriate with patients  
44 4 (2-4) 98% 100% 97% 1.00 
Involves patient in medication 
management  
38 3 (1-4) 89% 63% 97% 0.02 
Communication is clear, precise and 
appropriate with prescribers  
44 3.5 (2-4) 98% 100% 97% 1.00 
Communication is clear, precise and 
appropriate with nursing staff  
45 3 (2-4) 98% 100% 97% 1.00 
3.3 Team Work 
Recognises value of other pharmacy 
team members 
44 4 (3-4) 100% 100% 100% . 
Works effectively as part of pharmacy 
team 
43 4 (3-4) 100% 100% 100% . 
Passes on relevant information to 
pharmacy team 
39 4 (3-4) 100% 100% 100%  
Recognises value of other 
multidisciplinary team members 
47 4 (3-4) 100% 100% 100% . 
Works effectively as part of 
multidisciplinary team 
44 4 (3-4) 100% 100% 100%  
Recognises the roles of non-clinical 
staff 
34 4 (2-4) 97% 100% 96% 1.00 
Shares learning experiences with 
colleagues 
36 3 (2-4) 92% 78% 96% 0.15 
3.4 Professional Qualities 
Practices within professional code of 
ethics 
46 4 (3-4) 100% 100% 100% . 
Maintains confidentiality 48 4 (3-4) 100% 100% 100% . 
Demonstrates logic 50 3 (2-4) 98% 93% 100% 0.28 
Inspires confidence in others 46 3 (2-4) 96% 93% 97% 0.52 
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Demonstrates confidence 47 3 (2-4) 77% 65% 82% 0.26 
Recognises own limitations 49 4 (2-4) 98% 100% 97% 1.00 
Responsibility for own action 50 4 (3-4) 100% 100% 100% . 
Takes responsibility for patient care 50 4 (2-4) 98% 100% 97% 1.00 
* Ranking: 1 = Rarely, 2 = Sometimes, 3 = Usually, 4 = Consistently 
** General = Regional General Hospitals 
# Specialist = Specialist Paediatric Hospitals 
Table 8.3 lists the professional competencies, which were generally performed very well. 
Overall, most areas were performed well, with 68 of the 83 competency elements achieving at least 
80% of the evaluations “usually” or “consistently” undertaking that competency, and only five 
elements had a median score of less than “usually”.  There were 16 elements with a 100% result, 
including complying with code of ethics and patient confidentiality, communication and effective 
teamwork within pharmacy and multidisciplinary teams, and ensuring prescriptions were legible, 
legal and an appropriate dose prescribed. 
When comparing regional hospitals with paediatric hospitals, ten of the competency elements were 
undertaken more frequently in specialist paediatric hospitals.  Many of these related to 
communication with children and families, including assessment of the patient’s experience of 
medicines use (80% versus 33% usually/consistently, p=0.03), assessment of the patient’s ability to 
manage their medicines (73% versus 17%, p=0.02) and reconciliation of medication history (97% 
versus 67%, p=0.03).  Identifying the need to provide information to patients (96% versus 63%, 
p=0.03) and involving the patient in medication management (97% versus 63%, p=0.02) were also 
communication tasks more frequently undertaken in paediatric hospitals than regional hospitals.  
Knowledge of pathophysiology (83% versus 45%, p=0.02) and selection of appropriate 
formulation, concentrate or rate (97% versus 73%, p=0.05) were also higher in paediatric hospitals. 
No significant difference was found when comparing the Paediatric GLF to the Standard GLF.  
8.6 Discussion 
This study evaluated results from 50 direct observations of practice from pharmacists working with 
hospitalised children, which had not been previously investigated.  It included data spanning six 
years, from regional and tertiary hospitals.  
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Identified strengths and training needs 
Pharmacists working with children were found to undertake the routine legal and safety 
requirements for medication management of hospitalised patients, consistently well.  However, 
assessment of the patient’s understanding of their illness and treatment and assessment of adherence 
were poorly completed tasks.  Identified training priorities were related to the more complex areas 
involving clinical reasoning and required a deeper understanding of the medication consultation 
process.  This is similar to the results found from the initial implementation of the tool in 
Queensland.209  These competencies also require effective age-appropriate communication skills 
with children and families, which are commonly acknowledged gaps by new pharmacy 
graduates.99,103,355 
There were identified training needs related to documentation of medication related problems, 
medication action plans, recording interventions and clinical review activities.   Most of these 
improved across the population from the early to the last years of the study, associated with 
increasing use of standardised forms for documentation, such as the medication action plan.  It may 
be that these improve further with increased awareness of their importance, and the inclusion of 
these factors in the National Safety and Quality Health Service Standards, which are now linked to 
accreditation.333  
Specialist paediatric versus regional general hospitals 
There were significant differences between specialist paediatric hospitals in comparison to general 
or regional hospitals.   Pharmacists working in specialist paediatric hospitals had greater knowledge 
of pathophysiology and understanding of medication administration in the paediatric environment 
compared to those working in general hospitals.  Training priorities for general hospitals were also 
identified associated with communication with children and families, particularly in elements of 
patient history taking.   
The reasons for these results are unclear as it was not possible to consider factors such as 
experience and postgraduate education due to de-identification of the GLF evaluations.  A 
workforce snapshot of Australian hospital pharmacists from 2007 found that the proportion of 
pharmacists with postgraduate qualifications and those with greater than ten years experience was 
greater in regional hospitals (medium and large) than specialist paediatric hospitals.371  It is 
unknown whether this is the case for this cohort.  It is possible that professional isolation is a factor, 
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as most pharmacists working in the general or regional hospitals are the only paediatric pharmacist 
in that site and may not have easy access to a professional mentor in the specialty. 
Despite the uncertainty of conclusions for these results, it is clear that training and development 
opportunities to improve the paediatric specific knowledge and skills of pharmacists need to be 
provided in a suitable format for pharmacists in regional areas to access, not only for those in 
tertiary paediatric sites. 
Paediatric GLF versus Standard GLF 
The results from the Paediatric GLF were not significantly different to the Standard GLF.  This 
provides some reassurance that the additional descriptors included in the Paediatric GLF did not 
make the competency more difficult to achieve, however the very small numbers in this sub-group 
make any further conclusions difficult. 
Comparison to other research 
Our findings were similar to those from studies undertaken in the UK and Australia.  The original 
work from the UK also found that ensuring the legality of prescriptions was a competency which is 
consistently performed well, which should be considered a ubiquitous competence of registered 
pharmacists.207  A recent study reviewing recommendations on professional development for 220 
GLF evaluations, found a similar set of recommendations to our study related to improvement in 
knowledge of pharmacology, pathophysiology, interactions and side effects.295  This study also 
found recommendations for improvement in documentation of clinical pharmacy review activities 
and some recommendations to improve patient history assessment.  Therefore these areas are not 
unique to the paediatric field, although communication with children and families offer specific 
challenges. 
Limitations 
There are limitations with using retrospective de-identified data.  Years of experience and 
qualifications of the practitioners were not known, and it was not possible to pair two or more 
sequential assessments performed for the one practitioner to identify any change in practice over 
time.  The self-assessment and comments made by the pharmacists themselves and the evaluators 
were not included, which may have added depth to the analysis and may be useful to include in 
future studies in the area.   
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The results also do not take into account local practices or systems.  If the local expectation of 
service does not include recording of pharmacist interventions, or the use of a medication action 
plan, then a rating of “rarely” for that competency element does not necessarily indicate inadequate 
competency of the individual pharmacists.   
There were 15 different pharmacists as evaluators, which despite regular revalidation of evaluators, 
may have added variation in the evaluations undertaken.  The same training was completed for all 
assessors, including training workshops and hands on training with experience of three GLFs 
completed to satisfaction before being accredited as an evaluator, and re-evaluation occurred every 
2-3 years.  In the early stages of the GLF implementation project inter-rater reliability was tested, 
however this has not been undertaken in more recent years.209  Despite this standardised training, 
there may have been variation in approach and assessment between evaluators. 
Future of the GLF 
The GLF itself has now been largely replaced for use in Australia by a similar tool called the shpa 
clinical competency assessment tool (or “shpaclinCAT”), which was developed by the Society of 
Hospital Pharmacists of Australia and based on the same content as the GLF.370,372  The primary 
role of the shpaclinCAT remains for formative assessment of individual pharmacists to provide 
structured feedback and to develop personalised development plans. 
The GLF has been expanded for use in other specialty areas such as cancer care, where the original 
(generic) competency elements were used, with expanded descriptors and some additional 
competency elements.136  This study supports the use of these competency evaluation tools in 
specialised environments, with ongoing work required to develop supplementary documents to 
describe additional or differing requirements in specialty areas. 
The other important area in pharmacy internationally at present is the evaluation of advanced 
pharmacy practice.  The GLF (and shpaclinCAT) could be used to provide evidence of high-level 
clinical practice in some domains such as “Expert Professional Practice”.  It has been used as a 
method of assessment in formal postgraduate training in clinical pharmacy and a related tool was 
successfully used in evaluation of advanced practice with critical care pharmacists.208,286,328  
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8.7 Manuscript Conclusion 
This study successfully used the GLF to identify strengths and priority training areas in knowledge 
and skills of pharmacists working in paediatrics.  Areas that were not consistently undertaken well 
included detailed assessment of patient history, and recording a medication action plan.  In addition, 
challenging areas such as knowledge of paediatric pathophysiology and effective communication 
with children and families were identified as training needs.  These findings can be used to 
prioritise training opportunities for pharmacists working in paediatrics, particularly in a format 
accessible for pharmacists working in regional areas. 
8.8 Chapter Conclusion: 
This study has confirmed the hypothesis that training and development priorities of paediatric 
pharmacists can be identified by reviewing the strengths and weaknesses, recorded by direct 
observation of pharmacists working in clinical practice.   
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9 Chapter Nine: Assessment of Advanced Paediatric 
Pharmacy Practice: A Pilot Study 
9.1 Introduction 
This research investigates the following assessment methods for the evaluation of paediatric 
pharmacists against an advanced practice competency framework: 
• Direct observation of practice 
• Peer review 
• Portfolio review 
• Oral interview (viva voce) 
• Knowledge assessments (using postgraduate qualifications and CPD records) 
• Self assessment 
This chapter follows on from the advanced practice focus group study (described in Chapter 6), 
where components of advanced practice of paediatric knowledge and skills, communication, 
leadership, education, and research skills were defined.  In that chapter portfolio review, peer 
review and direct observation of practice were recommended as methods of assessment for 
advanced practice.  Direct observation of practice using the General Level Framework was 
investigated in Chapter 8, demonstrating its usefulness as a generic formative assessment tool in the 
paediatric setting.  In this project it was tested as a tool for summative assessment.  This project 
further investigates the use of pharmacist interventions as evidence for advanced practice, as 
described in Chapter 7.  
The hypothesis of this project was: 
Advanced level paediatric pharmacy practice is most reliably evaluated using multiple 
assessment methods.   
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9.2 Background 
The efforts towards definition and recognition of advanced pharmacy practice in recent years have 
been positive steps in a maturing profession.1  Internationally, frameworks that articulate expected 
competencies for pharmacists at a general level have been used to support practice for some 
decades.  More recently, frameworks applicable for advanced practice have also been introduced.   
The first advanced practice framework was the Advanced and Consultant Level Framework 
(ACLF), developed in the UK in 2005.115  This framework was recently adopted by the Royal 
Pharmaceutical Society (RPS) as the basis of practice evaluation for admission to the faculty of the 
Royal Pharmaceutical Society.119   
In Australia, the ACLF was adapted in a number of areas of specialty practice, including cancer 
care, emergency medicine, infectious diseases, cardiology and palliative care.136-138  One of the 
earliest of these adaptations was in paediatrics, when the Society of Hospital Pharmacists of 
Australia Committee of Specialty Practice in Paediatrics developed a paediatric version of the 
ACLF in 2008, with funding from Queensland Health, called the Paediatric ALF.133-135  This work 
led to the development of an Australian Advanced Pharmacy Practice Framework (APPF) in 2012, 
which was established after extensive consultation and collaboration between a number of 
Australian pharmacy groups.141 This was a generic tool, designed for all pharmacy work 
environments, and therefore does not contain the paediatric specific information included in the 
Paediatric ALF.  The APPF was endorsed by the Pharmacy Board of Australia in 2013, followed by 
endorsement of the Australian Pharmacy Council (APC) to be the entity responsible for 
credentialing of advanced pharmacy practitioners.141  Work in advanced pharmacy practice has 
continued to progress, and in May 2014 the APC released the first consultation paper regarding 
evaluation and credentialing of advanced practice pharmacists.373 
Health practitioner groups have used a variety of methods to assess competency over recent 
decades.  Portfolio reviews, direct observation of practice, peer review, clinical examinations, 
supervisor feedback, case based discussions, interviews (or viva voce) and knowledge based 
examinations have all been used in varied forms to assess practice in medical, nursing and allied 
health fields.  Each of these methods contributes to the evaluation of different aspects of practice: 
expert knowledge and skills, teamwork and communication, managerial and leadership skills, 
education and research achievements.  Combinations of assessment methods have been tested for 
reliability in postgraduate medical education.292,326,327 
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Assessment of experienced practitioners, including those practicing at an advanced level, has 
different requirements to assessment of new graduates.  In the USA, advanced practice is 
recognised by the Board of Pharmacy Specialties (BPS), which certifies pharmacists in specialty 
areas using a case based multiple-choice examination.124  A BPS certification in paediatric 
pharmacy is due to be available from 2015.100,128   In the UK, a combination of assessment methods 
has been successfully used in advanced critical care pharmacy practice for some time.286  In late 
2013 a combination of portfolio review and testimonials was introduced to the first round of 
assessments for membership of the RPS Faculty as advanced practice pharmacists.374  However 
none of these assessment models have been used or evaluated in Australia for advanced pharmacy 
practice assessment, and none specifically in the paediatric setting. 
9.3 Aim 
The aim of this study was to investigate the reliability, acceptability and relevance of six different 
assessment methods in evaluating advanced pharmacy practice by Australian paediatric 
pharmacists. 
9.4 Method 
9.4.1 Recruitment 
Four Australian tertiary paediatric hospitals (the Royal Children’s Hospital in Brisbane, Royal 
Children’s Hospital in Melbourne, Children’s Hospital at Westmead in Sydney, and the Women’s 
and Children’s Hospital in Adelaide) took part in the research, with a minimum of five pharmacists 
to be recruited from each site.  An information session was provided at each site by the researcher 
(SS), with an open invitation to attend sent via email from the Director of Pharmacy and/or the site 
investigator to all pharmacists at the site.  Pharmacists from the study sites who had participated in a 
previous focus group study on the same topic were individually invited via email to attend.355   
• Inclusion criteria:  registered pharmacists with three or more years of pharmacy experience.  
• Exclusion criteria: pharmacists who did not anticipate being able to complete the assessment 
tasks in 12 months, and those with less than three years experience.   
Pharmacists identified by the site investigators as possible advanced practitioners were specifically 
encouraged to participate, however all pharmacists with 3 or more years experience were eligible to 
participate.   
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Participants were recruited between January and March 2013, and assessments completed over the 
subsequent 12 months.  Evaluators included four pharmacists and one consultant paediatrician, each 
experienced in practitioner development.   
Verbal and written information on the project was provided to participants, and written consent was 
obtained from each participant.  Principal ethics approval was obtained from the Royal Children’s 
Hospital Health Research Ethics Committees (HREC/12/QRCH/216) and the University of 
Queensland Ethics Committee.  Subsequent ethics and institutional approval was obtained from the 
remaining study sites. 
9.4.2 Paediatric Advanced Level Framework 
The competency standard used was the Australian Paediatric Advanced Level Framework (ALF), 
which contained the same six competency clusters relating to advanced practice as the original 
ACLF from the UK:  Professional Practice; Building Working Relationships; Leadership; 
Management; Education, Training and Development; and Research and Evaluation.115,133  The 
paediatric-specific knowledge and skills overlaid the generic content in the Professional Practice 
cluster, whereas the other clusters remained applicable to any area of advanced practice.  A sample 
of the Paediatric ALF is provided in Appendix A. 
Each of the assessments were scored against the specific competencies within each of the six 
clusters on a rating scale of 1 to 3 where a level 3 was equivalent to advanced practice.  An overall 
score for the cluster was determined.  “Half” scores were permitted per cluster, where participants 
fully met the competency standards at the lower level, but only partially at the higher level (e.g. 
2.5).  
9.4.3 Self-Assessment 
Each participant undertook a self-assessment three times during the project.  This was to identify 
any change in perception of practice over time, and to review the correlation with other assessment 
methods.  A global self-assessment of advanced practice (on a scale of 1-3, with ‘half’ scores 
permitted) was recorded at the time of recruitment to the project, a more detailed self-assessment 
against each cluster was undertaken part way through the project in conjunction with the peer 
review assessment, and a final global self-assessment was carried out at the completion of the 
project.  The detailed mid-project self-assessment was used in comparison with other assessment 
methods. 
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9.4.4 Direct Observation 
Direct observation evaluations were used for pharmacists working in direct patient care roles.  A 
minimum of one evaluation, completed within the past two years, was required for assessment.  
Standardised tools were used, either the General Level Framework or the shpaclinCAT, which had 
been successfully used as formative assessment tools in a range of practice settings.207,209-211,296-
298,375  The process of using the GLF (and shpaclinCAT) for practice evaluation was described in 
Chapter 8, and required approximately half a day to complete.  A sample of the shpaclinCAT is 
provided in Appendix B.   
Evaluators were trained in clinical education and feedback and in the use of the specific tool, with 
standardised training provided by educators from Queensland Health and/or the Society of Hospital 
Pharmacists of Australia, as described by Coombes et al in 2010.209  At the time of the study, two 
sites were routinely using the shpaclinCAT as a professional development tool for staff engaged in 
direct patient care; one site was implementing its use; and one site had not yet begun to implement 
its use.  Researchers provided support to evaluators undertaking the assessments in sites where the 
shpaclinCAT was not routinely in use.  Direct observation assessments were scored from 1-3 
against the competencies in the Professional Practice and the Building Working Relationships 
clusters of the ALF based on the assessor rating for the competencies, written comments by 
assessors, and patient complexity. 
9.4.5 Peer Review 
Peer review was undertaken using an adaptation of a tool used by the UK critical care group.286  
The participant and each peer evaluator were asked to rate the participant on a scale of 1-3 for each 
of the six clusters in the ALF, guided by a summarised paragraph that described each level of 
practice for the clusters included in the ALF.  Evaluators were also asked to provide general 
comments and suggestions for further activities to progress professional development.  The text of 
the survey questions is included in Appendix D. 
Participants were asked to nominate six to eight peers from a range of backgrounds, including 
pharmacy, medical, nursing and allied health peers; administrative and technical staff; students or 
more junior staff reporting to the pharmacist; and direct supervisors or line managers.  A matrix of 
escalating seniority of evaluators was recommended depending on the experience of the pharmacist.  
It was recommended that participants choose colleagues who would provide honest feedback and 
advice on professional development.   
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Evaluation comments were collated with the self-assessment and mean competency scores into a 
report for the participant.  The feedback was discussed either face-to-face or over the telephone with 
a researcher (SS).  The pharmacist was asked to write a short summary of important points and a 
development plan based on the feedback provided. 
Reviews were undertaken using SurveyMonkey® (SurveyMonkey Inc, Palo Alto, CA, USA).  Its 
suitability for this purpose was tested in a pilot survey.  Review surveys were facilitated by a 
researcher (SS).   
9.4.6 Knowledge Assessment – Postgraduate Qualifications and CPD 
Records 
Continued Professional Development (CPD) records and formal qualifications were reviewed to 
evaluate whether existing methods of knowledge assessment could be used in Australia, as an 
alternative to the examination used for Board of Pharmacy Specialties certification currently used in 
the United States.128  A record of CPD is required for registration as a pharmacist in Australia.  
Development activities that include assessment are encouraged.  They are classed as “Group 2” 
activities and thus earn twice as many CPD points per hour of activity compared to activities that do 
not include assessment. Participants were asked to provide their CPD record for the previous two 
years, including their total CPD credit points and, specifically, their Group 2 (i.e. assessed) credit 
points.   
To assess formal qualifications, participants were asked to provide the total number of 
qualifications, to specify the level achieved (i.e. Postgraduate Certificate, Postgraduate Diploma, 
Masters or PhD), and to describe any paediatric components in the training and assessment.  This 
information was analysed in relation to the relevant clusters in the Paediatric ALF (Professional 
Practice, and Education, Training and Development).  
9.4.7 Portfolio Review 
All participants were asked to compile a professional portfolio addressing the competencies in the 
Paediatric ALF soon after recruitment to the study.  Participants were given guidance on 
preparation of the portfolio.  Electronic format using the ALF document was preferred; however, 
any format was permitted.  Examples of alternatives included a matrix format in a spread sheet, or a 
simple summary as part of curriculum vitae.  One of the researchers (SS) reviewed each portfolio, 
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discussed the results with the participant, and developed a learning plan in collaboration with the 
participant.   
At the end of the study, the participants were asked to update the portfolio and submit it for review 
to an evaluation panel.   Key pieces of supporting evidence were suggested for inclusion, including:  
curriculum vitae, current position description, Mini-PAT (as described below), publications, 
presentations (provided and attended), and direct observations of practice.  Participants were 
permitted to include any files they felt provided evidence in support of their level of practice.  A 
cloud-based file-sharing platform (Dropbox®, Dropbox Inc, San Francisco, CA, USA) was used to 
share the documents electronically between each participant and the panel members.  A minimum 
of two panel experts evaluated the portfolio and scored it from 1-3 against each cluster, with 
feedback provided to each participant on achievements and suggested development activities. 
Participants and evaluation panel members were asked their opinion on the most and least useful 
pieces of evidence to include in a portfolio to demonstrate advanced practice, using the following 
examples: 
• Advanced Level Framework (adding evidence against the different competencies); 
• ClinCAT or GLF (direct observation of practice); 
• CPD records (continued professional development); 
• Intervention reports or case based demonstrations; 
• Mini-PAT (the summarised peer review from colleagues); 
• Presentations or lectures given; 
• Project Reports; 
• Research - published articles; 
• Research - conference or seminar abstracts, posters or presentations; 
• Student or learner feedback (as an educator); 
• Thank-you or other acknowledgements (e.g. emails from colleagues); 
• Written references. 
9.4.8 Oral Interview (viva voce) 
A panel of 2-4 experts was convened for each viva panel.   Panel members included a medical 
consultant and senior pharmacists with at least 20 years experience, each experienced in practitioner 
development and evaluation.  A researcher (SS) was present as an observer at each of the vivas, 
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recording written notes for each session.  Vivas were undertaken face to face, via videoconference 
and telephone.  Video conferencing used two freely available internet based tools: WebEx® (Cisco 
Systems Inc, San Jose, CA, USA) and FaceTime® (Apple Inc, Cupertino, CA, USA). 
The viva was semi-structured, with each participant asked to define an advanced practice 
pharmacist and to describe what they regarded as their own strengths and weaknesses.  Questions 
were asked regarding specific components of their submitted portfolio in order to confirm or clarify 
points, explore certain aspects of their experience and add detail where required.  At the conclusion 
of the interview, participants were asked to articulate what level they considered most applicable to 
their current practice.  
Panel members independently reviewed the electronic portfolios prior to the viva and scored against 
each ALF cluster (from 1-3) based on the portfolio alone.  Panel members scored against each 
cluster again after the viva allowing researchers to determine whether the viva changed rating 
scores. 
9.4.9 Methods for Analysis 
Participant Feedback 
A feedback survey was sent to all participants at the end of the study, using SurveyMonkey® 
(SurveyMonkey Inc, Palo Alto, CA, USA).  Both quantitative and qualitative data was obtained.  
Survey questions were designed to determine participants’ views on the value of each method for 
professional development and for practice evaluation.  Quantitative data was obtained using 
multiple choice question which were based on those used in previous competency evaluation 
research and which asked participants to rate their extent of agreement with the following 
statements about each of the assessment methods:209   
• a positive experience that allowed me to reflect honestly on my practice and plan my future 
development; 
• an extremely taxing process that provided little benefit to me; 
• an inspiring experience that has given me renewed enthusiasm for pharmacy practice; 
• a fair method of evaluation of advanced practice. 
A combination of the questions above using a five point Likert matrix scale from “Strongly 
Disagree” to “Strongly Agree” was used.    
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For each method, participants were asked open-ended questions to obtain general feedback.  
Participants were also specifically asked what was their preferred evidence for inclusion in a 
professional portfolio.  In addition, viva participants were asked questions about viva format and 
about their personal experience of the viva.  A condensed feedback survey was used in evaluators 
and participants who had withdrawn from the study.   
Each of the surveys were piloted before use. Survey questions are included in Appendix C.  
Qualitative thematic analysis of feedback was undertaken using nVivo for Mac Beta® (QSR 
International Pty Ltd, Doncaster, Vic, AUS). 
Assessment Scores 
The scores for each assessment method for each individual cluster were compared for pharmacists 
who had completed three or more assessment methods.  No gold standard was used.  Assessment 
method scores were compared using the Skillings-Mack test, which is the non-parametric 
equivalent of ANOVA, and which is used where there are more than two measures and missing 
observations (i.e. not all methods were able to assess against each advanced practice cluster).  
Where differences amongst the group of assessment methods were identified, the Wilcoxon Signed 
Rank test was used to test paired data, with Bonferroni adjustment for multiple comparisons.  All 
tests were two-sided and P-values <0.05 were considered statistically significant.   
Intraclass Correlation Coefficients (ICC) were used to determine the reliability of scores across the 
assessment methods using different combinations of methods.   
Scores for each of the participants were ranked, with the top scoring participants for each evaluator 
identified.  The top ranked participants were discussed between the evaluators to identify those 
participants who were considered by the panel to be advanced practitioners.  The characteristics of 
these participants were then compared against the existing framework. 
Stata 12.0 (StataCorp, College Station, TX, USA) was used for statistical analysis. 
9.5 Results 
9.5.1 Participant Demographics 
A total of 36 pharmacists consented to be part of the project, between 7 to 11 per site.  During the 
study period 12 participants withdrew from the study, leaving 24 pharmacists to complete the study. 
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At completion of the project, 21 pharmacists had submitted three or more assessments required for 
comparison of score reliability.   A total of 103 individual assessments were submitted for 
evaluation.   
Participant demographics for each site are included in 9.1. 
Table 9.1  Site and Participant Demographics 
 Initial 
recruitment 
(Male/Female) 
Remained in 
study 
Completed 
minimum 3 
assessments 
Site 1 10 (2/8) 9 8 
Site 2 11 (2/9) 3 2 
Site 3 8 (2/6) 7 6 
Site 4 7 (1/6) 5 5 
Total 36 (7/29) 24 21 
Reasons for Withdrawal 
Eight participants who had withdrawn from the study provided feedback at the completion of the 
study.  “Work commitments” was the most common reason for withdrawal, accounting for 60% of 
the withdrawals.  Illness, and resignation or a change of role were also contributing factors.  
9.5.2 Individual Assessment Methods 
Self Assessment 
All participants completed a self-assessment of practice at the commencement of the project.  At 
that time half of the participants (18) considered their practice to be at or approaching an advanced 
level (Level 3 in the Paediatric ALF).  All but one of the remainder considered their practice 
approaching or at Level 2.  Three of the four pharmacists who identified themselves as level 3 at the 
beginning of the project, were confirmed as level 3 by the panel at the end of the project, with the 
remaining pharmacist assessed at between 2 and 3.  Self assessment provided evidence against each 
of the six clusters. 
Self-assessment scores remained reasonably consistent over the time of the project, as shown in 
Figure 9.1 below.  Half the participants did not change their self-assessment score.  Only three 
participants increased their self-assessed level of practice, and seven participants decreased their 
self-assessed level. 
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Figure 9.1 Change in self-assessment scores from beginning to the end of the 
research project 
Direct Observation 
Eleven of the pharmacists in the study were evaluated using direct observation.  Of those eleven, ten 
provided feedback on the process and its findings.   
The direct observation tools used (the GLF or shpaclinCAT) provided evidence for the Professional 
Practice and Working Relationships clusters; however the current descriptors did not provide 
evidence at Level 3.   
Multi Source Peer Review 
A total of 23 pharmacists participated in peer review (Mini-PAT).  Feedback was received from 20 
study participants.  An average of eight peers were invited to provide reviews, with an average of 
seven responses per pharmacist.  Each participant received peer review feedback from (on average) 
one doctor, one nurse, three pharmacists and two other staff, usually pharmacy administration or 
technical staff.   
Peer review provided evidence against each of the six clusters.  
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Knowledge Assessment  
A total of 24 pharmacists provided information on postgraduate qualifications and CPD records.  15 
(38%) had undertaken postgraduate training, with nearly half of those at Masters level.  Of the 
qualifications undertaken, nine (60%) had some paediatric content and assessment, although no 
paediatric specific qualifications were undertaken.   
Of the 18 pharmacists who submitted knowledge assessment information, six (33%) did not 
routinely record CPD points.  The average total CPD points per participant per year was 126, with 
an average of 31 Group 2 points.  There was no correlation between the level of practice and 
number of recorded CPD points.  Pharmacists with the highest recorded CPD were those who were 
currently undertaking postgraduate training.   
Knowledge assessment provided evidence against the Professional Practice and Education clusters.  
Portfolio Review 
All 24 of the pharmacists prepared a portfolio at the commencement of the project, of whom 17 
pharmacists submitted a portfolio for review as summative assessment.  Feedback was received 
from 19.  Most of the participants used the Paediatric ALF itself as a tool to document their 
evidence of competency, however some chose to use a simple matrix format, or simply addressed 
the competencies in their curriculum vitae.   
The portfolio (regardless of format) provided evidence against each of the six clusters. 
Viva voce 
Eight pharmacists participated in the viva voce.  Panels ranged from two to four members.  Viva 
voce were undertaken face-to-face (3), via videoconference (2), and by telephone (3), with an 
average duration of 45 minutes.  Panel size varied, from two (5), three (1) to four (2) members.  The 
quality of the videoconferencing was not satisfactory; hence the final three vivas were conducted 
via teleconference. 
The viva provided evidence against each of the six clusters. 
For each participant, the evaluator scores before the viva (based on portfolio alone) changed after 
the viva by at least half a level in at least one cluster.  Figure 9.2 shows the change in mean 
assessment score for each participant and cluster (i.e eight participants and six clusters = 48 mean 
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changes in score).  The cluster with the most change in scores after the viva was leadership.  Overall 
mean scores increased after the viva for four of the eight participants, and decreased for the other 
four.  
 
Figure 9.2  Change in average scores after viva (per cluster) 
9.5.3 Comparison of Assessment Scores 
Mean Scores for each assessment method 
Table 9.2  Scores for each assessment method against each cluster 
Cluster  Self Assessment Portfolio Viva 
Peer 
Review Knowledge 
Direct 
Observation 
Professional 
Practice 
N 21 17 8 21 18 11 
Mean 2.29 2.31 2.59 2.51 1.72 1.77 
Sd .64 .40 .39 .38 .60 .26 
Working 
Relationships 
N 21 17 8 21 0 11 
Mean 2.14 2.32 2.48 2.43 . 1.82 
Sd .57 .41 .48 .26 . .25 
Leadership 
N 20 17 8 21 0 0 
Mean 1.95 2.01 2.26 2.12 . . 
Sd .51 .59 .43 .30 . . 
Management 
N 20 17 8 21 2 0 
Mean 2.4 2.13 2.15 2.30 1 . 
Sd .50 .53 .36 .34 0 . 
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Cluster  Self Assessment Portfolio Viva 
Peer 
Review Knowledge 
Direct 
Observation 
Education 
N 20 17 8 21 18 0 
Mean 2.2 2.2 2.39 2.27 2.06 . 
Sd .70 .41 .56 .42 .80 . 
Research 
N 20 17 8 21 0 0 
Mean 1.95 1.74 1.85 2.01 . . 
Sd .69 .56 .66 .46 . . 
Table 9.2 shows that direct observation and knowledge assessment did not provide evidence for 
every cluster.  Where evidence was available, both direct observation and knowledge assessment 
scored lower than any of the other assessment methods.   
Comparison of Methods 
The Skillings-Mack test was used to identify whether there was a significant difference between the 
scores for methods for each cluster. This analysis found a statistically significant difference in 
assessment scores for Professional Practice (p<0.001), Working Relationships (p=0.026), 
Management (p=0.007) and Research (p=0.036).  The Leadership and Education clusters were not 
significantly difference (p=0.334 and p=0.294 respectively).  The statistical analysis of scores in the 
remaining clusters are listed below in Table 9.3, with the Wilcoxon Signed Rank test used to test 
each pair of methods to identify which combinations are different.  The Bonferroni correction was 
applied to the results from the Wilcoxon Signed-Rank tests, resulting in a significance level of 
p<0.003 where six assessments were used (15 pairs: Professional practice), p<0.005 where five 
assessments were used (10 pairs: Working Relationships and Management), and p<0.008 where 
four assessments were used (6 pairs: Research).   
Table 9.3  Comparison of pairs of assessment methods per cluster (p-values) 
  Portfolio Viva Peer 
Review 
Knowledge Direct 
Observation 
Professional 
Practice 
Skillings-Mack 
Test p<0.001 
Self 0.286 0.569 0.192 0.001* 0.006 
Portfolio  0.771 0.003 0.002* 0.041 
Viva   0.228 0.079 0.094 
Peer 
Review 
   <0.001* 0.006 
Knowledge     0.800 
Working 
Relationships 
Self 0.234 0.716 0.033  0.154 
Portfolio  0.325 0.046  0.136 
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  Portfolio Viva Peer 
Review 
Knowledge Direct 
Observation 
Skillings-Mack 
Test p=0.026 
Viva   0.233  0.842 
Peer 
Review 
    0.004* 
Management 
Skillings Mack 
Test p=0.007 
Self 0.007 0.062 0.257 0.180  
Portfolio  0.019 0.023 0.180  
Viva   0.049 Unable  
Peer 
Review 
   0.180  
Research 
Skillings Mack 
Test p=0.036 
Self 0.013 0.203 0.866   
Portfolio  0.725 0.010   
Viva   0.036   
When pairs of assessment methods were compared, the scores for knowledge and direct observation 
assessments were the two methods that were statistically different to other assessment methods.  
The combinations of methods determined to be statistically significantly different (using the 
Bonferroni correction) are highlighted in bold in Table 9.3.  It is noted that the use of the Bonferroni 
correction to avoid the risk of Type 1 error is considered to be quite conservative, and the small 
number of scores for some of the methods contribute to the lack of significance and in some cases 
inability to calculate a difference as there were no paired comparisons (such as viva versus 
knowledge for the management cluster). 
Correlation of Scores using Combinations of Methods 
The agreement between combinations of assessment methods was evaluated using the intra-class 
correlation coefficient (ICC).  This is the correlation between the scores from any two or more 
randomly chosen assessments of the same individual.  The closer the ICC towards 1, the more 
similar the scores are for each method for each individual pharmacist, with an ICC of 0.8 
considered ideal for competency assessment.376,377  The ICC for all assessment methods was tested 
initially, then for the three methods most strongly supported by the participants (peer review, 
portfolio review and viva voce).  
Table 9.4 shows that the level of agreement between scores was low when all methods were 
included.  However, there was closer agreement when only portfolio, peer review and viva voce 
were included. 
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Table 9.4  Intra-Class Correlation for Combinations of Methods 
Cluster All Six Methods  Viva, Portfolio & Peer Review 
 ICC 95% CI P-value ICC 95% CI P-value 
Prof Practice 0.246 0.097 – 0.466 <0.001 0.476 0.207 – 0.715 0.004 
Working 
Relationships 
0.256 0.092 – 0.490 0.003 0.427 0.169 – 0.677 NS 
Leadership 0.426 0.210 – 0.660 NS 0.443 0.182 – 0.690 NS 
Management 0.372 0.161 – 0.613 <0.001 0.568 0.302 – 0.777 0.005 
Education 0.467 0.273 – 0.682 NS 0.667 0.441 – 0.834 0.034 
Research 0.506 0.288 – 0.720 0.004 0.419 0.156 – 0.672  0.001 
NS = Non statistically significant.  ICC = Intra-class Correlation Coefficient, CI = Confidence Interval 
9.5.4 Feedback 
Feedback was received from 34 people in total, comprising 22 participants who had completed the 
project, 8 participants who withdrew from the project without completing it, 4 evaluators.  Of the 12 
participants in total who withdrew from the study, 8 provided feedback and four did not. Two 
participants who completed the study were unable to be contacted for feedback.  Qualitative 
feedback was gathered via open-ended questions contained in the survey, as well as personal 
communications recorded during portfolio review and viva voce assessments in the course of the 
research project itself. Results below show the quantitative feedback from survey respondents 
regarding the assessment methods, and extracted themes from the qualitative feedback. 
Quantitative feedback about individual assessment methods 
Survey results comparing the individual assessment methods are included in Table 9.5 with 
feedback results separated according to the three categories of respondent: those participants who 
completed the project, participants who withdrew from the project, and evaluators. 
These results show that the portfolio review, peer review and direct observation had the strongest 
support from participants as tools for professional development (positive experience allowing 
developing planning, and inspiring experience with renewed enthusiasm for practice).  Whereas 
portfolio review, viva voce and peer review had the strongest support from participants as fair 
evaluation tools for advanced practice.   
Panel members considered peer review and viva voce to be the fairest evaluation methods.  They 
found the portfolio review process to be particularly taxing. 
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Table 9.5 Quantitative Survey Feedback on Assessment Methods 
Assessment 
Method # Respondents 
Positive 
(Ranking) 
Taxing* 
(Ranking) 
Inspiring* 
(Ranking) 
Fair 
Evaluation* 
(Ranking) 
 
 % of respondents “Somewhat Agree” or “Strongly Agree” 
Portfolio      
Participants 19 100% (1) 5% (3) 68% (4) 95% (1) 
Withdrawn 6    86% (1) 
Evaluators 4  50%  50% (4) 
Viva      
Participants 8 88% (4) 13% (6) 75% (3) 88% (2) 
Withdrawn 5    60% (4) 
Evaluators 4  0%  100% (1) 
Peer Review      
Participants 20 95% (2) 0% (1) 85% (1) 85% (3) 
Withdrawn 5    60% (4) 
Evaluators 4  0%  100% (1) 
Postgrad      
Participants 15 60% (6) 7% (3) 60% (5) 73% (4) 
Withdrawn 5    60% (4) 
Evaluators 4  0%  50% (4) 
CPD       
Participants 17 76% (5) 12% (5) 41% (6) 64% (6) 
Withdrawn 5    80% (2) 
Evaluators 4  0%  50% (4) 
Direct Observation      
Participants 10 90% (3) 0% (4) 80% (2) 70% (5) 
Withdrawn 5    80% (2) 
Evaluators 3  0%  67% (3) 
* Positive refers to the percentage of respondents who agreed or strongly agreed that ‘the assessment was a positive experience that 
allowed me to reflect honestly on my practice and plan my future development’.  Taxing refers to the percentage of respondents who 
agreed or strongly agreed that ‘the assessment was an extremely taxing process that provided little benefit to me’.  Inspiring refers the 
percentage of respondents who agreed or strongly agreed that ‘the assessment was an inspiring experience that has given me renewed 
enthusiasm for pharmacy practice’.  Finally “fair evaluation” refers to the percentage of respondents who agreed or strongly agreed that 
‘the assessment was a fair evaluation of advanced practice’. 
Direct Observation of Practice 
The participants felt that direct observation of practice using tools such as the GLF or shpaclinCAT 
was valuable for professional development but not suitable as a summative assessment tool for 
advanced practice.  The criteria within these tools were not designed to evaluate advanced practice 
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and did not match the descriptors in the ALF for advanced practice.  A number of participants also 
commented on the need for multiple evaluations, whether for formative or summative assessment 
purposes.  
ClinCAT is a good tool but not for this particular thing, it’s more process orientated. 
(Participant 28) 
Refreshing for advanced practitioners to have new eyes on their clinical work, and works 
both ways - assessor also learns and can incorporate great ideas into general clinical 
practice. (Participant 13) 
I think direct observation is extremely valuable to assess a practitioner who is working at an 
advanced level (Evaluator 3) 
Peer Review 
The participants were very positive regarding the use of the Mini-PAT as a development tool.  
However, there were some concerns from participants regarding its use as an advanced practice 
evaluation method because of the potential for bias when the peers are chosen by the pharmacist 
themselves. They also noted that it was difficult for some peers (particularly those from other 
disciplines) to be aware of all the different aspects of practice and experience.   
It was valuable to know my peers' perceptions of my practice. It was also surprising in that I 
was rated higher by my peers than I perceived myself. (Participant 26) 
I think the opinion of people you work with every day are more valuable than how you can 
answer questions for one hour. (Participant 3) 
Not completely convinced this is an adequate assessment as it relies on choosing peers who 
both have seen evidence of your level of expertise but also that they adequately note that in 
the assessment. (Participant 10) 
I found the feedback provided in the Mini-PAT to be very honest and constructive. In the 
normal business of day to day work it is uncommon to receive frank comments and positive 
feedback and it was a pleasant reminder to me that in general I was on the "right track".  
Unfortunately not all supervisors feel comfortable to provide this type of feedback either in 
the work environment or in formal performance appraisals, so for me it was a pleasant 
experience to receive encouraging and constructive feedback. (Participant 9) 
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Postgraduate Qualifications 
There were a number of comments related to the importance of currency if training was undertaken 
some years ago, relevance to current scope of practice, and the absence of paediatric specific 
training in Australia.  Both participants and evaluators felt that postgraduate qualifications were not 
a discriminatory evaluation method for advanced practice. 
I believe that undertaking my post graduate studies was extremely beneficial and 
stimulating for me at the time it occurred, however the relevance for my current field of 
work is less significant, so as a tool in assessing advanced level practice for me, it is not 
particularly useful. It should depend specifically on the subjects involved in the post 
graduate studies and the recency of the study, not just the fact that it had been completed. 
(Participant 9) 
Current Postgraduate Qualifications available in Australia I feel does not provide relevant 
assessments of paediatric pharmacists practicing levels. (Participant 30) 
CPD Records 
One third of the participants did not routinely maintain a CPD record, although all were clearly 
undertaking ongoing professional development.  Comments from participants indicated that many 
recorded enough “CPD points” for registration purposes.  However the recorded CPD was not 
linked to a professional development plan. 
Not completely convinced that CPD is an adequate assessment as it may provide 
information about areas that the person being assessed is interested in. May not provide 
adequate information of their overall performance or level of experience. (Participant 10) 
Portfolio 
The participants considered the portfolio review process to be helpful and worthwhile, providing 
professional direction.  Nevertheless, there were numerous negative comments regarding the time 
required to prepare a portfolio in the current format.  Participants estimated that it took between 2-4 
hours to prepare the portfolio, and the discussion with the evaluator took 1-3 hours.  Participants 
who had previously maintained a professional portfolio found the process quicker than those for 
whom this was a new process, and those who prepared well before the discussion session gained 
more from the process than those who had spent minimal time in preparation.  Panel members also 
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found the portfolio evaluation process time-consuming because of the large numbers of evidence 
examples. 
I found the portfolio review to be an excellent experience, as it gave me direct feedback on 
where all my current and past activities 'fit' in terms of my level of practice, and also 
provided ideas of how I could extend certain activities for personal development. 
(Participant 13) 
It was a time consuming process, however I found it to be a positive experience. It helped 
give direction to my future professional development plans. (Participant 30) 
I think it is a very valuable piece of work. However the time required to put the portfolio 
together and other commitments for the participants were very extensive to be completed 
with a busy workload. (Participant 24) 
Suggestions were made to improve the process with the use of clearer guidelines for evidence, 
electronic tools including hyperlinks to evidence, and a two-page summary such as used for funding 
grant proposals.  The items of evidence with the highest preference from participants and evaluators 
for inclusion in an advanced practice portfolio were the ALF, peer review (Mini-PAT), research 
(published or conference presentations), and direct observation (using the clinCAT or GLF).  Least 
preferred evidence were CPD records, thankyou notes or other acknowledgements, written 
references and student feedback. 
An internet based electronic format for portfolio maintenance and submission was preferred by a 
majority of participants (69%), although an electronic format on a personal device, such as a USB 
stick, was preferred by the evaluators.  There was significant difficulty for participants in accessing 
Dropbox in the workplace, and there were some concerns expressed regarding the security of cloud-
based platforms. 
Viva Voce 
Participants were generally quite anxious before the viva (5 out of 8 were apprehensive or anxious) 
with half of the participants feeling ‘a little better’ or ‘much better’ after the viva.  Most participants 
found the opportunity to discuss their career progress and to receive feedback and direction for the 
future to be very helpful and 7 out of 8 participants found the viva to be a positive experience.  Two 
participants initially felt ‘a little worse’ after the viva, and found the process challenging as it 
identified gaps in their practice they were not previously aware of.  On reflection, though they 
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found the process beneficial overall.  One participant felt ‘much worse’ after the viva (see comment 
below).  Some participants would have liked to know more detail about the format and likely 
questions prior to the viva.  Other participants expressed the view that the ability to “think on your 
feet” in response to unforeseen questions demonstrated oral communication skills. 
Most participants (86%) felt that the viva gave the opportunity to provide additional information to 
support their level of practice.  All of the evaluators felt that the viva was valuable and should be a 
component of future credentialing processes.  They felt that the format of the viva should be more 
structured, with defined questions.  Evaluators preferred three members on the panel.  Participants 
felt that four panel members were too many, and that one panel member should be a subject expert. 
The discussion and feedback was tremendous - again providing validation of current level 3 
activities and guidance on how to move level 2 to 3. This should be part of all advanced 
level practice reviews, as it demonstrates oral communication skills described in evidence 
and ability to think on your feet. (Participant 13) 
I found the oral viva process very satisfying, a bit like a good performance appraisal should 
be, but with external perspective and fresh ideas, which, can sometimes only come from 
outside your direct place of work.  (Participant 9) 
I certainly think this is important part of any assessment of advanced practice as it is a way 
of confirming and evaluating the material submitted. (Participant 11) 
I felt 100% worse about my skills and experience after doing the oral viva. I also felt 
attacked and interrogated. Not a positive experience at all.  (Participant 32) 
Mostly very revealing – great opportunity to expand on points identified in the portfolio 
(Evaluator 4) 
Professional Development Opportunities 
Some pharmacists made comments informally and via the final survey regarding their perceptions 
of insufficient support and encouragement for professional development within their organisation. 
Despite differing perceptions of inadequate development culture between the sites, there was no 
difference in the amount of time provided in working hours to undertake assessment tasks, which 
was minimal at all sites.  
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From my institutions perspective, it needs to have a mandatory component, or be 
incorporated into performance or annual review. Many practitioners here were keen to 
participate but withdrew due to time pressures at work. If all roles came with the 
expectation of annual review of practice and evidence, and time and resources were 
allocated to allow this, there would have been more uptake. (Participant 13) 
Research 
Many participants described a desire to be more involved in research, but they were uncertain how 
to begin.  All were involved in quality improvement activities; however, only the more experienced 
staff routinely shared these experiences via conference presentation.  Few participants had 
published.  The participants described a number of barriers to undertaking research including:  lack 
of research culture within individual departments and organisations; lack of financial or 
administrative support; uncertainty about where to start; and lack of mentors to ask for advice.  
Those who had undertaken research activities had commonly undertaken the work in their own time 
(often as a component of postgraduate education assessment), identified funding opportunities 
themselves, or had left the organisation to enable development of research skills. 
9.5.5 Mapping Advanced Practitioners against the Framework 
The expert panel identified five participants they considered advanced pharmacy practitioners (i.e. 
predominantly Level 3).  Table 9.6 summarises the levels of practice (from 1 to 3) of the five 
participants (identified as practitioners A-E) against the condensed Paediatric ALF competencies.  
This table shows that not all of the advanced practitioners achieved Level 3 in all individual 
competencies of overall clusters, although almost all of the remaining competencies were at Level 
2. 
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Table 9.6  Advanced practitioners' competency levels mapped against ALF 
competencies 
 Condensed competency descriptor at Level 3 Advanced Practitioners 
A  B C D E 
 Years of practice >25 >30 >25 >25 >20 
Professional 
Practice 
Advances knowledge base in defined areas      
Advances pharmaceutical care programs      
Responsible for patient service   3   
Ability in difficult and dynamic situations, makes 
decisions in absence or conflicting data      
Interprets health policy and establishes standards for 
others      
Building 
Working 
Relationships 
Communication of complex topics with large groups, snr 
managers, hostile environments      
Works across boundaries, provides expert advice and is 
opinion leader external to organisation      
Leadership Long term, sector wide planning, participates in creating 
national policy, shapes agenda      
Shares vision at higher level, innovation to improve 
service delivery, linked to organisational goals      
Motivates others at a higher level  2    
Management Accountable for delivery of national priorities at a higher 
level      
Reconfigures the use of available resources   2  2 
Accountable for setting and monitoring of standards at a 
higher level  3   3 
Accountable for risk management at higher level     3 
Accountable for performance management at a higher 
level   2  2 
Managed a project or change at higher level     2 
Education, 
Training and 
Development 
Develops role model behaviour in others, mentors 
outside of team.  3    
Designs course of study, shapes higher education 
qualifications, and national education policy, contributes 
to multidisciplinary and external CPD. 
 2    
Higher postgraduate qualifications (Masters/PhD).   1  2  
Research and 
Evaluation 
Peer review activities within specialty   3  2 
Designs specialist research strategy, critical review of 
protocols, peer reviewed publication   2 2  
Applies research evidence to shape organisational 
procedures/policies      
Supervises postgraduate students  2 2 2 2 
Leadership in specialist research.  2 2 2 2 
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How well do the ALF clusters match the identified advanced practitioners? 
Professional Practice:  All identified advanced practitioners had significant experience in 
paediatrics, two with broad experience and three with specialist experience.  All had greater than 20 
years experience.  Only one was in a clinical team based role, although all but one had some 
responsibility for a patient service.  All had advanced the knowledge base via contribution to 
published guidelines, references texts and research literature.  All had evidence at Level 3 across 
each competency within this cluster. 
Working Relationships: All were sought out as opinion leaders, involved in complex, high level 
committees and clinical groups making difficult decisions in potentially hostile environments.  All 
had evidence at Level 3 across each competency within this cluster. 
Leadership:  All were involved at a state or national level with decision-making bodies, 
influencing policy and agenda.  Appropriate evidence for motivation of others at a higher level was 
difficult to produce for some participants.  All but one of the advanced practitioners had evidence at 
Level 3 across each competency in this cluster. 
Management:  Three had roles with direct supervision, managing a team or department.  Two 
managed a complex service without direct supervision responsibility.  All were involved in 
development and implementation of standards of practice, performance management and risk 
management at an organisational level, though few were directly accountable for these tasks.  Three 
of the advanced practitioners had evidence at Level 3 across each of the competencies in the 
management cluster. 
Education, Training and Development: None had impact on national education policy, however 
all contributed to the education of pharmacists and other health professionals outside of their 
institution and discipline.  All except one had ongoing education roles with tertiary institutions and 
professional organisations, as regular contributors to seminars, lectures and tutorials.  All except 
one had postgraduate qualifications, three at Masters level.  For many participants, their role 
modelling and mentoring activities at a high level were undocumented and evidence was difficult to 
produce.  Two of the advanced practitioners had evidence at Level 3 for every competency in the 
Education cluster. 
Research and Evaluation: All had participated in specialist research, and shared research widely 
via conference presentations.  Three had published in peer reviewed journals, and one as a first 
author.  Those who had not published were uncertain of how to move from quality improvement 
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activities shared via conference to published research:  for example, how to start writing a 
manuscript, and where to find suitable mentors or co-investigators.  Only one of the advanced 
practitioners had evidence at Level 3 for every competency within the research cluster. 
How do the advanced practitioners differ from the other practitioners? 
The Level 3 advanced practitioners had an average of 26 years experience in comparison to 9 years 
experience for those at Level 2.  They were more likely to be involved in state, national and 
international level groups as recognised experts in their field, and involved in significant national 
projects to improve quality of care.  All had contributed to research to improve knowledge and 
practice, with the advanced group sharing research widely including in some cases by publication, 
in comparison to the non-advanced group who were more likely to share only via conference 
presentations.   
9.6 Discussion 
This study has piloted a series of six assessment methods to evaluate advanced pharmacy practice.  
This is an important step towards formal recognition of advanced pharmacy practitioners in 
Australia. 
9.6.1 Self-assessment 
There was close correlation between those participants who considered themselves to be advanced 
practitioners at the beginning of the project with those who were assessed as advanced practitioners 
by the expert panel.  Scores from self-assessment were not significantly different to those from the 
other assessment methods, except knowledge assessment and direct observation.  The process of 
working through the framework improved familiarity with the expectations of an advanced 
practitioner.  This indicates that the process of working through an advanced practice framework in 
preparation for an application for formal recognition should provide sufficient guidance to current 
level of practice to avoid a large number of unsuitable applications. 
9.6.2 Direct observation 
The General Level Framework and shpaclinCAT tools used in this study have been used 
successfully as formative assessment tools in a variety of general clinical practice settings.209,210,296  
However, in this study the shpaclinCAT was not found to be a reliable evaluation tool to 
differentiate advanced practice, primarily as it does not articulate advanced level competencies.  A 
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customised tool such as the Mini-CEX used by the Critical Care group in the UK may be a suitable 
alternative for advanced practice assessment for those working in direct patient care roles.286  It is 
still unlikely that key advanced competencies such as ‘advancing the knowledge base’ would be 
demonstrated in a single period of observation.  The use of external experts for the evaluations 
would likely improve consistency and robustness of the process, however would add significantly 
to the cost.  Nevertheless, direct observation assessments would be valuable evidence as a 
component of a portfolio to demonstrate ongoing commitment to (and improvement in) clinical 
practice, particularly if undertaken regularly.   
9.6.3 Multi Source Peer Review 
Multi source peer review was a reliable advanced practice assessment method that provided 
comparable scores to the other methods.  Feedback from the peer review process as a development 
tool and evaluation tool was overwhelmingly positive, confirming the experiences from the 
UK.286,311,312,328  However, there were some concerns raised by participants regarding its future use 
for high stakes assessment, because of the possibility that the choice of evaluators by the 
pharmacists themselves could introduce bias, as found by Archer and McAvoy 313  In our study the 
reviewers focused on providing feedback to the pharmacist for their own professional development, 
although the reviewers were also informed that it was part of a research project for assessment.  It is 
possible that the reviewers would have scored differently if the feedback were used for high stakes 
summative assessment, as found by Burford et al.309 
9.6.4 Knowledge Assessment 
The knowledge assessments included in this study did not provide reliable scores when compared to 
the other assessment methods.  The scores were statistically significantly different from those for 
other assessment methods.  Just over one-third of the pharmacists had undertaken formal 
postgraduate training, which is slightly higher than the general hospital pharmacy population, 
according to a workforce survey from 2007 where 29% of the population and 30% of pharmacists 
working in specialist women’s and children’s hospitals had postgraduate qualifications.371  Most 
pharmacists considered that undertaking formal postgraduate qualifications was a positive 
experience.  However there were doubts regarding their use for assessment of advanced practice as 
set out in the APPF.141  These results are similar to those from the previous focus group study where 
formal postgraduate training was not thought to be a mandatory component of advanced practice.355  
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When considering qualifications specific to the practice area, none of the pharmacists in this study 
group had undertaken specific paediatric training.  This was due to the lack of available training in 
paediatric pharmacy in Australia.  For some pharmacists this formed a barrier which prevented any 
further postgraduate training.  It also makes it unfeasible for postgraduate training to be used as a 
mandatory component of assessment of advanced pharmacy practice.  The BPS Certification in 
Paediatrics (available from 2015) may change this perception in the future, although this will not be 
a local qualification, and will only provide assessment of knowledge rather than specific training in 
itself.100 
CPD records were not considered by the participants or evaluators to be either useful or reliable as 
an assessment method for advanced practice.  Although all participants undertook significant 
professional development activities, one third of the participants did not routinely record their CPD.  
It was apparent that many pharmacists did not see the value of recording CPD except as a 
registration requirement.  
9.6.5 Portfolio 
A portfolio provided reliable scores when compared to the other assessment methods for advanced 
practice, and was strongly supported by participants and evaluators as a development and evaluation 
tool.  Feedback from the portfolio review was very positive as a development tool, despite the 
significant time required preparing the portfolio using the Paediatric ALF as a framework.  The 
process of collating evidence was considered a positive experience, in identifying where the 
practitioner was on the journey to advanced practice.  This was enhanced when the portfolio was 
discussed with a mentor.   
There was also strong support for portfolio review as an evaluation method for advanced practice as 
it allowed the opportunity to present evidence across a wide range of competency areas, and this is 
consistent with experiences in nursing and allied health where portfolios are a significant 
component of advanced practice evaluation.149  However a portfolio for evaluation must be shorter 
and more targeted than one used for professional development over a lifetime, and should be more 
selective than a portfolio used for formative assessment or appraisal, as described by other 
commentators.277,279  Use of a structured template, and careful structured selection of portfolio 
evidence, such as used for the RPS Faculty membership, is required to avoid excessively large 
portfolios, and ensure the evaluation process for panel members is sustainable. 
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9.6.6 Viva voce: 
The interview (or viva voce) provided comparable scores to the other methods, and was considered 
to be a fair evaluation method of advanced practice by all evaluators and all but one participant.  It 
provided a valuable opportunity for evaluators to investigate evidence in the professional portfolio, 
and participants to explain their contribution to practice.  Face-to-face format was preferred, 
however this may have been influenced by the poor video quality of the videoconferencing 
technique used during the study.  This may be less of a barrier with more reliable videoconferencing 
technology in the future, with potential to reduce costs.  A panel comprising 2-3 members 
(including a subject expert) was recommended by participants and evaluators, although the skills of 
the panel members may be more important than the number of members.  Appropriate training for 
panel members, and consistency of approach between different panels and interviews will be 
essential for the use of this approach in the future. 
The results of this study correlate with published research into the use of interviews as a reliable 
selection tool.  Interviews, involving face-to-face contact with a single or multiple interviewers with 
varying degrees of structure, have been widely used for workplace recruitment for over 100 
years.378 However, the reliability and validity of interviews as a selection tool for assessment of 
health practitioners and admission to training programs has been questioned.322,378-380  Standard 
interviews are no longer required for competitive grant selection and have become less commonly 
used for medical school entry.380  More recent research has introduced a modified format of 
interviews called “Multiple Mini Interviews” which have been found to be a more reliable, 
acceptable and feasible method for assessment in medical officers but would add to the cost.380,381  
The format of the interview or viva had an impact in this study.  Some participants preferred a more 
structured format with defined questions.  This recommendation is consistent with recent research 
that recommended structured interviews offer more reliability than a free-form interview format.  
Behavioural interview questions (where applicants were asked to recall what they had actually done 
in particular situations) more reliably differentiated candidates than a descriptive or scenario 
question (where applicants are asked what they thought they would do in a particular situation) to 
predict future performance.323-325,382   
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9.6.7 Combinations of methods 
This study investigates combinations of assessment methods, as is increasingly used in high-stakes 
assessments in health fields.  This includes the recent work by the RPS Faculty where a portfolio, 
curriculum vitae and testimonials are used for assessment of advanced practice and membership of 
the Faculty.119,374   
In the medical field, admission to an advanced training program (including general paediatrics) with 
the Royal Australasian College of Physicians (RACP) requires completion of an accredited basic 
training program and passing of the RACP written and oral examinations.143  Completion of 
advanced training requires multiple formative assessments each year, including case based 
discussions and Mini-CEX’s, combined with summative assessments of supervisors reports at the 
end of each training rotation and a significant research project.143  This approach is supported by 
recent research in the medical field which found that a portfolio which combines seven Mini-
Clinical Examinations (Mini-CEX), eight direct observation of procedural skills and one multi 
source peer review was a feasible and reliable method of high stakes assessment.292  A similar study 
found a minimum of four case based discussions, four Mini-CEX and 6-14 observations of 
procedural skills were required to achieve a reliable result in obstetrics and gynaecology setting.327 
In our study, the combination of the three assessment methods (viva voce, multi source peer review 
and portfolio review) provided a higher Intra-class Correlation Coefficient than all six methods 
combined.  These were also the tools most strongly supported by participants and panel members 
for evaluation of advanced practice, and had reliably consistent scores across each cluster. 
9.6.8 How well does the existing framework match current advanced 
practitioners? 
In this study, the participants identified as advanced practitioners met every Level 3 requirement for 
the clusters of Professional Practice, Working Relationships and Leadership.  The three remaining 
clusters were not all met at level 3 for all practitioners, however almost all individual competencies 
met the requirements of Level 2.  This is consistent with the original work from the UK, where the 
majority of “leading-edge practitioners” also did not meet the highest level for the Education and 
Research clusters.114  There are some additional limitations with the current terminology in the 
framework such as ‘accountable’, which may reflect the practitioner’s defined role within an 
organisation, rather than the pharmacist’s actual practice or impact which may be broader than their 
official role. 
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9.6.9 Limitations 
There were a number of limitations to this pilot study.  Recruitment was a convenience sample of 
pharmacists from four tertiary paediatric hospitals.  Therefore participants cannot be assumed to 
represent the beliefs, opinions or experiences of all Australian pharmacists.  Only 20% of the 
participants were male, which was lower than the proportion of males in the registered pharmacist 
population, however may be more representative of the hospital pharmacist population.383   
Methods were chosen based on those that were currently in common use, in order to maximise 
future sustainability.  This imposed limitations, as tools developed for specific purposes 
(particularly for formative assessment such as the GLF or shpaclinCAT) may not be appropriate for 
use in high stakes summative assessment.  The expert panels were not the same for each of the 
participants, and there was small degree of difference in scoring between evaluators (maximum half 
a point).  However, the use of ranking for each panel member assisted in identifying the highest-
ranking participants.  This is also a ‘real world’ scenario where varied composition of panels is 
likely. 
Feedback from participants may have been influenced by the positive relationship developed with 
the researcher over the course of the study.  The high proportion of “somewhat agree” or “strongly 
agree” feedback for each of the multiple choice questions about methods was in contrast to the 
sometimes negative or ambivalent qualitative feedback from the participants for some of the 
methods.  Hence the quantitative data was analysed to identify the methods with the strongest 
support, and this data was combined with the qualitative feedback to reach conclusions. 
One third of the participants withdrew from the study.  Withdrawal by participants was 
predominantly attributed to work commitments, as work time was not generally provided to 
undertake the assessment tasks.  Despite the differences in withdrawal rates across the different 
sites, there was no difference between study sites as to the work time provided to participate in the 
assessments for this study.  This is also a ‘real-world’ situation where most workplaces have limited 
allocation of time within the workday to complete professional development activities.  
The commencement of this study pre-dated the release of the Australian Advanced Pharmacy 
Practice Framework (APPF), and therefore used the Paediatric ALF, which was the framework in 
use at the time.  The broad competency statements within each of the documents are very similar; 
therefore the results should be transferrable to the APPF.   
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9.6.10 Future Work 
Development of Advanced Practice 
It was clear that there is a need for research support for pharmacists across all levels of practice.  
Most pharmacists in the study expressed a desire to be more involved in research and to share their 
quality improvement activities via publication, but were ‘uncertain of where to start’, and could not 
identify suitable colleagues to approach for advice.  This was consistent with recently published 
research by Grzeskowiak et al that found that only 10% of abstracts on paediatric topics presented 
at an Australian national pharmacy conference were subsequently published.384  These gaps provide 
opportunities for professional organisations, tertiary institutions, employers and research institutes 
to become more involved with providing focused training in this area, including linking early career 
researchers with more experienced research mentors and supporting opportunities for research 
funding. 
The current detailed format of the paediatric practice component in the Paediatric ALF makes it 
time intensive to use as a portfolio for assessment, although it has been valuable as a development 
tool.  Following the recent introduction of the generic Advanced Pharmacy Practice Framework 
(APPF), there is a need for an aligned restructure of the paediatric component of the Advanced 
Level Framework (ALF).  This would form a separate curriculum for professional practice learning 
in paediatrics – and thus facilitate progress to advanced practice.   
A user-friendly electronic portfolio will need to be developed, that supports professional 
development through the linking of evidence across different competencies.  Ideally this would link 
development planning, and recording of self-reflection and CPD activities to improve the current 
disconnection between professional development and CPD recorded for registration purposes.  The 
same portfolio will need to have the functionality to extract a portion of the content for advanced 
practice assessment purposes.   
Assessment of Advanced Practice 
The endorsement of the APPF by the Pharmacy Board of Australia, the nomination of the APC as 
the credentialing body, and the release of the first consultation paper on evaluation of advanced 
practice were all important steps in formal recognition of advanced practice pharmacists in 
Australia.141,373  The next step will be the design of advanced practice evaluation of Australian 
pharmacists.  The results from this study support the use of portfolio review, multi source peer 
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review and a viva voce as suitable evaluation methods for advanced practice.  It also confirmed the 
approach of the Royal Pharmaceutical Society and the experience from the first phase of RPS 
Faculty members.112,374  Further work will be needed to develop an electronic portfolio for 
assessment purposes (as discussed above), to provide guidance on appropriate evaluators for peer 
review, to identify and train suitable members for viva panels.   
Additional assessment methods for professional practice may be valuable for pharmacists working 
in direct patient care roles, such as Case Based Discussion and customised Mini-CEX.  However 
the feasibility of identifying appropriately trained assessors for individual specialties may influence 
the practicality of these for routine use. 
Advanced Practice and Patient Outcomes 
The cohort of pharmacists in this study had contributed significantly to improving the care of 
individual patients and contributing to significant improvements in safety and quality at an 
institutional and national level.  The challenge for future research will be to measure and quantify 
the value of this contribution in patient outcomes. 
9.7 Conclusion 
This study has demonstrated the reliability of multiple assessment methods to evaluate advanced 
paediatric pharmacy practice, with portfolio review, peer review and viva voce the most effective.  
These three tools provided consistent scores in combination, and were supported by the participants 
and panel members as preferred evaluation tools for advanced practice.  Postgraduate qualifications 
and CPD records can be included as evidence in a portfolio but not as stand-alone assessment 
methods.  Direct observation tools such as the General Level Framework or shpaclinCAT are 
valuable tools for development, but are not suitable for assessment of advanced practice.  Future 
work is required to develop a suitable electronic portfolio that can be used for both professional 
development and summative assessment.  Practical aspects regarding resourcing, appropriately 
trained expert panels and format for a viva voce, and facilitation of multi source peer review will 
need to be determined by the credentialing body.  Significant gaps remain in support for 
pharmacists to develop research skills and more effectively undertake and translate important 
quality improvement activities at a local and national level.  
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10 Chapter Ten: Thesis Discussion and Conclusion 
10.1 Introduction to Chapter Ten 
This thesis describes a series of projects investigating the characteristics and assessment methods 
for advanced paediatric pharmacist practitioners and their contribution to improved safety and 
quality of medication use in children.  Case identification methods and evidence for quality 
improvement activities has expanded rapidly over the past few years, alongside inclusion of 
medication safety as a separate standard for accreditation in Australia and rapid uptake of safety 
initiatives at a national level.  The successful strategies in one institution as described in this thesis 
reflect these changes and improvements in safety and quality.  At the commencement of this 
project, advanced pharmacy practice was still a concept being grappled with by the general 
pharmacy population.  However, with the sharing of early results from this research, and the 
ongoing efforts by many at a national and international level, formal recognition of advanced 
pharmacy practice in Australia is now on the horizon. 
10.2 Summary of the key findings 
What is advanced paediatric pharmacy practice? 
The journey towards advanced practice was first described in detail by the Advanced and 
Consultant Level Framework in 2005.115  In the absence of general or advanced level specialty 
training in paediatric pharmacy in Australia, a paediatric version of the ACLF, called the Paediatric 
Advanced Level Framework (ALF), was developed in 2008.133  At the commencement of this 
research, the paediatric ALF had been in use in Australian paediatric hospitals as a development 
tool but not for formal assessment of practice. 
The research described in this thesis investigated the definition, significance and potential 
assessment of advanced paediatric pharmacy practice to Australian paediatric pharmacists via a 
series of focus groups with 31 paediatric pharmacists (described in Chapter 6).  These pharmacists 
described sound clinical skills, excellent communication and interpersonal skills, skills in education, 
leadership and a commitment to quality improvement as key components of an advanced practice 
pharmacist.   The pharmacists considered that advanced pharmacy practice was essentially the same 
for paediatrics as for other areas of practice, with the addition of knowledge of paediatric diseases, 
drug handling in children as well as developmentally appropriate communication skills with 
children and families.  The focus groups also recommended the use of portfolio review, peer review 
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and direct observation as assessment methods for advanced pharmacy practice.  These were further 
investigated in Chapter 9. 
The feedback from these focus groups confirmed the concepts articulated in the Paediatric ALF, 
including knowledge, skills, attitudes and behaviours, to be appropriate for the Australian paediatric 
pharmacy environment. 
How does a paediatric pharmacist develop advanced practice? 
The Paediatric ALF provided a practitioner-driven development pathway for paediatric pharmacists, 
including suggestions for strategies to develop and demonstrate competency across six clusters and 
three levels of practice.  Two of the professional development strategies described in the Paediatric 
ALF were investigated in this research project as potential methods to develop and assess advanced 
practice within paediatrics.  
The first of these was the General Level Framework (GLF), a generic competency assessment tool 
using direct observation of practice, in use at the time in many Australian hospitals.  The research in 
Chapter 8 described a retrospective analysis of 50 GLFs undertaken in pharmacists working with 
children in Queensland public hospitals.  This analysis found that pharmacists were consistently 
undertaking the routine legal and safety requirements including dose checking and ensuring 
prescriptions were legal and legible.  Gaps were identified in clinical documentation and the more 
detailed clinical tasks of patient history assessment and recording of a medication action plan.  
Identified training needs included knowledge of paediatric pathophysiology and effective 
communication with children and families.  Regional areas were particularly in need of assistance.  
This study confirmed the role of the GLF as a valuable tool for development and formative 
assessment of general clinical pharmacy skills, and appropriate for the paediatric environment.  
However, it did not include specific paediatric content or advanced level competencies. 
The second set of tools investigated was documentation of pharmacist interventions, as described in 
Chapter 7.  This study involved retrospective review of 600 pharmacist interventions recorded by 
paediatric pharmacists over eight years, matched to the skills described in the Paediatric ALF.  The 
findings of this study were that the recorded interventions demonstrated increasing skill over time 
towards advanced practice, including identification of drug related problems, appropriate resolution 
of problems, communication and negotiation skills with patients and other health practitioners.  
Intervention recording, and reflective review of interventions, is a valuable strategy for professional 
development and can be used as evidence for developing practice.  The skill level described in the 
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interventions matched the global level of practice assessed via an expert panel in the advanced 
practice assessment project described in Chapter 9. 
Examples of advanced practice often include practice changes to improve safety but are commonly 
achieved weeks or months after the initial intervention was recorded.  Therefore these interventions 
would not be documented in a routine intervention record.  In addition, some advanced level 
practice improvement activities involve populations of patients rather than a single patient and 
therefore also not recorded as part of routine intervention documentation.  The use of more complex 
case based demonstrations and reports or publication of quality improvement activities may be 
more useful as evidence of skill for pharmacists practicing at an advanced level. 
How do pharmacists know they are practicing at an advanced level? 
The focus group project described in Chapter 6, identified portfolio review, peer review and direct 
observation of practice as preferred methods for assessment of advanced practice.  The advanced 
practice assessment project described in Chapter 9, piloted six different potential assessment 
methods to evaluate advanced pharmacy practice.  A total of 36 pharmacists from four Australian 
paediatric hospitals initially enrolled in the project and 24 completed the study.  Portfolio review 
and peer review were both confirmed as appropriate assessment methods, as they provided reliable 
assessment scores and were strongly supported by participants and evaluators for both formative 
and summative assessment.  An oral interview (or viva voce) was also supported by pharmacists 
and evaluators as a means of structured analysis of portfolio evidence and had reliable scores across 
all competency clusters.  Direct observation of practice using the GLF or shpaclinCAT was 
supported as a development tool for formative assessment but not as a fair evaluation tool for 
summative assessment of advanced practice.  This moderates some of the findings in the GLF 
assessment research described in Chapter 8.  Knowledge assessments using postgraduate 
qualifications and CPD records are suitable for inclusion in a professional portfolio but not as 
separate methods of assessment of advanced practice. 
What does advanced pharmacy practice mean for children? 
The majority of the research into the value or impact of pharmacists on patient care has been based 
on prevention of adverse medication events.  Hence this research investigated activities and skills to 
improve medication safety in hospitalised children. 
The initial adverse medication event study described in Chapter 4 investigated six months of 
administrative coding (using ICD-10) in combination with clinical incident reports and pharmacist 
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interventions to identify adverse medication events.  This study found that each case identification 
method detected different events with very little overlap.  Pharmacist interventions identified the 
most error, but few cases involving harm, as these were largely near-miss events where the 
pharmacist resolved the error before it reached the patient.  Incident reports identified events 
involving error, and some occasions of harm, with little duplication with other sources.  ICD-10 
coding identified the most events involving harm but few instances of error, therefore did not detect 
potentially preventable adverse medication events.  The time required to investigate ICD-10 coded 
events using manual chart review was prohibitive for ongoing use for the subsequent research 
within this project where focus was on error reduction and safety improvement.   
This project demonstrated the large number of documented pharmacist interventions that improve 
the safety of medication use in children.  These interventions were largely changes in therapy for 
individual patients where the knowledge and skills required (such as knowledge of appropriate 
medication doses and identification and resolution of medication related problems) are expected of 
pharmacists early in their career.  In contrast, the more complex and broader changes at a system or 
institutional level required more advanced skills.  The use of intervention reports to demonstrate the 
skill progression over time towards advanced practice was investigated in Chapter 7, as described 
above. 
Activities to improve safety and prevention of adverse medication events were investigated in more 
depth in Chapter 5.  This research in one paediatric hospital investigated eight years of medication 
related events identified by clinical incident and pharmacist intervention reports.  The nearly 11,000 
separate recorded events identified trends in types of medications, risk characteristics and proximal 
causes of errors and harm.  A proportion of total reported events were used for analysis to minimise 
the impact of reporting bias.  A significant reduction in reported chemotherapy-protocol-related 
prescribing errors was identified, suggesting the positive effect of prescribing restrictions, 
education, standardised charts, and electronic prescribing systems to decrease errors.  A downward 
trend in reported errors involving potassium also demonstrated the impact of increased awareness, 
forcing functions, clinical guidelines and multidisciplinary involvement.   
These positive changes in safety required significant multidisciplinary involvement and strong 
executive endorsement.  Importantly, the skills required of health practitioners (including 
pharmacists) to increase medication safety and decrease risk were investigated.  These were found 
to include leadership, education, risk management, project management, teamwork, communication 
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and skills in research methodology such as evaluation, analysis and reporting.  These skills are the 
same as those described for an advanced practice pharmacist, including in the paediatric setting. 
The research projects involving adverse medication events demonstrated more than just the positive 
influence on safety for individual patients, they also demonstrated the changes pharmacists have 
contributed towards improvement in quality of care at a system level and the advanced skills 
required to undertake these quality improvement activities. 
10.3 Recommendations for future research 
This research project has confirmed that formal recognition of advanced pharmacy practice is 
suitable and appropriate for Australian pharmacists.   Progress towards this has already been made, 
utilising the early results of this research project.  It is recommended that evaluation of advanced 
practice should include portfolio review using an electronic format, peer review using suitable 
assessors, and a viva voce using structured questioning with an expert panel.  Further evaluation 
should be undertaken regarding the reliability of these measures using larger groups of pharmacists. 
Once a cohort of advanced practitioners has been identified, further research is recommended into 
the direct patient benefits achieved by advanced pharmacy practitioners as part of the healthcare 
team.  This research should include paediatric settings.  Another consideration to be included is the 
different needs and considerations in regional hospitals versus specialist metropolitan hospitals, 
taking into account the gaps identified in the GLF research described in this thesis. 
Future work should include adaptation of the current Paediatric ALF into a paediatric curriculum 
for pharmacy.  This curriculum should be incorporated into educational opportunities available to 
pharmacists across all sites, including regional and community settings.  Work has already started in 
this area in response to the findings of this research thesis, with development and launching of an 
online Paediatric Pharmacy Learning Package available via the education platform of the Society of 
Hospital Pharmacists of Australia.  Future work should also include formal postgraduate training in 
paediatrics, with multidisciplinary involvement and collaboration with international colleagues and 
organisations. 
Future research on quality and safety of medicines use should include multiple case identification 
methods.  Automated trigger tools and ICD-10 coding should be used alongside voluntary reporting 
where electronic medical records enable feasibility on an ongoing basis.  Pharmacists have a clear 
and important role in medication safety at an individual patient and system-wide level, and should 
be key members of patient safety groups within organisations.  Specific training in patient safety, 
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including data analysis and change management strategies, should be available to accelerate skill 
development for pharmacists new to this area. 
Development of research skills in pharmacists was also a significant gap identified in these research 
projects.  Pharmacists are clearly performing at a high level, contributing to significant 
improvements in individual patient care and to significant system improvement.  However sharing 
important cases and success factors from quality improvement activities can be an important 
learning opportunity for all health practitioners.  Improved research skills within the profession will 
also improve the overall quality of improvement activities even though these may not have been 
routinely considered ‘research’.  Work is underway in this area with research content in 
professional conferences increasing over the past two years and the first Research Seminar by the 
Society of Hospital Pharmacists of Australia is scheduled for November 2014.  Improved research 
culture within the pharmacy profession, formal linkages with research institutions and access to 
research training provided by professional, academic and research organisations may assist in this 
area. 
Analysis of publications arising from paediatric conference presentations should be repeated in 
coming years to determine whether positive impact has been made on research output by the 
paediatric pharmacy profession.384   
As mentioned above, it is important that future research focuses on measurement of direct patient 
outcomes, such as harm, readmission rates, length of stay, and biochemical markers, in addition to 
analysis of the needs of hospitalised children and their families; rather than limiting research 
analysis to audits or merely counting errors and adverse events.    
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10.4 Conclusion 
This research project has reinforced the important contribution paediatric pharmacists make to 
improve safety and quality of care for hospitalised children.   The components of advanced practice 
were found to include more than merely knowledge of how drugs work, but include high-level 
leadership, communication, education, risk management and research skills.  Assessment methods 
of pharmacists on the journey towards advanced practice were investigated, with portfolio review, 
peer review and viva voce identified as the most reliable and acceptable methods of summative 
assessment of advanced pharmacy practice.   
It is clear from this research that as pharmacists progress in development of advanced practice their 
contribution to patient care increases; from prevention of adverse drug events at an organisational 
level or broader, education of others at a multidisciplinary and tertiary level, and leading and 
contributing to research activities to advance knowledge and patient care practice.  
  
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 194 
 
11 References 
1. Coombes I, Bates I, Duggan C, Galbraith K. Developing and Recognising Advanced 
Practitioners in Australia: An Opportunity for a Maturing Profession? J Pharm Pract Res 
2011.41(1):17-20. 
2. Bates I, Davies G, Carter S, Quinn J, McRobbie D, Hall G, et al. Advancing and improving 
practice in pharmacy: "elitism" a dirty word? Pharm J 2009.283:149. 
3. United Nations. Global Strategy for Women's and Children's Health. New York: United 
Nations; 2010. 
4. World Health Organisation. Promoting Safety of Medicines for Children. Geneva:   World 
Health Organisation; 2007. 
5. Hill MK, Pawsey M, Cutler A, Holt JL, Goldfeld SR. Consensus standards for the care of 
children and adolescents in Australian health services. Med J Aust 2011.194(2):78-82. 
6. Freed GL, Sewell JR, Spike NA. Challenges to children’s health care in an ageing Australia. 
Med J Aust 2011.195(8):436-7. 
7. Jacobi A. Introduction. Am J Dis Child 1911.1(1):1-5. 
8. Lindell-Osuagwu L, Sepponen K, Farooqui S, Kokki H, Hameen-Anttila K, Vainio K. 
Parental reporting of adverse drug events and other drug-related problems in children in 
Finland. Eur J Clin Pharmacol 2013.69(4):985-94. 
9. Rashed AN, Wong ICK, Cranswick N, Hefele B, Tomlin S, Jackman J, et al. Adverse Drug 
Reactions in Children - International Surveillance and Evaluation (ADVISE): A Multicentre 
Cohort Study. Drug Saf 2012.35(6):481-94. 
10. Cousins D, Clarkson A, Conroy S, Choonara I. Medication Errors in Children – an Eight 
Year Review Using Press Reports. Paediatr Perinat Drug Ther 2002.5(2):52-8. 
11. Queensland Health. Clinical Incident Management Implementation Standard (CIMIS). 
Brisbane: Queensland Health; 2009. 
12. Institute for Safe Medication Practices. Frequently Asked Questions [Internet]. 2012 [cited 
2012 Jul 22]; Available from: http://www.ismp.org 
13. National Coordinating Council for Medication Error Reporting and Prevention. What is a 
Medication Error? [Internet]. 2011 [cited 2011 Oct 07]; Available from: 
http://www.nccmerp.org 
14. Dean B, Barber N, Schachter M. What is a prescribing error? Qual Health Care 
2000.9(4):232-7. 
15. Ghaleb MA, Barber N, Franklin BD, Wong ICK. The incidence and nature of prescribing 
and medication administration errors in paediatric inpatients. Arch Dis Child 
2010.95(2):113-8. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 195 
16. Ghaleb MA, Barber N, Dean Franklin B, Wong ICK. What constitutes a prescribing error in 
paediatrics? Qual Saf Health Care 2005.14(5):352-7. 
17. Wakefield J. Patient Safety: From Learning to Action. First Queensland Health Report on 
Clinical Incidents and Sentinel Events. Brisbane: Queensland Health; 2007. 
18. Patient Safety and Quality Improvement Service. Patient safety: from learning to action 
2012. Brisbane: State of Queensland (Queensland Health); 2012. 
19. Morimoto T. Adverse drug events and medication errors: detection and classification 
methods. Qual Saf Health Care 2004.13(4):306-14. 
20. Griffin FA, Resar RK. IHI Global Trigger Tool for Measuring Adverse Events (Second 
Edition). Cambridge: Institute for Healthcare Improvement; 2009. 
21. Klopotowska JE, Wierenga PC, de Rooij SE, Stuijt CC, Arisz L, Kuks PF, et al. The effect 
of an active on-ward participation of hospital pharmacists in Internal Medicine teams on 
preventable Adverse Drug Events in elderly inpatients: protocol of the WINGS study 
(Ward-oriented pharmacy in newly admitted geriatric seniors). BMC Health Serv Res.  
2011;11(1):124.  DOI: 10.1186/1472-6963-11-124 
22. Klopotowska JE, Wierenga PC, Stuijt CCM, Arisz L, Dijkgraaf MGW, Kuks PFM, et al. 
Adverse drug events in older hospitalized patients: results and reliability of a comprehensive 
and structured identification strategy. PLoS ONE.  2013;8(8):e71045.  DOI: 
10.1371/journal.pone.0071045 
23. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L. Relationship between 
medication errors and adverse drug events. J Gen Intern Med 1995.10(4):199-205. 
24. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse 
drug events and potential adverse drug events. Implications for prevention. ADE Prevention 
Study Group. JAMA 1995.274(1):29-34. 
25. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, et al. Systems 
analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995.274(1):35-43. 
26. Holdsworth MT, Fichtl RE, Behta M, Raisch DW, Mendez-Rico E, Adams A, et al. 
Incidence and impact of adverse drug events in pediatric inpatients. Arch Pediatr Adolesc 
Med 2003.157(1):60-5. 
27. Runciman WBW, Roughead EEE, Semple SJS, Adams RJR. Adverse drug events and 
medication errors in Australia. Int J Qual Health Care 2003.15:i49-i59. 
28. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 
2005.28(10):851-70. 
29. Cimino MA, Kirschbaum MS, Brodsky L, Shaha SH. Assessing medication prescribing 
errors in pediatric intensive care units. Pediatr Crit Care Med 2004.5(2):124-32. 
30. Kaushal R. Using chart review to screen for medication errors and adverse drug events. Am 
J Health-Syst Pharm 2002.59(23):2323-5. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 196 
31. Potts A, Barr F, Gregory D, Wright L, Patel N. Computerized physician order entry and 
medication errors in a pediatric critical care unit. Pediatrics 2004.113:59-63. 
32. King WJ, Paice N, Rangrej J, Forestell GJ, Swartz R. The effect of computerized physician 
order entry on medication errors and adverse drug events in pediatric inpatients. Pediatrics 
2003.112:506-9. 
33. World Health Organisation. International Drug Monitoring: The Role of National Centres. 
Geneva: World Health Organisation; 1972. 
34. Aronson JK. Medication errors: definitions and classification. Br J Clin Pharmacol 
2009.67(6):599-604. 
35. Kunac DL, Kennedy J, Austin N, Reith D. Incidence, preventability, and impact of Adverse 
Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a 
prospective observational cohort study. Paediatr Drugs 2009.11(2):153-60. 
36. World Health Organisation. Glossary of terms used in Pharmacovigilance. Geneva: World 
Health Organisation; 2011. 
37. Gazarian M, Graudins LV. Long-Term Reduction in Adverse Drug Events: An Evidence-
Based Improvement Model. Pediatrics.  2012;129(5):e1334-e42.  DOI: 10.1542/peds.2011-
1902 
38. SHPA Committee of Specialty Practice in Clinical Pharmacy. SHPA Standards of Practice 
for Clinical Pharmacy. J Pharm Pract Res 2005.35(2):122-46. 
39. Bürkle T, Müller F, Patapovas A, Sonst A, Pfistermeister B, Plank-Kiegele B, et al. A new 
approach to identify, classify and count drug-related events. Br J Clin Pharmacol 2013.76 
Suppl 1:56-68. 
40. Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human: Building a Safer Health System. 
Washington: National Academies Press; 2000. 
41. Australian Commission on Safety and Quality in Health Care. Literature Review: 
Medication Safety in Australia. Sydney: Commonwealth of Australia; 2013. 
42. Folli HL, Poole RL, Benitz WE, Russo JC. Medication Error Prevention by Clinical 
Pharmacists in Two Children's Hospitals. Pediatrics 1987.79:718-22. 
43. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication 
errors and adverse drug events in pediatric inpatients. JAMA 2001.285(16):2114-20. 
44. Huynh C, Jani Y, Wong ICK, Dewchand B, Tomlin S. What is the current practice of 
medicines reconciliation in children nationally in the UK? Int J Pharm Pract 2012.21(1):62-
5. 
45. Huynh C, Wong ICK, Tomlin S, Terry D, Sinclair A, Wilson K, et al. Medication 
discrepancies at transitions in pediatrics: a review of the literature. Paediatr Drugs 
2013.15(3):203-15. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 197 
46. Terry DRP, Solanki GA, Sinclair AG, Marriott JF, Wilson KA. Clinical significance of 
medication reconciliation in children admitted to a UK pediatric hospital: observational 
study of neurosurgical patients. Paediatr Drugs 2010.12(5):331-7. 
47. Barber ND, Batty R, Ridout DA. Predicting the rate of physician-accepted interventions by 
hospital pharmacists in the United Kingdom. Am J Health-Syst Pharm 1997.54(4):397-405. 
48. Wong ICK, Ghaleb MA, Franklin BD, Barber N. Incidence and nature of dosing errors in 
paediatric medications: a systematic review. Drug Saf 2004.27(9):661-70. 
49. Fernandez-Llamazares CM, Calleja-Hernández M-Á, Manrique-Rodríguez S, Pérez-Sanz C, 
Durán-García E, Sanjurjo-Sáez M. Prescribing errors intercepted by clinical pharmacists in 
paediatrics and obstetrics in a tertiary hospital in Spain. Eur J Clin Pharmacol 2012.68:1339-
45. 
50. Matlow AG, Baker GR, Flintoft V, Cochrane D, Coffey M, Cohen E, et al. Adverse events 
among children in Canadian hospitals: the Canadian Paediatric Adverse Events Study. Can 
Med Assoc J 2012.184(13):E709-18. 
51. Conroy S, Sweis D, Planner C, Yeung V, Collier J, Haines L, et al. Interventions to reduce 
dosing errors in children: a systematic review of the literature. Drug Saf 2007.30(12):1111-
25. 
52. Kozer E. Medication Errors in Children. Pediatr Clin North Am 2006.53(6):1155-68. 
53. Lesar TS. Errors in the use of medication dosage equations. Arch Pediatr Adolesc Med 
1998.152(4):340-4. 
54. Levine SR, Cohen M, Blanchard N, Federico F, Magelli M, Lomax C, et al. Guidelines for 
preventing medication errors in pediatrics. J Pediatr Pharmacol Ther 2001.6:426-42. 
55. Wong ICK, Wong LYL, Cranswick NE. Minimising medication errors in children. Arch Dis 
Child 2009.94(2):161-4. 
56. Rowe C, Koren T, Koren G. Errors by paediatric residents in calculating drug doses. Arch 
Dis Child 1998.79(1):56-8. 
57. Davis T. Paediatric prescribing errors. Arch Dis Child 2011.96(5):489-91. 
58. Lesar TS. Tenfold medication dose prescribing errors. Ann Pharmacother 
2002.36(12):1833-9. 
59. Doherty C, Mc Donnell C. Tenfold Medication Errors: 5 Years' Experience at a University-
Affiliated Pediatric Hospital. Pediatrics 2012.129(5):916-24. 
60. Chappell K, Newman C. Potential tenfold drug overdoses on a neonatal unit. Archives of 
Disease in Childhood - Fetal and Neonatal Edition 2004.89(6):F483-F4. 
61. Baber N, Pritchard D. Dose estimation for children. Br J Clin Pharmacol 2003.56(5):489-93. 
62. Sanghera N, Chan P-Y, Khaki ZF, Planner C, Lee KKC, Cranswick NE, et al. Interventions 
of hospital pharmacists in improving drug therapy in children: a systematic literature review. 
Drug Saf 2006.29(11):1031-47. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 198 
63. Koren G, Barzilay Z, Greenwald M. Tenfold errors in administration of drug doses: a 
neglected iatrogenic disease in pediatrics. Pediatrics 1986.77(6):848-9. 
64. Crouch BI, Caravati EM, Moltz E. Tenfold therapeutic dosing errors in young children 
reported to U.S. poison control centers. Am J Health-Syst Pharm 2009.66(14):1292-6. 
65. Simpson JH. Reducing medication errors in the neonatal intensive care unit. Arch Dis Child 
Fetal Neonatal Ed 2004.89(6):F480-F2. 
66. Shirkey H. Editorial comment: therapeutic orphans. J Pediatr 1968.72(1):119-20. 
67. Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, et al. 
The status of paediatric medicines initiatives around the world—what has happened and 
what has not? Eur J Clin Pharmacol 2011.68(1):1-10. 
68. Beggs S. Australian Report on Pediatric Medication Issues. Paediatr Drugs 2009.11(1):38-
40. 
69. Conroy S. Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 
2002.4(6):353-9. 
70. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis 
Child Fetal Neonatal Ed 1999.80(2):F142-4. 
71. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in 
paediatric wards: prospective study. BMJ 1998.316:343-5. 
72. Conroy S. Association between licence status and medication errors. Arch Dis Child 
2011.96(3):305-6. 
73. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug 
reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 
2011.68(1):21-8. 
74. Phan H, Leder M, Fishley M, Moeller M, Nahata M. Off-label and unlicensed medication 
use and associated adverse drug events in a pediatric emergency department. Pediatr Emerg 
Care 2010.26(6):424-30. 
75. Mukattash T, Trew K, Hawwa AF, McElnay JC. Children’s views on unlicensed/off-label 
paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 2011.68(2):141-8. 
76. Committee on Drugs. Off-Label Use of Drugs in Children. Pediatrics 2014.133(3):563-7. 
77. Schaad UB. Drug therapy in children: still more art than science. Curr Opin Infect Dis 
2001.14(3):301-2. 
78. Paediatric Medicines Advisory Group. Outcome Statement of the Paediatric Medicines 
Advisory Group meeting [Internet]. Department of Health and Ageing; 2011 [updated 2011 
Sep 20; cited 2012 May 29]; Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-pmag-public-
documents-20-sept11 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 199 
79. Sinha YK, Craig JC, Barclay P, Taitz J, South M, Coulthard K, et al. Drug approval 
processes in Australian Paediatric Hospitals. Arch Dis Child 2010.95(9):739-44. 
80. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental Pharmacology -- Drug Disposition, Action, and Therapy in Infants and 
Children. N Engl J Med 2003.349(12):1157-67. 
81. Steering Committee on Quality Improvement and Management and Committee on Hospital 
Care American Academy of Pediatrics. Policy Statement - Principles of Pediatric Patient 
Safety: Reducing Harm Due to Medical Care. Pediatrics 2011.127(6):1199-210. 
82. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and 
toddlers: pediatric pharmacovigilance between present and future. Expert Opin Drug Saf 
2012.11(1):95-105. 
83. Kunac DL, Kennedy J, Austin NC, Reith DM. Risk Factors for Adverse Drug Events and 
Medication Errors in Paediatric Inpatients: Analysis by Admission Characteristics. J Pharm 
Pract Res 2010.40(4):290-3. 
84. Kunac DL, Reith DM. Preventable medication-related events in hospitalised children in 
New Zealand. NZMJ 2008.121(1272):17-32. 
85. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies 
and safety alerts. Arch Dis Child 2009.94(9):724-8. 
86. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric Adverse Drug Events in the 
Outpatient Setting: An 11-Year National Analysis. Pediatrics 2009.124(4):744-50. 
87. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. 
Arch Dis Child 2002.87(6):462-6. 
88. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported Adverse Drug Events in Infants and 
Children Under 2 Years of Age. Pediatrics.  2002;110(5):e53.  DOI: 10.1542/peds.110.5.e53 
89. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs 
cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 
2007.63(2):136-47. 
90. Buck ML, Connor JJ, Snipes CJ, Hopper JE. Comprehensive pharmaceutical services for 
pediatric patients. Am J Hosp Pharm 1993.50(1):78-84. 
91. Provost GP. Opportunities for the pharmacist in pediatric drug therapy. Am J Hosp Pharm 
1969.26(5):251. 
92. Ellis M. The clinical pharmacist on a pediatric unit. Hosp Top 1969.47(11):81-9. 
93. Nahata MC. Evolution of Pediatric Clinical Pharmacy. Ann Pharmacother 2006.40(6):1170-
1. 
94. Levin RH. Clinical Pharmacy Practice in a Pediatric Clinic. Drug Intell Clin Pharm 
1972.6:171-6. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 200 
95. Munzenberger P, Sister E, Heins M. The role of a pharmacist on the pediatric unit of a 
general hospital. Am J Hosp Pharm 1972.29(9):755-60. 
96. Stucky ER, American Academy of Pediatrics Committee on Drugs, American Academy of 
Pediatrics Committee on Hospital Care. Prevention of medication errors in the pediatric 
inpatient setting. Pediatrics 2003.112(2):431-6. 
97. Sullivan JE, Buchino JJ. Medication errors in pediatrics - the octopus evading defeat. J Surg 
Oncol 2004.88(3):182-8. 
98. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist 
participation on physician rounds and adverse drug events in the intensive care unit. JAMA 
1999.282(3):267-70. 
99. Stacey SR, Turner SC, Coulthard KP, Miller H. Paediatric pharmacy in Australia: Where 
have we come from and where do we need to go? J Pharm Pract Res 2013.43(1):45-8. 
100. Board of Pharmacy Specialties. Specialties: Pediatric Pharmacy Washington: Board of 
Pharmacy Specialties (BPS)2014 [updated 2014 May 10; cited 2014 Apr 10]; Available 
from: http://www.bpsweb.org/specialties/pediatricpharmacy.cfm 
101. International Pharmaceutical Federation (FIP). FIP reference paper on the effective 
utilization of pharmacists in improving maternal, newborn and child health. Hyderabad: 
International Pharmaceutical Federation; 2011. 
102. Conroy S. Paediatric pharmacy - drug therapy. Hospital Pharmacist 2003.10:49-57. 
103. Pesaturo KA, Ramsey EZ, Johnson PN, Taylor LM. Introduction to pediatric pharmacy 
practice: reflections of pediatrics practitioners. Am J Health-Syst Pharm 2008.65(14):1314-
9. 
104. Turner S. A spoonful of sugar makes the medicine go down? Australian Pharmacist 
2001.20:386-91. 
105. Bhatt-Mehta V, Buck ML, Chung AM, Farrington EA, Hagemann TM, Hoff DS, et al. 
Recommendations for meeting the pediatric patient's need for a clinical pharmacist: a joint 
opinion of the Pediatrics Practice and Research Network of the American College of 
Clinical Pharmacy and the Pediatric Pharmacy Advocacy Group. Pharmacotherapy 
2013.33(2):243-51. 
106. Kennedy M, Phan H, Benavides S. The Role of the Pediatric Pharmacist in Personalized 
Medicine and Clinical Pharmacogenomics for Children: Pediatric Pharmacogenomics 
Working Group. J Pediatr Pharmacol Ther 2011.16(2):118-22. 
107. Worthington R, Corbett M. Pharmacy Services to a Paediatric Cystic Fibrosis Clinic. In: 
Paper presented at: Seventh Australasian Cystic Fibrosis Conference; 2007 Aug 11-14; 
Sydney, Australia; 2007. 
108. Brook S. Why is the regulation of advanced practice essential? Br J Nurs 2011.20(16):996-
1000. 
109. Nursing and Midwifery Board of Australia. Endorsement as a nurse practitioner registration 
standard. Melbourne: Australian Health Practitioner Regulation Agency; 2012. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 201 
110. The Royal Australasian College of Physicians. Advanced Training in General Paediatrics. 
2012 Program Requirements Handbook Sydney: The Royal Australasian College of 
Physicians; 2012. 
111. Bond C. An evidence base for professional competence. Int J Pharm Pract 2009.17(2):77. 
112. Joint Partners Credentialing Task Group. Professional recognition and professional 
advancement: For our practitioners, for our profession and for our patients. London: Royal 
Pharmaceutical Society; 2013. 
113. Australian Pharmacy Council. Advanced and Extended Pharmacy Practice: An 
Environmental Snapshot. Canberra: Australian Pharmacy Council; 2013. 
114. Meadows N, Webb D, McRobbie D, Antoniou S, Bates I, Davies G. Developing and 
validating a competency framework for advanced pharmacy practice. Pharm J 
2004.273:789-92. 
115. Competency Development and Evaluation Group. Advanced to Consultant Level 
Framework. London: CoDEG; 2005. 
116. Department of Health. Adult Critical Care: Specialist Pharmacy Practice. London: 
Department of Health; 2005. 
117. Middleton H, Sanders S, Christou M, Lau S, Sowter J. Education and training - a 
professional development framework. Hospital Pharmacist 2008.15:175-6. 
118. Adams V, Blake D, Corlett S, Godward D, Low J, McMurray A, et al. Competency 
Framework for Specialist Oncology Pharmacists. London: British Oncology Pharmacy 
Association 2004. 
119. Royal Pharmaceutical Society. The RPS Advanced Pharmacy Framework (APF). London: 
Royal Pharmaceutical Society; 2013. 
120. Avery AJ, Pringle M. Extended prescribing by UK nurses and pharmacists. BMJ 
2005.331(7526):1154-5. 
121. Nissen L. Pharmacist prescribing: What are the next steps? Am J Health-Syst Pharm 
2011.68:e57-61. 
122. Fittock A. Non-medical prescribing by nurses, optometrists, pharmacists, podiatrists and 
radiographers - A quick guide for commissioners. Liverpool:   National Prescribing Centre; 
2010. 
123. Accreditation Council for Pharmacy Education. Accreditation Standards and Guidelines for 
the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree. Chicago: 
Accreditation Council for Pharmacy Education; 2011. 
124. Giberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through 
Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. Rockville:  Office of 
the Chief Pharmacist. U.S. Public Health Service; 2011. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 202 
125. American Society of Health-System Pharmacists. ASHP Accreditation Standard for 
Postgraduate Year One (PGY1) Pharmacy Residency Programs. Bethesda: American 
Society of Health-System Pharmacists; 2012. 
126. Pharmacy Board of Australia. ￼Intern pharmacist guide. Melbourne: Australian Health 
Practitioner Registration Agency; 2012. 
127. American Society of Health-System Pharmacists. Educational Outcomes, Goals, and 
Objectives for Postgraduate year Two (PGY2) Pharmacy Residencies in Pediatrics. 
Bethesda: American Society of Health-System Pharmacists; 2008. 
128. Board of Pharmacy Specialties. 2012 Candidate’s Guide. Washington: Board of Pharmacy 
Specialties; 2012. 
129. Board of Pharmacy Specialties. 2012 Recertification Guide. Washington: Board of 
Pharmacy Specialties; 2012. 
130. Council on Credentialing in Pharmacy. Credentialing in Pharmacy: a resource paper. 
Washington: Council on Credentialing in Pharmacy; 2010. 
131. American College of Clinical Pharmacy, Shord SS, Schwinghammer TL, Badowski M, 
Banderas J, Burton ME, et al. Desired professional development pathways for clinical 
pharmacists. Pharmacotherapy.  2013;33(4):e34-42.  DOI: 10.1002/phar.1251 
132. Pharmaceutical Society of Australia. National Competency Standards Framework for 
Pharmacists in Australia. Deakin: Pharmaceutical Society of Australia; 2010. 
133. Stacey S, Turner S, Tait P, Worthington R, Graudins L, Bogovic A, et al. Development of 
an Advanced Level Competency Framework for Paediatric Pharmacists. In: Paper presented 
at: Medicines Management 2008, The 34th SHPA National Conference; 2008 Sep 4-7; 
Adelaide, Australia. 
134. Stacey S, Avent M, Coombes I, Coombes J. Four years' experience with the advanced level 
framework - what have we learned and has it made a difference? In: Paper presented at: 
Medicines Management 2011, The 37th SHPA National Conference; 2011 Nov 10-13; 
Hobart, Australia. 
135. Stacey S, Coombes J. Integration of paediatric pharmacy training from undergraduate to 
advanced practice - implementation of a paediatric advanced level competency framework. 
In: Paper presented at: Medicines Management 2010, The 36th SHPA National Conference; 
2010 Nov 11-14; Melbourne, Australia. 
136. Carrington C, Weir J, Smith P. The development of a competency framework for 
pharmacists providing cancer services. J Oncol Pharm Pract 2011.17(3):168-78. 
137. Donegan E. An advanced practice framework and learning package for emergency medicine 
pharmacists: what the new kids on the block will need to know. In: Paper presented at: 
Medicines Management 2011: The 37th SHPA National Conference, 2011 Nov 12; Hobart, 
Australia. p. 41. 
138. Porter S. Advanced level framework for the development of cardiology pharmacists. In: 
Paper presented at: the Medicines Management 2010: The 36th SHPA National Conference, 
2010 Nov 13; Melbourne, Australia. p. 60. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 203 
139. Southern Health Pharmacy Department. Advanced Level Competency Framework 
Infectious Diseases. Melbourne: Southern Health Pharmacy Department; 2009. 
140. Ciabotti L, Hodgkinson M, Larmour I, Senturk-Raif R. Structured training, education and 
professional development for pharmacists - implementation of general level and advanced 
level competency frameworks (GLF and ALF). In: Paper presented at: Medicines 
Management 2009: The 35th SHPA National Conference, 2009 Nov 06; Perth, Australia. p. 
198. 
141. Advanced Pharmacy Practice Framework Steering Committee. An Advanced Pharmacy 
Practice Framework for Australia. Deakin West: Pharmaceutical Society of Australia; 2012. 
142. Advanced Pharmacy Practice Framework Steering Committee. Communique from the 
Advanced Pharmacy Practice Framework Steering Commitee [Internet]. 2012 [updated 2012 
Nov 9; cited 2012 Nov 12]; Available from: http://www.psa.org.au/archives/7131 
143. The Royal Australasian College of Physicians. General Paediatrics Advanced Training 
Curriculum. Sydney: The Royal Australasian College of Physicians; 2010  
144. Women's and Children's Health Network. Diploma in Child Health South Australia. 
Adelaide: Women's and Children's Health Network; 2012. 
145. Children's Hospital at Westmead, University of Sydney. ￼Diploma in Child Health. 
Sydney: University of Sydney; 2012. 
146. Daly WMW, Carnwell RR. Nursing roles and levels of practice: a framework for 
differentiating between elementary, specialist and advancing nursing practice. J Clin Nurs 
2003.12(2):158-67. 
147. Australian Nursing Federation. Competency standards for the advanced registered nurse.   
Rozelle: Australian Nursing Federation; 2004. 
148. Australian Confederation of Paediatric and Child Health Nurses. ￼Competencies for the 
Specialist Paediatric and Child Health Nurse. Sydney: Australian Confederation of 
Paediatric and Child Health Nurses; 2006. 
149. Australian Physiotherapy Association. APA Physiotherapist Title Program. Camberwell: 
Australian Physiotherapy Association; 2012. 
150. Knoppert D, Arenas-Lopez S, McArtney R. The infancy of an international pediatric 
pharmacy network. Paediatr Drugs 2008.10(2):71-3. 
151. Poole RL. The History of PPAG: The First 30 Years. J Pediatr Pharmacol Ther 
2010.15(2):72-80. 
152. Tomlin S. Neonatal and Paediatric Pharmacists Group (NPPG). Paediatr Perinat Drug Ther 
2001.4(3):101-2. 
153. Royal Pharmaceutical Society, Neonatal and Paediatric Pharmacists Group. Neonatal and 
Paediatric Care: Expert Professional Practice Curriculum. London: Royal Pharmaceutical 
Society Faculty; 2014. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 204 
154. Kunac DL, Turner S. Initial Experience with a Paediatric Pharmacy E-Mail Network. Aust J 
Hosp Pharm 2001.31(2):139-42. 
155. Graudins LV, Turner S, Kunac D. Paedpharm: Paediatric Pharmacy Network. J Pharm Pract 
Res 2009.39(4):290-2. 
156. Meyers RS, Costello-Curtin J. Implementing a pediatric pharmacy educational program for 
health-system pharmacists. Am J Pharm Educ.  2011;75(10 ):Article 205.  DOI: 
10.5688/ajpe7510205 
157. Conard LAE, Fortenberry JD, Blythe MJ, Orr DP. Pharmacists' attitudes toward and 
practices with adolescents. Arch Pediatr Adolesc Med 2003.157(4):361-5. 
158. Munzenberger PJ, Thomas RL, Edwin SB, Tutag-Lehr V. Pharmacists' Perceived 
Knowledge and Expertise in Selected Pediatric Topics. J Pediatr Pharmacol Ther 
2011.16(1):47. 
159. Stewart D, Rouf A, Snaith A, Elliott K, Helms PJ, McLay JS. Attitudes and experiences of 
community pharmacists towards paediatric off-label prescribing: a prospective survey. Br J 
Clin Pharmacol 2007.64(1):90-5. 
160. Low JK, Baldwin JN, Greiner GE. Pediatric Pharmacy Education for U.S. Entry-Level 
Doctor of Pharmacy Programs. Am J Pharm Educ 1999.63(3):323-7. 
161. Lavoie A, Gerber P. Pediatric pharmacotherapy content of Canadian undergraduate 
pharmacy curricula. Canadian Pharmacists Journal 2008.141(4):228-33. 
162. Prescott WA, Dahl EM, Hutchinson DJ. Education in Pediatrics in US Colleges and Schools 
of Pharmacy. Am J Pharm Educ.  2014;78(3):Article 51.  DOI: 10.5688/ajpe78351 
163. Flynn EA, Barker KN, Pepper GA, Bates DW, Mikeal RL. Comparison of methods for 
detecting medication errors in 36 hospitals and skilled-nursing facilities. Am J Health-Syst 
Pharm 2002.59(5):436-46. 
164. Snyder RA, Fields W. A model for medication safety event detection. Int J Qual Health Care 
2010.22(3):179-86. 
165. Perez B, Knych SA, Weaver SJ, Liberman A, Abel EM, Oetjen D, et al. Understanding the 
barriers to physician error reporting and disclosure: a systemic approach to a systemic 
problem. Journal of Patient Safety 2014.10(1):45-51. 
166. Wakefield JG, McLaws M-L, Whitby M, Patton L. Patient safety culture: factors that 
influence clinician involvement in patient safety behaviours. Qual Saf Health Care 
2010.19(6):585-91. 
167. Brilli RJ, McClead RE, Crandall WV, Stoverock L, Berry JC, Wheeler TA, et al. A 
comprehensive patient safety program can significantly reduce preventable harm, associated 
costs, and hospital mortality. The Journal of Pediatrics 2013.163(6):1638-45. 
168. Muething SE, Goudie A, Schoettker PJ, Donnelly LF, Goodfriend MA, Bracke TM, et al. 
Quality improvement initiative to reduce serious safety events and improve patient safety 
culture. Pediatrics.  2012;130(2):e423.  DOI: 10.1542/peds.2011-3566 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 205 
169. Guy J, Persaud J, Davies E, Harvey D. Drug Errors: What Role do Nurses and Pharmacists 
have in Minimizing the Risk? Journal of Child Health Care 2003.7(4):277-90. 
170. Mangino PD. Role of the pharmacist in reducing medication errors. J Surg Oncol 
2004.88(3):189-94. 
171. Dean B, Schachter M, Vincent C, Barber N. Prescribing errors in hospital inpatients: their 
incidence and clinical significance. Qual Saf Health Care 2002.11(4):340-4. 
172. Williams SD, Phipps DL, Ashcroft DM. Understanding the attitudes of hospital pharmacists 
to reporting medication incidents: A qualitative study. Research in Social and 
Administrative Pharmacy 2012.9(1):80-9. 
173. Patterson ME, Pace HA, Fincham JE. Associations between communication climate and the 
frequency of medical error reporting among pharmacists within an inpatient setting. Journal 
of Patient Safety 2013.9(3):129-33. 
174. Barker KN, Flynn EA, Pepper GA. Observation method of detecting medication errors. Am 
J Health-Syst Pharm 2002.59(23):2314-6. 
175. Schneider MP, Cotting J, Pannatier A. Evaluation of nurses' errors associated in the 
preparation and administration of medication in a pediatric intensive care unit. Pharm World 
Sci 1998.20(4):178-82. 
176. Bruce J, Wong I. Parenteral drug administration errors by nursing staff on an acute medical 
admissions ward during day duty. Drug Saf 2001.24(11):855-62. 
177. Baines RJ, Langelaan M, de Bruijne MC, Asscheman H, Spreeuwenberg P, van de Steeg L, 
et al. Changes in adverse event rates in hospitals over time: a longitudinal retrospective 
patient record review study. BMJ Quality & Safety 2013.22(4):290-8. 
178. Lemon V, Stockwell DC. Automated Detection of Adverse Events in Children. Pediatr Clin 
North Am 2012.59(6):1269-78. 
179. Forster AJ, Jennings A, Chow C, Leeder C, van Walraven C. A systematic review to 
evaluate the accuracy of electronic adverse drug event detection. J Am Med Inform Assoc 
2011.19(1):31-8. 
180. Bates DW. Using information technology to screen for adverse drug events. Am J Health-
Syst Pharm 2002.59(23):2317-9. 
181. Franklin BD, Birch S, Savage I, Wong I, Woloshynowych M, Jacklin A, et al. 
Methodological variability in detecting prescribing errors and consequences for the 
evaluation of interventions. Pharmacoepidemiology and Drug Safety 2009.18(11):992-9. 
182. Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ. Development, testing, and 
findings of a pediatric-focused trigger tool to identify medication-related harm in US 
children's hospitals. Pediatrics 2008.121(4):e927-35. 
183. Tham E, Calmes HM, Poppy A, Eliades AB, Schlafly SM, Namtu KC, et al. Sustaining and 
Spreading the Reduction of Adverse Drug Events in a Multicenter Collaborative. Pediatrics 
2011.128(2):e438-e45. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 206 
184. Kirkendall ES, Kloppenborg E, Papp J, White D, Frese C, Hacker D, et al. Measuring 
adverse events and levels of harm in pediatric inpatients with the Global Trigger Tool. 
Pediatrics 2012.130(5):e1206-14. 
185. Stausberg J. International prevalence of adverse drug events in hospitals: an analysis of 
routine data from England, Germany, and the USA. BMC Health Serv Res.  2014;14:125.  
DOI: 10.1186/1472-6963-14-125 
186. Stausberg J, Hasford J. Drug-related admissions and hospital-acquired adverse drug events 
in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. BMC 
Health Serv Res.  2011;11:134.  DOI: 10.1186/1472-6963-11-134 
187. Bates DW, Evans RS, Murff H, Stetson PD, Pizziferri L, Hripcsak G. Detecting Adverse 
Events Using Information Technology. J Am Med Inform Assoc 2003.10(2):115-28. 
188. Hohl CM, Karpov A, Reddekopp L, Stausberg J. ICD-10 codes used to identify adverse 
drug events in administrative data: a systematic review. J Am Med Inform Assoc.  2013;0:1-
11.  DOI: 10.1136/amiajnl-2013-002116 
189. Honigman B, Lee J, Rothschild J, Light P, Pulling RM, Yu T, et al. Using computerized 
data to identify adverse drug events in outpatients. Journal of the American Medical 
Informatics Association : JAMIA 2001.8(3):254-66. 
190. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related 
admissions according to method of detection, admission urgency and medical department 
specialty. BMC Clin Pharmacol 2009.9(1):8  doi:10.1186/472-6904-9-8. 
191. Jha AK, Kuperman GJ, Teich JM, Leape L, Shea B, Rittenberg E, et al. Identifying adverse 
drug events: development of a computer-based monitor and comparison with chart review 
and stimulated voluntary report. Journal of the American Medical Informatics Association : 
JAMIA 1998.5(3):305-14. 
192. Nwulu U, Nirantharakumar K, Odesanya R, McDowell SE, Coleman JJ. Improvement in the 
detection of adverse drug events by the use of electronic health and prescription records: An 
evaluation of two trigger tools. Eur J Clin Pharmacol 2013.69(2):255-9. 
193. Christiaans-Dingelhoff I, Smits M, Zwaan L, Lubberding S, van der Wal G, Wagner C. To 
what extent are adverse events found in patient records reported by patients and healthcare 
professionals via complaints, claims and incident reports? BMC Health Serv Res 
2011.11(1):49. 
194. Olsen S, Neale G, Schwab K, Psaila B, Patel T, Chapman EJ, et al. Hospital staff should use 
more than one method to detect adverse events and potential adverse events: incident 
reporting, pharmacist surveillance and local real-time record review may all have a place. 
BMJ Quality & Safety 2007.16(1):40-4. 
195. Koren G. Trends of medication errors in hospitalized children. J Clin Pharmacol 
2002.42(7):707-10. 
196. Isa NM, Taylor MW, Helms PJ, McLay JS. How well are general practice trainees prepared 
for paediatric prescribing? Br J Clin Pharmacol 2009.67(3):370-3. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 207 
197. Likic R, Maxwell SRJ. Prevention of medication errors: teaching and training. Br J Clin 
Pharmacol 2009.67(6):656-61. 
198. Davey AL, Britland A, Naylor RJ. Decreasing paediatric prescribing errors in a district 
general hospital. Qual Saf Health Care 2008.17(2):146-9. 
199. Conroy S, Carroll WD. Prescribing in paediatrics. Archives of Disease in Childhood - 
Education and Practice 2009.94(2):55-9. 
200. Sullivan KM, Suh S, Monk H, Chuo J. Personalised performance feedback reduces narcotic 
prescription errors in a NICU. BMJ Quality & Safety 2013.22(3):256-62. 
201. Kidd L, Shand E, Beavis R, Taylor Z, Dunstan F, Tuthill D. Prescribing competence of 
junior doctors: does it add up? Arch Dis Child 2010.95(3):219-21. 
202. Kozer E, Scolnik D, Macpherson A, Rauchwerger D, Koren G. The effect of a short tutorial 
on the incidence of prescribing errors in pediatric emergency care. Canadian Journal of 
Clinical Pharmacology 2006.13(3):e285-91. 
203. Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve prescribing 
competency: a systematic review. BMJ Open 2013.3(8):3291. 
204. Brennan N, Mattick K. A systematic review of educational interventions to change 
behaviour of prescribers in hospital settings, with a particular emphasis on new prescribers. 
Br J Clin Pharmacol 2013.75(2):359-72. 
205. Maxwell S, Mucklow J. e-Learning initiatives to support prescribing. Br J Clin Pharmacol 
2012.74(4):621-31. 
206. McQueen DS, Begg MJ, Maxwell SRJ. eDrugCalc: an online self-assessment package to 
enhance medical students' drug dose calculation skills. Br J Clin Pharmacol 2010.70(4):492-
9. 
207. Antoniou S, Webb DG, McRobbie D, Davies JG, Wright J, Quinn J, et al. A controlled 
study of the general level framework: Results of the South of England competency study. 
Pharmacy Education 2005.5(3-4):201-7. 
208. Burrows J, Kirkpatrick C, Coombes I, Cardiff L, Lum E. The impact on clinical practice of a 
postgraduate clinical pharmacy programme, incorporating competency-based performance 
evaluation. Pharmacy Education 2013.13(1):177-82. 
209. Coombes I, Avent M, Cardiff L, Bettenay K, Coombes J, Whitfield K, et al. 
￼￼Improvement in Pharmacist’s Performance Facilitated by an Adapted Competency-
Based General Level Framework. J Pharm Pract Res 2010.40(2):111-8. 
210. Mills E, Farmer D, Bates I, Davies G, Webb DG. The General Level Framework: use in 
primary care and community pharmacy to support professional development. Int J Pharm 
Pract 2008.16(5):325-31. 
211. Meštrović AA, Staničić ZZ, Hadžiabdić MOM, Mucalo II, Bates II, Duggan CC, et al. 
Individualized education and competency development of Croatian community pharmacists 
using the general level framework. Am J Pharm Educ 2012.76(2):Article 23. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 208 
212. Fortescue EB, Kaushal R, Landrigan CP, McKenna KJ, Clapp MD, Federico F, et al. 
Prioritizing Strategies for Preventing Medication Errors and Adverse Drug Events in 
Pediatric Inpatients. Pediatrics 2003.11:722-9. 
213. Kaushal R, Goldmann D, Keohane C, Christino M, Honour M, Hale A, et al. Adverse Drug 
Events in Pediatric Outpatients. Ambul Pediatr 2007.7(5):383-9. 
214. Frey B, Buettiker V, Hug M, Waldvogel K, Gessler P, Ghelfi D, et al. Does critical incident 
reporting contribute to medication error prevention? Eur J Pediatr 2002.161(11):594-9. 
215. Merry AF, Anderson BJ. Medication errors - new approaches to prevention. Pediatr Anesth 
2011.21(7):743-53. 
216. Weant KA, Humphries RL, Hite K, Armitstead JA. Effect of emergency medicine 
pharmacists on medication-error reporting in an emergency department. Am J Health-Syst 
Pharm 2010.67(21):1851-5. 
217. Costello JL, Torowicz DL, Yeh TS. Effects of a pharmacist-led pediatrics medication safety 
team on medication-error reporting. Am J Health-Syst Pharm 2007.64(13):1422-6. 
218. Dean B, Schachter M, Vincent C, Barber N. Causes of prescribing errors in hospital 
inpatients: a prospective study. The Lancet 2002.359:1373-8. 
219. Roehr B. US hospital incident reporting systems do not capture most adverse events. BMJ 
2012.344:e386. 
220. Steering Committee on Quality Improvement and Management and Committee on Hospital 
Care. Principles of Pediatric Patient Safety: Reducing Harm Due to Medical Care. Pediatrics 
2011.127(6):1199-210. 
221. Westbrook JI, Baysari MT, Li L, Burke R, Richardson KL, Day RO. The safety of 
electronic prescribing: manifestations, mechanisms, and rates of system-related errors 
associated with two commercial systems in hospitals. Journal of the American Medical 
Informatics Association : JAMIA 2013.20(6):1159-67. 
222. Jani YH, Barber N, Wong ICK. Paediatric dosing errors before and after electronic 
prescribing. Qual Saf Health Care 2010.19(4):337-40. 
223. Walsh KE, Landrigan CP, Adams WG, Vinci RJ, Chessare JB, Cooper MR, et al. Effect of 
Computer Order Entry on Prevention of Serious Medication Errors in Hospitalized Children. 
Pediatrics 2008.121(3):e421-e7. 
224. Han YY. Unexpected Increased Mortality After Implementation of a Commercially Sold 
Computerized Physician Order Entry System. Pediatrics 2005.116(6):1506-12. 
225. Del Beccaro MA. Computerized Provider Order Entry Implementation: No Association 
With Increased Mortality Rates in an Intensive Care Unit. Pediatrics 2006.118(1):290-5. 
226. van Rosse F, Maat B, Rademaker CMA, van Vught AJ, Egberts ACG, Bollen CW. The 
Effect of Computerized Physician Order Entry on Medication Prescription Errors and 
Clinical Outcome in Pediatric and Intensive Care: A Systematic Review. Pediatrics 
2009.123(4):1184-90. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 209 
227. Kozer E. Medication errors in children. Paediatr Drugs 2009.11(1):52-4. 
228. Buehler JW, Smith LF, Wallace EM, Heath CW, Kusiak R, Herndon JL. Unexplained 
deaths in a children's hospital. An epidemiologic assessment. N Engl J Med 
1985.313(4):211-6. 
229. Wong I, Conroy S, Collier J, Haines L, Sweis D, Yeung V, et al. Co-operative of Safety of 
Medicines in Children (COSMIC): Scoping study to identify and analyse interventions used 
to reduce errors in calculation of paediatric drug doses. London: University of London; 
2014. 
230. Manrique-Rodriguez S, Sánchez-Galindo A, Fernandez-Llamazares CM, Lopez-Herce J, 
Echarri-Martinez L, Escudero-Vilaplana V, et al. Smart pump alerts: All that glitters is not 
gold. Int J Med Inf 2012.81:344-50. 
231. Manrique-Rodríguez S, Sánchez-Galindo AC, de Lorenzo-Pinto A, Gonzalez-Vives L, 
López-Herce J, Carrillo-Álvarez A, et al. Implementation of smart pump technology in a 
paediatric intensive care unit. Health Informatics Journal. Forthcoming 2014.DOI: 
10.1177/1460458213518058. 
232. Walsh KE, Kaushal R, Chessare JB. How to avoid paediatric medication errors: a user's 
guide to the literature. Arch Dis Child 2005.90(7):698-702. 
233. Kaushal R, Bates DW, Abramson EL, Soukup JR, Goldmann DA. Unit-based clinical 
pharmacists' prevention of serious medication errors in pediatric inpatients. Am J Health-
Syst Pharm 2008.65(13):1254-60. 
234. Wang JK, Herzog NS, Kaushal R, Park C, Mochizuki C, Weingarten SR. Prevention of 
pediatric medication errors by hospital pharmacists and the potential benefit of 
computerized physician order entry. Pediatrics 2007.119(1):e77-85. 
235. Isaac R, Gerrard A. PICU pharmacist interventions: what can they tell us? Arch Dis Child 
2011.45(e1):1-2. 
236. Kalina M, Tinkoff G, Gleason W, Veneri P, Fulda G. A multidisciplinary approach to 
adverse drug events in pediatric trauma patients in an adult trauma center. Pediatr Emerg 
Care 2009.25(7):444-6. 
237. Fernandez-Llamazares CM, Calleja-Hernandez MA, Manrique-Rodriguez S, Perez-Sanz C, 
Duran-Garcia E, Sanjurjo-Saez M. Impact of clinical pharmacist interventions in reducing 
paediatric prescribing errors. Arch Dis Child 2012.97:564-8. 
238. Fernandez-Llamazares CM, Pozas M, Feal B, Cabañas MJ, Villaronga M, Hernández-Gago 
Y, et al. Profile of prescribing errors detected by clinical pharmacists in paediatric hospitals 
in Spain. Int J Clin Pharm 2013.35(4):638-46. 
239. Zhang C, Zhang L, Huang L, Luo R, Wen J. Clinical Pharmacists on Medical Care of 
Pediatric Inpatients: A Single-Center Randomized Controlled Trial. PLoS ONE 
2012.7(1):e30856. 
240. Chisholm-Burns MA, Graff Zivin JS, Lee JK, Spivey CA, Slack M, Herrier RN, et al. 
Economic effects of pharmacists on health outcomes in the United States: A systematic 
review. Am J Health-Syst Pharm 2010.67(19):1624-34. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 210 
241. Dooley MJ, Allen KM, Doecke CJ, Galbraith KJ, Taylor GR, Bright J, et al. A prospective 
multicentre study of pharmacist initiated changes to drug therapy and patient management in 
acute care government funded hospitals. Br J Clin Pharmacol 2004.57(4):513-21. 
242. Graham N. An economic analysis of Clinical Pharmacy Interventions in a government 
funded paediatric specialist hospital: a pilot study [Masters thesis].  St Lucia, Qld: 
University of Queensland; 2007. 
243. Graham N, Cottrell N, Stacey S, Dade M, Stephens J-A. An economic analysis of Clinical 
Pharmacy Interventions in a government funded paediatric specialist hospital: a pilot study. 
In: Paper presented at: The Society of Hospital Pharmacists of Australia 28th Federal 
Conference; 2007 Nov; Sydney, Australia; 2007. 
244. Krupicka MI, Bratton SL, Sonnenthal K, Goldstein B. Impact of a pediatric clinical 
pharmacist in the pediatric intensive care unit. Crit Care Med 2002.30(4):919-21. 
245. Larochelle JM, Ghaly M, Creel AM. Clinical pharmacy faculty interventions in a pediatric 
intensive care unit: an eight-month review. J Pediatr Pharmacol Ther 2012.17(3):263-9. 
246. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical Pharmacists and Inpatient 
Medical Care: A Systematic Review. Arch Intern Med 2006.166(9):955-64. 
247. Suehs BT, Mican LM, Campbell AH. Retrospective evaluation of an inpatient psychiatric 
pharmacist consultation service. J Am Pharm Assoc 2011.51(5):599-604. 
248. Young S, Young S, Bishop L, Bishop L, Twells L, Twells L, et al. Comparison of 
pharmacist managed anticoagulation with usual medical care in a family medicine clinic. 
BMC Family Practice 2011.12(1):88. 
249. Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and 
end-stage renal disease patients: a systematic literature review. BMC Nephrol 
2011.12(1):35. 
250. González-Martin G, Joo I, Sánchez I. Evaluation of the impact of a pharmaceutical care 
program in children with asthma. Patient Educ Couns 2003.49(1):13-8. 
251. de Vries TW, van den Berg PB, Duiverman EJ, de Jong-van den Berg LTW. Effect of a 
minimal pharmacy intervention on improvement of adherence to asthma guidelines. Arch 
Dis Child 2010.95(4):302-4. 
252. Chen C, Lee DSH, Hie SL. The impact of pharmacist's counseling on pediatric patients' 
caregiver's knowledge on epilepsy and its treatment in a tertiary hospital. Int J Clin Pharm 
2013.35(5):829-34. 
253. Cies JJ, Varlotta L. Clinical pharmacist impact on care, length of stay, and cost in pediatric 
cystic fibrosis (CF) patients. Pediatr Pulmonol 2013.48(12):1190-4. 
254. El Borolossy R, El Wakeel L, El Hakim I, Badary O. Implementation of clinical pharmacy 
services in a pediatric dialysis unit. Pediatr Nephrol 2014.29(7):1259-64. 
255. Marconi GP, Claudius I. Impact of an Emergency Department Pharmacy on Medication 
Omission and Delay. Pediatr Emerg Care 2012.28(1):30. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 211 
256. Kennedy I. Learning from Bristol: The Report of the Public Inquiry into children's heart 
surgery at the Bristol Royal Infirmary 1984-1995. London: The Stationary Office; 2001. 
257. Hill LH, Delafuente JC, Sicat BL, Kirkwood CK. Development of a competency-based 
assessment process for advanced pharmacy practice experiences. Am J Pharm Educ 
2006.70(1):Article 01. 
258. Cervero R. Professional practice, learning, and continuing education: an integrated 
perspective. International Journal of Lifelong Education 1992.11(2):91-101. 
259. Benner P. From novice to expert : excellence and power in clinical nursing practice. Menlo 
Park, Calif: Addison-Wesley Pub. Co., Nursing Division; 1984. 
260. Cantillon P, Sargeant J. Giving feedback in clinical settings. BMJ 2008.337:a1961. 
261. Miller GE. The assessment of clinical skills/competence/performance. Academic Medicine 
1990.65(9 Suppl):S63-S7. 
262. Epstein RM, Hundert EM. Defining and assessing professional competence. JAMA 
2002.287(2):226-35. 
263. Jefferies A, Simmons B, Ng E, Skidmore M. Assessment of multiple physician 
competencies in postgraduate training: utility of the structured oral examination. Adv Health 
Sci Educ Theory Pract 2011.16(5):569-77. 
264. Epstein RM. Assessment in medical education. N Engl J Med 2007.356(4):387-96. 
265. Matheson C. The educational value and effectiveness of lectures. The Clinical Teacher 
2008.5(4):218-21. 
266. Prober CG, Heath C. ￼Lecture Halls without Lectures — A Proposal for Medical 
Education. N Engl J Med 2012.366(18):1657-9. 
267. Crouch MA. An advanced cardiovascular pharmacotherapy course blending online and face-
to-face instruction. Am J Pharm Educ 2009.73(3):Article 51. 
268. Flowers SK, Vanderbush RE, Hastings JK, West D. Web-based multimedia vignettes in 
advanced community pharmacy practice experiences. Am J Pharm Educ 2010.74(3):39. 
269. White AM, Albertson B, Muncey L. Development and implementation of a clinical 
pharmacist training and assessment program. Am J Health-Syst Pharm 2012.69:278-81. 
270. Morris JLJ, Knoderer CAC. Assessment of web-based training modules on learning 
facilitation for advanced pharmacy practice experiences in pediatrics. J Pediatr Pharmacol 
Ther 2011.16(3):210-5. 
271. Gordon M, Chandratilake M, Baker P. Improved junior paediatric prescribing skills after a 
short e-learning intervention: a randomised controlled trial. Arch Dis Child 
2011.96(12):1191-4. 
272. Govaerts MJB, Wiel MWJ, Schuwirth LWT, Vleuten CPM, Muijtjens AMM. Workplace-
based assessment: raters’ performance theories and constructs. Adv Health Sci Educ Theory 
Pract 2013.18. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 212 
273. Reece A, Klaber R. Maximising learning on ward rounds. Archives of Disease in Childhood 
- Education and Practice 2012.97(2):61-7. 
274. Challis M. AMEE Medical Education Guide No. 11 (revised): Portfolio-based learning and 
assessment in medical education. Med Teach 1999.21(4):1-17. 
275. Wilkinson TJ, Challis M, Hobma SO, Newble DI, Parboosingh JT, Sibbald RG, et al. The 
use of portfolios for assessment of the competence and performance of doctors in practice. 
Med Educ 2002.36(10):918-24. 
276. Royal College of General Practitioners. The use of portfolio-based learning in continuing 
medical education. In: Occasional Paper 63: Portfolio-based Learning in General Practice: 
Royal College of General Practitioners; 1993.  p. 19-20. 
277. Nagler A, Andolsek K, Padmore JS. The unintended consequences of portfolios in graduate 
medical education. Acad Med 2009.84(11):1522-6. 
278. Mathers NJ, Challis MC, Howe AC, Field NJ. Portfolios in continuing medical education--
effective and efficient? Med Educ 1999.33(7):521-30. 
279. Roberts C, Newble DI, O'Rourke AJ. Portfolio-based assessments in medical education: are 
they valid and reliable for summative purposes? Med Educ 2002.36(10):899-900. 
280. Garrett BM, MacPhee M, Jackson C. Evaluation of an eportfolio for the assessment of 
clinical competence in a baccalaureate nursing program. Nurse Educ Today 
2013.33(10):1207-13. 
281. Nursing and Midwifery Board of Australia. ￼Endorsement as a nurse practitioner.  Guide 
for submitting a portfolio: Pathway 2. Melbourne: Australian Health Practitioner Regulation 
Agency; 2012. 
282. Briceland LL, Hamilton RA. Electronic reflective student portfolios to demonstrate 
achievement of ability-based outcomes during advanced pharmacy practice experiences. Am 
J Pharm Educ 2010.74(5). 
283. McDuffie CH, Sheffield MC, Miller MS, Duke LJ, Rogers SP. Web-based portfolios for 
pharmaceutical care plans during advanced pharmacy practice experiences. Am J Pharm 
Educ 2010.74(4):59. 
284. Office of the Queensland Parliamentary Counsel. Health Practitioner Regulation National 
Law Act 2009. State of Queensland; 2010. p. 1-311. 
285. Pharmacy Board of Australia. Continuing professional development registration standard. 
Melbourne: Pharmacy Board of Australia; 2010. 
286. McKenzie C, Borthwick M, Thacker M, Shulman R, Offord R, Tomlin M, et al. Developing 
a process for credentialing advanced level practice in the pharmacy profession using a multi-
source evaluation tool. Pharm J 2011.286:1-5. 
287. Purcell K. Use of performance portfolios for pharmacy personnel. Am J Health-Syst Pharm 
2009.66(9):801-4. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 213 
288. Singh T, Modi JN. Workplace based assessment: a step to promote competency based 
postgraduate training. Indian Pediatr 2013.50(6):553-9. 
289. Jubraj B, Innes A, Kavanagh R. Dispel the myths and see the benefits of workplace-based 
assessments￼. Pharm J 2011.287:467. 
290. Hayden SR, Dufel S, Shih R. Definitions and competencies for practice-based learning and 
improvement. Acad Emerg Med 2002.9(11):1242-8. 
291. Norcini J, Burch V. Workplace-based assessment as an educational tool: AMEE Guide No. 
31. Med Teach 2007.29(9):855-71. 
292. Moonen-van Loon JMW, Overeem K, Donkers HHLM, van der Vleuten CPM, Driessen 
EW. Composite reliability of a workplace-based assessment toolbox for postgraduate 
medical education. Advances in Health Sciences Education 2013.18(5):1087-102. 
293. McRobbie D, Webb D, Bates I, Wright J, Davies J. Assessment of clinical competence: 
designing a competence grid for junior pharmacists. Pharmacy Education 2002.1(2):67-76. 
294. Goldsmith GM, Bates IP, Davies JG, McRobbie D, Webb DG, Wright J, et al. A Pilot Study 
to Evaluate Clinical Competence in Junior Grade Pharmacy Practitioners. Pharmacy 
Education 2003.3(2):127-34. 
295. Costello J, Cardiff L, Coombes I. Practice evaluation and identification of learning 
and  development needs using the General Level Framework – are we meeting pharmacists 
needs? Pharmacy Education 2013.13(1):129-33. 
296. Rutter V, Wong C, Coombes I, Cardiff L, Duggan C, Yee M-L, et al. Use of a general level 
framework to facilitate performance improvement in hospital pharmacists in Singapore. Am 
J Pharm Educ 2012.76(6):Article 107. 
297. Society of Hospital Pharmacists of Australia. shpaclinCAT. Clinical Competency 
Assessment Tool for Australian Pharmacists. Collingwood: The Society of Hospital 
Pharmacists of Australia; 2010. p. 1-45. 
298. Alderman C. Clinical Pharmacy and Competency Assessment. J Pharm Pract Res 
2010.40(1):6-7. 
299. Norcini JJ, Blank LL, Duffy FD, Fortna GS. The mini-CEX: a method for assessing clinical 
skills. Ann Intern Med 2003.138(6):476-81. 
300. Hawkins RE, Margolis MJ, Durning SJ, Norcini JJ. Constructing a Validity Argument for 
the Mini-Clinical Evaluation Exercise: A Review of the Research. Academic Medicine 
2010.85(9):1453-61. 
301. Nair BR, Alexander HG, McGrath BP, Parvathy MS, Kilsby EC, Wenzel J, et al. The mini 
clinical evaluation exercise (mini-CEX) for assessing clinical performance of international 
medical graduates. Med J Aust 2008.189(3):159-61. 
302. The Royal Australasian College of Physicians. PREP Advanced Training in Paediatric 
Emergency Medicine Program Requirements Handbook. Sydney: The Royal Australasian 
College of Physicians; 2012. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 214 
303. Basu I, Parvizi S, Chin K. The perception of online work-based assessments. The Clinical 
Teacher 2013.10(2):73-7. 
304. Tomisato S, Venter J, Weller J, Drachman D. Evaluating the Utility, Reliability, and 
Validity of a Resident Performance Evaluation Instrument. Acad Psychiatry 
2014.38(4):458-63. 
305. Abdulla A. A critical analysis of mini peer assessment tool (mini-PAT). J R Soc Med 
2008.101(1):22-6. 
306. Archer JC, Norcini J, Davies HA. Use of SPRAT for peer review of paediatricians in 
training. BMJ 2005.330(7502):1251-3. 
307. Archer J, Norcini J, Southgate L, Heard S, Davies H. mini-PAT (Peer Assessment Tool): A 
Valid Component of a National Assessment Programme in the UK? Adv Health Sci Educ 
Theory Pract 2006.13(2):181-92. 
308. Whitehouse A, Hassell A, Bullock A, Wood L, Wall D. 360 degree assessment (multisource 
feedback) of UK trainee doctors: Field testing of team assessment of behaviours (TAB). 
Med Teach 2007.29(2-3):171-6. 
309. Burford B, Illing J, Kergon C, Morrow G, Livingston M. User perceptions of multi-source 
feedback tools for junior doctors. Med Educ 2010.44(2):165-76. 
310. Murphy DJ, Bruce DA, Mercer SW, Eva KW. The reliability of workplace-based 
assessment in postgraduate medical education and training: a national evaluation in general 
practice in the United Kingdom. Advances in Health Sciences Education 2009.14(2):219-32. 
311. Patel JP, West D, Bates IP, Eggleton AG, Davies G. Early experiences of the mini-PAT 
(Peer Assessment Tool) amongst hospital pharmacists in South East London. Int J Pharm 
Pract 2009.17(2):123-6. 
312. Patel JP, Sharma A, West D, Bates IP, Davies JG, Abdel-Tawab R. An evaluation of using 
multi-source feedback (MSF) among junior hospital pharmacists. Int J Pharm Pract 
2011.19(4):276-80. 
313. Archer JC, McAvoy P. Factors that might undermine the validity of patient and multi-source 
feedback. Med Educ 2011.45(9):886-93. 
314. Vivekananda-Schmidt P, MacKillop L, Crossley J, Wade W. Do assessor comments on a 
multi-source feedback instrument provide learner-centred feedback? Med Educ 
2013.47(11):1080-8. 
315. Coombes JA, McGuire TM, Harrhy KL, McRobbie D, Davies JG, Fleming G. Piloting an 
Objective Structured Clinical Examination to Evaluate the Clinical Competency of Pre-
RegistrationPharmacists. J Pharm Pract Res 2003.33(3):194-8. 
316. McRobbie D, Fleming G, Ortner M, Bates I, Davies JG. Evaluating skills and competencies 
of pre-registration pharmacists using objective structured clinical examinations (OSCEs). 
Pharmacy Education 2006.6(2):133-8. 
317. Barman A. Critiques on the Objective Structured Clinical Examination. Ann Acad Med 
Singapore 2005.34(8):478-82. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 215 
318. Haines ST, Andrus MR, Badowski M, Bradbury MM, Canales AE, Cavanaugh JM, et al. 
Board Certification of Pharmacist Specialists. Pharmacotherapy 2011.31(11):1146-9. 
319. Westanmo A, Wu X, Carmichael JM, Dennis SJ. Improvement of competence after 
preparation for board certification examination. Am J Health-Syst Pharm 2012.69(3):186-
90. 
320. Murdoch-Eaton D, Sandars J. Reflection: moving from a mandatory ritual to meaningful 
professional development. Arch Dis Child 2014.99(3):279-83. 
321. Brown JO. Know Thyself: The Impact of Portfolio Development on Adult Learning. Adult 
Educ Quarterly 2002.52(3):228-45. 
322. Cobourne MT. What's wrong with the traditional viva as a method of assessment in 
orthodontic education? J Orthod 2010.37(2):128-33. 
323. Macan T. The employment interview: A review of current studies and directions for future 
research. Human Resource Management Review 2009.19(3):203-18. 
324. Barrick MR, Shaffer JA, DeGrassi SW. What you see may not be what you get: 
Relationships among self-presentation tactics and ratings of interview and job performance. 
J Appl Psychol 2009.94(6):1394-411. 
325. Eva KW, Macala C. Multiple mini-interview test characteristics: 'tis better to ask candidates 
to recall than to imagine. Med Educ 2014.48(6):604-13. 
326. Hull L, Birnbach D, Arora S, Fitzpatrick M, Sevdalis N. Improving surgical ward care: 
development and psychometric properties of a global assessment toolkit. Ann Surg 
2014.259(5):904-9. 
327. Homer M, Setna Z, Jha V, Higham J, Roberts T, Boursicot K. Estimating and comparing the 
reliability of a suite of workplace-based assessments: an obstetrics and gynaecology setting. 
Med Teach 2013.35(8):684-91. 
328. Costa MH, Shulman R, Bates I. A credentialing process for advanced level pharmacists: 
participant feedback. Pharm J 2012.288:1-5. 
329. Breen KJ. Revalidation - what is the problem and what are the possible solutions? The 
Medical journal of Australia 2014.200(3):153-6. 
330. Stacey S, Coombes I, Wainwright C, Klee B, Miller H, Whitfield K. Characteristics of 
adverse medication events in a children's hospital. Journal of Paediatrics and Child Health. 
Forthcoming.  2014.  DOI: 10.1111/jpc.12684 
331. Noble DJ, Pronovost PJ. Underreporting of patient safety incidents reduces health care's 
ability to quantify and accurately measure harm reduction. Journal of Patient Safety 
2010.6(4):247-50. 
332. Cox AR, Anton C, Goh CH, Easter M, Langford NJ, Ferner RE. Adverse drug reactions in 
patients admitted to hospital identified by discharge ICD-10 codes and by spontaneous 
reports. Br J Clin Pharmacol 2001.52(3):337-9. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 216 
333. Australian Commission on Safety Quality in Health Care. National Safety and Quality 
Health Service Standards. Sydney: ACSQHC, Commonwealth of Australia; 2011. 
334. Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year 
period. Pediatrics 2006.118(2):555-62. 
335. Goldstein LH, Berlin M, Saliba W, Elias M, Berkovitch M. Founding an adverse drug 
reaction (ADR) network: a method for improving doctors spontaneous ADR reporting in a 
general hospital. J Clin Pharmacol 2013.53(11):1220-5. 
336. National Coordinating Council for Medication Error Reporting and Prevention. NCC MERP 
Index for Categorizing Medication Errors: National Coordinating Council for Medication 
Error Reporting and Prevention; 2001 [updated 2001 Feb 20; cited 2014 Jul 31]; Available 
from: http://www.nccmerp.org/medErrorCatIndex.html 
337. Kale A, Keohane CA, Maviglia S, Gandhi TK, Poon EG. Adverse drug events caused by 
serious medication administration errors. BMJ Quality & Safety 2012.21(11):933-8. 
338. High Risk Medicines Working Party. High risk medicines — feeling the PINCH! 
Melbourne: Department of Health, Victoria; 2006. 
339. Rashed AN, Wong ICK, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors 
associated with adverse drug reactions in hospitalised children: international multicentre 
study. Eur J Clin Pharmacol 2011.68(5):801-10. 
340. Hodgkinson MR, Dirnbauer NJ, Larmour I. Identification of Adverse Drug Reactions Using 
the ICD-10 Australian Modification Clinical Coding Surveillance. J Pharm Pract Res 
2009.39(1):19-23. 
341. Takata GS, Taketomo CK, Waite S. Characteristics of medication errors and adverse drug 
events in hospitals participating in the California Pediatric Patient Safety Initiative. Am J 
Health-Syst Pharm 2008.65(21):2036-44. 
342. Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse Drug 
Reactions in Children—A Systematic Review. PLoS ONE 2012.7(3):e24061. 
343. Wilson DG, McArtney RG, Newcombe RG, McArtney RJ, Gracie J, Kirk CR, et al. 
Medication errors in paediatric practice: insights from a continuous quality improvement 
approach. Eur J Pediatr 1998.157(9):769-74. 
344. Fernandez CV, Gillis-Ring J. Strategies for the prevention of medical error in pediatrics. 
The Journal of Pediatrics 2003.143(2):155-62. 
345. Otero P, Leyton A, Mariani G, Ceriani Cernadas JM, Committee atPS. Medication Errors in 
Pediatric Inpatients: Prevalence and Results of a Prevention Program. Pediatrics 
2008.122(3):e737-e43. 
346. Wakefield J. Patient Safety: From Learning to Action IV. Fourth Queensland Health Report 
on Clinical Incidents and Sentinel Events in the Queensland Public Health System 2008/9. 
Brisbane: Queensland Health; 2011. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 217 
347. Kozer E, Seto W, Verjee Z, Parshuram C, Khattak S, Koren G, et al. Prospective 
observational study on the incidence of medication errors during simulated resuscitation in a 
paediatric emergency department. BMJ 2004.329(7478):1321-0. 
348. Kozer E, Scolnik D, Macpherson A, Keays T, Shi K, Luk T, et al. Variables Associated 
With Medication Errors in Pediatric Emergency Medicine. Pediatrics 2002.110(4):737-42. 
349. Ross LM, Wallace J, Paton JY. Medication errors in a paediatric teaching hospital in the 
UK: five years operational experience. Arch Dis Child 2000.83(6):492-7. 
350. Long AL, Horvath MM, Cozart H, Eckstrand J, Whitehurst J, Ferranti J. Tailoring adverse 
drug event surveillance to the paediatric inpatient. Qual Saf Health Care 2010.19(5):e40. 
351. Coombes ID, Stowasser DA, Reid C, Mitchell CA. Impact of a standard medication chart on 
prescribing errors: a before-and-after audit. Qual Saf Health Care 2009.18(6):478-85. 
352. Coombes ID, Reid C, McDougall D, Stowasser D, Duiguid M, Mitchell C. Pilot of a 
National Inpatient Medication Chart in Australia: improving prescribing safety and enabling 
prescribing training. Br J Clin Pharmacol 2011.72(2):338-49. 
353. Herzer KR, Mirrer M, Xie Y, Steppan J, Li M, Jung C, et al. Patient safety reporting 
systems: sustained quality improvement using a multidisciplinary team and "good catch" 
awards. Joint Commission journal on quality and patient safety / Joint Commission 
Resources 2012.38(8):339-47. 
354. Rinke ML, Bundy DG, Velasquez CA, Rao S, Zerhouni Y, Lobner K, et al. Interventions to 
Reduce Pediatric Medication Errors: A Systematic Review. Pediatrics Forthcoming 
2014.10.1542/peds.2013-3531. 
355. Stacey SR, Coombes I, Wainwright C, Cardiff L, Whitfield K. What does advanced practice 
mean to Australian paediatric pharmacists? A focus group study. Int J Pharm Pract 
Forthcoming 2014.10.1111/ijpp.12113. 
356. Coombes I, Kirsa SW, Dowling HV, Galbraith K, Duggan C, Bates I. Advancing pharmacy 
practice in Australia: The importance of national and global partnerships. J Pharm Pract Res 
2012.42(4):261-3. 
357. Duggan C. The Society has plans afoot that will help you to stand out from the crowd. The 
Pharmaceutical Journal 2013.290:25. 
358. College of Pharmacy Practice and Faculty of Neonatal and Paediatric Pharmacy. General 
Paediatric Competencies. London: College of Pharmacy Practice and Faulty of Neonatal and 
Paediatric Pharmacy; 2006. 
359. Maddux MS. Preliminary Request for the Board of Pharmacy Specialties to Consider a New 
Specialty. Lenexa: American College of Clinical Pharmacy; 2011. 
360. Advanced Pharmacy Practice Framework Steering Committee. Advanced Pharmacy 
Practice.  A Consultation Paper for the Pharmacy Profession. Deakin West: Pharmaceutical 
Society of Australia; 2012. 
361. Burch VC, Seggie JL. Use of a structured interview to assess portfolio-based learning. Med 
Educ 2008.42(9):894-900. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 218 
362. Rutter PM. The introduction of observed structured clinical examinations(OSCEs) to the M. 
Pharm degree pathway. Pharmacy Education 2002.1(3):173-80. 
363. Board of Pharmacy Specialties. Board of Pharmacy Specialties Announces New Specialties 
in Critical Care Pharmacy and Pediatric Pharmacy 2013 [updated 2013 Apri 15; cited 2013 
Apr 24]; Available from: http://bpsweb.org/news/pr_041513.cfm 
364. O'Leary KM, Kirsa SW, Dowling HV, Allinson YM, Coombes I. A Professional 
Development Framework for Pharmacists. J Pharm Pract Res 2012.42(4):259-61. 
365. SHPA Committee of Specialty Practice in Clinical Pharmacy. Standards of Practice for 
Clinical Pharmacy Services. Overview: Standards of Practice for Clinical Pharmacy 
Services. J Pharm Pract Res 2013.43(2 (suppl)):S2-S5. 
366. Pharmaceutical Society of Australia. Standard and guidelines for pharmacists performing 
clinical interventions. Deakin West: Pharmaceutical Society of Australia; 2011. 
367. SHPA Committee of Specialty Practice in Clinical Pharmacy. Standards of Practice for 
Clinical Pharmacy Services. Chapter 13. Documenting Clinical Activities. J Pharm Pract 
Res 2013.43(2 (suppl)):S42-S6. 
368. Dunbar JA, Reddy P, Beresford B, Ramsey WP, Lord RSA. In the wake of hospital 
inquiries: impact on staff and safety. Med J Aust 2007.186(2):80-3. 
369. Van Der Weyden MB. The Bundaberg Hospital scandal: the need for reform in Queensland 
and beyond. Med J Aust 2005.183(6):284-5. 
370. Jenkins N. Hospital talk: SHPA identifying learning needs with competency assessment 
tools. AJP: The Australian Journal of Pharmacy 2013.94(1118):42. 
371. O'Leary KM, Allinson YM. Snapshot of the Australian Public Hospital Pharmacy 
Workforce in 2007. J Pharm Pract Res 2009.39(1):28-33. 
372. Keen N. Clinical Pharmacy and Competency Assessment. J Pharm Pract Res 2010.40(1):6-
7. 
373. Australian Pharmacy Council. Evaluation and Credentialing of Advanced Practice 
Pharmacists: First Round Consultation.   Australian Pharmacy Council; 2014 Jun. 
374. Lawrence J. Recognising pharmacy’s professional role models: the first Faculty members. 
The Pharmaceutical Journal 2013.291:456. 
375. Stacey S, Coombes I, Wainwright C, Whitfield K. Using the "General Level Framework" to 
identify gaps in knowledge and skills to prioritise professional development activities for 
paediatric pharmacists. In: Paper presented at: Neonatal and Paediatric Pharmacists Group 
19th Annual Conference; 2013 Nov 09; London, United Kingdom. 
376. McGill DA, van der Vleuten CPM, Clarke MJ. Supervisor assessment of clinical and 
professional competence of medical trainees: a reliability study using workplace data and a 
focused analytical literature review. Advances in Health Sciences Education 
2011.16(3):405-25. 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 219 
377. McGill DA, van der Vleuten CPM, Clarke MJ. A critical evaluation of the validity and the 
reliability of global competency constructs for supervisor assessment of junior medical 
trainees. Advances in Health Sciences Education 2013.18(4):701-25. 
378. Levashina J, Hartwell CJ, Morgeson FP, Campion MA. The Structured Employment 
Interview: Narrative and Quantitative Review of the Research Literature. Personnel 
Psychology 2013.67(1):241-93. 
379. Prideaux D, Roberts C, Eva K, Centeno A, McCrorie P, McManus C, et al. Assessment for 
selection for the health care professions and specialty training: consensus statement and 
recommendations from the Ottawa 2010 Conference. Med Teach 2011.33(3):215-23. 
380. Siu E, Reiter HI. Overview: what's worked and what hasn't as a guide towards predictive 
admissions tool development. Adv in Health Sci Educ 2009.14(5):759-75. 
381. Pau A, Jeevaratnam K, Chen YS, Fall AA, Khoo C, Nadarajah VD. The Multiple Mini-
Interview (MMI) for student selection in health professions training - a systematic review. 
Med Teach 2013.35(12):1027-41. 
382. Huffcutt AI, Van Iddekinge CH, Roth PL. Understanding applicant behavior in employment 
interviews: A theoretical model of interviewee performance. Human Resource Management 
Review 2011.21(4):353-67. 
383. Mak VSL, Clark A, March G, Gilbert AL. The Australian pharmacist workforce: 
employment status, practice profile and job satisfaction. Aust Health Rev 2013.37(1):127-
30. 
384. Grzeskowiak LE, Thomas AE. Paediatric and Perinatal Health Abstracts at SHPA National 
Conferences: Trends in Presentation and Subsequent Publication. J Pharm Pract Res 
2014.44(1):22-5. 
 
 
 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 220 
Appendix A: Paediatric ALF (Section 1.1 Professional Practice – Expert Knowledge) 
1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
1.1 Expert Knowledge 
The following are examples of the knowledge expected of a paediatric pharmacist at each level of career.  A specialist pharmacist would be 
expected to have all the knowledge listed for a rotational pharmacist in addition to the majority of the specialist level knowledge base.  An 
expert paediatric pharmacist would be expected to have a reasonable understanding of all of the knowledge criteria listed for a specialist 
pharmacist (with the understanding that an expert in one or two specialities e.g. oncology and parenteral nutrition would not be expected to 
have specialist or expert knowledge of all other specialities).  An expert paediatric pharmacist is expected to be taking the knowledge listed 
under specialist (and expert if stated) and applying it to larger groups of patients to improve patient care 
Demonstrates general pharmaceutical knowledge in 
core areas. 
Demonstrates specialist pharmaceutical 
knowledge in defined area(s). 
Advances the knowledge 
base in the defined area 
1.1.1 
Knowledge: 
Child Health 
Issues 
 
(Core Knowledge) 
Demonstrates an understanding of the concepts of family-
centered care 
Demonstrates a good knowledge of concordance in 
children and their carers, including issues surrounding 
medicines in school. 
Explains how disease processes impact medication therapy 
(including drug handling, concordance and quality of life). 
Understanding of common child health issues and priorities 
locally and globally. 
Demonstrated understanding of the ethics of medical care 
in children (including consent for treatment, research and 
clinical trial design). 
Demonstrates a high level understanding of 
the challenges of adolescence including 
transition to adult care, dealing with chronic 
illness, concordance and sexual health. 
Demonstrates a high level understanding of 
the complexity of ethics in paediatric medical 
care (see also cluster 6). 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  SHPA Advanced Paediatrics Seminar or  
Workshop 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
SHPA Paediatrics Seminar  Member of, or provide advice to a local 
group or committee 
 Records of consultation 
requests from clinicians and 
pharmacists interstate and 
internationally 
 
Observational assessment (Paed GLF or equivalent)  Records of consultation requests from 
clinicians and pharmacists locally 
 
Postgraduate qualifications (with paediatric content)  Active member of PaedPharm network  Published research  
Member of PaedPharm network  Interventions at a specialist/advanced level  Interventions at an expert level  
Individual examples 
 
 
  
1.1.2 
Knowledge: 
Drug 
Administration 
 
(Core Knowledge) 
Demonstrate an understanding of the challenges of drug 
administration in children (e.g. palatability, extemporaneous 
formulations)   
Demonstrate a practical understanding of routes of 
administration of drugs in children, including parenteral 
administration, and various venous access devices and IV 
delivery systems (e.g. IV push, infusion, piggyback, Y site, 
syringe pumps).   
Demonstrates a basic knowledge of enteral feeds, PEGs 
and NGTs and implications for drug administration. 
Demonstrates a high level understanding of 
the issues surrounding drug administration 
problems in paediatrics and how they can be 
addressed.   
 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, 
conferences, seminars 
 
Clinical rotations in paediatric areas  Active teaching role within institution   
Case presentations to department  SHPA Advanced Paediatrics Seminar 
or  Workshop 
 Member of, or provide 
advice to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
  
SHPA Paediatrics Seminar  Records of consultation requests from 
clinicians and pharmacists locally 
 Records of consultation 
requests from clinicians and 
pharmacists interstate and 
internationally 
 
Observational assessment (Paed GLF or equivalent)  Active member of PaedPharm network   
Postgraduate qualifications (with paediatric content)  Interventions at a specialist/advanced 
level 
 Published research  
Member of PaedPharm network    Interventions at an expert 
level 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
Individual examples 
 
 
  
1.1.3 
Knowledge: 
Child 
Development, 
Growth and 
Nutrition 
 
(Core Knowledge) 
Knowledge of usual weights for age and acceptable ranges, 
along with the implications of extremes of body weight on 
drug dosing. 
Be familiar with the growth and development of a healthy 
child, including body size, sensory changes, eating, 
behaviour and sleep. 
Demonstrate a basic understanding of specialised 
nutritional formulas used in children. 
Demonstrate a basic understanding of the safe use of 
parenteral nutrition in children. 
Understanding of TPN requirements for 
neonates and children and how to monitor 
and adjust regimens including 
compatibilities. 
 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas  Certified Nutrition Support Pharmacist 
(e.g. BCNSP or CNSC) 
 
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
Postgraduate qualifications (with paediatric content)  Active member of PaedPharm  Published research  
Member of PaedPharm network  Interventions at a specialist/advanced level  Interventions at an expert level  
Individual examples 
 
 
  
1.1.4 
Knowledge: 
Drug Handling 
 
(Core Knowledge) 
Demonstrate a basic knowledge of the pharmacokinetic and 
pharmacodynamic changes in children of different ages.  
Explains the differences in drug absorption, distribution, 
metabolism and elimination for neonatal, paediatric and 
adolescent patients compared to adult patients.  Describes 
Demonstrate an advanced level of 
understanding and application of 
pharmacokinetics and pharmacodynamics in 
children.  (e.g. different metabolic pathways, 
adaptation of renal function in neonates, 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
how these processes mature. 
Explains why younger children have a different potential for 
Adverse Drug Reactions. 
Demonstrated understanding of how obesity effects drug 
handling in children. 
protein binding). 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
Postgraduate qualifications (with paediatric content)  Active member of PaedPharm  Published research  
Member of PaedPharm network  Interventions at a specialist/advanced 
level 
 Interventions at an expert level  
Individual examples 
 
 
  
1.1.5 
Knowledge: 
Clinical 
Governance &  
Medication Safety 
 
(Core Knowledge) 
Have an understanding of the issues related to equity of 
access of medicines in children (e.g. unlicensed and off-
label use). 
Demonstrate an understanding of the medication safety 
challenges in childhood, and the strategies to prevent or 
reduce medication misadventure.  (e.g. oral syringes, 
paediatric medication chart, smart pumps, child resistant 
packaging). 
Lists high risk medications in neonates, infants and children 
if inappropriately prepared or administered. 
Demonstrated knowledge of current local 
and international medication safety priorities 
in paediatrics, including the Medication 
Safety Self-Assessment. 
Active involvement in local medication safety 
initiatives.  
Identifies medication safety 
issues at a local, state or 
national level, drives safety 
improvement initiatives and 
shares results with peers and 
appropriate forums. 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Assistance with medication chart audits  Review of Australian and international  
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
literature (e.g. ISMP Bulletins) 
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state  national, or 
international group or 
committee(e.g. CHA 
Medication Safety ERG) 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee (e.g. Drug and 
Therapeutics Committee, Medication 
Safety Committee) 
 
Attendance at Human Error and Patient Safety Course, 
Root Cause Analysis training (or equivalent) 
 Interventions at a specialist/advanced level  Published research (especially 
practice-based) 
 
  Review of institutional smart pump data-
set 
 Interventions at an expert level  
Individual examples 
 
 
  
1.1.6 
Knowledge: 
Fluids & 
Electrolytes 
 
(Core Knowledge) 
Knowledge of the basic fluid requirements of children in 
terms of volume and content.  Knows the potential for fluid 
overload from IV administration, particularly in neonates, 
and children on TPN. 
Knowledge of appropriate IV fluids in children. 
Demonstrate a good knowledge of issues 
surrounding intravenous therapy: 
compatibility, extravasation, displacement 
volumes, types of lines, methods of 
administration, pumps  
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
1.1.7 
Knowledge: 
Pain & Sedation 
 
(Core Knowledge) 
Understand the basic concepts of pain management and 
procedural sedation in paediatrics, including drugs and 
doses appropriate in different inpatient and outpatient 
settings. 
Familiar with common pain scores and assessments used 
in children. 
Understand concepts of: Patient Controlled 
Analgesia, Nurse Controlled Analgesia, 
Epidural, Nerve Blocks etc. 
Be aware of the treatment options and 
overall management of the palliative patient. 
Demonstrated understanding of current 
theories on pain management in children – 
including use of minimally invasive 
pharmacological and non-pharmacological 
therapies. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas (e.g. PICU, post-
surgery, emergency medicine, pain clinics) 
 
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.8 
Knowledge: 
Primary Care, 
Public Health and 
Preventative 
Medicine 
 
(Core Knowledge) 
Be aware of the current National Immunisation Schedule, 
including cold chain requirements. 
Be aware of the issues related to indigenous health, 
including family dynamics, infectious diseases (scabies, 
rheumatic fever, ear infections), belief systems and 
spirituality. 
Demonstrated understanding of the common (often minor) 
paediatric illnesses which present to primary care 
physicians and how to manage (see also emergency 
Be capable and confident to discuss the 
issues surrounding public health strategies 
such as immunisation. 
Active involvement in injury prevention at a 
local level (e.g. poisoning prevention, child 
resistant packaging etc). 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
medicine section) 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Cultural Awareness Training  Member of, or provide advice to a local 
group or committee 
 
Examples of interventions documented  
Postgraduate qualifications (with paediatric content)  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.9 
Knowledge: 
Emergency 
Medicine 
 
(Core Knowledge) 
Knowledge of the simple management of burns. 
Knowledge of the management of common childhood 
illnesses such as febrile illnesses, otitis media, asthma, 
URTI, croup, gastroentertis. (see also infectious diseases, 
immunology, gastroenterology and respiratory sections). 
Demonstrate a sound knowledge of the management of 
dehydration and fluid replacement in children. 
Knowledge of the epidemiology of childhood 
injury, including poisoning, envenomation 
and strategies for injury prevention in 
children. 
Knowledge of current protocols for 
resuscitation of the collapsed child. 
 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric emergency care  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
SHPA Emergency Medicine Seminar  Interventions at a specialist/advanced level  Published research  
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.10 
Knowledge: 
Respiratory 
Demonstrate a good understanding of paediatric asthma 
and the treatment options (including devices) available. 
Demonstrate an understanding of the treatment of common 
respiratory disorders such as cough, hayfever, bronchiolitis 
and croup. 
Demonstrate a basic knowledge of cystic fibrosis and its 
treatment. 
Demonstrates an advanced understanding 
and application of the current management 
of cystic fibrosis and emerging evidence for 
treatment options. 
Demonstrates an advanced knowledge of 
the management of severe asthma, 
bronchiolitis and bronchiectasis. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric respiratory areas  Attendance at Cystic Fibrosis Conferences  
Case presentations to department  Member of, or provide advice to a local 
group or committee 
 Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Active teaching role within institution  
 
 eCystic Fibrosis Review 
(http://www.hopkinscme.net/ofp/eCysticFib
rosisReview/index.html) 
 Published research  
  Interventions at a specialist/advanced level  Interventions at an expert level  
Individual examples 
 
 
 
 
  
1.1.11 
Knowledge: 
Nephrology and 
Genito-urinary 
Disorders 
Knowledge of the acute management of urinary tract 
infections, basic knowledge of the diagnosis and treatment 
of vesico-ureteric reflux and current recommendations for 
prophylaxis. 
Demonstrate a sound knowledge of the management of 
enuresis. 
Demonstrate a general knowledge of 
haemolytic uraemic syndrome and nephrotic 
syndrome and their treatment. 
Demonstrate a general knowledge and 
application of dialysis and dose adjustment 
in renal failure. 
Demonstrate a high level 
knowledge of renal 
replacement therapy (e.g. 
dialysis). 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
Demonstrate a basic understanding of the management of 
acute glomerulonephritis. 
Demonstrate an understanding of the 
management of renal transplantation. 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric nephrology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.12 
Knowledge: 
Neurology 
Demonstrate a good understanding of the the types of 
seizures in children, and the treatment of paediatric 
epilepsy and febrile convulsions. 
Demonstrate an understanding of the 
management of more complex neurological 
disorders, e.g. brain injury, cerebral palsy, 
movement disorders, Ventriculo-peritoneal 
(VP) shunts, Guillian Barre and other 
neuromuscular disorders, headache and 
migraine in children, and management of 
neurodevelopmental delay. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric neurology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
Individual examples 
 
 
  
1.1.13 
Knowledge: 
Mental Health 
Demonstrate an understanding of Attention Deficit 
Hyperactivity Disorder and the current treatment options. 
Demonstrate a basic understanding of the common 
treatment options for anorexia nervosa and depression in 
children and adolescents. 
Demonstrate an understanding of the 
complexities of the management of eating 
disorders, including re-feeding syndrome. 
Demonstrate a good working knowledge of 
the current evidence for pharmacotherapy of 
major psychiatric disorders affecting children 
(e.g. anxiety, depression, psychoses, autistic 
spectrum disorder)  
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric mental health areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.14 Knowledge: Endocrinology 
Demonstrate a basic understanding of the management of 
Type 1 diabetes and the implications for treatment options 
in children. 
Demonstrate a basic understanding of the monitoring and 
treatment of growth disorders in children. 
Demonstrate a basic understanding of the physiology of 
puberty. 
Be able to describe the treatment of the 
complications of diabetes such as diabetic 
ketoacidosis, hypo- and hyperglycaemia. 
Demonstrate an understanding of the 
management of more complicated endocrine 
disorders, e.g. bone diseases (including 
osteogenesis imperfecta, management of 
AVN and osteoporosis), congenital adrenal 
hyperplasia, diabetes insipidus, Turners 
Demonstrate an understanding 
of the rationale behind the 
common endocrinology tests 
and what the results represent. 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
Syndrome. 
Demonstrate an understanding of the risk 
factors of long term steroid use and 
appropriate treatment in period of stress. 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric endocrinology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.15 
Knowledge: 
Gastroenterology  
Understand the principles of rehydration 
Understand the pharmacology behind the treatment of 
gastro-oesophageal reflux and colic in children. 
Demonstrate an understanding of the management of 
nausea, vomiting, constipation and encopresis. 
Demonstrate an understanding of the 
management of inflammatory bowel 
disorders. 
Demonstrate an understanding of the 
management of significant GI bleeds.  
Demonstrate an understanding of the 
management of liver disorders and the 
management of liver transplantation. 
 
Demonstrate an understanding 
of the treatment options for 
short gut syndrome. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric gastroenterology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice  
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 to, a state, national or 
international group or 
committee 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.16 
Knowledge: 
Rheumatology 
 Understand the treatment of juvenile arthritis, 
including pain management. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric rheumatology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.17 
Knowledge: 
Immunology 
Demonstrate an understanding of common allergies in 
children and the basic management of allergy and 
anaphylaxis. 
Show an understanding of the disease state 
and treatment of Kawasaki Disease and 
Chronic Granulomatous Disease. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric immunology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice  
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 to, a state, national or 
international group or 
committee 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.18 
Knowledge: 
Haematology and 
Oncology 
(See also Cancer 
Services 
Competency 
Framework) 
Demonstrate a basic understanding of the management of 
children with cancer, including standard management of 
febrile neutropenia.  
Demonstrate an understanding of supportive care, mouth 
care and infective prophylaxis. 
Demonstrate a basic understanding of bleeding disorders 
as they present in children. 
 
Demonstrate a sound understanding of 
Acute Lymphoblastic Leukaemia (ALL) and 
its treatment. 
Demonstrate knowledge of the treatment of 
febrile neutropenia, sickle cell disease, 
anaemia. 
Demonstrate an understanding of the 
treatment options and management required 
for bone marrow transplantation. 
Demonstrate an understanding of the 
appropriate use of antithrombotic therapy in 
children, including monitoring. 
Demonstrate an understanding of tumour 
lysis syndrome, and contemporary therapies. 
Demonstrate an understanding 
of current common clinical 
trials underway in paediatric 
oncology, including an 
understanding of the 
reasoning behind treatment 
options. 
 Examples of evidence: (tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric oncology and 
haematology areas 
 
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
Attendance at SHPA Oncology Seminars  Attendance at ANZSIG, ISOPP, COSA 
and/or COG 
 Published research  
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
  Interventions at a specialist/advanced level  Interventions at an expert level  
Individual examples 
 
 
  
1.1.19 
Knowledge: 
Cardiology 
Demonstrate a basic understanding of the common types of 
congenital heart defects including Patent Ductus Arteriosus. 
Demonstrates a basic understanding of appropriate use of 
SBE prophylaxis. 
Demonstrate an understanding of the 
management of hypertensive crisis, 
pulmonary hypertension, arrhythmias and 
rheumatic heart disease. 
Demonstrate an understanding of the 
management of cardiac transplant. 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric cardiology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.20 
Knowledge: 
Infectious 
Diseases 
Have a basic understanding of common childhood bacterial 
and viral infections, including treatment and prophylaxis. 
(e.g. URTI, UTI, pneumonia, meningitis, surgical 
prophylaxis). 
Demonstrate a sound understanding of the acute and 
chronic management of otitis media, otitis externa and glue 
ear in children. 
Understand the management of fever in children, including 
appropriate use of antipyretics and treatment of pyrexia of 
Demonstrate an understanding of the 
management of chronic, severe and/or less 
common paediatric infections (eg sepsis, TB, 
HIV, CMV). 
Demonstrate an understanding of the causes 
and management of common tropical 
diseases presenting in children. 
Demonstrate an understanding 
of the theory and application of 
antibiotic governance in the 
paediatric setting. 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
unknown origin. 
Have an understanding of the standard management of 
bone, skin and joint infections in children. 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
 
 
  
1.1.21 
Knowledge: 
Metabolic 
Disorders and 
Genetics 
Have a basic understanding of common genetic variations 
in drug handling (e.g. G6PD deficiency) 
Demonstrate an understanding of common 
metabolic disorders such as phenylketonuria, 
urea cycle disorders and glycogen storage 
disorders. 
Demonstrate an understanding 
of complex metabolic 
disorders and treatment 
options available. 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric metabolic diseases areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
1.1.22 
Knowledge: 
Obstetrics and 
Neonatology 
Understand the developmental changes in the neonate, 
with particular regard to drug metabolism and excretion. 
Explains how disease processes impact medication 
therapy, especially conditions frequently encountered in 
premature infants. 
Familiar with the standard prophylaxis of haemorrhagic 
disease of the newborn, neonatal immunisation, routine 
management of neonatal jaundice & neonatal abstinence 
syndrome, and standard neonatal screening tests (e.g. 
APGAR). 
Identify the organisms associated with both early onset and 
late onset neonatal sepsis and the appropriate empiric 
therapy. 
Have a basic understanding of drugs in breast milk, and 
safety of medicines in pregnancy, including awareness of 
the most useful references for drugs in pregnancy and 
lactation. 
Awareness of common obstetric conditions (e.g. 
hyperemesis, constipation) and their appropriate 
management to minimise risk to the neonate. 
Demonstrated understanding of common 
neonatal problems and their treatment: e.g. 
Respiratory Distress Syndrome, Patent 
Ductus Arteriosus, neonatal abstinence 
syndrome, neonatal apnoea, necrotising 
enterocolitis. 
Advanced knowledge of drugs in pregnancy 
& breastfeeding, including risk assessment 
and patient focused advice. 
Demonstrated understanding of common 
advanced obstetric complications (e.g. pre-
term labour, premature rupture of 
membranes, gestational diabetes, 
hypertension, PUPPS, postpartum 
haemorrhage and substance abuse), and 
their management and implications for the 
neonate. 
Demonstrated understanding of 
management of pre-existing chronic medical 
conditions during pregnancy to minimise risk 
to the mother and baby (e.g. renal & cardiac 
disease, epilepsy) 
 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in neonatology areas  
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples    
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1. Professional Practice 
Improving standards of paediatric pharmaceutical care 
 Competency Level Descriptors 
No. Competency Foundation  (Rotational)  
Excellence 
(Advanced/Specialist) 
Mastery  
(Expert/Consultant) 
 
1.1.23 
Knowledge: 
Critical Care 
Demonstrate an understanding of the standard treatment 
requirements for a ventilated child, including prophylaxis for 
stress ulceration, and sedation. 
Demonstrate an understanding of the 
appropriate use of inotropes, management of 
multi-organ failure (e.g. CVVHDF) and the 
impact of this on medication use.. 
Demonstrate an understanding of the varied 
options for respiratory support in an intensive 
care environment (PEEP, CPAP, PS). 
Demonstrate an understanding of the 
management of acute brain injury in the 
PICU environment. 
 
Demonstrate a sound 
understanding of the patient 
journey in the intensive care 
unit, including use of 
prognostic scoring and end of 
life decisions. 
Demonstrate an understanding 
of resuscitation broadly in a 
paediatric environment – e.g. 
fluids, adrenaline, alternate 
routes of administration (e.g. 
intraosseus, endotracheal) 
Examples of evidence: 
(tick boxes) 
Child Health Learning Package  Case presentations to ground rounds, 
conferences 
 Education on topic at a high 
level - university, conferences, 
seminars 
 
Clinical rotations in paediatric critical care areas (e.g. 
PICU, NICU) 
 
Case presentations to department  Active teaching role within institution  Member of, or provide advice 
to, a state, national or 
international group or 
committee 
 
Examples of interventions documented  Member of, or provide advice to a local 
group or committee 
 
  Interventions at a specialist/advanced level  Published research  
    Interventions at an expert level  
Individual examples 
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Appendix B: shpaclinCAT 
The following pages show a selection of the shpaclinCAT competency assessment tool, 
indicating the level of performance criteria included. 
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__________________________________________________________ 
 
shpaclinCAT 
Clinical Competency Assessment Tool  
for Australian Pharmacists  
____________________________________________________ 
 
Assessment Tool with Evaluation 
 
Version 2010 
 
 
Pharmacist Details 
 
 Evaluator Details 
 
 
Name 
 
 
 
Name  
Position 
 
 
 
Position  
Site 
 
   
Date of Evaluation 
 
   
 
 
Frequency Ranges for Assessment Ratings 
 
Rating  Definitions Percentage expression 
Consistently Consistently demonstrates the expected standard practice, with 
very rare lapses 
85-100% 
Usually Demonstrates expected standard practice with occasional 
lapses 
51-84% 
Sometimes Demonstrates expected standard practice less than half of the 
time observed. Much more haphazard than “mostly” 
25-50% 
Rarely Very rarely meets the standard expected.  No logical thought 
process appears to apply 
0-24% 
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shpaclinCAT: Competency Assessment Tool with Evaluation for Australian Pharmacists  Page 2 of 45 
 
Part One:  Delivery of Patient Care 
__________________________________________________________ 
 
Competency Unit 1.1: Medication History 
 
Element Performance Criteria & Evidence Guide 
 
 
1.1.1 
Relevant patient 
background  
 
 
Retrieve relevant information 
Obtain and contextualise the following patient information as applicable: 
 Age –consider patient’s likely ability to metabolise/excrete medicines, and implications for appropriate 
selection of medicine and dosage 
 Gender – consider impact of gender on therapeutic decision making 
 Height and weight 
 Pregnancy/lactation status 
 Immunisation status 
 Ethnic background/religion– consider pharmaceutical implications including pharmacogenetic factors 
 Social background – consider impact on patient’s ability to manage their medicines 
 Details of regular general practitioner/community pharmacy/other as appropriate 
 Patient’s ability to communicate (cognitive function, alertness, mental acuity, psychological state) and 
requirements for communication aids e.g. glasses, hearing aids, need for interpreter service 
 Presenting condition – consider the possibility of adverse drug reactions, poor adherence, inadequate dosing, 
inappropriate therapy as a contributor to hospital presentation/morbidity 
 Working diagnosis - consider appropriate evidence based therapy 
 Previous medical history – identify potential medicine and/or disease contraindications and ensure that 
management of the presenting complaint does not compromise a co-morbidity 
 Relevant laboratory or other findings (if available) - focus on findings that will affect decisions regarding 
medicines, including 
 renal function 
 electrolytes 
 liver function 
 full blood count 
 cardiac markers 
 general observations 
 relevant previous therapeutic drug monitoring results 
 Utilise appropriate sources to obtain information e.g. 
 ward handover sheet 
 health care professionals (including pharmacists, nurses, doctors, allied health professionals) 
 medical notes (including advance care directive) and transfer summaries from referring institution 
 laboratory results systems 
Self  Rarely Sometimes Usually Consistently Unable to Comment 
Comment 
 
Evaluation Rarely Sometimes Usually Consistently Unable to Comment 
Comment  
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shpaclinCAT: Competency Assessment Tool with Evaluation for Australian Pharmacists  Page 3 of 45 
 
 
Element Performance Criteria & Evidence Guide 
 
 
1.1.2 
Introduction to 
consultation 
Provide clear introduction to the consultation 
 Greet patient 
 Establish patient identity 
 Introduce self and other colleagues as applicable 
 Confirm time is convenient 
 Establish a rapport with the patient and/or carer to support ongoing communication 
 Respect the patient’s right to decline an interview or consultation, or to choose a more appropriate time 
Self  Rarely Sometimes Usually Consistently Unable to Comment 
Comment 
 
Evaluation Rarely Sometimes Usually Consistently Unable to Comment 
Comment  
Agree on an agenda with the patient 
 Explain purpose of discussion e.g. taking a medication history, medicine specific counselling or a medication 
chart review 
Self  Rarely Sometimes Usually Consistently Unable to Comment 
Comment 
 
Evaluation Rarely Sometimes Usually Consistently Unable to Comment 
Comment  
 
1.1.3 
Questioning 
technique 
 
Use appropriate questioning to obtain relevant information from the patient 
 Determine who the most appropriate person is to discuss the patient’s medications with 
 Use appropriate nonverbal language e.g. adopt a suitable position, maintain eye contact, actively listen 
 Use appropriate language i.e. non judgmental, non alarmist, reassuring and using terminology and phrasing  
the patient/carer  will understand (avoid use of medical jargon) 
 Ask relevant and succinct questions using an appropriate technique i.e. a mixture of open and closed 
questions 
 Avoid interrupting the patient/carer 
 Avoid leading or negative questions 
Self  Rarely Sometimes Usually Consistently Unable to Comment 
Comment 
 
Evaluation Rarely Sometimes Usually Consistently Unable to Comment 
Comment  
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Appendix C: Feedback Questions for Advanced Practice 
Assessment Participants 
1. What level of practice did you consider yourself before you started the project, and what 
level of practice do you consider yourself now you have completed the project. (With 
Level 1 being foundation or general level practice, and Level 3 being "Mastery" or 
"Advanced" level) 
• Before you started the project 
• After you completed the project 
2. The portfolio was presented electronically via an internet storage provider (dropbox). 
What is your preferred format to present your portfolio? 
• Electronic, personal (e.g. USB stick or similar) 
• Electronic, internet based (e.g. dropbox or similar) 
• Paper based (e.g. printed copies provided to panel members) 
• Other 
3. Overall, I found the portfolio review to be: (5 point Likert scale from Strongly agree to 
Strongly Disagree for each of the following statements) 
• A positive experience that allowed me to reflect honestly on my practice and 
future development. 
• An extremely taxing process that provided little benefit to me. 
• An inspiring experience that has given me renewed enthusiasm for pharmacy 
practice. 
• A fair method of evaluation of advanced practice 
4. Overall, I found the oral viva to be... (5 point Likert scale from Strongly agree to 
Strongly Disagree for each of the following statements) 
• A positive experience that allowed me to reflect honestly on my practice and 
future development. 
• An extremely taxing process that provided little benefit to me. 
• An inspiring experience that has given me renewed enthusiasm for pharmacy 
practice. 
• A fair method of evaluation of advanced practice 
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5. Overall, I found the Mini-PAT to be... (5 point Likert scale from Strongly agree to 
Strongly Disagree for each of the following statements) 
• A positive experience that allowed me to reflect honestly on my practice and 
future development. 
• An extremely taxing process that provided little benefit to me. 
• An inspiring experience that has given me renewed enthusiasm for pharmacy 
practice. 
• A fair method of evaluation of advanced practice 
6. Overall, I found knowledge assessments... (5 point Likert scale from Strongly agree to 
Strongly Disagree for each of the following statements, separate questions for CPD 
recording and postgraduate qualifications) 
• A positive experience that allowed me to reflect honestly on my practice and 
future development. 
• An extremely taxing process that provided little benefit to me. 
• An inspiring experience that has given me renewed enthusiasm for pharmacy 
practice. 
• A fair method of evaluation of advanced practice 
7. Overall, I found direct observation of practice to be... (5 point Likert scale from Strongly 
agree to Strongly Disagree for each of the following statements) 
• A positive experience that allowed me to reflect honestly on my practice and 
future development. 
• An extremely taxing process that provided little benefit to me. 
• An inspiring experience that has given me renewed enthusiasm for pharmacy 
practice. 
• A fair method of evaluation of advanced practice 
8. What do you consider are the MOST useful pieces of evidence to demonstrate level of 
practice? This could be what you found most useful, or what you might consider useful in 
the future. (Multiple selections can be chosen) 
• Advanced Level Framework (adding evidence against the different competencies) 
• Mini-PAT (the summarised peer review from your colleagues) 
• ClinCAT or GLF (direct observation of your practice) 
• Thank-you or other acknowledgements (e.g. emails from colleagues) 
• Presentations or lectures given 
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• Student or learner feedback (as an educator) 
• CPD records 
• Written references 
• Intervention reports or case based demonstrations 
• Project Reports 
• Research - published articles 
• Research - conference or seminar abstracts, posters or presentations 
9. What do you consider are the LEAST useful pieces of evidence to demonstrate level of 
practice? (Multiple choices can be selected) 
• (same options as for Question 8 above) 
10. Do you have any other comments regarding the project, or suggestions on how to 
improve advanced practice assessment in the future? (free text) 
 
 
Oral Viva Participants were also asked the additional questions: 
1. What format was the oral viva you participated in? 
• Face to face 
• Videoconference (via Webex) 
• Videoconference (via FaceTime) 
• Telephone 
2. How many people were in your evaluation panel? (Not counting Sonya Stacey as an 
observer) 
3. How did you feel before the oral viva? 
• Quite anxious 
• A little apprehensive 
• Neutral 
• Comfortable 
• Confident 
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4. How did you feel after the oral viva? 
• Much better 
• A little better 
• The same 
• A little worse 
• Much worse 
5. Did you feel the oral viva gave you the opportunity to provide additional information or 
evidence to support your level of practice (above presenting your portfolio alone)? 
• Yes, No or Not Sure 
6. What other comments do you have, or suggestions on how to improve the oral viva 
process for the future? (free text) 
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Appendix D: Multi Source Peer Review Survey (Mini-PAT) 
1. Introduction 
Welcome to the Advanced Pharmacy Practice 360 degree appraisal form for paediatrics. 
You have been asked to complete this because a pharmacist is undergoing an evaluation and has 
designated you as a referee for part of the process. At present, this type of evaluation is 
infrequent, you are unlikely to be inundated with such requests in future.  The candidate is 
evaluated in a number of different assessments, of which this is just one part. 
This appraisal survey is structured according to the format of a competency framework 
developed by the Society of Hospital Pharmacists of Australia Committee of Specialty Practice 
in Paediatrics. 
Competencies are clustered into 6 main areas with three levels of advanced practice for each 
area.  There is a paragraph with some explanatory sentences for each of the three levels, which 
are a condensed version of the competency framework and provided to help you gauge the likely 
level of practice of the candidate pharmacist. 
The 6 areas are:  
• Expert Professional Practice  
• Building Working Relationships  
• Leadership  
• Management  
• Education, Training and Development  
• Research and Evaluation 
You will be asked about each area in turn. 
In each area, please indicate the level of practice the pharmacist routinely works at (in your 
opinion) by clicking on one box. Please note that it is unusual for a pharmacist to attain the 
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highest level of practice in all areas, and it is not necessary to have achieved all of the 
explanatory points to be considered working at that specific level. 
Please also write brief comments in each of the areas where possible.  The comments from all 
the referees will be consolidated together anonymously and fed back to the candidate. 
There is also a text box for suggestions that you may have about development opportunities 
available to the candidate. 
 
 
2. About you 
Please could you indicate how long you have known the candidate? 
Please indicate which professional group you would describe yourself as belonging to:- 
• Doctor  
• Nurse  
• Pharmacist  
• Allied Health Professional 
• Other (please specify) 
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3. Expert Professional Practice  
Please assign a level of competence for the candidate by clicking on ONE BUTTON ONLY.  
Examples of practice that suggest the candidate is working at a particular level are provided to 
assist you. 
If you do not believe the candidate meets level 1, or you feel that that you cannot comment on 
this aspect of the framework, then please state this in the comments box and do not select a 
button. 
The candidate does not have to perform all listed activities to achieve a rating at that level, but 
should perform activities that are generally of the same level of complexity or require the same 
depth of knowledge / skill as the examples given. 
Please also add comments in the text boxes below (e.g. brief examples of the candidates practice 
that support the grade assigned, strengths and weaknesses). This is optional, but comments are 
exceptionally helpful for the evaluation panel when reviewing the candidate’s performance and 
as consolidated feedback to the pharmacist themselves. 
LEVEL 1: Demonstrated general pharmaceutical knowledge in paediatric patients.  Able to plan, 
manage, monitor, advise and review pharmaceutical care programs for general paediatric patients 
at an individual patient level.  Able to make decisions, problem-solve, prioritise in a timely 
manner and within organisational constraints. 
LEVEL 2: Demonstrates in depth pharmaceutical knowledge in paediatric patients.  Able to plan, 
manage, monitor, advise and review specialist pharmaceutical care plans for groups of paediatric 
patients, including high acuity patients.  Able to problem-solve and make decisions in complex 
situations in a timely manner, where limited information is available and multiple factors are 
involved.  Able to describe reasoning and evidence behind recommendations to others. 
LEVEL 3:  Able to identify knowledge gaps and advances the knowledge base in paediatrics.  
Advances pharmaceutical care programmes for large groups of paediatric patient groups, 
including development and implementation of new policies and procedures for use in the 
paediatric environment.  Able to advocate on behalf of individual patients or service groups at a 
state or national level.  Able to use skills to manage difficult and dynamic situations, make 
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decisions in the absence of evidence or data or when there is conflicting information, and resolve 
large scale or complex service problems. 
Having reviewed the candidate against the examples above, are there any initiatives / projects in 
your location that the candidate could become involved with that aids their professional 
development and / or improves patient care? 
 
4. Building Working Relationships 
Please assign a level of competence for the candidate by clicking on ONE BUTTON ONLY.  
Examples of practice that suggest the candidate is working at a particular level are provided to 
assist you. 
If you do not believe the candidate meets level 1, or you feel that that you cannot comment on 
this aspect of the framework, then please state this in the comments box and do not select a 
button. 
The candidate does not have to perform all listed activities to achieve a rating at that level, but 
should perform activities that are generally of the same level of complexity or require the same 
depth of knowledge / skill as the examples given. 
Please also add comments in the text boxes below (e.g. brief examples of the candidates practice 
that support the grade assigned, strengths and weaknesses). This is optional, but comments are 
exceptionally helpful for the evaluation panel when reviewing the candidate’s performance and 
as consolidated feedback to the pharmacist themselves. 
LEVEL 1:  Demonstrates use of appropriate communication with individual patients, colleagues 
and clinicians as part of a multidisciplinary team.  Able to communicate where the content of the 
discussion is clear.  Able to persuade others about individual episodes of care, and negotiates 
effectively.  Able to communicate effectively with children and families in a developmentally 
appropriate fashion, including respectful listening, empathy and appropriate reassurance.  
Effective and proactive member of the multidisciplinary team and of other professional groups. 
LEVEL 2:  Demonstrates the use of appropriately selected communication skills with small 
groups of patients, colleagues, senior clinicians and managers within the organization.  Able to 
communicate effectively with children and families in an empathetic and respectful manner in 
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complex situations using appropriate verbal and body language.  Able to persuade or influence 
and negotiate with the multidisciplinary team with regard to complex cases, organizational 
change, guidelines and protocols.  Active member of multidisciplinary and specialty professional 
groups with acknowledged expertise in the defined area of practice. 
LEVEL 3:  Demonstrates ability to present complex, sensitive or contentious information to 
large groups of patients, clinicians and senior managers.  Motivates the multidisciplinary and 
pharmacy team.  Able to utilize high level negotiation and conflict management skills and 
communicate effectively in a hostile, antagonistic or highly emotive atmosphere.  Acknowledged 
within a muldisciplinary team as a leader in the defined area of practice, and sought as an 
opinion leader from within and outside the organization.  Works across geographical and 
professional boundaries to build relationships, share information, plans and resources. 
Having reviewed the candidate against the examples above, are there any initiatives / projects in 
your location that the candidate could become involved with that aids their professional 
development and / or improves patient care? 
 
5. Leadership 
Please assign a level of competence for the candidate by clicking on ONE BUTTON ONLY.  
Examples of practice that suggest the candidate is working at a particular level are provided to 
assist you. 
If you do not believe the candidate meets level 1, or you feel that that you cannot comment on 
this aspect of the framework, then please state this in the comments box and do not select a 
button. 
The candidate does not have to perform all listed activities to achieve a rating at that level, but 
should perform activities that are generally of the same level of complexity or require the same 
depth of knowledge / skill as the examples given. 
Please also add comments in the text boxes below (e.g. brief examples of the candidates practice 
that support the grade assigned, strengths and weaknesses). This is optional, but comments are 
exceptionally helpful for the evaluation panel when reviewing the candidate’s performance and 
as consolidated feedback to the pharmacist themselves. 
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LEVEL 1:  Understands local organizational structures and service delivery, governance and 
partnerships.  Ensures compliance with local policies.  Understands and contributes to 
department and unit vision and service improvement activities.  Able to motivate self to achieve 
goals.  Implements local changes and service improvement projects agreed by the unit or 
organization. 
LEVEL 2:  Understands culture and climate and can plan with the whole organization in mind. 
Able to incorporate national healthcare policy into local practice. Raises and/or deals with 
identified issues at a unit level.  Creates clear vision for the future.  Develops and implements 
innovation from outside the organization.  Able to motivate individuals in the team. 
LEVEL 3:  Plans long term and actively participates in creating national healthcare guidelines 
and policies.  Convinces and motivates others to share the vision at higher level (beyond the 
team), develops and leads innovation strategies at an organizational level to demonstrably 
improve service delivery. 
Having reviewed the candidate against the examples above, are there any initiatives / projects in 
your location that the candidate could become involved with that aids their professional 
development and / or improves patient care? 
 
6. Management 
Please assign a level of competence for the candidate by clicking on ONE BUTTON ONLY.  
Examples of practice that suggest the candidate is working at a particular level are provided to 
assist you. 
If you do not believe the candidate meets level 1, or you feel that that you cannot comment on 
this aspect of the framework, then please state this in the comments box and do not select a 
button. 
The candidate does not have to perform all listed activities to achieve a rating at that level, but 
should perform activities that are generally of the same level of complexity or require the same 
depth of knowledge / skill as the examples given. 
Please also add comments in the text boxes below (e.g. brief examples of the candidates practice 
that support the grade assigned, strengths and weaknesses). This is optional, but comments are 
 Advanced Paediatric Pharmacy Practice: What is it, how do you get there and what does it mean for children? 251 
exceptionally helpful for the evaluation panel when reviewing the candidate’s performance and 
as consolidated feedback to the pharmacist themselves. 
LEVEL 1:  Understands the process for resource utilization at a departmental level, including 
necessity for managing own time and conflicting priorities.  Understands and conforms to local 
standards of practice. Proactively manages own data collection for financial, risk management, 
performance indicators as required by organization.  Able to carry out small individual projects 
without guidance. 
LEVEL 2:  Demonstrates ability to effectively manage resources including personal time a small 
team.  Able to supervise students and less experienced pharmacists and performance manage a 
small team.  Develops, implements and monitors standards of practice at a team level, including 
management of risk management issues and policies and protocols for the team.  Able to 
successfully manage a small project and/or change process for the team. 
LEVEL 3:  Demonstrates ability to manage, allocate and reconfigure available resources and 
understands competing factors at an institutional, state and national level.  Able to performance 
manage a large team or department.  Sets and monitors standards of practice at a departmental 
and/or institutional level, including resolution of risk management issues and development of 
policies and procedures.  Able to successfully plan, supervise and manage the implementation a 
project or change management process beyond the team/workplace or across disciplines. 
 
Having reviewed the candidate against the examples above, are there any initiatives / projects in 
your location that the candidate could become involved with that aids their professional 
development and / or improves patient care? 
 
7. Education, Training and Development 
Please assign a level of competence for the candidate by clicking on ONE BUTTON ONLY.  
Examples of practice that suggest the candidate is working at a particular level are provided to 
assist you. 
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If you do not believe the candidate meets level 1, or you feel that that you cannot comment on 
this aspect of the framework, then please state this in the comments box and do not select a 
button. 
The candidate does not have to perform all listed activities to achieve a rating at that level, but 
should perform activities that are generally of the same level of complexity or require the same 
depth of knowledge / skill as the examples given. 
Please also add comments in the text boxes below (e.g. brief examples of the candidates practice 
that support the grade assigned, strengths and weaknesses). This is optional, but comments are 
exceptionally helpful for the evaluation panel when reviewing the candidate’s performance and 
as consolidated feedback to the pharmacist themselves. 
LEVEL 1:  Role model to junior pharmacists, technicians and peers.  Teaches within pharmacy 
and to nursing staff and other allied health professionals.  Reflects on the effectiveness of 
teaching conducted.  Maintains own CPD portfolio and evaluates own learning. 
LEVEL 2:  Role model at a local level and externally.  Mentors others within the team.  Teaches 
to wider multidisciplinary team, senior staff, and undergraduate and postgraduate students. Able 
to plan and deliver an effective learning experience, and assess the performance and learning 
needs of others.  Ongoing participation in professional development activities including 
postgraduate qualifications. 
LEVEL 3: Role model for pharmacy and wider multidisciplinary team and able to develop role 
model behavior in others. Able to mentor other advanced level pharmacists, including outside the 
organization and the profession.  Recognised as a peer reviewer of clinical practice within 
specialty area.  Able to design and manage a course of study including appropriate teaching, 
assessment and study methods.  Shapes and contributes to professional development and 
education for the profession or other disciplines, including state/national level.  Commitment to 
own professional development via higher postgraduate qualifications. 
Having reviewed the candidate against the examples above, are there any initiatives / projects in 
your location that the candidate could become involved with that aids their professional 
development and / or improves patient care? 
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8. Research and Evaluation 
Please assign a level of competence for the candidate by clicking on ONE BUTTON ONLY.  
Examples of practice that suggest the candidate is working at a particular level are provided to 
assist you. 
If you do not believe the candidate meets level 1, or you feel that that you cannot comment on 
this aspect of the framework, then please state this in the comments box and do not select a 
button. 
The candidate does not have to perform all listed activities to achieve a rating at that level, but 
should perform activities that are generally of the same level of complexity or require the same 
depth of knowledge / skill as the examples given. 
Please also add comments in the text boxes below (e.g. brief examples of the candidates practice 
that support the grade assigned, strengths and weaknesses). This is optional, but comments are 
exceptionally helpful for the evaluation panel when reviewing the candidate’s performance and 
as consolidated feedback to the pharmacist themselves. 
LEVEL 1:  Able to critically evaluate published evidence.  Can give examples of evidence gaps.  
Performs audits and presents results locally. Understands research governance and works as a 
member of the research team at supply and clinical information level. 
LEVEL 2:  Able to critically evaluate published evidence in the context of paediatric specialty 
practice.  Able to formulate research questions within the specialty for use within the team to 
direct research efforts.  Submits work to peer reviewed national conferences.  Writes evidence 
based guidelines that are implemented at a local level.  Contributes to research supervision in 
collaboration with others.  Involved in clinical trials at planning/implementation level. 
LEVEL 3:  Undertakes peer review activities within the specialty (e.g. journal publications, 
conference abstracts, guidelines).  Able to design a successful strategy to address research 
questions within the specialty. Demonstrates authorship of primary evidence and outcomes in 
peer-reviewed media.  Member of clinical governance team, working parties or service 
improvement groups.  Writes or co-writes evidence based guidelines that are implemented at a 
state or national level.  Supervises students undertaking postgraduate research. Works with 
researchers and/or clinical trials teams at a state and national level, making a contribution to 
large and/or multi-centre research studies. 
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Having reviewed the candidate against the examples above, are there any initiatives / projects in 
your location that the candidate could become involved with that aids their professional 
development and / or improves patient care? 
 
9. Finish 
Thank you for completing this evaluation. Your answers will provide valuable information for 
the evaluation panel when assessing this candidate. 
We appreciate that the referee process takes time and effort to complete. We are constantly 
trying to make this process more efficient. If you have any comments or suggestions to make 
about the format of this evaluation form please add them to the text box below. 
 
 
10. Thank you! 
 
 
 
 
 
 
 
